

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549



FORM 10-K

(Mark One)

ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the fiscal year ended December 31, 2025

OR

TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from _____ to _____
Commission file number 001-38769

The Cigna Group

(Exact name of registrant as specified in its charter)

| | |
|--|--------------------------------------|
| Delaware | 82-4991898 |
| (State or other jurisdiction of incorporation or organization) | (I.R.S. Employer Identification No.) |
| 900 Cottage Grove Road, Bloomfield, Connecticut | 06002 |
| (Address of principal executive offices) | (Zip Code) |
| (860) 226-6000 | |
| Registrant's telephone number, including area code | |

| Securities registered pursuant to Section 12(b) of the Act: | | |
|---|-------------------|---|
| Title of each class | Trading Symbol(s) | Name of each exchange on which registered |
| Common Stock, Par Value \$0.01 | CI | New York Stock Exchange, Inc. |

| Securities registered pursuant to Section 12(g) of the Act: |
|---|
| NONE |

| | Yes | No |
|---|-------------------------------------|-------------------------------------|
| Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. | <input checked="" type="checkbox"/> | <input type="checkbox"/> |
| Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act. | <input type="checkbox"/> | <input checked="" type="checkbox"/> |
| Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. | <input checked="" type="checkbox"/> | <input type="checkbox"/> |
| Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). | <input checked="" type="checkbox"/> | <input type="checkbox"/> |
| Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of "large accelerated filer," "accelerated filer," "smaller reporting company" and "emerging growth company" in Rule 12b-2 of the Exchange Act. | | |
| Large accelerated filer | <input checked="" type="checkbox"/> | <input type="checkbox"/> |
| Accelerated filer | <input type="checkbox"/> | <input type="checkbox"/> |
| Non-accelerated filer | <input type="checkbox"/> | <input type="checkbox"/> |
| Smaller reporting company | <input type="checkbox"/> | <input type="checkbox"/> |
| Emerging growth company | <input type="checkbox"/> | <input type="checkbox"/> |
| If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. | <input type="checkbox"/> | <input type="checkbox"/> |
| Indicate by check mark whether the registrant has filed a report on and attestation to its management's assessment of the effectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report. | <input checked="" type="checkbox"/> | <input type="checkbox"/> |
| If securities are registered pursuant to Section 12(b) of the Act, indicate by check mark whether the financial statements of the registrant included in the filing reflect the correction of an error to previously issued financial statements. | <input type="checkbox"/> | <input type="checkbox"/> |
| Indicate by check mark whether any of those error corrections are restatements that required a recovery analysis of incentive-based compensation received by any of the registrant's executive officers during the relevant recovery period pursuant to §240.10D-1(b). | <input type="checkbox"/> | <input type="checkbox"/> |
| Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Act). | <input type="checkbox"/> | <input checked="" type="checkbox"/> |

The aggregate market value of the voting stock held by non-affiliates of the registrant as of June 30, 2025 was approximately \$88.0 billion.

As of January 30, 2026, 263,528,277 shares of the registrant's Common Stock were outstanding.

DOCUMENTS INCORPORATED BY REFERENCE

Part III of this Form 10-K incorporates by reference information from the registrant's definitive proxy statement related to the 2026 Annual Meeting of Shareholders.

TABLE OF CONTENTS

| | <u>Page</u> |
|--|--------------------|
| Cautionary Statement | |
| PART I | |
| Item 1. Business | 1 |
| Item 1A. Risk Factors | 18 |
| Item 1B. Unresolved Staff Comments | 32 |
| Item 1C. Cybersecurity | 32 |
| Item 2. Properties | 33 |
| Item 3. Legal Proceedings | 34 |
| Item 4. Mine Safety Disclosures | 34 |
| Information about Our Executive Officers | 34 |
| PART II | |
| Item 5. Market for Registrant's Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities | 34 |
| Item 6. [Reserved] | 36 |
| Item 7. Management's Discussion and Analysis of Financial Condition and Results of Operations | 36 |
| Item 7A. Quantitative and Qualitative Disclosures about Market Risk | 52 |
| Item 8. Financial Statements and Supplementary Data | 53 |
| Item 9. Changes in and Disagreements with Accountants on Accounting and Financial Disclosure | 110 |
| Item 9A. Controls and Procedures | 110 |
| Item 9B. Other Information | 111 |
| Item 9C. Disclosure Regarding Foreign Jurisdictions that Prevent Inspections | 111 |
| PART III | |
| Item 10. Directors, Executive Officers and Corporate Governance | 111 |
| Item 11. Executive Compensation | 112 |
| Item 12. Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters | 112 |
| Item 13. Certain Relationships and Related Transactions, and Director Independence | 112 |
| Item 14. Principal Accountant Fees and Services | 112 |
| PART IV | |
| Item 15. Exhibits and Financial Statement Schedules | 113 |
| Item 16. Form 10-K Summary | 119 |
| Signatures | 120 |
| Index to Financial Statement Schedules | FS-1 |

CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS

This Annual Report on Form 10-K contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are based on The Cigna Group's current expectations and projections about future trends, events and uncertainties. These statements are not historical facts. Forward-looking statements may include, among others, statements concerning future financial or operating performance, including our ability to improve the health and vitality of those we serve; future growth, business strategy and strategic or operational initiatives; economic, regulatory or competitive environments, particularly with respect to the pace and extent of change in these areas and the impact of developing inflationary and interest rate pressures; financing or capital deployment plans and amounts available for future deployment; our prospects for growth in the coming years; strategic transactions and their expected benefits; and other statements regarding The Cigna Group's future beliefs, expectations, plans, intentions, liquidity, cash flows, financial condition or performance. You may identify forward-looking statements by the use of words such as "believe," "expect," "project," "plan," "intend," "anticipate," "estimate," "predict," "potential," "may," "should," "will" or other words or expressions of similar meaning, although not all forward-looking statements contain such terms.

Forward-looking statements are subject to risks and uncertainties, both known and unknown, that could cause actual results to differ materially from those expressed or implied in forward-looking statements. Such risks and uncertainties include, but are not limited to: our ability to manage health care costs and respond to price competition, inflation and other pressures that could compress our margins or result in premiums that are insufficient to cover the cost of services delivered to our customers; our ability to compete effectively, differentiate our products and services from those of our competitors and adapt to changes in an evolving and rapidly changing industry; our ability to develop and effectively implement products and services to improve the accessibility, affordability and transparency of health care; changes in drug pricing or industry pricing benchmarks; our ability to maintain relationships with one or more key pharmaceutical manufacturers or if payments made or discounts provided decline; changes in the pharmacy provider marketplace or pharmacy networks; the potential for actual claims to exceed our estimates related to expected medical claims; our ability to develop and maintain satisfactory relationships with health care payors, physicians, hospitals, other health service providers and with producers and consultants; potential liability in connection with managing medical practices and operating pharmacies, onsite clinics and other types of medical facilities; uncertainties surrounding participation in government-sponsored programs and providing services to payors who participate in government-sponsored programs; the substantial level of government regulation over our business and the potential effects of new laws or regulations or changes in existing laws or regulations; compliance with applicable privacy, security and data laws, regulations and standards; the outcome of litigation, regulatory audits and investigations; compliance costs and potential failure of our prevention, detection and control systems; our ability to invest in and properly maintain our information technology and other business systems; our ability to prevent or contain effects of a potential cyberattack or other privacy or data security incident; risks related to our use of artificial intelligence and machine learning; dependence on success of relationships with third parties; risk of significant disruption within our operations or among key suppliers or third parties; political, legal, operational, regulatory, economic and other risks that could affect our multinational operations, including currency exchange rates; risks related to strategic transactions and realization of the expected benefits of such transactions, as well as integration or separation difficulties or underperformance relative to expectations which could lead to an impairment charge; our ability to achieve our strategic and operational initiatives; unfavorable economic and market conditions, the risk of a recession or other economic downturn and resulting impact on employment metrics, stock market or changes in interest rates; risks related to a downgrade in financial strength ratings of our insurance subsidiaries; the impact of our significant indebtedness and the potential for further indebtedness in the future; credit risk related to our reinsurers; as well as more specific risks and uncertainties discussed in Part I, Item 1A – Risk Factors and in Part II, Item 7 – Management's Discussion and Analysis of Financial Condition and Results of Operations of this Form 10-K, and as described from time to time in our future reports filed with the Securities and Exchange Commission.

You should not place undue reliance on forward-looking statements, which speak only as of the date they are made, are not guarantees of future performance or results, and are subject to risks, uncertainties and assumptions that are difficult to predict or quantify. The Cigna Group undertakes no obligation to update or revise any forward-looking statement, whether as a result of new information, future events or otherwise, except as may be required by law.

PART I

Item 1. BUSINESS

OVERVIEW

The Cigna Group®, together with its subsidiaries (either individually or collectively referred to as the "Company," "we," "us" or "our"), is a global health company.

Our Focused Mission

The Cigna Group is a global health company committed to creating a better future for every individual and every community. Powered by our dedicated people and valued brands, we advance our mission to ***improve the health and vitality of those we serve*** by staying grounded in the needs of our customers and patients - delivering a personalized, transparent and affordable health care experience. We focus on leading the way to partner and innovate solutions for better health.

At The Cigna Group our global workforce of approximately 67,700 colleagues strives to fulfill our mission to improve the health and vitality of more than 185 million customer relationships in more than 30 markets and jurisdictions (as of December 31, 2025). We play an important role in the health care system, and the breadth and depth of our customer relationships - as well as our approximately 1.7 million relationships with health care providers, clinics and facilities - give us opportunities to drive positive change.

We have two segments: Evernorth Health Services® and Cigna Healthcare®. The Evernorth Health Services segment, through our Pharmacy Benefit Services and Specialty and Care Services operating segments, provides independent and coordinated health solutions and capabilities to enable the health care system to work better and help people live healthier lives. Cigna Healthcare, the health benefits segment of The Cigna Group, provides comprehensive medical and coordinated solutions to customers and clients served by our U.S. Healthcare and International Health operating segments.

Together, Evernorth Health Services and Cigna Healthcare combine pharmacy and medical capabilities to create solutions that improve affordability, transparency and health outcomes. This combination helps us anticipate needs, accelerate innovation and deliver personalized experiences for customers and patients at scale.

Information about Segments

We present the financial results of our businesses in the following segments (see the "Executive Overview" section of Management's Discussion and Analysis of Financial Condition and Results of Operations ("MD&A") located in Part II, Item 7 of this Form 10-K for a financial summary):

Evernorth Health Services includes our Pharmacy Benefit Services and Specialty and Care Services operating segments, which provide independent and coordinated health solutions and capabilities to enable the health care system to work better and help people live healthier lives.

Cigna Healthcare includes our U.S. Healthcare and International Health operating segments, which provide comprehensive medical and coordinated solutions to clients and customers.

Other Operations comprises the remainder of our business operations, which includes certain continuing, run-off and other non-strategic businesses.

Corporate reflects amounts not allocated to operating segments, including net interest expense (defined as interest on corporate financing less net investment income on investments not supporting segment and other operations), certain litigation matters, expense associated with our frozen pension plans, charitable contributions, operating severance, certain overhead and enterprise-wide project costs, and eliminations for products and services sold between segments.

See the "Executive Overview - Key Transactions and Business Developments" section of our Management's Discussion and Analysis of Financial Condition and Results of Operations located in Part II, Item 7 of this Form 10-K for discussion of key developments impacting the segments.

Commitments to Better

Through our Commitments to Better, we embarked on a new, multiyear chapter to accelerate our ongoing evolution and industry leadership. We know we play an important role in a health care system that needs changing for the better, and we are determined to lead that change for the health and vitality of those we serve. We have many roles in the health care system to deliver better outcomes to our customers, including helping to make healthcare more affordable, administering health care claims and working to reduce health care waste. The Cigna Group has established five key areas of focus, and several initial specific actions, to improve the health of its customers and increase the value it provides:

- **Easier access to care:** address challenges customers face by making processes simpler, easier and faster.
- **Better support:** provide customers with more support and resources to navigate the health care system.
- **Better value:** drive better value for customers and patients.
- **Accountability:** stand behind our commitments to our customers and patients.
- **Transparency:** provide information on how we are continuously improving to serve our customers better.

Other Information

The Cigna Group, through its predecessor companies, was incorporated in Delaware in 1981.

The financial information included in this Form 10-K for the fiscal year ended December 31, 2025 is presented in conformity with accounting principles generally accepted in the United States of America ("GAAP") unless otherwise indicated. Industry rankings and percentages set forth herein are for the year ended December 31, 2025, unless otherwise indicated. In addition, statements set forth in this document concerning our rank or position in an industry or particular line of business have been developed internally based on publicly available information unless otherwise noted.

You can access our website at <http://www.thecignagroup.com> to learn more about our company. We make annual, quarterly and current reports and proxy statements and amendments to those reports available, free of charge, through our website as soon as reasonably practicable after we electronically file these materials with, or furnish them to, the Securities and Exchange Commission ("SEC"). We also use our website as a means of disclosing material information and for complying with our disclosure obligations under the SEC's Regulation FD (Fair Disclosure). Important information, including news releases, analyst presentations and financial information regarding The Cigna Group is routinely posted on our website. Accordingly, investors should monitor the Investor Relations portion of our website, in addition to following our press releases, SEC filings, and public conference calls and webcasts. The information contained on, or that may be accessed through, our website is neither incorporated by reference into nor a part of this report. See also "Code of Ethics and Other Corporate Governance Disclosures" in Part III, Item 10 of this Form 10-K for additional information regarding the availability of our Codes of Ethics on our website.

EVERNORTH HEALTH SERVICES

Evernorth Health Services includes our Pharmacy Benefit Services and Specialty and Care Services operating segments, which provide independent and coordinated health solutions and capabilities to enable the health care system to work better and help people live healthier lives.

Evernorth Health Services offers a full suite of products and services that both (a) enables our clients to combine our products and services to create a comprehensive benefit offering designed to manage prescription drugs and provide independent and coordinated health solutions and capabilities and (b) addresses the needs of a shared customer base across both operating segments of Evernorth Health Services. Our ability to deliver this broad array of health care services on either a standalone or combined basis between its two operating segments enables us to drive incremental growth. Additionally, many Evernorth Health Services offerings are available within Cigna Healthcare solutions.

How We Deliver

- **Deep clinical expertise** in evaluating medicines, digital therapeutics and other health solutions for efficacy and value to assist clients in selecting a cost-effective formulary as well as in leveraging evidence-based guidelines to ensure patients receive the most medically appropriate treatments.
- **Affordable solutions** that provide more value and align incentives between the patient, health care professional and plan sponsor.
- **Modular portfolio** tailored to client needs, using the combined strengths and capabilities of Evernorth Health Services, as well as strategic partnerships, to deliver better, more efficient care for patients; better experiences for clients, providers and customers; and enhanced choices for clients and customers through our open architecture model.
- **Talented, experienced and caring people who operate in a culture of innovation and partnership** to solve complex problems across a fragmented health care ecosystem, fueled by data and expertise that drives purposeful innovation.
- **Commitment to improving the health care experience for patients and physicians** through easier access to care, better support, better value, accountability and transparency.

Principal Products and Services

Pharmacy Benefit Services

- *Pharmacy Benefits.* We drive high-quality, cost-effective pharmacy care through a range of services. We adjudicate drug claims from retail network participants and provide retail pharmacy network administration, benefit design consultation, drug utilization review, drug formulary management and other services.
 - *Retail Pharmacy Network Administration.* We contract with retail pharmacies to provide prescription drugs to customers of the pharmacy benefit plans our clients offer. We negotiate with pharmacies throughout the United States to discount drug prices and offer national and regional network options responsive to client preferences related to cost containment, convenience of access for customers and network performance.
 - *Benefits Design Consultation.* We consult with our clients on how best to structure and leverage the pharmacy benefit to meet plan objectives for affordable and sustainable access to the prescription medications customers need to stay healthy and to ensure the safe and effective use of those medications.
 - *Drug Utilization Review.* When pharmacies submit claims for prescription drugs to us, we review them in real time for health and safety. If issues are detected, we then alert the dispensing pharmacy. Clients may also choose to enroll in programs that result in communications about potential therapy concerns being sent to prescribers after the initial claim submission.
 - *Drug Formulary Management.*
 - Formularies are lists of drugs with designations that may be used to determine one component of drug coverage and customer out-of-pocket costs as well as communicate plan preferences in competitive therapeutic drug categories. Our formulary management services support clients in establishing formularies that assist customers and physicians in choosing clinically appropriate, cost-effective drugs and prioritize access, safety and affordability.
 - We administer specific formularies for our clients, including standard formularies developed by Express Scripts® Pharmacy Benefit Services ("Express Scripts") and custom formularies in which we play a more limited role. Many of our clients select standard formularies, governed by both internal and independent committees that make recommendations for formularies that first consider clinical results separate from price considerations.
 - We manage our clients' rebate arrangements, with most choosing to receive the greater of a minimum rebate guarantee or a contractually agreed-upon percentage of rebates. In some rebate arrangements, Express Scripts takes on the risk of securing the rebate value necessary to meet the value guaranteed to its client. The actual amount of value secured by Express Scripts is dependent upon the result of its negotiations for rebates. In 2025, for clients covered under our pharmacy benefit contracts, Express Scripts shared over 95% of the drug formulary management rebates it received with its integrated clients, and more than two-thirds of clients received 100% of rebates.
 - *Medical Drug Management.* We offer a comprehensive range of services with guaranteed savings for managing medically billed specialty drugs. Our solutions apply utilization management, site of care management and claims prepayment review to help ensure patient safety and healthier outcomes and reduce wasteful spend.
 - *Administration of Group Purchasing Organizations.* We participate in various group purchasing organizations that negotiate pricing for the purchase of pharmaceuticals or formulary rebates with pharmaceutical manufacturers on behalf of their participants.

- Value-Based Programs. We offer a variety of solutions aimed at helping clients reduce costs and enhance clinical outcomes. These programs include SafeGuardRx®, Express Scripts Patient Assurance®, Evernorth EncircleRxSM and Evernorth EnReachRxSM.
- Evernorth Wholesale Marketplace. Evernorth Wholesale Marketplace® offers a suite of flexible, private label pharmacy benefit manager solutions including but not limited to a pharmacy rebate program, a retail network program, value-based solutions, a medical rebate program and utilization management policies. These offerings are captured under either our drug formulary administrative service arrangements or our formulary processing arrangements.
- Transparent Rebate-free Model. Evernorth Health Services has announced a transformative new pharmacy benefits model to make discounts negotiated with drug companies available upfront to customers buying their medications, lowering their costs at the counter. Cigna Healthcare will adopt this new model for its fully insured customers beginning in 2027. It will become the standard model available for Evernorth Health Services pharmacy benefit clients beginning in 2028.
- Home Delivery Pharmacy. Our Express Scripts® Pharmacy offers free standard shipping of medications nationwide, usually in a 90-day supply, directly to the customer's home and allows for automatic refills on eligible medications and unrestricted telephone access to customer care advocates and specially trained pharmacists. Our Evernorth EnGuideSM Pharmacy ("EnGuide Pharmacy") was established in 2025 to focus on the growing population of customers that are prescribed GLP-1 medications requiring clinical support. Express Scripts Pharmacy operations consist of 11 licensed pharmacies, inclusive of four fulfillment pharmacies located in Arizona, Indiana, Missouri and New Jersey. EnGuide Pharmacy operations consist of two licensed pharmacies, inclusive of one fulfillment pharmacy located in Ohio.

Specialty and Care Services

- Specialty Pharmacy. Specialty medications are primarily characterized as high-cost medications for the treatment of complex and rare diseases. These medications broadly include those with frequent dosing adjustments, intensive clinical monitoring, the need for customer training, specialized product administration requirements or medications limited to certain specialty pharmacy networks by manufacturers. The front-end of our pharmacy, anchored by Accredo® Specialty Pharmacy ("Accredo"), is organized into Therapeutic Resource Centers, where pharmacists focus their practice of pharmacy by condition. Accredo provides support for customers through our specially trained clinicians, network of in-home nursing services, nationwide footprint, drug reimbursement services and highly tailored clinical care programs. Our Specialty Pharmacy operations consist of 35 licensed pharmacies.
- Health System Services. Health System Services includes CuraScript SD by Evernorth®, which is a specialty distributor of pharmaceuticals and medical supplies (including injectable and infusible pharmaceuticals and medications to treat specialty and rare or orphan diseases) directly to health care providers, including clinics and hospitals in the United States for office or clinic administration. We provide distribution services primarily to health care providers who treat customers with chronic diseases and regularly order costly specialty pharmaceuticals. This business operates four distribution centers and ships most products overnight within the United States. It is a contracted supplier with most major group purchasing organizations and leverages its distribution platform to operate as a third-party logistics provider for certain pharmaceutical companies.
- Care Services. We offer clinical programs to help our clients, including third-party administrators, drive better whole-person health outcomes through our Care Delivery (MD Live by Evernorth® ("MD Live") virtual care) and Care Management (EviCore by Evernorth® ("EviCore") benefits management, behavioral health services, network services and health coaching capabilities) offerings.

Clients and Customers

We provide products and services in the Evernorth Health Services segment to clients and customers, as described below.

- Clients. We provide services to managed care organizations, health insurers, third-party administrators, employers, union-sponsored benefit plans, workers' compensation plans, government health programs, providers, clinics, hospitals and others. We provide services to a majority of clients in our Cigna Healthcare segment.
- Customers. Prescription drugs are dispensed to patients connected to the service offerings we provide to clients. Prescription drugs are dispensed primarily through networks of retail pharmacies under nonexclusive contracts with us and via home delivery pharmacies, including Express Scripts Pharmacy, and specialty pharmacies, including Accredo.

Evernorth Health Services has three clients that each drive significant revenues for the segment:

- Express Scripts and Centene Corporation ("Centene") have a multiyear agreement, which began January 1, 2024, to manage pharmacy benefit services for Centene's customers, providing them with access to the extensive Express Scripts national network of retail pharmacies.

- Express Scripts and Prime Therapeutics LLC ("Prime") have agreements to deliver improved choice and affordability for Prime's clients and customers by enhancing retail pharmacy networks, providing access to Accredo and Express Scripts Pharmacy, and providing pharmaceutical manufacturer value.
- The Department of War (previously the Department of Defense) TRICARE® is the military health care program available to active-duty service members, active-duty family members, National Guard and Reserve members and their family members, retirees and retiree family members, survivors and certain former spouses.

Competition

The primary competitive factors in the industry include the ability to negotiate with retail pharmacies to ensure retail pharmacy networks meet the needs of clients and customers; provide home delivery and specialty pharmacy services; negotiate with drug manufacturers to lower the cost of prescription drugs; manage cost and quality of specialty drugs; specialize in claim adjudication and benefit administration; improve access, outcomes, and efficiencies within the health care ecosystem; deliver quality primary and behavioral care in virtual-led hybrid settings and in the workplace; navigate the complexities of government-reimbursed business including Medicare, Medicaid and the public exchanges; and use the information obtained about drug, behavioral and medical utilization patterns and consumer behavior to reduce costs for clients and customers and assess the level of service provided.

Our focus on improving the health and vitality of those we serve will allow us to further differentiate ourselves from our primary competitors. Our primary competitors include independent and managed care pharmacy benefit managers; retail, home delivery and specialty pharmacies; specialty drug distributors; health plans; third-party benefit administrators; group purchasing organizations; clinical solutions companies; health care data analytics companies; and care services providers.

Suppliers

We maintain an inventory of brand-name and generic pharmaceuticals in our home delivery pharmacies, specialty pharmacies and specialty distributor. Our specialty pharmacies and specialty distributor also carry biopharmaceutical products to meet the needs of our customers, including pharmaceuticals for the treatment of rare or chronic diseases; if a drug is not in our inventory, we can generally obtain it from a supplier within a reasonable amount of time.

We purchase pharmaceuticals either directly from manufacturers or through authorized wholesalers. Evernorth Health Services uses one wholesaler for approximately half of our pharmaceutical purchases, but holds contracts with other wholesalers if needs for an alternate source arise. Generic pharmaceuticals are generally purchased directly from manufacturers.

CIGNA HEALTHCARE

Cigna Healthcare includes our U.S. Healthcare and International Health operating segments, which provide comprehensive medical and coordinated solutions to clients and customers. U.S. Healthcare provides medical plans and other benefits and solutions for insured and self-insured clients as well as for individual and family plan customers. International Health provides health care solutions in our international markets, as well as health solutions for globally mobile individuals and employees of multinational organizations.

How We Deliver

- **Multifaceted approach to affordability** with a focus on high-quality care to lower costs and drive better outcomes through deep collaborative partnerships with high-performing providers and superior clinical expertise and analytics to guide customers to the highest quality, most affordable sites of care and reduce health care waste.
- **Talented and experienced people** who bring a highly consultative orientation to market and partner with clients to understand their business and goals to address the unique health needs of their population.
- **Modular portfolio of products, services and funding options** that provides choice and enables us to build and tailor a unique combination to meet the specific needs of each client.
- **Partnering with Evernorth** to deliver a spectrum of integrated solutions that create value and savings for our customers, clients and provider partners.
- **Commitment to improving the health care experience for patients and physicians** through easier access to care, better support, better value, accountability and transparency.

We offer administrative services only ("ASO") and insurance funding options to employers, groups and individuals along with other health care benefits and solutions to improve the quality of care, lower costs and help customers achieve better health outcomes. Funding options, referring to the entity assuming financial risk, are described in the Premiums and Fees section below.

Principal Products and Services

U.S. Healthcare Medical Plans

- *Employer Medical Plans* are offered by our insurance companies, health maintenance organizations ("HMOs") and third-party administrators ("TPAs"), and include Open Access Plus, LocalPlus[®] and HMO options. These plans use cost-sharing incentives to encourage the use of "in-network" rather than "out-of-network" health care providers. We also offer Preferred Provider Organization ("PPO") plans that feature broader provider access than the other plans, do not require referrals and typically have a higher cost-share for out-of-network services. Plans are offered nationwide, and our funding solutions include ASO (self-funded), insured guaranteed cost ("GC") and insured experience rated ("ER").
 - *Consumer-Driven Products* are paired with employer medical plans and offer customers a tax-advantaged way to pay for eligible health care expenses. Health Savings Accounts, Health Reimbursement Accounts and Flexible Spending Accounts encourage customers to play an active role in managing their health and health care costs.
- *Individual and Family Plans ("IFP")* are Patient Protection and Affordable Care Act and related amendments ("ACA") compliant exclusive provider organizations ("EPOs") or HMO plans marketed to individuals under age 65 without access to health care coverage through an employer or government program such as Medicare or Medicaid. Customers receive comprehensive health care benefits and have access to a local network of health care providers who have been selected with cost and quality in mind. Plans are currently offered in 11 states with a GC funding solution.

Sold Businesses

On March 19, 2025, the Company completed the sale of our Medicare Advantage, Medicare Individual Stand-Alone Prescription Drug Plans, Medicare and Other Supplemental Benefits, and CareAllies[®] businesses to Health Care Service Corporation ("HCSC," and such transaction, the "HCSC transaction"). Prior to the disposal date, U.S. Healthcare's results include these businesses. See Note 5 to the Consolidated Financial Statements for further information.

U.S. Healthcare Benefits and Solutions

The following benefits and solutions are offered nationwide with various funding options to enhance the benefits from our health care medical plans.

- *Behavioral Health* solutions consist of a broad national network of providers, including one of the largest virtual networks in the United States; specialty case and utilization management; a 24/7-accessible crisis intervention phone line; employee assistance programs; and work/life programs.
- *Consumer Health Engagement* solutions include an array of health management, disease management and wellness programs to improve customers' health and well-being.
- *Cost Containment Programs* are designed to reduce the cost of covered health care services and supplies by reducing out-of-network costs, protecting customers from balance billing and educating customers regarding the availability of lower cost in-network services. We negotiate discounts with out-of-network providers, review provider bills and recover overpayments.
- *Dental* solutions include HMO plans, PPO plans, EPO plans, traditional indemnity plans and a discount program. Employers and other groups may purchase our products as standalone products or in conjunction with medical products. IFP standalone dental PPO plans are available in 49 states and sold to individuals under age 65 and retirees without access to dental coverage through an employer or a government program.
- *Pharmacy Management* solutions and benefits may be combined with our medical and behavioral health offerings by leveraging the capabilities of Evernorth Health Services.
- *Stop-Loss* insurance coverage is offered to self-funded clients whose group health plans are administered by Cigna Healthcare. Stop-loss insurance provides reimbursement for claims in excess of a predetermined amount for individuals, the entire group or both.

International Health

- *Global Health Care* offerings include medical, dental, pharmacy, vision, life, accidental death and dismemberment, and disability risks. We provide products and services that meet the needs of multinational employers, intergovernmental and nongovernmental organizations, and globally mobile individuals with a focus on keeping employees healthy and productive. Products and services are offered worldwide except as limited by applicable law and include ASO, GC and ER funding options.
- *Local Health Care* offerings include medical, dental, pharmacy and vision as well as life coverage. Customers include employers and individuals located in specific geographies (China, Singapore, Hong Kong, Spain and India, along with various countries in the Middle East) where the products and services are purchased. Offerings include ASO, GC and ER funding options.

Premiums and Fees

- ASO. Plan sponsors (i.e., employers, unions and other groups) create self-funded group health plans to fund all claims and may purchase stop-loss insurance to limit exposure. We earn fees for providing access to our participating provider networks, claims administration services, and other benefits and solutions. ASO arrangements represent approximately 32% of 2025 segment revenues and 79% of Cigna Healthcare medical customers as of December 31, 2025.
- Insured.
GC and ER. Individual and group insurance premium rates generally must be approved by the applicable state regulatory agency, and state or federal laws may restrict or limit the use of rating methods. Premium rates are established at the beginning of a policy period and may be based in whole or in part on prior experience and include estimates of future claims costs over the fixed contract period. With the exception of ER policies, we generally cannot adjust premium rates to reflect actual claims experience until the next policy period, and the policyholder does not share in actual claim experience. We retain any margin if costs are less than the premium charged (subject to minimum medical loss ratio ("MLR") rebate requirements) and bear the risk for costs in excess of the premium charged.

The ACA subjects individual and small group policy rate increases above an identified threshold to review by the United States Department of Health and Human Services ("HHS"), and our U.S. Healthcare medical plans are subject to minimum MLR requirements. The MLR represents the percentage of premiums used to pay claims and expenses for activities that improve the quality of care. If we do not satisfy the prescribed MLR, statutes require premium refunds to policyholders.

GC and ER insured arrangements represent approximately 68% of 2025 segment revenues (which includes Medicare Advantage prior to the HCSC transaction) and 21% of Cigna Healthcare medical customers as of December 31, 2025.

See the "Business – Regulation" section of this Form 10-K for additional information about MLR requirements.

Market Segments

Cigna Healthcare serves medical customers across the following market segments:

- National Accounts. Employers with 3,000 or more eligible employees.
- Middle Market. Employers with 500 to 2,999 eligible employees, solutions for third-party payors, Taft-Hartley plans and other groups.
- Select. Employers with 51 to 499 eligible employees.
- Small. Employers with 2 to 50 eligible employees.
- IFP. Individual health insurance coverage both on and off the public exchanges.
- International Health. Includes multinational employers and globally mobile individuals, and employers and individuals in specific countries outside of the United States.
- Medicare Advantage (sold business in 2025). Includes individuals who are Medicare-eligible, as well as employer group-sponsored post-65 retirees.

Clients and Customers

We provide clients and customers with access to a mix of medical and other health care benefits and solutions.

- Clients. Employers, TPAs, union-sponsored benefit plans and other groups.
- Customers. Individuals who access our offerings through an employer-sponsored plan, government-sponsored plan in Medicare Advantage prior to the HCSC transaction, IFP or other individual plan, or other insured group.

Primary Distribution Channels

- Brokers and Consultants. Sales representatives distribute our products and solutions through a broad group of brokerage and consulting firms as well as individuals.
- Direct. Cigna Healthcare sales representatives distribute our products and solutions directly to employers, unions, and other groups or individuals. Various products may also be sold directly to insurance companies, HMOs and TPAs.
- Private Exchanges. We partner with select private exchanges that provide employees of participating clients access to health insurance, targeting participation to those models that best align with our mission and value proposition.
- Public Exchanges. Cigna Healthcare offers individual ACA-compliant policies through public health insurance exchanges in select geographies.

Competition

The primary competitive factors affecting our business are quality of care and cost-effectiveness of service and provider networks, effectiveness of medical care management, products that meet the needs of our clients and customers, total cost management, technology, and effectiveness of marketing and sales. Financial strength, as indicated by ratings issued by nationally recognized rating agencies, is also a competitive factor. Our health advocacy capabilities, holistic approach to consumer engagement, breadth of product offerings, and clinical care and health management capabilities, along with an array of product funding solutions, are competitive advantages. Our primary competitors include national insurers, local health plans, TPAs, dental insurers, independent and managed care pharmacy benefit managers, global insurers, and local non-U.S. insurers.

Provider Networks and Partnerships

- *Participating Provider Networks.* We provide our customers with a national network of participating health care providers; hospitals; and other facilities, pharmacies and providers of health care services and supplies. As of December 31, 2025, our U.S. network had approximately 1.7 million physicians, including specialists, and over 6,000 hospitals. We have strategic alliances with several regional managed care organizations to gain access to their provider networks and discounts.
- *Network Strength and Stability.* We successfully maintain a broad provider network with high levels of provider retention to ensure our customers have access to high-quality care at affordable, competitive rates.
- *Provider Partnerships.* We partner with a variety of provider groups in value-based payment arrangements to continuously improve the quality of care for those we serve. With more than 200 arrangements with primary care groups, our flagship program is the Cigna Collaborative Accountable Care program, which rewards providers for improving quality outcomes and medical cost performance. As of December 31, 2025, we had approximately 100 arrangements with specialist groups across a variety of disciplines that include incentives for enhanced care coordination or reimbursements for meeting cost and quality goals. We also had contracts with more than 200 hospital systems, involving more than 750 hospitals, with reimbursements tied to quality metrics.
- *Site of Care Optimization.* We encourage the use of clinically appropriate settings to reduce the cost of care while ensuring high-quality care and service through our clinical programs. Through our clinical programs and partnership with EviCore, we guide care to the most appropriate settings, reducing unnecessary costs while preserving quality and service, and offer virtual care options, including MD Live, to improve convenience and access.

OTHER OPERATIONS

Other Operations comprises the remainder of our business operations, which includes certain continuing, run-off and other non-strategic businesses.

Continuing Business

Corporate-Owned Life Insurance. The principal products of the corporate-owned life insurance ("COLI") business are permanent insurance contracts sold to corporations to provide coverage on the lives of certain employees for financing employer-paid future benefit obligations. Permanent life insurance provides coverage that, when adequately funded, does not expire after a term of years. The contracts are primarily nonparticipating universal life policies. Fees for universal life insurance products consist primarily of mortality and administrative charges assessed against the policyholder's fund balance. Interest credited and mortality charges for universal life and mortality charges on variable universal life may be adjusted prospectively to reflect expected interest and mortality experience. To reduce our exposure to large individual losses, we purchase reinsurance from unaffiliated reinsurers.

Run-off Businesses

Settlement Annuity Business. Our settlement annuity business is a closed, run-off block of single premium annuity contracts. These contracts are primarily liability settlements, with approximately 10% of the liabilities associated with guaranteed payments not contingent on survivorship. Non-guaranteed payments are contingent on the survival of one or more parties involved in the settlement.

Reinsurance. Our reinsurance operations are an inactive business in run-off. In February 2013, we effectively exited the variable annuity reinsurance business by reinsuring 100% of our future exposures, net of retrocessional arrangements in place at that time, up to a specified limit. For additional information regarding this reinsurance transaction and the arrangements that secure our reinsurance recoverables, see Note 10 to the Consolidated Financial Statements.

Individual Life Insurance and Annuity and Retirement Benefits Businesses. The individual life insurance and annuity business and the retirement benefits business were sold through reinsurance agreements in 1998 and 2004, respectively. For more information

regarding the arrangements that secure our reinsurance recoverables for the retirement benefits business, see Note 10 to the Consolidated Financial Statements.

MISCELLANEOUS

- Revenues from a single pharmacy benefit client were approximately 19% and 16% of total revenue from external customers for the years ended December 31, 2025 and 2024, respectively. These amounts were reported in the Evernorth Health Services segment.
- Revenues from U.S. Federal Government agencies, under a number of contracts, were 11% and 15% of total revenue from external customers for the years ended December 31, 2024 and 2023, respectively. These amounts were reported in the Evernorth Health Services and Cigna Healthcare segments.
- The Company does not rely on business from one or a few brokers or agents.

INVESTMENT MANAGEMENT

Our investment operations provide investment management and related services for our various businesses, including the insurance-related invested assets. For additional information about invested assets, see the "Investment Assets" section of the MD&A and Notes 11 and 12 to the Consolidated Financial Statements.

We manage our investment portfolios to reflect the underlying characteristics of related insurance and contractholder liabilities and capital requirements, as well as regulatory and tax considerations pertaining to those liabilities and state investment laws. Insurance and contractholder liabilities range from short-duration health care products to longer-term obligations associated with COLI products and the run-off settlement annuity business. Assets supporting these liabilities are managed in segregated investment portfolios to facilitate matching of asset durations and cash flows to those of corresponding liabilities. Investment results are affected by the amount and timing of cash available for investment, economic and market conditions and asset allocation decisions. We routinely monitor and evaluate the status of our investments, obtaining and analyzing relevant investment-specific information and assessing current economic conditions, trends in capital markets and other factors, such as industry-sector, geographic and property-specific information.

DIGITAL, DATA AND TECHNOLOGY

The Cigna Group investments in digital, data and technology are focused on cultivating robust, innovative digital-first capabilities to better engage with customers and stakeholders.

Our Commitments to Better. The Cigna Group is on a multiyear journey toward making the health care experience better for those we serve. We are taking action on our five commitments, which are outlined above. The Cigna Group is driving meaningful improvements for all customers through strong governance and collaboration across the organization. These partnerships guide our efforts to enhance health outcomes for the millions we serve while ensuring transparency and accountability every step of the way.

Innovation. At the core of the Company's strategic priorities lies a culture of innovation and enablement - one that empowers a customer-centric, digital-first, virtual-led vision for health care. The advancement of our internal innovative capabilities and strategic partnerships empowers teams to continuously challenge conventions, embrace experimentation and produce new and more effective ways to engage with our customers to help close gaps in care, optimize treatment and improve outcomes.

The Cigna Group is committed to innovative, transformative changes by reimagining our operating models, products and interactions to create new sources of value. We use artificial intelligence ("AI") to support health care transformation by helping to enable the next generation of accessible, effective, affordable and enhanced health care solutions. AI models can facilitate personalized solutions for individuals, inform earlier interventions and simplify health care experiences. There is human engagement in claims reviews, including expert decisions made by physicians or employees at The Cigna Group. Given this, we consider most of the AI models we use as augmented intelligence, providing information to human experts for further consideration, in combination with many other factors evaluated in care and benefit administration decisions.

To ensure our practices and solutions are consistent with our commitment to health equity and to facilitate compliance with applicable laws and regulations, we have a dedicated team and governance structure in place, known as Enterprise Model Governance ("EMG"). Our EMG team oversees the development, deployment and monitoring of AI models driven by our Responsible AI Principles: validity and reliability, safety, privacy, fairness, transparency, and accountability. EMG is governed by the EMG Board, consisting of senior

leaders from across the company, with representation from business, clinical, privacy, legal, internal audit, information protection and other departments. The EMG Board oversees an enterprise-wide model approval and governance process for review of AI models in use or in development across the enterprise.

We also have established comprehensive governance processes for new capabilities, such as generative AI ("Gen AI"). Our AI Center of Enablement ("AI COE") expands on EMG and brings together individuals from across our technology, privacy, data governance, security, legal, compliance, marketing and other teams to evaluate and approve Gen AI use cases. The AI COE ensures these use cases align with our Responsible AI Principles and adhere to health care privacy and security requirements.

Data and Analytics. Data and analytics power the Company's strategy, fueling informed decisions, deeper insights and accelerated growth. We are creating technology that drives AI processes and enables predictive, personalized and adaptive business outcomes. We conduct timely, rigorous and objective research and analysis that informs evidence-based medical and pharmacy benefit management decisions and evaluates the clinical, economic and individual impact of enhanced benefit designs and programs, ultimately resulting in rich, integrated data that helps to provide differentiated outcomes. The combination of our predictive analytics, and our machine learning ("ML") and deep learning capabilities help to uncover trends, anticipate needs and create actionable intelligence that assists and accelerates decision-making of our health care professionals, improves operational efficiency and enables greater innovation. Our data-driven approach to building products and solutions provides personalized and customized care across the entire continuum for the populations we serve. These solutions predict emerging health needs, close gaps in care and drive cost savings, all while focusing on improving the health and vitality of the lives we touch.

Digital. Our digital health focus has shown value across the enterprise by reimagining the future of health care and creating engaging experiences that give customers the right information at the right time. We are positioning our lines of business for today's market pressures while ensuring we are building a sustainable advantage through data, insights and digital innovation. We drive efficiencies, improve sentiment and create market differentiation, while accelerating our path toward personalized, AI-driven solutions for customers, clients and providers. We deliver digital products and features at scale with a commitment to security, resiliency and compliance. Our digital strategy also focuses on the drive from analog to digital, which complements the growth strategy of The Cigna Group, creates efficiency and amplifies the value of existing offerings, as well as creates option value with industry-leading personalization and precision to drive better health and business outcomes. Cybersecurity protections continue to be a top priority across The Cigna Group digital offerings to further strengthen our security posture and grow the trust of those we serve. See Part I, Item 1C - "Cybersecurity" of this Form 10-K for additional information regarding our cybersecurity practices and governance.

Technology Operations. Our technology team consistently maintains a high degree of availability and reliability to our various information systems critical to client and customer care operations, providers, and overall customer experience. Within Evernorth Health Services, uninterrupted point-of-sale electronic retail pharmacy claims processing is a significant operational requirement for our business. We believe we have substantial capacity for growth in our U.S. pharmacy claims processing facilities. Our pharmacy technology platform allows us to safely, rapidly and accurately adjudicate over two billion adjusted prescriptions annually. Our technology helps retail pharmacies focus on patient care, and our real-time safety checks help avoid medication errors. The Cigna Group companies hold over 540 U.S. patents. We use these patents to protect our proprietary technological advances and to differentiate ourselves in the market. We are not substantially dependent on any single patent or group of related patents. We are not aware of any facts that could materially impact the continuing use of our intellectual property.

HUMAN CAPITAL MANAGEMENT

The mission of The Cigna Group is to improve the health and vitality of those we serve. A healthy and diverse global workforce is essential to achieving our mission and our business growth strategies. We continually invest in our employees by supporting their health and vitality, providing fair and market-competitive compensation, and fostering opportunities for growth and development. As of the end of 2025, The Cigna Group employed approximately 67,700 employees worldwide, with about 88% of our employees based in the United States. Roughly 97% of our workforce is full-time. At year-end 2025, our global workforce was approximately 69% women and 31% men, and about 40% of our U.S. employees identified as ethnic minorities. We have a long-standing and deep commitment to cultivating a purpose and performance driven workforce that is equipped and empowered to drive growth and innovation across our businesses.

Health, Vitality and Other Benefits. Supporting our employees' health and vitality is not only a core value, it's a critical business imperative. Each year, we make continued investments to help ensure our workforce is healthy, engaged and empowered to advance our mission and business strategy, ultimately creating long-term shareholder value.

In 2025, The Cigna Group invested approximately 20% of total payroll in health, well-being and other benefits. These investments include comprehensive medical and pharmacy coverage, paid time off, life and disability programs, 401(k) contributions, and retirement-related benefits for our employees in the United States.

Beyond traditional medical and pharmacy benefits, we provide multidimensional wellness programs designed to support many aspects of well-being (physical, mental, financial and social health) while promoting overall vitality. We also encourage employees to voluntarily share additional demographic information, such as military veteran status or disability, so we can tailor resources and programs to meet their unique needs and perspectives.

Talent Acquisition, Development and Retention. Our talent acquisition and rewards strategies are designed to attract and retain skilled employees who are committed to our mission. We strive to reach a broad and diverse pool of candidates to engage and recruit top talent across all levels and functions of the Company. In 2025, the voluntary turnover rate was approximately 9% for all employees.

Our compensation practices, rooted in our pay-for-performance philosophy, promote fair and competitive pay through measures such as benchmarking compensation by role, eliminating inquiries regarding applicants' compensation history from the hiring process and monitoring for potential disparities. Within the U.S., female employees of The Cigna Group earn more than 99 cents for every dollar earned by similarly situated male employees, and employees from underrepresented groups earn more than 99 cents for every dollar earned by similarly situated white employees. On a global basis, across the entire Company, female employees at The Cigna Group earn more than 99 cents for every dollar earned by similarly situated male employees.

Our online learning platform and career development tools, including a career portal and career planning tool, offer a broad range of training, education and development resources to all employees. In 2025, based on internal data, employees on average engaged in 45 hours of learning through these resources. Our leadership development strategy, anchored by The Cigna Group Leader Profile and aligned with our mission and enterprise goals, serves to cultivate leadership capabilities for people leaders and critical segments across our organization through innovative programs and resources. The Cigna Group also offers an education reimbursement program for both full-time and part-time employees who meet the continuing education criteria. We believe these strategies and programs contribute to employee engagement and retention and prepare our employees to meet our needs now and in the future.

CORPORATE IMPACT AND SUSTAINABILITY

The Cigna Group corporate impact and sustainability framework is structured around four connected pillars that underscore our enterprise mission to improve the health and vitality of those we serve. We drive action through this framework to deliver on our vision: to transform the ecosystem of health into one that is well-functioning, sustainable, accessible and equitable - advancing better health for all. Our commitment to this vision guides us in our value-creation strategy as we strive to meet the needs of our many stakeholders. The four pillars of this framework are as follows:

Healthy Society. We are committed to understanding and addressing social determinants of health and improving medical quality and access while lowering health risks, promoting preventive health interventions and coordinating all aspects of care. We drive progress by aligning our products and services with value-based care models, leveraging integrated benefits, managing drug costs through innovation, expanding digital offerings and reviewing coverage policies for health equity. We also give back through charitable giving and volunteerism in communities where we operate around the world.

Healthy Workforce. We believe that employers play a vital role in the health care system, and we strive to be a model for others by prioritizing and investing in the health and vitality of employees within our own company. We aim to cultivate a workforce that is equipped and empowered to drive growth and innovation across our diverse businesses. See further discussion of this pillar within Part I, Item 1 "Human Capital Management" section above.

Healthy Environment. We believe that responsible environmental stewardship can improve health and vitality and also makes sound business sense. We strive to identify new efficiencies and make strategic investments that reduce our environmental impacts and our operating costs.

Healthy Company. We have a deep and long-held commitment to strong governance as well as ethical and resilient business practices. This includes protecting the sensitive data of our clients and customers by ensuring cybersecurity incident response preparedness, as well as supporting a responsible supply chain.

REGULATION

We are regulated by federal, state and international legislative and executive bodies and agencies, which generally have discretion to issue regulations and interpret and enforce laws and rules. These regulations can vary significantly from jurisdiction to jurisdiction, and the regulations and interpretations thereof may also change periodically. We expect continued legislative and regulatory debate of issues related to our businesses, and executive, judicial or legislative intervention could further impact the regulatory landscape for the health services industry. Our international subsidiaries face an increasingly complex regulatory dynamic, including as a result of rigorous regulations and the impact of geopolitical developments or tensions.

Many aspects of our business are directly regulated by federal and state laws and administrative agencies, such as HHS, Centers for Medicare and Medicaid Services ("CMS"), the Internal Revenue Service ("IRS"), the U.S. Departments of Labor ("DOL") and Treasury, the Office of Personnel Management ("OPM"), the Defense Health Agency ("DHA"), the Federal Trade Commission ("FTC"), the SEC, the Office of the National Coordinator for Health Information Technology, state departments of insurance, state boards of health and state boards of pharmacy. Our business practices may also be shaped by enforcement actions of federal agencies, such as the Department of Justice ("DOJ"), state agencies and judicial decisions.

In addition, aspects of our business are subject to indirect regulation. The self-funded benefit plans sponsored by our U.S. employer clients are regulated under federal law. These self-funded clients expect us to administer their plans in compliance with the regulatory requirements applicable to them.

Our business operations and the books and records of our regulated businesses are routinely subject to regulatory examination and audit at regular intervals by state insurance and HMO regulatory agencies, state boards of pharmacy, CMS, DOL, and OPM to assess compliance with applicable laws and regulations. Our operations are also subject to nonroutine examinations, audits and investigations by various state and federal regulatory agencies, generally as the result of a complaint. In addition, we may be subject to examination or investigation of our clients whose group benefit plans we administer on their behalf. As a result, we routinely receive subpoenas and other demands or requests for information from various state insurance and HMO regulatory agencies, state attorneys general, the HHS Office of Inspector General ("HHS-OIG"); the DOJ; the FTC; the DOL; and other state, federal and international authorities. We may also be called upon by members of the U.S. Congress, state legislators, state regulators or attorneys general to provide information regarding certain business practices. If The Cigna Group is determined to have failed to comply with applicable laws or regulations, these examinations, audits, investigations, reviews, subpoenas and demands may (a) result in fines, penalties, injunctions, consent orders or other settlement agreements (such as corporate integrity agreements or loss of licensure); (b) suspend or exclude us from participation in government programs or limit our ability to sell or market our products; (c) require changes in business practices; (d) damage relationships with the agencies that regulate us and affect our ability to secure regulatory approvals necessary for the operation of our business; or (e) damage our brand and reputation.

Even where we believe that we are in compliance with the various laws and regulations, any enforcement actions by federal, state or international government officials alleging noncompliance with these rules and regulations could subject us to penalties or restructuring or reorganization of our business. For a discussion of the risks related to our compliance with these laws and regulations, please see the "Risk Factors" section located in Part I, Item 1A of this Form 10-K.

Federal Legislative Developments

In February 2026, the U.S. Congress enacted the Consolidated Appropriations Act, 2026, which includes multiple provisions applicable to pharmacy benefit manager ("PBM") operations. These provisions are expected to impact pharmacy benefit arrangements in the commercial market and the Medicare Part D program, with varying effective dates. The ultimate impact of these provisions will depend, in part, on future regulatory guidance and implementation by the HHS and the DOL, among other federal agencies.

With respect to employer-sponsored health plans subject to the Employee Retirement Income Security Act ("ERISA"), the legislation includes provisions, effective beginning in August 2028, that require PBMs to remit 100% of certain rebates, fees and other remuneration to plan sponsors. In addition, the legislation imposes enhanced disclosure and reporting requirements intended, among other things, to increase transparency into PBM compensation and prescription drug spending.

The legislation also includes provisions affecting PBM services provided in connection with Medicare Part D plans that, beginning in January 2028, prohibit PBMs from receiving compensation that is directly or indirectly linked to the list price of a covered Part D drug, limiting PBM compensation to bona fide service fees. In addition, beginning January 2029, under the legislation, Medicare Part D plan sponsors will be required to contract with any pharmacy that is willing and able to meet standard contract terms and conditions. The Company continues to monitor legislative and regulatory developments regarding the Consolidated Appropriations Act, 2026; however, the full impact of these provisions on PBM operations cannot be determined at this time.

The Patient Protection and Affordable Care Act

The ACA governs significant aspects of the U.S. health care system that affect insured and self-insured health benefit plans and PBMs. Our business model is impacted by the ACA and may be impacted by additional, future changes to the ACA, including our relationships with current and future producers and health care providers, products, service providers, and technologies. The ACA, among other things, created health insurance exchanges for individuals and small group employers to purchase insurance coverage and implemented minimum MLRs for our Cigna Healthcare business. The ACA allows states to adopt MLR requirements that are more stringent than those established by the ACA. Other provisions of the ACA in effect include reduced Medicare Advantage payment rates, the requirement to cover preventive services with no enrollee cost-sharing, a ban on the use of lifetime and annual limits on the dollar amount of essential health benefits, increased restrictions on rescinding coverage, extended coverage of dependents up to age 26, restrictions on differential pricing, and certain pharmacy benefit transparency requirements. In 2021, in response to the COVID-19 pandemic, the federal government temporarily expanded eligibility for ACA subsidies to higher-income people who did not otherwise qualify and increased ACA subsidies for lower-income people who already qualified in 2021 and 2022, among other actions. These ACA subsidies expired on December 31, 2025. The Inflation Reduction Act of 2022 extended the increased premium tax credits for individuals enrolled in ACA-qualified health plans through December 31, 2025, which were not renewed.

Health Care Fraud and Abuse Laws

Our products and services are subject to health care fraud, waste and abuse laws, including the federal False Claims Act ("False Claims Act"), state false claims acts, federal and state anti-kickback laws, and the federal Civil Monetary Penalties Law. These laws and related regulations prohibit a wide range of activities, including kickbacks in return for customer referrals, billing for unnecessary medical services, beneficiary inducement, upcoding and improper marketing. The regulations and contractual requirements in this area are complex, frequently modified, and subject to administrative discretion and judicial interpretation.

Noncompliance with such laws may result in enforcement and other actions, including civil and criminal penalties, substantial financial liabilities (including treble damages under the False Claims Act), and exclusion from participation in federal and state health care programs. Additionally, private individuals have brought and may bring *qui tam*, or "whistleblower," suits under the False Claims Act, which authorizes the payment of a portion of any recovery to the individual bringing suit. Any changes to such laws, and the implementation of any regulations that would eliminate the anti-kickback regulatory safe harbors on which we rely, may impact our ability to engage in certain arrangements, such as price concessions, including rebates, that are offered by pharmaceutical manufacturers to plan sponsors or PBMs under the Medicare Part D program.

Government Procurement Regulations

The Cigna Group is required to comply with applicable federal and state procurement laws and regulations which govern eligibility, bidding, contract performance, and ongoing operational obligations for entities participating in government purchasing and contracting activities. As an example, we have a contract with the DHA that subjects us to applicable Federal Acquisition Regulations ("FAR") and the FAR Supplement, which govern federal government contracts. Further, there are other federal and state laws applicable to our DHA arrangement and our arrangements with other clients that may be subject to government procurement regulations. In addition, certain of our clients participate as contracting carriers in the Federal Employees Health Benefits Program administered by the OPM, which includes various pharmacy benefit management standards.

Laws and Regulations Affecting Pharmacy Benefit Plan Design, Administration and Pharmacy Network Access

The federal government and states have laws, regulations and guidance that affect our ability, or our clients' ability, to limit access to pharmacy provider networks or that prohibit plan sponsors from implementing certain network and benefit plan design features, including provisions relating to the pharmacy benefit. These laws can negatively impact the use of cost-saving network and benefit configurations for plan sponsors or affect access. One state recently enacted legislation prohibiting PBMs from owning or operating pharmacies within the state, which affects vertically integrated entities such as ours and is currently the subject of ongoing litigation. Similarly, the federal government and some states have issued laws, regulations and guidance that impose restrictions and generate additional costs by limiting our ability to maximize efficiencies that could otherwise be gained through certain prescription and refill processes or by imposing mandated coverage of certain benefits, conditions or U.S. Food and Drug Administration ("FDA")-approved drugs that may also restrict certain therapeutic interventions.

Pharmacy Benefit Manager and Drug Pricing Regulation

Our pharmacy benefit management services are subject to numerous laws and regulations that govern critical practices, including disclosure, receipt and retention of rebates and other payments received from pharmaceutical manufacturers; certain pharmacy contracting practices, including disclosure of cost information to customers; pharmacy reimbursement mandates; the receipt and

retention of transmission fees from contracted pharmacies; performance-based price concessions; pharmacy price concessions to drug prices at the point of sale; audits of contracted pharmacies; use of, administration of or changes to drug formularies, the use and disclosure of maximum allowable cost ("MAC") pricing, or clinical programs; "most favored nation" pricing, which provides that a pharmacy participating in a specific government program must give the program the best price the pharmacy makes available to any third-party plan; disclosure of data to third parties; drug utilization management practices; the level of duty a PBM owes its clients or customers; configuration of pharmacy networks; the operations of our subsidiary pharmacies; fiduciary requirements; referrals to affiliated pharmacies; disclosure of negotiated provider reimbursement rates; disclosure of negotiated drug rebates; calculation of certain customer cost-share for prescription drug claims; pricing that includes differential or spread (i.e., a difference between the drug price charged to the plan sponsor by a PBM and the price paid by the manager to the dispensing provider); disclosure of fees associated with administrative service agreements and patient care programs that are attributable to customers' drug utilization; utilization management; and registration or licensing of PBMs.

Pharmacy and Pharmaceutical Distribution Regulation

We are licensed to do business as a pharmacy in the states in which our pharmacies are located, and the health care professionals who we employ are also licensed by, and subject to the laws and regulations of, state boards of pharmacy and other governmental authorities. Participation in Medicare and Medicaid programs requires our pharmacies to comply with the applicable Medicare and Medicaid provider rules and regulations and exposes the pharmacies to reimbursement, claims submission, pricing and other changes. In addition to the health care fraud and abuse laws and the privacy and security laws described above, our home delivery and specialty pharmacy operations are also subject to extensive federal and state laws and regulations that govern the labeling, packaging, repackaging, compounding, storing, holding, disposal, distribution, advertising, misbranding, adulteration, transfer, handling and security of prescription drugs and the dispensing of prescription, over-the-counter, hazardous and controlled substances, as well as laws enforced by the U.S. Drug Enforcement Administration, the FDA, state-controlled substance authorities, the FTC and the United States Postal Service. Violations of pharmacy laws and regulations may result in warning letters, civil and criminal penalties, seizures, suspension, termination or revocation of licenses and registrations, restrictions on facilities or operations, and other enforcement actions.

Certain of our subsidiaries engage in pharmaceutical distribution operations, which are subject to state and federal licensing, reporting and compliance requirements, including state drug distribution licensing regulations, supply chain security laws and controlled substances monitoring requirements. If we fail to satisfy state or federal regulatory expectations, we could be subject to fines, suspension or revocation of our distributor licenses, restrictions on operation, and other enforcement actions.

Privacy, Security and Data Standards Regulations

On the federal level, we are subject to a number of sector-specific regulations related to the creation, collection, dissemination, receipt, maintenance, protection, use, transmission, disclosure, privacy, confidentiality, security, availability, integrity, disposal and other processing of protected health information ("PHI") and other personally identifiable information ("PII"). The federal Health Insurance Portability and Accountability Act of 1996, as amended, and the regulations that implement such laws (collectively, "HIPAA") impose requirements on covered entities and business associates (and we are both) that address the privacy and security of PHI, regulate permissible uses and disclosures of PHI, and impose breach notification requirements. Violations of HIPAA may result in enforcement actions; civil and criminal penalties; and settlement, resolution and monitoring agreements. State attorneys general may also bring civil actions seeking injunctions or damages in response to violations of HIPAA that threaten the privacy of state residents, and violations of privacy, data-security or HIPAA-related requirements could subject us to private litigants or other claims under state or common law theories. We may also be held liable under HIPAA for violations by our vendors. There can be no assurance that we will not be the subject of an investigation, audit or compliance review regarding our compliance with HIPAA. HIPAA does not preempt more stringent state health privacy laws and regulations, which may protect the health information of certain individuals, such as minors, and certain types of sensitive health information, such as transgender care, HIV/AIDS status, reproductive health information, genetic information, and mental and behavioral health.

Other U.S. federal and state consumer privacy laws typically exempt data and/or entities subject to HIPAA, but several states, such as Washington, Nevada and Connecticut, have enacted privacy laws to protect consumer health data and require consent for the collection, use, sharing and other processing of consumer health data. These laws apply to data that is collected outside the scope of HIPAA. In addition, 19 states have enacted comprehensive state data privacy laws governing certain categories of personal information such as employee and business partner data, website visitor information, and customer data collected by entities not subject to HIPAA. Under these laws, consumer rights to access, correction, and deletion limit how we may collect and process such residents' personal information. All 50 U.S. states have laws requiring companies to notify individuals and state regulatory authorities in the event of certain data breaches. Moreover, the U.S. Congress has considered, and in the future will likely consider, proposals from time to time for comprehensive privacy and data security legislation to which we may be subject if enacted. These laws and others may impact our businesses and practices.

The federal government has also enacted final regulations on interoperability and information blocking to support the seamless and secure access, exchange and use of electronic health information by and between patients, enrollees and entities, such as payors and health care providers. The regulations impact how industry participants, including us, comply with disclosure requirements and share information with individuals and other health care organizations.

The federal Gramm-Leach-Bliley Act and its implementing regulations generally place restrictions on the disclosure of nonpublic information to nonaffiliated third parties and requires financial institutions, including insurers, to provide customers with notice regarding how their nonpublic personal information is used, including an opportunity to "opt out" of certain disclosures. State departments of insurance and certain federal agencies adopted implementing regulations as required by federal law.

Under Section 5 of the Federal Trade Commission Act ("FTC Act"), the FTC has jurisdiction over certain privacy and security practices deemed unfair and deceptive acts and practices in or affecting commerce, which includes unfair and deceptive practices with respect to consumer privacy rights and safeguarding of PHI and PII. In addition to the FTC Act, the FTC also enforces other federal laws relating to consumers' privacy and security. The FTC has also been active with respect to companies' use of data and AI, specifically ensuring fair and equitable use of these tools, and AI remains an FTC area of enforcement focus. More broadly, the federal government has made AI development a priority, with executive orders from successive administrations addressing its adoption and regulation. U.S. state legislatures and regulators are similarly interested in the use of AI, particularly where it may impact decision-making in the delivery of insurance or health care services. A handful of states, such as California, Colorado and Texas, have either passed legislation or issued regulatory guidance concerning AI. Additionally, the National Association of Insurance Commissioners ("NAIC"), an organization of state insurance regulators, established the Innovation, Cybersecurity and Technology Committee to provide a forum for regulators to learn about, monitor and confer on emerging technology issues, including, among others, cybersecurity and AI. State Departments of Insurance, state attorneys general, and other state government agencies and legislatures are increasingly aware and active in providing guidance in the AI space.

The Cybersecurity Information Sharing Act of 2015 encouraged organizations to share cyber threat indicators with the federal government and, among other things, directed HHS to develop a set of voluntary cybersecurity best practices for organizations in the health care industry. States have issued regulations specifically related to cybersecurity, which may differ or conflict from state to state. In October 2017, the NAIC adopted the Insurance Data Security Model Law, which creates rules for insurers and other covered entities addressing data security, investigation and notification of breaches. This includes maintaining an information security program based on ongoing risk assessment, overseeing third-party service providers, investigating data breaches and notifying regulators of a cybersecurity event. As the model law is intended to serve as model legislation only, states will need to enact legislation for the model law to become mandatory and enforceable. To date, 28 states have enacted some form of the model law.

Over the past several years, the federal government has increasingly focused on the cybersecurity requirements applicable to government contractors, including enhanced guidance and regulation. These include compliance with the Privacy Act of 1974, the Defense Federal Acquisition Regulation Supplement cybersecurity requirements, the Cybersecurity Maturity Model Certification (phasing in between November 2025 and November 2028 and based on the National Institute of Standards and Technology ("NIST") standards), the Federal Information Security Modernization Act, and the White House's 2021 Executive Order on Improving the Nation's Cybersecurity.

Certain of our businesses are also subject to the Payment Card Industry Data Security Standard ("PCI DSS"), which is designed to protect credit card account data as mandated by payment card industry entities.

In addition, we are or may become subject to international laws, rules and regulations governing privacy, data protection, information security, AI and wider data regulation, such as the European Union's General Data Protection Regulation ("GDPR"), the European Union Artificial Intelligence Act (the "EU AI Act"), and the Digital Operational Resilience Act, which can be more stringent than those in the United States. Complying with these laws may increase our compliance costs or necessitate changes to our business activities, and any failure to comply could result in regulatory investigations, fines or other penalties. Some non-U.S. jurisdictions are also instituting data residency regulations requiring that data be maintained within the respective jurisdiction or otherwise restricting transfer of personal data across borders unless specified regulatory requirements are met.

Consumer Protection Laws

We engage in direct-to-consumer activities and are therefore subject to federal and state regulations applicable to electronic communications and other consumer protection laws and regulations, such as the Telephone Consumer Protection Act and the CAN-SPAM Act. We face increased risk under such laws and may be subject to consumer or other lawsuits, penalties, enforcement actions and sanctions. The FTC and state attorneys general are also increasingly exercising their regulatory and enforcement authorities in the areas of consumer privacy, including with respect to drug pricing, rebate, formulary or contracting practices, and data security.

State and federal policymakers have taken actions intended to increase transparency and predictability of health care costs for consumers and protect consumers from certain out-of-network surprise bills. For example, the Transparency in Coverage rule issued by HHS, the DOL and the Department of the Treasury now requires most group health plans and health insurance issuers in the individual and group markets to publicly disclose price and cost-sharing information for all items and services to participants and enrollees.

The federal No Surprises Act and state laws prohibit health care providers, in certain situations, from balance billing the patient and require providers to work directly with insurers to agree on out-of-network reimbursement or use defined arbitration processes like independent dispute resolution. These laws and regulations vary in their approach, impacting consumers and the health care system as a whole.

Additionally, most states have consumer protection laws that have been the basis for investigations and multistate settlements relating to financial incentives provided by drug manufacturers to retail pharmacies in connection with product conversion programs. Such statutes have also been cited as the basis for claims or investigations by state attorneys general relative to privacy and data security. Further, states continue to leverage their market conduct examination authority in both the health insurance and PBM contexts, which adds to the regulatory complexity that exists in the health care space.

Employee Retirement Income Security Act

Our domestic subsidiaries sell most of their products and services to sponsors of employee benefit plans that are governed by ERISA. ERISA is a complex set of federal laws and regulations enforced by the IRS and the DOL, as well as the courts. ERISA regulates certain aspects of the relationship between us, the employers that maintain employee welfare benefit plans subject to ERISA and the participants in such plans. Certain of our domestic subsidiaries are also subject to requirements imposed by ERISA affecting claim payment and appeals procedures for individual health insurance and insured and self-insured group health plans and for the insured plans we administer.

Medicare and Medicaid Regulations

Through our subsidiaries, we provide services to Medicare Part D plan sponsors, Medicare Advantage Prescription Drug Plans, and employers and clients offering Medicare Part D benefits to Medicare Part D eligible beneficiaries, including those dually eligible for Medicare and Medicaid benefits ("dual-eligible"). We participate in state Medicaid programs directly or indirectly through our clients that are Medicaid managed care contractors. We also perform certain Medicaid subrogation services and certain delegated services for clients, including utilization management, which are regulated by federal and state laws.

Government-sponsored health care programs are regulated by HHS and its agencies such as CMS, state Medicaid agencies, the HHS-OIG, DOJ, and other federal and state agencies, and we are subject to risks associated with audits of our performance and audits to determine compliance with contracts and regulations. A company's ability to obtain payment (and the determination of the amount of such payments) and retain business is subject to compliance with CMS' numerous and complex regulations and requirements that are subject to administrative discretion, review and enforcement. In July 2025, Congress enacted the Budget Reconciliation Act of 2025, which included provisions affecting Medicare and Medicaid, including measures expected to reduce federal Medicaid spending and modify Medicaid eligibility, among other changes. Noncompliance with state and federal laws and regulations may result in significant consequences, including fines and penalties, exclusion from the Medicare and Medicaid programs, corrections of improper payments and criminal penalties.

On March 19, 2025, the Company completed the HCSC transaction. See Note 5 to the Consolidated Financial Statements for further information.

Office of Foreign Assets Control Sanctions and Anti-Money Laundering

We are also subject to regulation by the Office of Foreign Assets Control of the U.S. Department of the Treasury, which administers and enforces economic and trade sanctions against targeted foreign jurisdictions and regimes based on U.S. foreign policy and national security goals. Certain of our products are subject to the Department of the Treasury anti-money laundering regulations under the Bank Secrecy Act. In addition, we are subject to similar regulations in non-U.S. jurisdictions in which we operate.

Corporate Practice of Medicine and Other Laws

Many states in which our subsidiaries operate limit the practice of medicine to licensed individuals or professional organizations comprised of licensed individuals, and business corporations generally may not exercise control over the medical decisions of physicians. Statutes, regulations, and judicial and regulatory interpretations relating to the practice of medicine, fee-splitting between physicians, and referral sources and similar issues vary widely from state to state and are subject to change and varying interpretations. We believe that our health services operations comply with applicable state statutes regarding corporate practice of medicine, fee-splitting and similar issues. However, any enforcement actions by government officials alleging noncompliance with these statutes could subject us to penalties or restructuring or reorganization of our business.

Financial Reporting, Internal Control and Corporate Governance

State regulators closely monitor the financial condition of licensed insurance companies and HMOs. States regulate the form and content of statutory financial statements, the type and concentration of permitted investments, and corporate governance over financial reporting. Our insurance and HMO subsidiaries are required to file periodic financial reports and schedules with regulators in most of the jurisdictions in which they do business as well as annual financial statements audited by independent registered public accounting firms. Certain insurance and HMO subsidiaries are required to file an annual report of internal control over financial reporting with most jurisdictions in which they do business. Insurance and HMO subsidiaries' operations and financial statements are subject to examination by regulators. Many states have expanded regulations relating to corporate governance and internal control activities of insurance and HMO subsidiaries as a result of model regulations adopted by the NAIC with elements similar to corporate governance and risk oversight disclosure requirements under federal securities laws.

Guaranty Associations, Indemnity Funds, Risk Pools and Administrative Funds

Most states and certain non-U.S. jurisdictions require insurance companies to support guaranty associations or indemnity funds that are established to pay claims on behalf of insolvent insurance companies. Some states have similar laws relating to HMOs. In the United States, these associations levy assessments on member insurers licensed in a particular state to pay such claims. Certain states require HMOs to participate in guaranty funds, special risk pools and administrative funds.

Solvency and Capital Requirements

Many states have adopted some form of the NAIC model solvency-related laws and risk-based capital ("RBC") rules for life and health insurance companies and HMOs. The RBC rules recommend a minimum level of capital depending on the types and quality of investments held, the types of business written, and the types of liabilities incurred. If the ratio of the insurer's adjusted surplus to its RBC falls below statutorily required minimums, the insurer could be subject to regulatory actions ranging from increased scrutiny to conservatorship.

In addition, various non-U.S. jurisdictions prescribe minimum surplus requirements that are based upon solvency, liquidity and reserve coverage measures. Our HMOs and life and health insurance subsidiaries, as well as non-U.S. insurance subsidiaries, are compliant with applicable RBC and non-U.S. surplus rules.

Holding Company Laws

Our insurance companies and most of our HMOs are regulated under state insurance holding company laws and regulations, which are largely based on the NAIC's Insurance Holding Company System Regulatory Act and its companion model regulation. These regulations provide a framework for monitoring risks in insurance groups and generally require registration with the applicable state insurance departments; disclosure of enterprise risk information; and approvals of certain dividends, distributions and affiliate transactions. The regulations also generally require approval for acquisitions of control of an insurance company or HMO and authorize group-wide supervision to assess risk across the holding company structure, including the use of group capital calculation reporting and associated liquidity stress testing. The Cigna Group is subject to such testing as may be required by our lead state regulator.

Marketing, Advertising and Products

In most states, our insurance companies and HMO subsidiaries are required to certify compliance with applicable advertising regulations on an annual basis and comply with certain federal and state marketing, advertising, and communications laws and regulations.

Licensing, Registration and Utilization Management Requirements

Our insurance companies and HMO subsidiaries must be licensed by the jurisdictions in which they conduct business, and our international subsidiaries are often required to be licensed when entering new markets or starting new operations in certain jurisdictions. Additionally, certain subsidiaries contract to provide claim administration, utilization management and other related services for the administration of self-insured benefit plans and may be subject to state third-party administration and other licensing requirements and regulation, as well as URAC and other third-party accreditation requirements.

Certain states have adopted pharmacy benefit management registration, licensure or disclosure laws, which may mandate disclosure of various aspects of our financial practices, including those concerning pharmaceutical company revenue, prescribing processes, and client and provider audit terms. States have begun to enact laws exempting certain providers from pre-authorization requirements of insurers; laws standardizing the process for, and restricting the use of, utilization management rules; and laws shortening the time frames within which prescription drug prior authorization determinations must be made. The inability to apply pre-authorization requirements could lead to increased costs to plan sponsors and issuers by way of the provision of unnecessary services. The licensure requirements for our insurance companies and subsidiaries vary by jurisdiction and are subject to change.

Pharmacy and Professional Practice Requirements

State pharmacy professional practice laws, enforced by state boards of pharmacy, govern both the operation of the pharmacy as a licensed facility and the scope of practice of pharmacists and pharmacy technicians. These laws establish the definition of the “practice of pharmacy,” outlining authorized professional functions such as compounding, dispensing, labeling, drug-therapy management, and patient counseling, while specifying nondiscretionary tasks permitted for pharmacy technicians.

State boards of pharmacy also oversee pharmacy licensure and facility compliance, including requirements related to physical premises, storage conditions, security measures, prescription processing, recordkeeping, and adherence to federal and state controlled-substance standards. State law further defines operational parameters for pharmacies offering clinical services - such as collaborative drug-therapy management, immunization programs, or test-and-treat protocols by establishing relevant documentation, supervision and procedural requirements.

International Regulations

Our operations outside of the United States expose us to laws of multiple jurisdictions and the rules and regulations of various governing bodies and regulators, including those related to the provision of insurance, financial and other disclosures, the provision of health care-related services, corporate governance, privacy, data protection, data mining, data transfer, intellectual property, labor and employment, consumer protection, direct-to-consumer communications activities, tax, anti-corruption, and anti-money laundering. Foreign laws and rules may include requirements that are different from, or more stringent than, similar requirements in the United States.

Our operations in countries outside of the United States are subject to local regulations of the jurisdictions where we operate. In some cases, they are subject to regulations in the jurisdictions where customers reside, and in all cases, they are subject to the Foreign Corrupt Practices Act ("FCPA").

The FCPA prohibits offering, promising, providing or authorizing others to give anything of value to a foreign government official or employee to obtain or retain business or otherwise secure a business advantage. Outside of the United States, we may interact with government officials in several different capacities: as regulators of our insurance business; as clients or partners who are state-owned or partially state-owned; as health care providers who are employed by the government; as hospitals that are state-owned; and as officials issuing permits in connection with real estate transactions. Violations of the FCPA and other anti-corruption laws may result in severe criminal and civil sanctions as well as other penalties. Countries in which we do business also have anti-corruption laws to which we are subject, such as the UK Bribery Act of 2010. As international regulators often share information, any voluntary disclosures of violations may be shared with authorities in other countries, thus potentially exposing companies to liability and potential penalties in multiple jurisdictions.

Anti-money laundering requirements in countries where we do business also may impose obligations to collect certain information about each customer at time of sale or to risk rank each customer to determine possible future money laundering risk.

Item 1A. RISK FACTORS

As a large global health company operating in a complex industry, we encounter a variety of risks and uncertainties, which could have a material adverse effect on our business, liquidity, results of operations, financial condition or the trading price of our securities. You should carefully consider each of the risks and uncertainties discussed below, together with other information

contained in this Form 10-K, including the MD&A. These risks and uncertainties are not the only ones we face. Additional risks and uncertainties not presently known to us or that we currently believe to be immaterial may also adversely affect us. The following risk factors have been organized by category for ease of use; however, many of the risks may have impacts in more than one category. These categories, therefore, should be viewed as a starting point for understanding the significant risks facing us and not as a limitation on the potential impact of the matters discussed. Risk factors are not necessarily listed in order of importance.

Risks Related to Our Business as a Health Company

We must predict, price for and manage health care costs appropriately. We face price competition and other pressures that could compress our margins or result in premiums that are insufficient to cover the cost of services delivered to our customers.

Our profitability depends in part on our ability to accurately predict, price for and effectively manage future health care costs. Relatively small differences between predicted and actual medical costs or utilization rates as a percentage of revenue can result in significant changes in our financial results. In addition to appropriately pricing health care costs, we must accurately manage costs through medical management, product design, negotiation of favorable provider contracts and underwriting criteria. Our health care costs are also affected by external events that we cannot forecast or project and over which we have little or no control, including changes in laws and regulations, costly new treatments, new treatment guidelines, provider billing practices, inflation and changes in customers' health care utilization patterns, pandemics, natural disasters, and other large-scale medical emergencies. If we do not accurately price our health care costs, our business, cash flows, financial condition and results of operations could be materially adversely impacted.

While we compete on the basis of many service- and quality-related factors, we expect that price will continue to be a significant basis of competition. Our client contracts are subject to negotiation as clients seek to contain their costs, including by reducing benefits offered. Increasingly, our clients seek to negotiate performance guarantees that require us to pay penalties if the guaranteed performance standard is not met. Clients can easily move between our competitors and us. Our clients are well-informed and typically have knowledgeable consultants who seek competing bids from our competitors before contract renewal. For example, our Express Scripts client contracts generally have three-year terms and may be subject to periodic renegotiation of pricing terms based on market factors. If one or more of our large clients terminates or does not renew a contract for any reason, or if the provisions of a contract with a large client are modified with terms less favorable to us, our results of operations could be adversely affected, and we could experience a negative reaction in the investment community.

A significant loss of customers or clients resulting from our need to increase or maintain premiums, administrative fees or reimbursement levels could adversely affect our business, cash flows, financial condition and results of operations. In addition, as brokers and benefit consultants seek to enhance their revenue streams, they look to take on services that we typically provide. Each of these events could negatively impact our financial results.

Strong competition within the pharmacy benefit business has generated greater demand for lower product and service pricing, increased revenue sharing, and enhanced product and service offerings. These competitive factors have historically applied pressure on our operating margins and caused many companies, including us, to reduce the prices charged for products and services while sharing with clients a greater portion of the formulary rebates and related fees received from pharmaceutical manufacturers. If we are unable to respond effectively, including through the implementation of a rebate-free model for our pharmacy benefit services clients, these trends could negatively impact our ability to attract or retain clients or sell additional services, which could negatively impact our margins and have a material adverse effect on our business and results of operations. In addition, legislative reforms and regulatory or executive actions related to rebates, reporting, owned pharmacies and other activities may adversely affect our ability to price our pharmacy products and services appropriately, as well as our competitive position, cash flows, financial condition and results of operations.

Premiums in the Cigna Healthcare segment are generally set for a one-year period and are priced well in advance of the date on which the contract commences or renews. Federal and state regulatory agencies may restrict or prevent entirely our ability to implement changes in premium rates or collect certain administrative fees. Fiscal or other concerns related to the government-sponsored programs in which we participate may cause decreasing reimbursement rates, delays in premium payments, restrictions on implementing changes in premium rates or insufficient increases in reimbursement rates. Our participation in health insurance exchanges through our IFP offerings in certain states involves uncertainties associated with mix and volume of business and could adversely affect our results of operations, financial position and cash flows.

We operate in a highly competitive and evolving business environment, and our failure to compete effectively or differentiate our products and services from those of our competitors could materially adversely affect our results of operations, financial position and cash flows.

We operate in a highly competitive, evolving and rapidly changing industry. Industry shifts have resulted and could result from, among other things:

- a large intra- or inter-industry merger or industry consolidation;
- strategic alliances;
- new or alternative business models or new government options or offerings;
- continuing consolidation among physicians, hospitals and other health care providers, as well as changes in the organizational structures chosen by physicians, hospitals and health care providers;
- new market entrants, including those not traditionally in the health services industry;
- the ability of larger employers and clients to contract directly with providers;
- technological changes and rapid shifts in the use of technology, such as telehealth and AI;
- the impact or consequences of legislation, executive actions or regulatory changes including premium rate increases, public debates over drug pricing, government involvement in drug pricing and purchasing, and public debate over current or proposed legislation;
- impacts to distribution channels, including changes to the United States Postal Service or the consolidation of shipping carriers;
- increased drug acquisition cost or unexpected changes to drug pricing trend;
- changes in the generic/biosimilar drug market or the failure of new generic/biosimilar drugs to come to market; and
- changes in utilization of health care, prescription drugs or other covered services and items, including under risk-based contracts in the health benefit management market and for those businesses that utilize risk adjustment methodology.

Any significant shifts in the structure of the industry could alter industry dynamics and adversely affect our ability to attract or retain clients and customers. Our failure to anticipate or appropriately adapt to changes in the industry could negatively impact our competitive position and adversely affect our business and results of operations.

We must remain competitive to attract new customers, retain existing customers and further integrate additional product and service offerings. We are subject to significant market pressures brought about by customer and client needs, legislative and regulatory developments, and other market factors. Our competitors may have greater, better or more established capabilities, resources, market share, reputation or business relationships, or lower profit margin or financial return expectations. Unless we can demonstrate greater value to our clients through innovative and cost-effective product and service offerings in the rapidly changing health care industry, we may be unable to remain competitive, which could have a material adverse effect on our business, results of operations, financial position and cash flows.

Additionally, to succeed in this highly competitive marketplace, we must maintain a strong reputation. Increasingly, our customers, clients and investors consider our efforts on a variety of matters that could impact our stakeholders, including our employees and the communities in which we operate. Our reputation may be negatively impacted by a failure to meet customer expectations for consistent, transparent, high-quality and accessible care or by other significant events, including a failure to execute on customer or client contracts or strategic or operational initiatives, failure to comply with applicable laws or regulations, or failure to innovate and deliver cost-effective products and services that demonstrate greater value to our customers. Negative publicity may come as a result of adverse media coverage, litigation against us and other industry participants, the ongoing public debates over the affordability, accessibility and transparency of health care, and social media and other media relations activities.

Changes in drug pricing or industry pricing benchmarks could materially impact our financial performance.

Contracts in the prescription drug industry, including our contracts with retail pharmacy networks and our pharmacy and specialty pharmacy clients, generally use pricing metrics published by third parties as benchmarks to establish pricing for prescription drugs. If these benchmarks are no longer published by third parties; if we, or our contractual partners, adopt other pricing benchmarks for establishing prices within the industry; if legislation or regulation requires the use of other pricing benchmarks; or if future changes in drug prices substantially deviate from our expectations, the short- or long-term impacts may have a material adverse effect on our business and results of operations. Additionally, laws such as the Inflation Reduction Act have granted CMS the ability to negotiate drug prices for high-cost Medicare Part D and Part B drugs, and other federal and state legislative proposals and executive actions can lead to residual effects as drug companies adjust pricing strategies for broader marketplaces, impacting which medications are prioritized.

If we lose our relationship with one or more key pharmaceutical manufacturers, or if the payments made or discounts provided by pharmaceutical manufacturers decline, our business and results of operations could be adversely affected.

We maintain relationships with numerous pharmaceutical manufacturers, which provide us with, among other things, discounts for drugs we purchase to be dispensed from our home delivery and specialty pharmacies; discounts, in the form of rebates, for drug utilization; fees for administering rebate programs, including invoicing, allocating and collecting rebates; fees for services provided to pharmaceutical manufacturers by our specialty pharmacies; and access to limited distribution specialty pharmaceuticals by our specialty pharmacies.

Our contracts with pharmaceutical manufacturers are typically nonexclusive and terminable on relatively short notice by either party. The consolidation of pharmaceutical manufacturers, the termination or material alteration of our relationships, or our failure to renew contracts on market competitive terms could have a material adverse effect on our business and results of operations. In addition, arrangements between payors and pharmaceutical manufacturers have been the subject of debate in various public and governmental forums. Our announced commitment to developing a rebate-free model may alter manufacturer contracting dynamics. Adoption of new laws, rules or regulations, or changes in - or new interpretations of - existing laws, rules or regulations relating to any of these programs could materially adversely affect our business and results of operations.

If significant changes occur within the pharmacy provider marketplace, or if other issues arise with respect to our pharmacy networks, including the loss of or adverse change in our relationship with one or more key pharmacy providers, our business and results of operations could be adversely affected.

More than 65,000 pharmacies participated in one or more of our networks as of December 31, 2025. The 10 largest retail pharmacy chains represent approximately 47% of the total number of stores in our largest network. In certain geographic areas of the United States, our networks may be comprised of higher concentrations of one or more large pharmacy chains. Contracts with retail pharmacies are generally nonexclusive and are terminable on relatively short notice by either party. If one or more of the larger pharmacy chains terminates its relationship with us, or is able to renegotiate terms substantially less favorable to us, our customers' access to retail pharmacies or our business could be materially adversely affected. We could also face harm to our relationships with large pharmacy chains depending upon changing competitive conditions. Changes in the overall composition of our pharmacy networks, including changes due to legislative, regulatory or executive action, or reduced pharmacy access under our networks, could have a negative impact on our claims volume or our competitiveness in the marketplace, which could cause us to fall short of certain guarantees in our contracts with clients or otherwise materially adversely impact our business or results of operations.

The reserves we hold for expected medical claims are based on estimates that involve an extensive degree of judgment and are inherently variable. If actual claims exceed our estimates, our operating results could be materially adversely affected, and our ability to take timely corrective actions to contain future costs may be limited.

We maintain and record medical claims reserves in our Consolidated Balance Sheets for estimated future payments. Our estimates of health care costs payable are based on a number of factors, including historical claim experience. This estimation process requires extensive judgment. Considerable variability is inherent in such estimates, and the accuracy of the estimates is highly sensitive to a number of factors including, among others, changes in medical claims submission and processing patterns or procedures; changes in customer base and product mix; changes in the utilization of prescription drugs, medical or other covered items or services; changes in medical cost trends; changes in our health management practices; changes in regulations; and the introduction of new benefits and products. If we are not able to accurately and promptly anticipate and detect medical cost trends, our ability to take timely corrective actions to limit future costs and reflect our current benefit cost experience in our pricing process may be limited. Additionally, we must estimate the amount of rebates payable by us under the ACA's and CMS' minimum loss ratio rules and the amounts payable by us to, and receivable by us from, the federal government under the ACA's remaining premium stabilization program. Because establishing reserves is an inherently uncertain process involving estimates of future losses, there can be no certainty that ultimate losses will not exceed existing reserves, which may adversely affect our results of operations, financial position and cash flows.

If we fail to develop and maintain satisfactory relationships with health care payors, physicians, hospitals and other health service providers and with, producers and consultants, our business and results of operations may be adversely affected.

We contract with or employ physicians, hospitals and other health service providers and facilities to provide health services to our customers and patients. We also contract with health care payors (as a service provider to those payors). Our results of operations depend on our ability to contract for these services at competitive prices. In any particular market, physicians, hospitals and health service providers may enter into exclusive arrangements with competitors or simply refuse to contract with us, demand higher payments, or take other actions that could result in higher medical costs or less desirable products or services for our customers. In some markets, certain providers, particularly hospitals, physician/hospital organizations and multi-specialty physician groups, may have significant or controlling market positions that could result in a diminished bargaining position for us. If providers refuse to

contract with us, use their market position to negotiate more favorable contracts or place us at a competitive disadvantage, our ability to market products or to be profitable in those areas could be materially adversely affected. Additionally, certain regulations may impact our ability to obtain competitive prices. We establish collaborative care arrangements with physician groups, specialist groups, independent practice associations, hospitals and health care delivery systems to improve quality outcomes and medical cost performance. If such collaborative arrangements do not result in the lower medical costs that we project or do not improve value to our customers and clients, if we fail to attract health care providers to such arrangements or if we are less successful at implementing such arrangements than our competitors, our attractiveness to customers may be reduced and our ability to profitably grow our business or improve value for our customers, patients and clients may be adversely affected.

Our ability to develop and maintain satisfactory relationships with providers may also be negatively impacted by other factors not associated with us, such as increasing pressure on revenue and other pressures on health care providers; increasing consolidation activity among hospitals, physician groups and providers; and changes in Medicare or Medicaid reimbursement levels or programming. Many factors, including continuing consolidation among physicians, hospitals and other providers; the growth of accountable care organizations; vertical integration of providers and other entities; changes in the organizational structures chosen by physicians, hospitals and providers; new market entrants, including those not traditionally in the health services industry; and the use of new modes of health care delivery, including virtual care services, may affect the way providers interact with us and may change the competitive landscape in which we operate. In some instances, these organizations may compete directly with us, potentially affecting the way we price our products and services or causing us to incur increased costs if we change our operations to be more competitive.

Out-of-network providers for non-Medicare services are not limited by any agreement with us in the amounts they bill. While benefit plans place limits on the amount of charges that will be considered for reimbursement and regulations seek to prescribe payment levels, establish methodologies and dispute resolution processes, the outcome of disputes where we do not have a provider contract may cause us to pay higher medical or other benefit costs than we project.

Additionally, our products and services, including a broad range of medical, pharmacy, specialty health, and ancillary benefit offerings, are sold in part through non-exclusive producers and consultants for whose services and allegiance we compete. Our sales could be materially adversely affected if we are unable to attract, retain and support such independent producers and consultants or if our enterprise sales strategy is not appropriately aligned across product lines and producer relationships.

In managing medical practices and operating pharmacies, onsite clinics and other types of medical facilities, we may be subject to additional liability that could result in significant time and expense.

In addition to contracting with physicians and other health care providers for services, we employ physicians, pharmacists, nurses and other health care providers at our home delivery and specialty pharmacies, onsite low-acuity and primary care practices that we manage and operate for our customers, and certain clinics for our employees. We also provide virtual primary care, urgent care, dermatology services and behavioral health services through clinicians that we employ, as well as through third-party contractors. As such, we may be subject to liability for certain acts, omissions or injuries caused by our employees or agents, or that occur at one of these practices, pharmacies or clinics. The defense of any actions may require diverting personnel and other resources and incurring significant costs that could have a material adverse effect on our business, results of operations, financial condition, liquidity and reputation.

There are various risks associated with participating in government-sponsored programs and providing services to payors who participate in government-sponsored programs, including dependence upon government funding, compliance with government contracts, and increased regulatory oversight and enforcement.

Our Evernorth Health Services business provides services to government entities and payors participating in government health care programs, and our relationships with these government entities are subject to laws and regulations regarding government contracts. Additionally, through our U.S. Healthcare business, we contract with CMS and various state government agencies.

Our revenues from government-funded programs, including our government clients, are dependent, in whole or in part, upon annual funding from the federal government or applicable state or local governments. Funding for these programs is dependent on many factors outside our control, including general economic conditions, continuing government efforts to contain health care costs, budgetary constraints at the federal or applicable state or local level, and general political issues and priorities. These entities generally have the right to not renew or to cancel their contracts with us on short notice without cause or if funds are not available. Unanticipated changes in funding, such as the application of sequestration by the federal or state governments, retroactive rate adjustments, a delay by Congress in raising the federal debt ceiling, or the failure to provide for continued appropriations or regular ongoing scheduled payments to us, could substantially reduce our revenues or profitability or impact our liquidity.

Additionally, if we fail to comply with applicable state or federal regulatory or contractual requirements, including data submission, enrollment and marketing, provider network adequacy, provider directory accuracy, quality measures, claims payment, continuity of care, timely and accurate processing of appeals and grievances, oversight of first-tier downstream and related entities, and call center performance, we may be subject to administrative actions, including enrollment sanctions or contract termination, fines or other penalties or enforcement actions that could materially impact our profitability.

Legal, Regulatory and Public Policy Risks Arising from Our Business

Our business is subject to substantial government regulation, and new laws or regulations or changes in existing laws or regulations could have a material adverse effect on our business, results of operations, financial condition and liquidity.

Our business is regulated at the federal, state and international level. The laws and rules governing our business and related interpretations are increasing in number and complexity, are subject to frequent change, and can be inconsistent or in conflict with each other. Noncompliance with applicable regulations by us or third-party vendors could have material adverse effects on our business, results of operations, financial condition, liquidity and reputation.

We must identify, assess and respond to new trends in the legislative and regulatory environment, as well as comply with the various existing laws and regulations applicable to our business and respond to policymakers and enforcement agencies accordingly. We expect federal and state governments to continue to enact legislative and regulatory reforms that will or could materially impact various aspects of the health services system, including pharmacy benefits manager, drug pricing or insurance market reforms. These reforms could result in material changes to the way we conduct our business and could impact the market for our products.

Existing or future laws, regulations, actions by governmental or regulatory authorities, or judgments could force us to change how we conduct our business; affect the products and services we offer and where we offer them; restrict revenue and enrollment growth; increase our costs, including medical, operating, health care technology and administrative costs; increase our liability; and require enhancements to our compliance infrastructure and internal controls environment. For example, we are required to obtain and maintain approvals from state boards of pharmacy, departments of insurance, and other federal and state regulatory agencies to, among other things, market many of our products, expand into additional geographic or product markets, increase prices for certain regulated products, and consummate some of our acquisitions and dispositions. Delays in obtaining or failure to obtain or maintain these approvals could reduce our revenue or increase our costs. Additionally, we must maintain licenses and registrations in the jurisdictions in which we conduct business, and the suspension, material adverse modification or termination of such licenses and registrations could adversely affect operations. Such licensure subjects many of our business operations and products to state regulation, as well as risks associated with doing business in those jurisdictions. Failure to effectively implement or adjust our strategic and operational initiatives, such as reducing operating costs, adjusting premium pricing or benefit design, or transforming our business model in response to new laws, regulatory changes or executive actions may have a material adverse effect on our results of operations, financial condition and cash flows.

Our effective tax rate or tax payments could also be adversely affected by new laws or regulations, both within the United States and in other foreign jurisdictions in which we operate. While we believe that our historical tax positions are consistent with applicable laws, regulations and existing precedent, our tax positions could be challenged by relevant tax authorities, and we may not be successful in any such challenge. The market price of our securities may react to the announcement of such proposals.

Customers, investors, employees and other stakeholders have focused on corporate governance, environmental stewardship and social matters. Environmental, social and governance-related laws and regulations, including those aimed at restricting the consideration of these factors by companies and requiring climate- and sustainability-related disclosures, and related stakeholder expectations have resulted, and may in the future result, in increased expenses and management time and attention spent complying with or meeting such laws, regulations or expectations. Overall, environmental, social and governance matters, and related stakeholder reactions, which may be conflicting or divergent, may impact our reputation and have other business impacts which could adversely affect our business.

For more information on regulations affecting our business, see "Business – Regulation" in Part I, Item 1 of this Form 10-K.

If we fail to comply with applicable privacy, security and data laws, regulations and standards, our business and reputation could be materially adversely affected.

Most of our activities involve the receipt, use, storage, transmission or other processing of a substantial amount of PII, including PHI, as well as financial information (including payment card information) and other confidential and sensitive information about our clients and employees. The processing of such information is regulated at the federal, state, international and industry levels, and requirements are imposed on us by industry standards and contracts with clients. In some cases, such laws, rules, regulations, industry

standards and contractual requirements also apply to our vendors and require us to obtain written assurances of their compliance with such requirements.

At the federal level, we are subject to, among other laws and regulations, HIPAA, which requires business associates as well as covered entities to comply with specified privacy and security requirements. While we endeavor to provide appropriate protections through our contracts with our third-party service providers and in certain cases assess their security controls, we have limited oversight or control over their actions and practices. Several of our businesses act as business associates to their covered entity clients and, as a result, collect, receive, use, disclose, transmit and maintain PHI in order to provide services to these customers. If HHS alleges or finds noncompliance with HIPAA requirements or implements an enforcement action against us, it could have an adverse effect on our results of operations, financial position, cash flows and reputation. For example, in 2025, we responded to a voluntary HIPAA security rule audit from HHS's Office for Civil Rights ("OCR"). As participation in this audit was voluntary, the information provided did not result in any HIPAA enforcement action or civil monetary penalty; however, any serious compliance issues could open up subsequent compliance reviews that could include a range of remedies from OCR.

Additionally, we are, or may become, subject to U.S. state and international laws and regulations, as well as industry standards such as PCI DSS. These laws, regulations, rules, industry standards and contractual requirements are subject to change and the regulatory environment surrounding data security and privacy is increasingly demanding. Compliance with existing or new privacy, security and data laws, regulations and requirements may result in increased operating costs and may constrain or require us to alter our business model or operations. For more information on privacy regulations to which we are subject, see "Business – Regulation" in Part I, Item 1 of this Form 10-K.

Noncompliance or findings of noncompliance with applicable laws, regulations or requirements, or the occurrence of any privacy or security breach involving the misappropriation, loss or other unauthorized disclosure of PII, whether by us or by one of our third-party service providers, could materially adversely affect our business and reputation, including our results of operations, financial position and cash flows.

We face risks related to litigation, regulatory audits and investigations.

We are routinely involved in legal matters arising from our health services business, including but not limited to claims related to the dispensing of pharmaceutical products by our home delivery and specialty pharmacies; pharmacy benefit management services, such as formulary management services; health benefit management services; and provider services. Our pharmacy services operations are subject to liability arising from clinical quality, patient safety and other risks inherent in the dispensing, packaging and distribution of drugs, including claims related to purported dispensing and other operational errors.

We also have incurred and likely will continue to incur liability for practices and claims related to our health care business, such as marketing misconduct; failure to timely or appropriately pay for or provide health care services; provider network structure; poor outcomes for care delivered or arranged; provider disputes, including disputes over compensation or contractual provisions; ERISA claims; allegations related to calculations of cost-sharing; and claims related to our administration of self-funded business.

In addition, we are routinely involved in numerous claims, lawsuits, regulatory audits, investigations and other legal matters arising, for the most part, in the ordinary course of business. These legal matters could include civil claims (including tort and breach of contract claims) as well as claims arising from alleged violations of certain laws (such as consumer protection or false claims act laws). There are currently, and may be in the future, attempts to bring class action lawsuits against the Company and other companies in our industry; individual plaintiffs also may bring multiple claims regarding the same subject matter against us and other companies in our industry.

In addition, various government agencies have conducted investigations, inquiries and audits into certain pharmacy benefit management practices, which in certain instances have resulted in litigation or other adverse outcomes for our Company. For example, the FTC has released two staff reports on PBMs and the accessibility and affordability of prescription drugs. In September 2024, the FTC filed an administrative complaint against Express Scripts and two other PBMs, among others, for allegedly engaging in anticompetitive and unfair rebate practices related to insulin drug pricing. In February 2026, we reached a final settlement with the FTC, which resolved all FTC matters and litigation without a monetary penalty, finding of fault or admission of liability. The settlement requires, among other things, updates to our business practices related to affordability of medications of Express Scripts customers.

We are frequently the subject of regulatory market conduct and other reviews, audits and investigations by state insurance, health and welfare and pharmacy departments; attorneys general; the DOJ; the FTC; CMS; the DOL; the HHS-OIG; and comparable authorities in foreign jurisdictions. Additionally, we have previously been, and may in the future be, subject to *qui tam* actions in which the government may or may not intervene. Although our Medicare Advantage and Medicare Part D businesses were included in the HCSC

transaction, we may have indemnification obligations in certain circumstances related to regulatory audits that were ongoing at the time that transaction was completed. There also continues to be heightened review by federal and state regulators of business and reporting practices within the health services industry, including with respect to claims payment and related escheat practices, and increased scrutiny by other federal and state governmental agencies (such as state attorneys general) empowered to bring criminal actions in circumstances that could have previously given rise only to civil or administrative proceedings.

Court decisions and legislative and regulatory activities may increase our exposure to any type of claim. In some cases, substantial noneconomic or punitive damages may be sought. We procure insurance coverage to cover some of these potential liabilities, and we also self-insure a significant portion of our litigation risks. While we maintain some third-party insurance coverage, including excess liability insurance with third-party insurance carriers, certain liabilities or types of damages, such as punitive damages, may not be covered by insurance, insurers may dispute coverage, or the amount of insurance may be insufficient to cover the entire damages awarded. Resolving disputes is often expensive and disruptive, regardless of the outcome. Additionally, it is possible that the resolution of current or future legal matters and claims could result in changes to our industry and business practices, losses material to our results of operations, financial condition, and liquidity or damage to our reputation.

Moreover, regulatory investigations and audits have resulted in, and could result in, sanctions or changes to our business practices, including retroactive adjustments to certain premiums, corporate integrity agreements, restrictions on our ability to participate in government programs or exclusion from such programs, and our ability to market certain products or engage in business-related activities. We cannot predict what effect, if any, such government investigations and audits may ultimately have on us or on the industry in general. However, we will likely continue to experience government scrutiny and audit activity, which has resulted in, and may result in, civil penalties. Any failure, or alleged failure, to comply with various state and federal health care laws and regulations, including those directed at preventing fraud, waste and abuse in government-funded programs, has resulted in, and could in the future result in, investigations or litigation, such as actions under the federal False Claims Act and similar whistleblower statutes under state laws.

In addition, disclosure of an adverse investigation or audit or the imposition of fines or other sanctions could negatively affect our reputation in certain markets and make it more difficult for us to sell our products and services.

A description of material pending legal actions and other legal and regulatory matters is included in Note 22 to the Consolidated Financial Statements included in this Form 10-K. The outcome of litigation and other legal or regulatory matters is always uncertain.

Extensive health care regulation and enforcement, including fraud, waste and abuse laws, could increase our compliance costs, restrict our operations and expose us to significant liability.

Federal and state governments have made investigating and prosecuting health care and other insurance fraud, waste and abuse a priority. Fraud, waste and abuse prohibitions encompass a wide range of activities, including kickbacks for referral of customers, billing for unnecessary medical services, improper marketing and violations of patient privacy rights. Some of our businesses are also subject to federal and state laws and regulations that may impact our relationships with health care providers and customers, including laws on self-referrals, beneficiary inducements, false claims, fee-splitting, telemedicine, corporate practice of medicine, dispensing, packaging, fulfillment and distribution of controlled substances, other pharmaceutical products and medical devices, medical malpractice, consumer protection, product liability, narrow networks, provider tiering programs, provider contracts, overpayments, reimbursement of out-of-network claims, and licensure. The regulations and contractual requirements applicable to us are complex and subject to change and may affect our ability to market or provide our products or services. In addition, ongoing vigorous law enforcement, a highly technical regulatory scheme, and the Dodd-Frank Act and related regulations enhance regulators' enforcement powers and whistleblower incentives and protections. Our compliance efforts in this area will continue to require significant resources, and failure to comply with such regulation could adversely affect our reputation and also expose us to litigation and other proceedings, fines and penalties.

Operational Risks

Our business depends on our ability to effectively invest in, improve and properly maintain the uninterrupted operation, availability and data integrity of our information technology and other business systems.

Our business is highly dependent on maintaining effective information systems, as well as the integrity and timeliness of the data we use to serve our customers and health care providers and to operate our business. If our data were found to be inaccurate or unreliable due to fraud or other error, or if we, or any of the third-party providers or subcontractors that we or they engage, were to fail to maintain information systems and data integrity effectively, we could experience operational disruptions that may impact our clients, customers and health care providers and hinder our ability to provide or establish appropriate pricing for products and services, retain

and attract clients and customers, establish reserves, report financial results accurately and in a timely manner, and maintain regulatory compliance, among other things.

Any failure or disruption of our performance of, or our ability to perform, key business functions, including through unavailability or cyberattack of our information technology systems or those of third parties (including cloud service providers), could cause slower response times, decreased levels of service satisfaction and harm to our reputation. Our systems interface with and depend on third-party systems, and we could experience service denials if demand for such service exceeds capacity or a third-party system fails or experiences an interruption.

While we have adopted, and continue to enhance, business continuity and disaster recovery plans and strategies, there is no guarantee that such plans and strategies will be effective, which could interrupt the functionality of our information technology systems or those of third parties. Our failure to implement adequate business continuity and disaster recovery strategies could significantly reduce our ability to provide products and services to our customers and clients, which could have material adverse effects on our business and results of operations.

Our information technology strategy and execution are critical to our continued success. We must continue to invest in and maintain long-term solutions that will enable us to anticipate customer needs and expectations, enhance the customer experience, act as a differentiator in the market, and protect against cybersecurity risks and threats or other events that could disrupt our information technology systems. Our success is dependent, in large part, on maintaining the effectiveness of existing technology systems and continuing to deliver and enhance technology systems that support our business processes in a cost- and resource-efficient manner. Increasing regulatory and legislative changes will place additional demands on our infrastructure that could have a direct impact on resources available for other strategic initiatives. In addition, recent trends toward greater consumer engagement in health care require new and enhanced technologies, including applications for mobile devices. Connectivity among technologies is becoming increasingly important. We must also develop new systems to meet current market standards and keep pace with continuing changes in information processing technology, evolving industry and regulatory standards, and customer needs. Failure to do so may present compliance challenges and impede our ability to deliver services in a competitive manner. Further, because system development projects are long-term in nature, they may be more costly than expected to complete and may not deliver the expected benefits upon completion. Our failure to effectively invest in, implement improvements to and properly maintain the uninterrupted operation, availability and data integrity of our systems could adversely affect our results of operations, financial position, cash flow and internal controls over financial reporting.

As a large global health company, we and our vendors are subject to cyberattacks or other privacy or data security incidents. If we are unable to prevent or contain the effects of any such attacks, or fail to ensure vendors do the same, we may suffer exposure to substantial liability, reputational harm, loss of revenue or other damages.

Our business depends on our clients' and customers' willingness to entrust us with their PII, including PHI, that is subject to various privacy and data security laws and regulations, including data breach notification laws. Computer networks or systems may be vulnerable to intrusion, hacking, computer viruses or malware (including ransomware), denial of service attacks, credential stuffing, phishing and other social engineering attacks, supply chain attacks, programming errors, fraud or malice on the part of our employees or vendors, human error, terrorism, and other attacks by third parties or similar disruptive problems. We have been, and will likely continue to be, the target of computer viruses or other malicious codes, unauthorized access, cyberattacks or other computer-related penetrations. There have been, and will continue to be, large-scale cyberattacks within the health services industry. For example, Change Healthcare, a health technology company owned by UnitedHealth Group and a service provider for certain of our pharmacy benefit management services, was the victim of a ransomware attack in February 2024. This resulted in limited disruption of certain of our services and necessitated security validations for certain systems before we reconnected with Change Healthcare to resume such services. Additionally, hardware, software or applications we develop or procure from third parties may contain defects in design, manufacturer defects, software bugs or errors or other problems that could unexpectedly compromise information technology. Human or technological error has resulted in, and could in the future result in, for example, unauthorized access to and acquisition, disclosure, modification, misuse, loss or destruction of company, customer, or other third-party data or systems; theft of sensitive, regulated or confidential data, including PII and intellectual property; the loss of access to critical data or systems through ransomware, destructive attacks or other means; and business delays, service or system disruptions, or denials of service.

As we increase the amount of PII that we store and share digitally, our exposure to unauthorized uses and disclosures and data privacy and related cybersecurity risks increases, including the risk of undetected attacks, damage, loss, or unauthorized access or acquisition or misappropriation of proprietary information or PII. The cost of attempting to protect against these risks also increases. The health care data ecosystem is complex and requires data exchange with vendors, business partners, health care professionals, the government and others. If disruptions, data disclosures, security incidents or breaches are not detected quickly, their effect could be compounded. We have dedicated significant resources to implement privacy and security technologies, processes and procedures to protect PII and

provide employee awareness training around phishing, malware and other cyber risks; however, such measures may not be effective against all types of security incidents.

Cybersecurity threats are rapidly evolving, and those threats and the means for obtaining access to our proprietary systems are becoming increasingly sophisticated. Cyberattacks can originate from a wide variety of sources, including terrorists; nation states; nation-state supported actors; organized criminal groups; “hacktivists;” internal actors; or third parties, such as external service providers. The techniques used change frequently or are often not recognized until after they have been launched. For example, there continues to be an increase in new financial fraud schemes akin to ransomware attacks on large companies, whereby a cybercriminal installs a type of malicious software, or malware, that prevents a user or enterprise from accessing computer files, systems or networks and demands payment of a ransom for their return. Such threats also may see their frequency increased, and effectiveness enhanced, by the use of AI. Those parties may also attempt to fraudulently induce employees, customers or other users of our systems to disclose or inadvertently provide access to systems in order to gain access to our data or that of our customers. In addition, while we have certain standards for all vendors that provide services to us, our vendors and, in turn, their own service providers may become subject to the same types of security breaches. Finally, our offices may be vulnerable to security incidents or security attacks, acts of vandalism or theft, misplaced or lost data, human error or similar events that could negatively affect our systems and our customers' and clients' data.

The costs to eliminate or address security threats and vulnerabilities before or after a cyber incident could be significant. Our remediation efforts may not be successful and could result in interruptions, delays or cessation of service and loss of customers. As security threats continually evolve, we may be required to devote additional resources to modify or enhance our operational or security systems and networks and our cybersecurity program.

In addition, the unauthorized access to and the acquisition, use, disclosure or dissemination of information about us, our customers or other third parties could expose our customers and their private information to the risk of financial or medical identity theft. Unauthorized access to and the acquisition, use, disclosure or dissemination of information about our business and strategy could also negatively affect the achievement of our strategic initiatives. Such events could cause us to breach our contractual obligations and violate applicable laws. Any actual or perceived data security incident could negatively affect our ability to compete, our reputation, our customer base and our revenues and could expose us to mandatory disclosure requirements; government investigations, litigation and other enforcement proceedings; material fines, penalties or remediation costs; compensatory, special, punitive or statutory damages; consent orders; or other adverse actions, any of which could adversely affect our business, results of operations, financial condition or liquidity.

Our use of artificial intelligence and machine learning present regulatory and legal challenges that could negatively affect our business and our reputation.

Our use of AI and ML technologies, as well as more recent technological advances in AI/ML, pose risks to us and subject us to new and existing laws and regulations. The use of generative AI, a relatively new and emerging technology still in the early stages of commercial use, potentially exposes us to additional risks, such as damage to our reputation, competitive position, and business, legal and regulatory risks and additional costs. For example, generative AI has been known to produce false or “hallucinatory” inferences or output. Certain generative AI uses ML and predictive analytics, which can produce inaccurate, incomplete or misleading content; unintended biases and other discriminatory or unexpected results; or errors and inadequacies, any of which may not be easily detectable by us or any of our related service providers. Accordingly, while AI systems may help provide more tailored or personalized user experiences, if the content, analyses or recommendations that AI systems assist in producing on our platform are, or are perceived to be, deficient, inaccurate, biased, unethical or otherwise flawed, our reputation, competitive position and business may be materially and adversely affected.

While we are committed to responsible use of AI/ML and following applicable laws and regulations, and while we have made progress developing governance as to use of AI/ML by our organization, any failure to use AI/ML responsibly and to adhere to such laws, regulations and governance could have a material unfavorable effect on our business, results of operations and financial condition. Depending on how existing laws and regulations are interpreted, and as new laws go into effect, we may have to make changes to our business practices to comply with such obligations. These obligations may make it harder for us to conduct our business using AI/ML, lead to regulatory fines or penalties, require us to retrain our AI/ML, require us to comply with outside standards, or cease or limit our use of AI/ML. We may not be able to adequately anticipate or respond to these evolving laws and regulations, and we may need to expend additional resources to adjust our offerings in certain jurisdictions if applicable legal frameworks are inconsistent across jurisdictions. Moreover, because these technologies are highly complex and rapidly developing, it is not possible to predict all of the legal or regulatory risks that may arise relating to our use of such technologies.

Our use of AI/ML technologies has resulted and could continue to result in additional compliance costs, regulatory investigations and actions, and lawsuits. For example, we are currently subject to litigation claiming that we improperly used AI in the claims evaluation

process. If we are unable to use AI/ML, or if regulators restrict our ability to use AI/ML for certain purposes, it could make our business less efficient, result in competitive disadvantages, and subject us to potentially unfavorable business impacts. To the extent that we rely on or use the output of AI/ML, any inaccuracies, biases or errors could have unfavorable impacts on us, our business, and our results of operations or financial condition. The impact of regulatory and legal risks associated with AI/ML is largely unknown.

We are dependent on the success of our relationships with third parties for various services and functions.

To improve operating costs, productivity and efficiencies, we contract with third parties for the provision of specific services. Our operations may be adversely affected if a third party fails to satisfy its obligations, if the arrangement is terminated in whole or in part, or if there is a contractual dispute between us and the third party. Even though contracts are intended to provide certain protections, we have limited control over the actions of third parties. For example, noncompliance with any privacy or security laws and regulations, any security breach involving one of our third-party vendors, or a dispute between us and a third-party vendor related to our arrangement could have a material adverse effect on our business, results of operations, financial condition, liquidity and reputation.

Outsourcing also may require us to change our existing operations, adopt new processes for managing these service providers, or redistribute responsibilities to realize the potential productivity and operational efficiencies. Delays or difficulties in changing business processes, or the failure of our third-party vendors to perform as expected, may prevent us from realizing the anticipated economic and other benefits of these relationships, whether on a timely basis or at all. This could result in additional costs or regulatory compliance issues or create other operational or financial problems for us. Terminating or transitioning, in whole or in part, arrangements with key vendors could result in additional costs or penalties, risks of operational delays, or potential errors and control issues during the termination or transition phase. We may not be able to find an alternative vendor in a timely manner or on acceptable terms. If there is an interruption in business or loss of access to data resulting from a security breach, termination or transition in services, we may not be able to meet the demands of our customers and, in turn, our business, liquidity and results of operations could be adversely impacted.

A significant disruption in service within our operations or among our key suppliers or other third parties could materially adversely affect our business, liquidity and results of operations.

Our business is highly dependent upon our ability to perform, in an efficient and uninterrupted fashion, necessary business functions, such as claims processing and payment; the operation of internet support and customer call centers, data centers and corporate facilities; the processing of new and renewal business; the maintenance of appropriate shipment and storage conditions for prescriptions (such as temperature and protection from contamination); and home delivery processing. In some instances, our ability to provide services or products (including processing and dispensing prescriptions) depends on the availability of services and products provided by suppliers, providers, pharmaceutical manufacturers, vendors or shipping carriers. A disruption, or threat of disruption, in our supply chain, or an inability to access or deliver products that meet requisite quality safety standards and patient needs in a timely and efficient manner, could adversely impact our business. Increasing natural disasters in connection with climate change could also be a direct threat to us and our third-party vendors, service providers or other stakeholders. Natural disasters have impacted, and may continue to impact, our customers and pose a risk to our employees and facilities located in the affected region. Responses to such scenarios have included and may include, among other things, making temporary policy changes, such as waiving various medical requirements; assisting with replacement medications; transferring prescriptions; and expanding our help line.

We face political, legal, operational, regulatory, economic and other risks in connection with our international operations.

As a global company, our business is increasingly exposed to risks inherent in foreign operations, including challenges arising out from geopolitical conditions, evolving legal and regulatory environment, labor and cultural practices, local civil unrest or political controversy, and foreign currency exchange fluctuations. These factors may increase in significance as we continue to expand globally, and operating in new foreign markets may require considerable management time before operations generate any significant revenues and earnings. Any one of these challenges could negatively affect our operations or long-term growth.

International operations also require us to devote significant resources to implement controls and systems in new markets to comply with, and to ensure that our vendors and partners comply with, U.S. and foreign laws prohibiting bribery, corruption and money laundering, in addition to other regulations regarding, among other things, our products, direct-to-consumer communications, customer privacy, data protection and data residency. Violations of these laws and regulations could result in fines; criminal sanctions against us, our officers or employees, restrictions or outright prohibitions on the conduct of our business; and significant reputational harm. Our success depends, in part, on our ability to anticipate these risks and manage these challenges. Our failure to comply with laws and regulations governing our conduct outside of the United States, or to establish constructive relations with non-U.S. regulators, could have a material adverse effect on our business, results of operations, financial condition, liquidity and long-term growth. Please see "—Legal, Regulatory and Public Policy Risks Arising from our Business" above.

Strategic transactions involve risks, and we may not realize the expected benefits because of integration or separation difficulties, underperformance relative to our expectations, and other challenges, which could lead to an impairment charge.

As part of our strategy, we regularly consider and enter into strategic transactions, including mergers, acquisitions, joint ventures, licensing arrangements, divestitures and other relationships (collectively referred to as "strategic transactions"). The risks we may face with respect to such strategic transactions include:

- significant competition for attractive targets and opportunities, and we may be unable to identify or successfully complete strategic transactions;
- the inability to complete any strategic transactions on terms favorable to us within the expected time frames, or at all;
- divestitures may result in continued financial exposure, including increased costs due to potential litigation, contingent liabilities, and indemnification of the buyer related to, among other things, lawsuits, regulatory matters, or tax liabilities, following the completion of any other such transaction;
- the anticipated benefits from any strategic transactions may not be fully realized or may take longer to realize than expected;
- integration and separation activities may result in additional and unforeseen expenses, including facilities and systems consolidation or separation costs and costs to retain key employees, as well as decreases in expected revenues, earnings or cash flows;
- the carrying value of goodwill or other intangible assets - which, as of December 31, 2025, was approximately \$73.5 billion, representing 47% of our total consolidated assets - may be materially and adversely impacted if acquired businesses do not perform as expected, or if future evaluations require impairment charges that could materially affect our results of operations and shareholders' equity in the period in which the impairment occurs;
- the issuance of additional common stock could dilute ownership interests of our shareholders, or the incurrence of additional debt could increase costs and impact our ability to access capital in the future in connection with a strategic transaction;
- the integration of businesses may cause increasing complexity in our systems and internal controls and could cause us to fail to meet our financial reporting obligations; and
- announcements related to an acquisition could have an adverse effect on the market price of our common stock and other securities.

Further, joint ventures and equity investments present risks that are different from acquisitions, including risks related to specific operations and finances of the businesses we invest in; selection of appropriate parties; differing objectives of the various parties; competition between and among parties; compliance activities (including compliance with applicable CMS requirements); growing of the business in a manner acceptable to all parties; the maintenance of positive relationships among the parties, clients and customers; and initial and ongoing governance of joint ventures and customer and business disruption that may occur upon a joint venture termination. For example, in the year ended December 31, 2024, we determined our investment in VillageMD was fully impaired and recorded a \$2.7 billion loss in Net investment gains/losses in our Consolidated Statements of Income.

See Note 19 to the Consolidated Financial Statements for more information on goodwill and intangibles.

Future performance of our business will depend on our ability to execute our strategic and operational initiatives effectively.

The future performance of our business depends on our ability to effectively implement and execute our strategic and operational initiatives. Strategic execution risk may be heightened by the complexity across our pharmacy services and health care businesses. In particular, our strategic and operational performance depends on our ability to:

- grow and support our product portfolio, expand our addressable markets, develop and effectively implement products and services to improve the accessibility, affordability and transparency of healthcare, and identify and introduce the proper mix, coordination or integration of products that the marketplace will accept;
- evaluate drugs for efficacy, value and price to assist clients in selecting a cost-effective formulary;
- offer cost-effective home delivery pharmacy and specialty services;
- access or continue accessing key drugs and successfully penetrate key treatment categories in our specialty pharmacy business;
- deliver discounts to health benefit providers;
- transition health care providers from volume-based, fee-for-service arrangements to a value-based system;
- improve medical cost competitiveness in our targeted markets;
- manage our medical, pharmacy, administrative and other operating costs effectively;
- contract with health care providers, pharmacy providers and pharmaceutical manufacturers on market competitive terms; and
- develop and create responsible data and analytic solutions to support and improve outcomes for our products, services and solutions, including creating and developing solutions and services through partnerships with other industry participants.

We will be unable to rapidly respond to competitive, economic and regulatory changes if we do not make important strategic and operational decisions quickly; define our appetite for risk; implement new governance, managerial and organizational processes smoothly; and communicate roles and responsibilities clearly. If our strategic and operational initiatives fail or are not executed effectively, our business may be unable to grow as planned, and our consolidated financial position and results of operations could be negatively affected.

Financial Risks

Economic and market conditions affect the value of our financial instruments and the value of particular assets and liabilities, investment income, and interest expense.

As an insurer, we have substantial investment assets that support insurance and contractholder deposit liabilities and surplus requirements in our regulated companies. The market values of our investments vary depending on economic and market conditions with no offsetting change in the value of a portion of our liabilities. A substantial portion of our investment assets are in fixed interest-yielding debt securities of varying maturities and commercial mortgage loans. The value of these investment assets can fluctuate significantly with changes in market conditions. In addition, an economic contraction could result in delay in payment of principal or interest by issuers, or defaults by issuers, reducing our investment income and requiring us to write down the value of our investments.

Significant stock market or interest rate declines could result in unfunded pension obligations, resulting in the need for additional plan funding by us and increased pension expenses.

We currently have overfunded obligations in our frozen pension plan. A significant decline in the value of the plan's equity and fixed income investments, or unfavorable changes in applicable laws or regulations, could materially increase our expenses and change the timing and amount of required plan funding. This could reduce the cash available to us, including our subsidiaries. We are also exposed to interest rate and equity risk associated with our pension obligations. Sustained declines in interest rates could have an adverse impact on the funded status of our pension plans and our reinvestment yield on new investments. See Note 17 to the Consolidated Financial Statements for more information on our obligations under the pension plans.

A downgrade in the financial strength ratings of our insurance subsidiaries could adversely affect new sales and retention of current business, and a downgrade in our debt ratings would increase the cost of borrowed funds and could negatively affect our ability to access capital.

Financial strength, claims-paying ability and debt ratings by recognized rating organizations are each important factors in establishing the competitive position of insurance and health benefits companies. Ratings information by nationally recognized rating agencies is broadly disseminated and generally used throughout the industry. We believe that the claims-paying ability and financial strength ratings of our principal insurance subsidiaries are important factors in marketing our products to certain customers. Our debt ratings impact both the cost and availability of future borrowings and, accordingly, our cost of capital. Each of the rating agencies reviews ratings periodically, and current ratings may not be maintained in the future. A downgrade of any of these ratings could make it more difficult to either market our products successfully or raise capital to support business growth.

We maintain significant indebtedness in the ordinary course of business and may incur further indebtedness in the future. Our indebtedness could adversely affect our financial condition and our ability to react to economic or industry changes, and could divert our cash flow from operations for debt service costs, leaving us with less cash flow from operations available to fund growth, stock repurchases, dividends and other corporate purposes.

The total indebtedness of The Cigna Group was approximately \$31.5 billion as of December 31, 2025. Carrying indebtedness:

- requires us to dedicate a portion of our cash flow from operations to debt payments, thereby reducing the availability of cash flow to fund our operations and growth strategy;
- increases our vulnerability to general adverse economic and industry conditions, which may require us to dedicate an even greater percentage of our cash to the payment of principal and interest on our debt and limit our access to capital markets;
- exposes us to increases in interest rates to the extent that increased interest expense is not offset by increased income from our investment assets; and
- limits our flexibility in planning for, or reacting to, changes in or challenges relating to our business and industry.

The covenants in our debt instruments may have the effect of restricting our financial and operating flexibility to respond to significant changes in business and economic conditions, among other things. We may incur or assume significantly more debt in the future, which may subject us to additional restrictive covenants and increase the risks described above. If our cash flow and capital resources

are insufficient to service our debt obligations, we may be forced to seek additional dividends from our subsidiaries, sell assets, seek additional equity or debt capital, or restructure our debt.

Unfavorable developments in economic conditions may adversely affect our business, results of operations and financial condition.

Many factors, including geopolitical issues, future economic downturns, man-made disasters, natural disasters (including those as a result of climate change) and pandemics, availability and cost of credit, and other capital and consumer spending, can negatively impact the U.S. and global economies. Our results of operations could be materially adversely affected by the impact of unfavorable economic conditions on our clients and customers (both employers and individuals), health care providers, pharmacy manufacturers, pharmacy providers, and third-party vendors. For example:

- Employers may take action to reduce their operating costs by modifying, delaying or canceling plans to purchase our products, or making changes in the mix of products purchased that are unfavorable to us.
- Higher unemployment rates, employee attrition (including challenges filling open positions in light of a competitive job market) and workforce reductions could result in lower enrollment in our employer-based plans (including an increase in the number of employees who opt out of employer-based plans) or our individual plans.
- Significant disruption or volatility in the capital and credit markets could affect our ability to access those markets for additional borrowings or increase costs.
- Because of unfavorable economic conditions or legislation and regulation affecting employer-sponsored coverage, employers may stop offering health care coverage to employees or elect to offer this coverage on a voluntary, employee-funded basis as a means to reduce their operating costs.
- If clients are not successful in generating sufficient funds or are precluded from securing financing, they may not be able to pay, or may delay payment of, accounts receivable that are owed to us.
- Our clients or potential clients may force us to compete more vigorously on factors such as price and service to retain or obtain their business.
- Our clients may be acquired, consolidated, or otherwise fail to successfully maintain or grow their business or workforce, which could reduce the number of customers we serve or otherwise result in lower than anticipated utilization of our services.
- A prolonged unfavorable economic environment could adversely impact the financial position of hospitals and other health care providers, potentially increasing our medical costs.
- Our third-party vendors could significantly and quickly increase their prices or reduce their output to reduce their operating costs (our business depends on our ability to perform necessary business functions in an efficient and uninterrupted fashion).
- Other insurers' financial condition may be weakened, increasing the risk that we will receive significant assessments for obligations of insolvent insurers pursuant to guaranty associations, indemnity funds, or other similar laws and regulations.

The occurrence of these events have led, and may lead, to a decrease in our customer base, revenues or margins or an increase in our operating costs.

In addition, during and following a prolonged unfavorable economic environment, federal and state budgets could be materially adversely affected, resulting in reduced or delayed reimbursements or payments in government programs, such as Medicare and Social Security or under contracts with government entities. These budgetary pressures also could cause the government to impose new or higher taxes or assessments on us, such as premium taxes on insurance companies and HMOs and surcharges or fees on select fee-for-service and capitated medical claims. Although we could attempt to mitigate or cover our exposure from such increased costs through, among other things, increases in premiums, we may be unable to mitigate or cover all such costs, which may have a material adverse effect on our business, results of operations, financial condition and liquidity.

We are subject to the credit risk of our reinsurers.

We enter into reinsurance arrangements with other insurance companies, primarily in connection with acquisition or divestiture transactions when the underwriting company is not being acquired or sold. Under all reinsurance arrangements, reinsurers assume insured losses, subject to certain limitations or exceptions that may include a loss limit. These arrangements also subject us to various obligations, representations and warranties with the reinsurers. Reinsurance does not relieve us of liability as the originating insurer. We remain liable to the underlying policyholders if a reinsurer defaults on obligations under the reinsurance arrangement. Although we regularly evaluate the financial condition of reinsurers to minimize exposure to significant losses from reinsurer insolvencies, reinsurers may become financially unsound. If a reinsurer fails to meet its obligations under the reinsurance contract or if the liabilities exceed any applicable loss limit, we will be forced to cover the claims on the reinsured policies.

The collectability of amounts due from reinsurers is subject to uncertainty arising from a number of factors, including whether the insured losses meet the qualifying conditions of the reinsurance contract; whether reinsurers or their affiliates have the financial capacity and willingness to make payments under the terms of the reinsurance contract; and the magnitude and type of collateral

supporting our reinsurance recoverable, such as holding sufficient qualifying assets in trusts or letters of credit issued. Although a portion of our reinsurance exposures are secured, the inability to collect a material recovery from a reinsurer could have a material adverse effect on our results of operations, financial condition and liquidity.

Item 1B. UNRESOLVED STAFF COMMENTS

None.

Item 1C. CYBERSECURITY

Cybersecurity Strategy and Risk Management

Cybersecurity is a core element of our enterprise risk management strategy. Safeguarding business information, intellectual property, and the data of customers, patients, employees and business partners is vital for operational continuity, regulatory compliance and sustaining stakeholder trust.

Our comprehensive cybersecurity program is supported by policies and procedures designed to protect our systems and operations, as well as sensitive personal information and data, from foreseeable cybersecurity threats.

Core to our security model is our defense-in-depth framework, comprising multiple layers of processes and technologies that help prevent, detect and respond to threats. Our approach to safeguarding against external threats incorporates a suite of preventive technologies, including malicious email blocking, defenses against automated attacks and multifactor authentication. Event monitoring technologies run continuously, detecting suspected intrusion attempts and alerting our Cybersecurity Incident Response Team. We undertake a number of critical security processes to mitigate and protect against cybersecurity risks, which include but are not limited to (i) identity and access management; (ii) security awareness and training; (iii) security operations and monitoring; (iv) change management; (v) disaster recovery/business continuity; (vi) intelligence feeds; (vii) physical security; (viii) third-party vendor security reviews; (ix) vulnerability management/patching; and (x) cybersecurity incident reporting.

We routinely manage cybersecurity risks through a defined framework that includes activities aimed at the identification, assessment, treatment and monitoring of risks. Cybersecurity risk assessment results are used by senior management to make informed decisions about where to allocate resources to reduce cybersecurity risks and improve overall security posture. We examine our entire program annually with third parties and measure the program against generally accepted industry standards and frameworks, such as an internationally recognized security control framework established by the NIST and used by companies to assess and improve their ability to prevent, detect and respond to cyberattacks. Our cybersecurity policies and standards are reviewed annually and are mainly guided by the NIST 800-53 Cybersecurity Framework. In addition to the NIST framework, we leverage the International Organization for Standardization 27001 and 27002 standards.

To enhance our preparedness and practice our collective cybersecurity response capabilities, we conduct tabletop exercises with leaders, stakeholders, subject matter experts and certain executives. These events are developed in partnership with external security experts and designed to exercise and engage some of the most critical areas of cybersecurity incident response and preparedness through an interactive and evolving simulated scenario.

In addition to these internal measures, the effectiveness of components of our overall cybersecurity program is frequently evaluated by external third parties, which includes work performed over various levels of control assessments for specific business lines and core processes. These include Health Information Trust Alliance ("HITRUST") for health care data security, PCI DSS for payment security, and System Organization Controls 2 ("SOC 2") for information security and related controls for specific business lines and core processes. We also perform an annual maturity assessment and benchmark our security controls to identify opportunities to strengthen our cybersecurity program.

As part of our Global Threat Management Program, a dedicated Incident Handling Team, comprising both technical and management personnel, determines the severity of a validated cybersecurity event across the enterprise and is responsible for the development and ongoing maintenance of our comprehensive Global Incident Response Plan ("GIRP"). The GIRP is reviewed quarterly at a minimum but may be updated as needed based on lessons learned, changes in key teams or processes, or other circumstances as warranted, and the procedures therein are tested annually. The GIRP's incident handling procedures dictate our actions during each phase of an incident, including the assembly of a broad, cross-functional Computer Security Incident Response Team, the formulation of a response, and post-incident reviews and corrective actions.

Our information protection department maintains a risk register that is used to manage cybersecurity risks associated with its business activities, technology assets, and its interaction with internal and external business, information technology and security parties.

Cybersecurity risks are also periodically reviewed by Enterprise Risk Management to ensure appropriate oversight of cybersecurity risk management activities.

Suppliers that access, host or transmit our data are contractually required to comply with our Security Policies and Standards. Additionally, suppliers may be subject to periodic security audits or risk assessments, which include security questionnaires, security capabilities and maturity assessments, controls evidence reviews, application vulnerability assessments, public internet presence monitoring, and alignment reviews with service-specific industry standards. Follow-up activities are performed as needed. Contracts with suppliers also include critical security requirements, such as right to audit, technology requirements and hiring practices, including background checks for those who have access to our network. To further ensure supplier resilience and continuity, we regularly evaluate and assess our critical supplier relationships and business continuity plans, enabling us to quickly adapt and maintain operations in the event of prolonged disruption.

As of the date of this report, we do not believe that any risks from any cybersecurity threats, including as a result of any previous cybersecurity incidents, have materially affected or are reasonably likely to materially affect us, including our business strategy, results of operations or financial condition. However, future cybersecurity threats or incidents could materially affect us, including our business strategy, results of operations or financial condition. For more information on our cybersecurity-related risks, see Part I, Item 1A "Risk Factors – Operational Risks – As a large global health company, we and our vendors are subject to cyberattacks or other privacy or data security incidents. If we are unable to prevent or contain the effects of any such attacks, or fail to ensure vendors do the same, we may suffer exposure to substantial liability, reputational harm, loss of revenue or other damages."

Cybersecurity Governance

Our Board of Directors (the "Board") has ultimate oversight over our privacy and cybersecurity programs and strategy and is responsible for ensuring that we have risk management policies and processes in place to meet and mitigate evolving risks and threats. Certain members of our Board have cybersecurity certifications. Throughout 2025, the Board executed this oversight directly and through both the Audit Committee, for cybersecurity purposes, and the Compliance Committee, for privacy purposes. In these capacities, these committees were regularly briefed by the Global Chief Information Security Officer ("GCISO") and Chief Privacy Officer on cybersecurity and privacy matters. These briefings were designed to provide visibility about the identification, assessment and management of critical risks, audit findings, and management's risk mitigation strategies. Additionally, these briefings included information about current trends in the environment, incident preparedness, AI, and various components of our cybersecurity and privacy programs. On an annual basis, the Board reviews our cybersecurity program, including the threat landscape and related controls, and periodically conducts cybersecurity tabletop exercises.

Our dedicated cybersecurity team is led by our GCISO. Our current GCISO joined the Company in October 2023 and works closely with senior management to develop and innovate the cybersecurity and risk management strategies. Prior to joining the team, our GCISO held senior information security roles at other global organizations, where this individual defined information security strategies; built global information security programs; implemented cybersecurity capabilities that protect consumers, wholesale partners and brands; and oversaw the security of a global payment network, a corporate network and digital assets.

Beginning in 2026, oversight of cybersecurity matters has transitioned to the Board's Finance & Technology Committee. The Finance & Technology Committee now receives similar updates on cybersecurity and information protection programs from the GCISO as described above. Throughout 2025, the Compliance Committee, now the Audit & Compliance Committee, oversaw privacy risks and related matters, including through regular updates from our Chief Compliance and Risk Officer.

Item 2. *PROPERTIES*

At the end of 2025, our global real estate portfolio consisted of approximately 8.1 million square feet of owned and leased properties to support the operations of our reporting segments. Our domestic portfolio had approximately 6.3 million square feet in 42 states, District of Columbia and the U.S. Virgin Islands. Our international properties contain approximately 1.8 million square feet located throughout 23 countries.

Our principal domestic office locations include the Wilde Building, located at 900 Cottage Grove Road in Bloomfield, Connecticut (our corporate headquarters, which we own); the Evernorth Health Services leased corporate offices located at and around One Express Way in St. Louis, Missouri; and leased office space at Two Liberty Place, located at 1601 Chestnut Street in Philadelphia, Pennsylvania. These principal domestic office locations total approximately 1.8 million square feet.

The pharmacy operations consist of 11 home delivery pharmacies, 35 specialty pharmacies and four high-volume automated dispensing pharmacies located throughout the United States. Our high-volume automated dispensing pharmacies are located in Arizona, Indiana, Missouri and New Jersey.

We believe our properties are adequate and suitable for our business as presently conducted. The foregoing does not include information on investment properties.

Item 3. LEGAL PROCEEDINGS

The information contained under "Legal and Regulatory Matters" in Note 22 to the Consolidated Financial Statements of this Form 10-K is incorporated herein by reference.

Item 4. MINE SAFETY DISCLOSURES

Not applicable.

Information about Our Executive Officers

The principal occupations, ages and employment histories of our executive officers (as of February 26, 2026) are listed below.

DAVID M. CORDANI, 60, Chairman of the Board of The Cigna Group beginning January 2022; Chief Executive Officer beginning December 2009; Director beginning October 2009; President beginning June 2008; and Chief Operating Officer from June 2008 until December 2009.

ANN M. DENNISON, 55, Executive Vice President and Chief Financial Officer of The Cigna Group beginning March 2025; Deputy Corporate Financial Officer from January 2024 until March 2025. Executive Vice President and Chief Financial Officer of Nasdaq, Inc. from March 2021 until December 2023; Senior Vice President, Controller and Chief Accounting Officer from October 2015 until March 2021.

BRIAN EVANKO, 49, President and Chief Operating Officer of The Cigna Group beginning March 2025; Executive Vice President and Chief Financial Officer of The Cigna Group and President and Chief Executive Officer of Cigna Healthcare from January 2024 until March 2025; Executive Vice President and Chief Financial Officer of The Cigna Group from January 2021 until January 2024; President, Government Business from November 2017 until January 2021; and President, U.S. Individual Business from August 2013 until November 2017.

NICOLE S. JONES, 55, Executive Vice President, Chief Administrative Officer and General Counsel for The Cigna Group beginning September 2023; Executive Vice President and General Counsel of The Cigna Group from June 2011 until September 2023; Senior Vice President and General Counsel of Lincoln Financial Group from May 2010 until June 2011; Vice President and Deputy General Counsel of The Cigna Group from April 2008 until May 2010; and Corporate Secretary from September 2006 until April 2010.

DURGA PRASAD KOKA, 52, Executive Vice President and Global Chief Information Officer, The Cigna Group beginning September 2025; Senior Vice President, Information Technology from October 2021 until September 2025; SVP of Enterprise Solutions and Architecture, Hilton Worldwide from May 2020 until May 2021.

F. EVERETT NEVILLE, 61, Executive Vice President, Strategy and Business Development beginning January 2021; Senior Vice President, Value Creation and Solutions from August 1998 until December 2020.

PART II

Item 5. MARKET FOR REGISTRANT'S COMMON EQUITY, RELATED STOCKHOLDER MATTERS AND ISSUER PURCHASES OF EQUITY SECURITIES

As of December 31, 2025, the number of shareholders of record was 20,669. The Cigna Group's common stock is listed with, and trades on, the New York Stock Exchange under the symbol "CI."

In 2025, 2024 and 2023, The Cigna Group declared and paid quarterly cash dividends of \$1.51, \$1.40 and \$1.23 per share of The Cigna Group common stock, respectively.

On February 5, 2026, the Board of Directors declared the first quarter 2026 cash dividend of \$1.56 per share of The Cigna Group common stock to be paid on March 19, 2026 to shareholders of record on March 5, 2026. The Cigna Group currently intends to pay regular quarterly dividends, with future declarations subject to approval by its Board of Directors and the Board's determination that


the declaration of dividends remains in the best interests of The Cigna Group and its shareholders. See Note 8 to the Consolidated Financial Statements for further information on dividend payments.

For information on securities authorized for issuance under our existing equity compensation plans, see Item 12 under the heading "Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters."

Stock Price Performance Graph

The graph below compares the cumulative total shareholder return on our common stock for the five years ended December 31, 2025 with the cumulative total return of the Standard & Poor's ("S&P") 500 Index and the S&P 500 Health Care Index. The stock performance shown in the graph is not intended to forecast or be indicative of future performance.

Five-Year Cumulative Total Shareholder Return*
December 31, 2020 - December 31, 2025



| | 12/31/20 | 12/31/21 | 12/31/22 | 12/31/23 | 12/31/24 | 12/31/25 |
|---------------------------|----------|----------|----------|----------|----------|----------|
| The Cigna Group | \$ 100 | \$ 112 | \$ 165 | \$ 152 | \$ 142 | \$ 145 |
| S&P 500 | \$ 100 | \$ 129 | \$ 105 | \$ 133 | \$ 166 | \$ 196 |
| S&P 500 Health Care Index | \$ 100 | \$ 126 | \$ 124 | \$ 126 | \$ 129 | \$ 148 |

* Assumes that the value of the investment in The Cigna Group common stock and each index was \$100 on December 31, 2020 and that all dividends were reinvested.

Issuer Purchases of Equity Securities

The following table provides information about The Cigna Group share repurchase activity for the quarter ended December 31, 2025:

| Period | Total # of shares purchased ⁽¹⁾ | Average price paid per share ⁽¹⁾⁽³⁾ | Total # of shares purchased as part of publicly announced program ⁽²⁾ | Approximate dollar value of shares that may yet be purchased as part of publicly announced program ⁽³⁾ (in millions) |
|-----------------------|--|--|--|---|
| October 1 - 31, 2025 | 1,688 | \$ 304.63 | — | \$ 7,732 |
| November 1 - 30, 2025 | 3,738,069 | \$ 268.25 | 3,732,646 | \$ 6,730 |
| December 1 - 31, 2025 | 3,057 | \$ 274.35 | — | \$ 6,730 |
| Total | 3,742,814 | \$ 268.27 | 3,732,646 | N/A |

⁽¹⁾ Includes shares tendered by employees under the Company's equity compensation plans as follows: 1) payment of taxes on vesting of restricted stock (grants and units) and strategic performance shares and 2) payment of the exercise price and taxes for certain stock options exercised. Employees tendered 1,688 shares in October, 5,423 shares in November and 3,057 shares in December 2025.

⁽²⁾ Additionally, the Company maintains a share repurchase program authorized by the Board. Under this program, the Company may repurchase shares from time to time, depending on market conditions and alternate uses of capital. The timing and actual number of shares repurchased will depend on a variety of factors, including price, general business and market conditions, and alternate uses of capital. The share repurchase program may be effected through Rule 10b5-1 plans, open market purchases, each in compliance with Rule 10b-18 under the Exchange Act, or privately negotiated transactions. The program may be suspended or discontinued at any time and does not have an expiration date.

⁽³⁾ The average price paid per share and approximate dollar value of shares exclude the impact of excise tax.

Item 6. [Reserved]

Item 7. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

Management's Discussion and Analysis of Financial Condition and Results of Operations ("MD&A") is intended to provide information to assist you in better understanding and evaluating the financial condition of The Cigna Group as of December 31, 2025 compared with December 31, 2024 and our results of operations for 2025 compared with 2024 and 2023 and is intended to help you understand the ongoing trends in our business. For comparisons of our results of operations for 2024 compared with 2023, please refer to the previously filed MD&A included in Part II, Item 7 of our Form 10-K for the year ended December 31, 2024. We encourage you to read this MD&A in conjunction with our Consolidated Financial Statements included in Part II, Item 8 of this Annual Report on Form 10-K ("Form 10-K") and the "Risk Factors" contained in Part I, Item 1A of this Form 10-K.

Unless otherwise indicated, financial information in this MD&A is presented in accordance with accounting principles generally accepted in the United States of America ("GAAP"). See Note 2 to the Consolidated Financial Statements in this Form 10-K for additional information regarding the Company's significant accounting policies. In some of our financial tables in this MD&A, we present either percentage changes or "N/M" when those changes are so large as to become not meaningful. Changes in percentages are expressed in basis points ("bps").

In this MD&A, our consolidated measures "adjusted income from operations," earnings per share on that same basis and "adjusted revenues" are not determined in accordance with GAAP and should not be viewed as substitutes for the most directly comparable GAAP measures of "shareholders' net income," "earnings per share" and "total revenues." We also use pre-tax adjusted income (loss) from operations and adjusted revenues to measure the results of our segments.

The Company uses "pre-tax adjusted income (loss) from operations" and "adjusted revenues" as its principal financial measures of segment operating performance because management believes these metrics reflect the underlying results of business operations and facilitate analysis of trends in underlying revenue, expenses and profitability. We define adjusted income (loss) from operations as shareholders' net income (or income (loss) before income taxes less pre-tax income (loss) attributable to noncontrolling interests for the segment metric) excluding net investment gains/losses, amortization of acquired intangible assets and special items. The Cigna Group's share of certain investment results of its joint ventures reported in the Cigna Healthcare segment using the equity method of accounting are also excluded. Special items are matters that management believes are not representative of the underlying results of operations due to their nature or size. Adjusted income (loss) from operations is measured on an after-tax basis for consolidated results and on a pre-tax basis for segment results. Consolidated adjusted income (loss) from operations is not determined in accordance with GAAP and should not be viewed as a substitute for the most directly comparable GAAP measure, shareholders' net income. See the below Financial Highlights section for a reconciliation of consolidated adjusted income from operations to shareholders' net income.

The Company defines adjusted revenues as total revenues excluding the following adjustments: special items and The Cigna Group's share of certain investment results of its joint ventures reported in the Cigna Healthcare segment using the equity method of accounting. Special items are matters that management believes are not representative of the underlying results of operations due to their nature or size. We exclude these items from this measure because management believes they are not indicative of past or future

underlying performance of the business. Adjusted revenues is not determined in accordance with GAAP and should not be viewed as a substitute for the most directly comparable GAAP measure, total revenues. See the below Financial Highlights section for a reconciliation of consolidated adjusted revenues to total revenues.

See Note 23 to the Consolidated Financial Statements for additional discussion of these metrics and a reconciliation of income (loss) before income taxes to pre-tax adjusted income (loss) from operations, as well as a reconciliation of Total revenues to adjusted revenues. Note 23 to the Consolidated Financial Statements also explains that segment revenues include both external revenues and sales between segments that are eliminated in Corporate. Ratios presented in the segment discussion exclude the same items as adjusted revenues and pre-tax adjusted income (loss) from operations.

EXECUTIVE OVERVIEW

The Cigna Group, together with its subsidiaries (either individually or collectively referred to as the "Company," "we," "us" or "our"), is a global health company committed to creating a better future for every individual and every community. Our subsidiaries offer a differentiated set of pharmacy, medical, behavioral, dental, and related products and services. For further information on our business and strategy, see Part I, Item 1 - "Business" of this Form 10-K.

Financial Highlights

Consolidated Results of Operations (GAAP basis)

| (Dollars in millions) | For the Years Ended December 31, | | | Change | | Change | |
|---|----------------------------------|-----------------|-----------------|-----------------|--------------|-------------------|---------------|
| | 2025 | 2024 | 2023 | 2025 vs. 2024 | | 2024 vs. 2023 | |
| Pharmacy revenues | \$ 216,672 | \$ 185,362 | \$ 137,243 | \$ 31,310 | 17 % | \$ 48,119 | 35 % |
| Premiums | 40,261 | 45,996 | 44,237 | (5,735) | (12) | 1,759 | 4 |
| Fees and other revenues | 16,921 | 14,790 | 12,619 | 2,131 | 14 | 2,171 | 17 |
| Net investment income | 1,046 | 973 | 1,166 | 73 | 8 | (193) | (17) |
| Total revenues | 274,900 | 247,121 | 195,265 | 27,779 | 11 | 51,856 | 27 |
| Pharmacy and other service costs | 214,991 | 182,509 | 133,801 | 32,482 | 18 | 48,708 | 36 |
| Medical costs and other benefit expenses | 34,349 | 38,648 | 36,287 | (4,299) | (11) | 2,361 | 7 |
| Selling, general and administrative expenses | 14,617 | 14,844 | 14,822 | (227) | (2) | 22 | — |
| Amortization of acquired intangible assets | 1,743 | 1,703 | 1,819 | 40 | 2 | (116) | (6) |
| Total benefits and expenses | 265,700 | 237,704 | 186,729 | 27,996 | 12 | 50,975 | 27 |
| Income from operations | 9,200 | 9,417 | 8,536 | (217) | (2) | 881 | 10 |
| Interest expense and other | (1,408) | (1,435) | (1,446) | 27 | (2) | 11 | (1) |
| Net gain (loss) on sale of businesses | 13 | 24 | (1,499) | (11) | (46) | 1,523 | N/M |
| Net investment losses | (24) | (2,737) | (78) | 2,713 | (99) | (2,659) | N/M |
| Income before income taxes | 7,781 | 5,269 | 5,513 | 2,512 | 48 | (244) | (4) |
| Total income taxes | 1,493 | 1,491 | 141 | 2 | — | 1,350 | N/M |
| Net income | 6,288 | 3,778 | 5,372 | 2,510 | 66 | (1,594) | (30) |
| Less: Net income attributable to noncontrolling interests | 331 | 344 | 208 | (13) | (4) | 136 | 65 |
| Shareholders' net income | \$ 5,957 | \$ 3,434 | \$ 5,164 | \$ 2,523 | 73 % | \$ (1,730) | (34) % |
| Consolidated effective tax rate | 19.2 % | 28.3 % | 2.6 % | | (910) bps | | 2,570 bps |
| Medical customers (in thousands) | 18,118 | 19,147 | 19,780 | (1,029) | (5) % | (633) | (3) % |

Reconciliation of Shareholders' Net Income (GAAP) to Adjusted Income from Operations

| <i>(In millions)</i> | For the Years Ended December 31, | | | | | |
|--|----------------------------------|-----------|----------|-----------|----------|-----------|
| | 2025 | | 2024 | | 2023 | |
| | Pre-tax | After-tax | Pre-tax | After-tax | Pre-tax | After-tax |
| Shareholders' net income | | \$ 5,957 | | \$ 3,434 | | \$ 5,164 |
| Adjustments to reconcile to adjusted income from operations | | | | | | |
| Net investment (gains) losses ⁽¹⁾ | \$ (225) | (90) | \$ 2,533 | 2,529 | \$ 135 | 114 |
| Amortization of acquired intangible assets | 1,743 | 1,325 | 1,703 | 1,347 | 1,819 | 1,413 |
| Special items | | | | | | |
| Strategic optimization program | 749 | 565 | — | — | — | — |
| Deferred tax expenses (benefits), net | — | 427 | — | 84 | — | (1,071) |
| Integration and transaction-related costs | 327 | 247 | 275 | 211 | 45 | 35 |
| (Benefits) charges associated with litigation matters | (17) | (13) | — | — | 201 | 171 |
| Net (gain) loss on sale of businesses | (13) | (404) | (24) | (2) | 1,499 | 1,429 |
| Impairment of dividend receivable | — | — | 182 | 138 | — | — |
| Charge for organizational efficiency plan | — | — | — | — | 252 | 193 |
| Total special items | \$ 1,046 | 822 | \$ 433 | 431 | \$ 1,997 | 757 |
| Adjusted income from operations | | \$ 8,014 | | \$ 7,741 | | \$ 7,448 |

⁽¹⁾ Includes Net investment gains/losses as presented in our Consolidated Statements of Income, as well as the Company's share of certain investment results of its joint ventures reported in the Cigna Healthcare segment using the equity method of accounting, which are presented within Fees and other revenues in our Consolidated Statements of Income.

Reconciliation of Shareholders' Net Income (GAAP) to Adjusted Income from Operations

| <i>(Diluted earnings per share)</i> | For the Years Ended December 31, | | | | | |
|--|----------------------------------|-----------|---------|-----------|---------|-----------|
| | 2025 | | 2024 | | 2023 | |
| | Pre-tax | After-tax | Pre-tax | After-tax | Pre-tax | After-tax |
| Shareholders' net income | | \$ 22.18 | | \$ 12.12 | | \$ 17.39 |
| Adjustments to reconcile to adjusted income from operations | | | | | | |
| Net investment (gains) losses ⁽¹⁾ | \$ (0.84) | (0.34) | \$ 8.95 | 8.93 | \$ 0.45 | 0.38 |
| Amortization of acquired intangible assets | 6.50 | 4.94 | 6.01 | 4.76 | 6.13 | 4.77 |
| Special items | | | | | | |
| Strategic optimization program | 2.78 | 2.10 | — | — | — | — |
| Deferred tax expenses (benefits), net | — | 1.59 | — | 0.30 | — | (3.61) |
| Integration and transaction-related costs | 1.22 | 0.92 | 0.97 | 0.75 | 0.15 | 0.12 |
| (Benefits) charges associated with litigation matters | (0.06) | (0.05) | — | — | 0.68 | 0.58 |
| Net (gain) loss on sale of businesses | (0.05) | (1.50) | (0.08) | (0.02) | 5.05 | 4.81 |
| Impairment of dividend receivable | — | — | 0.64 | 0.49 | — | — |
| Charge for organizational efficiency plan | — | — | — | — | 0.85 | 0.65 |
| Total special items | \$ 3.89 | 3.06 | \$ 1.53 | 1.52 | \$ 6.73 | 2.55 |
| Adjusted income from operations | | \$ 29.84 | | \$ 27.33 | | \$ 25.09 |

⁽¹⁾ Includes Net investment gains/losses as presented in our Consolidated Statements of Income, as well as the Company's share of certain investment results of its joint ventures reported in the Cigna Healthcare segment using the equity method of accounting, which are presented within Fees and other revenues in our Consolidated Statements of Income.

Financial highlights by segment

| | For the Years Ended December 31, | | | Change | Change |
|--|----------------------------------|------------|------------|---------------|---------------|
| | 2025 | 2024 | 2023 | 2025 vs. 2024 | 2024 vs. 2023 |
| <i>(Dollars in millions, except per share amounts)</i> | | | | | |
| Revenues | | | | | |
| Adjusted revenues by segment | | | | | |
| Evernorth Health Services | \$ 234,953 | \$ 202,155 | \$ 153,499 | 16 % | 32 % |
| Cigna Healthcare | 47,163 | 52,914 | 51,205 | (11) | 3 |
| Other Operations | 674 | 828 | 596 | (19) | 39 |
| Corporate, net of eliminations | (8,139) | (8,798) | (9,978) | (7) | (12) |
| Adjusted revenues | 274,651 | 247,099 | 195,322 | 11 | 27 |
| Net investment results from certain equity method investments | 249 | 204 | (57) | 22 | N/M |
| Special item related to impairment of dividend receivable | — | (182) | — | N/M | N/M |
| Total revenues | \$ 274,900 | \$ 247,121 | \$ 195,265 | 11 % | 27 % |
| Shareholders' net income | \$ 5,957 | \$ 3,434 | \$ 5,164 | 73 % | (34) % |
| Adjusted income from operations | \$ 8,014 | \$ 7,741 | \$ 7,448 | 4 % | 4 % |
| Earnings per share (diluted) | | | | | |
| Shareholders' net income | \$ 22.18 | \$ 12.12 | \$ 17.39 | 83 % | (30) % |
| Adjusted income from operations | \$ 29.84 | \$ 27.33 | \$ 25.09 | 9 % | 9 % |
| Pre-tax adjusted income (loss) from operations by segment | | | | | |
| Evernorth Health Services | \$ 7,221 | \$ 7,001 | \$ 6,442 | 3 % | 9 % |
| Cigna Healthcare | 4,153 | 4,229 | 4,478 | (2) | (6) |
| Other Operations | 89 | (9) | 96 | N/M | N/M |
| Corporate, net of eliminations | (1,593) | (1,688) | (1,698) | (6) | (1) |
| Consolidated pre-tax adjusted income from operations | 9,870 | 9,533 | 9,318 | 4 | 2 |
| Income attributable to noncontrolling interests | 475 | 405 | 146 | 17 | 177 |
| Net investment gains (losses) ⁽¹⁾ | 225 | (2,533) | (135) | N/M | N/M |
| Amortization of acquired intangible assets | (1,743) | (1,703) | (1,819) | 2 | (6) |
| Special items | (1,046) | (433) | (1,997) | 142 | (78) |
| Income before income taxes | \$ 7,781 | \$ 5,269 | \$ 5,513 | 48 % | (4) % |

⁽¹⁾ Includes Net investment gains/losses as presented in our Consolidated Statements of Income, as well as the Company's share of certain investment results of its joint ventures reported in the Cigna Healthcare segment using the equity method of accounting, which are presented within Fees and other revenues in our Consolidated Statements of Income.

Key Transactions and Business Developments

Divestiture of Medicare Advantage and Related Businesses

On March 19, 2025, the Company completed the sale of our Medicare Advantage, Medicare Individual Stand-Alone Prescription Drug Plans, Medicare and Other Supplemental Benefits, and CareAllies[®] businesses to Health Care Service Corporation ("HCSC," and such transaction, the "HCSC transaction"). The final purchase price and total cash proceeds collected in 2025 were \$4.9 billion. See Note 5 to the Consolidated Financial Statements for further information.

Strategic Optimization Program

In the first quarter of 2025, the Company commenced an enterprise-wide initiative to evolve our business and deliver a more efficient and improved experience for our patients, providers and customers. In 2025, we reported total costs of \$749 million, pre-tax (\$565 million, after-tax) associated with this initiative. As we continue to evaluate additional opportunities to improve the overall efficiency and effectiveness of our operations, we anticipate future charges. See Note 16 to the Consolidated Financial Statements for further information.

We expect this initiative to generate annualized after-tax savings of at least \$500 million, a portion of which was realized in 2025.

Commentary: 2025 versus 2024

The commentary presented below, and the segment commentaries that follow, compare results for the year ended December 31, 2025 with results for the year ended December 31, 2024. Commentary regarding percentage changes (or bps) and dollar variances represents the driver's impact on the overall category.

Shareholders' net income increased 73%, primarily reflecting the absence of the impairment of VillageMD equity securities that was recorded in 2024.

Adjusted income from operations. See discussion of segment results in the "Segment Reporting" section.

Medical customers decreased 5%, primarily reflecting the closing of the HCSC transaction.

Pharmacy revenues increased 17%, primarily reflecting higher utilization of prescription drugs from customer growth in Evernorth Health Services.

Premiums decreased 12%, primarily driven by the impact of the HCSC transaction (-18%), partially offset by higher premium rates within our ongoing U.S. Healthcare businesses (+4%).

Fees and other revenues increased 14%, primarily reflecting growth in affordability services (defined in the "Segment Reporting" section) within our Pharmacy Benefit Services operating segment.

Net investment income increased 8%, primarily due to an increase in partnership income (17%) as well as the absence of the impairment of the dividend receivable in 2024 related to VillageMD accrued dividends (19%). These impacts were offset by lower average assets (23%), due in part to the impact of the HCSC transaction.

Pharmacy and other service costs increased 18%, primarily reflecting higher utilization of prescription drugs from customer growth in Evernorth Health Services.

Medical costs and other benefit expenses decreased 11%, primarily driven by the impact of the HCSC transaction (-18%), partially offset by higher medical costs within our ongoing U.S. Healthcare businesses (+7%).

Selling, general and administrative ("SG&A") expenses decreased 2%, primarily impacted by the HCSC transaction (-10%), partially offset by supporting business growth (+5%) and the strategic optimization program (+3%). See Note 16 to the Consolidated Financial Statements for further discussion of the strategic optimization program.

Net gain (loss) on sale of businesses decreased in 2025. The gain recorded in 2025 primarily reflects the HCSC transaction. The net gain reported in 2024 reflects the sale of a portion of an equity method investment, partially offset by an estimated loss on sale (primarily goodwill impairments) related to the HCSC transaction. See the "Divestiture of Medicare Advantage and Related Businesses" section above and Note 5 to the Consolidated Financial Statements for further discussion of the HCSC transaction.

Investment results improved in 2025, primarily reflecting the absence of the impairment of VillageMD equity securities that was recorded in 2024.

The effective tax rate decreased, primarily driven by the absence of a valuation allowance related to the impairment of equity securities recorded in 2024 (-1100 bps) and benefits related to the HCSC transaction (-400 bps), partially offset by an increased valuation allowance against foreign tax attributes (+500 bps). See Note 21 to the Consolidated Financial Statements for further discussion of these matters.

SEGMENT REPORTING

Evernorth Health Services Segment

Evernorth Health Services includes our Pharmacy Benefit Services and Specialty and Care Services operating segments, which provide independent and coordinated health solutions and capabilities to enable the health care system to work better and help people live healthier lives. As described in the introduction to Segment Reporting, the performance of Evernorth Health Services is measured using adjusted revenues and pre-tax adjusted income (loss) from operations.

The Company has renewed or extended contracts with the business's three largest clients through the end of the decade. Additionally, to further deliver value for the benefit of those we serve and to build a more sustainable model for health care, the Company will incur investment and transition costs to support its recently announced rebate-free model for pharmacy benefits, designed to lower

medication costs, improve transparency and support local pharmacies. As a result, we expect these efforts to impact pre-tax adjusted income from operations for Evernorth Health Services over the short term.

Key Factors Affecting Segment Performance

The key factors that impact the segment's revenues and income from operations are claims utilization, claims composition and contract affordability services. Specialty and Care Services revenues are also impacted by customer and client growth. These key factors are discussed further below. See Note 2 to the Consolidated Financial Statements in this Form 10-K for additional information on revenue and cost recognition policies for this segment.

Key factors that impact both Pharmacy Benefit Services and Specialty and Care Services:

- Pharmacy claim volume (also referred to as utilization) relates to processing prescription claims filled by retail pharmacies in our network and dispensing prescription claims from our home delivery and specialty pharmacies, along with other claims. Pharmacy claim volume is impacted by new clients or organic customer growth through the expansion of existing clients or through the loss of customers and business.
- The composition of claims generally considers the types of drugs, including the mix of claims among branded and higher priced specialty drugs compared to generic or biosimilar alternatives. We manage pharmaceutical manufacturer increases in prices through programs designed to reduce drug spend, providing positive impacts on our clients, our customers and us. Changes to claims mix, including types of drugs, distribution methods, pharmaceutical manufacturer prices, and alternative uses of drugs within our formularies continue to be a significant driver of our revenues and income from operations in the current environment.
- Our client contract pricing is impacted by our ongoing ability to negotiate favorable contracts for pharmacy network, pharmaceutical and wholesaler purchasing, and manufacturer rebates (also referred to as affordability improvements or affordability services). Through these affordability improvements, we seek to improve the effectiveness of our combined and standalone solutions for our clients by continuously innovating, improving affordability and implementing drug purchasing contract initiatives. Our continued affordability improvements further reduce drug costs for our customers and clients, and we share in the value delivered, which generally results in a favorable impact on our income from operations.

Key factors that impact Specialty and Care Services:

- Customer and client growth, both organic and new business, and key relationships in our Specialty and Care Services business generally results in increased revenues and income from operations. This includes client movement in our specialty pharmacy, specialty distribution services, virtual care, benefits management and behavioral health services as we expand our businesses.

Results of Operations

Financial Summary

| <i>(Dollars in millions)</i> | For the Years Ended December 31, | | | Change | | Change | |
|--|----------------------------------|------------|------------|---------------|----------|---------------|----------|
| | 2025 | 2024 | 2023 | 2025 vs. 2024 | | 2024 vs. 2023 | |
| Adjusted revenues ⁽¹⁾ | \$ 234,953 | \$ 202,155 | \$ 153,499 | \$ 32,798 | 16 % | \$ 48,656 | 32 % |
| Pre-tax adjusted income from operations ⁽¹⁾ | \$ 7,221 | \$ 7,001 | \$ 6,442 | \$ 220 | 3 % | \$ 559 | 9 % |
| Pre-tax margin ⁽¹⁾⁽²⁾ | 3.1 % | 3.5 % | 4.2 % | | (40) bps | | (70) bps |
| SG&A expense ratio ⁽³⁾ | 1.8 % | 1.9 % | 2.2 % | | (10) bps | | (30) bps |

⁽¹⁾ See Note 23 to the Consolidated Financial Statements for reconciliation of adjusted revenues and pre-tax adjusted income from operations to Total revenues and Income before income taxes, respectively.

⁽²⁾ Pre-tax margin is calculated as pre-tax adjusted income from operations divided by adjusted revenues.

⁽³⁾ SG&A expense ratio is calculated as segment selling, general and administrative expenses divided by adjusted revenues. See Note 23 to the Consolidated Financial Statements for further details.

In this selected financial information, we present adjusted revenues and pre-tax income from operations by our two operating segments, Pharmacy Benefit Services and Specialty and Care Services.

| Selected Financial Information | For the Years Ended December 31, | | | Change | Change |
|---|----------------------------------|--------------|--------------|---------------|---------------|
| | 2025 | 2024 | 2023 | 2025 vs. 2024 | 2024 vs. 2023 |
| <i>(Dollars and adjusted scripts in millions)</i> | | | | | |
| Total adjusted revenues | | | | | |
| Pharmacy Benefit Services | \$ 132,126 | \$ 111,822 | \$ 76,792 | 18 % | 46 % |
| Specialty and Care Services | 102,827 | 90,333 | 76,707 | 14 | 18 |
| Total adjusted revenues | \$ 234,953 | \$ 202,155 | \$ 153,499 | 16 % | 32 % |
| Pre-tax adjusted income from operations | | | | | |
| Pharmacy Benefit Services | \$ 3,506 | \$ 3,577 | \$ 3,469 | (2) % | 3 % |
| Specialty and Care Services | 3,715 | 3,424 | 2,973 | 8 | 15 |
| Total pre-tax adjusted income from operations | \$ 7,221 | \$ 7,001 | \$ 6,442 | 3 % | 9 % |
| Pharmacy claim volume ⁽¹⁾ | 2,222 | 2,120 | 1,585 | 5 % | 34 % |

⁽¹⁾ Non-specialty network prescriptions filled through 90-day programs and home delivery prescriptions are counted as three claims. All other network and specialty prescriptions are counted as one claim.

2025 versus 2024

Commentary in parentheses regarding percentage changes (or bps) represents the driver's impact on the overall category.

Adjusted revenues increased 16%, primarily reflecting higher utilization of prescription drugs from customer growth in Pharmacy Benefit Services (+6%) and Specialty and Care Services (+6%) and an increase due to claims composition in Pharmacy Benefit Services (+4%).

Pre-tax adjusted income from operations increased 3%, primarily reflecting specialty pharmacy growth in Specialty and Care Services (+6%), and contract affordability improvements and customer growth in Pharmacy Benefit Services (+1%), partially offset by strategic investments and initiatives to support business growth and improve the patient experience in Pharmacy Benefit Services (-3%) and Specialty and Care Services (-1%).

The **SG&A expense ratio** decreased 10 bps, primarily reflecting higher adjusted revenues as discussed above, offset by strategic investments and initiatives to support business growth.

Cigna Healthcare Segment

Cigna Healthcare includes our U.S. Healthcare and International Health operating segments, which provide comprehensive medical and coordinated solutions to clients and customers. As described in the introduction to Segment Reporting, performance of the Cigna Healthcare segment is measured using adjusted revenues and pre-tax adjusted income from operations.

On March 19, 2025, the Company completed the sale of our Medicare Advantage, Medicare Individual Stand-Alone Prescription Drug Plans, Medicare and Other Supplemental Benefits, and CareAllies businesses within the U.S. Healthcare operating segment. See "Key Transactions and Business Developments" for further discussion.

Key Factors Affecting Segment Performance

The key factors that impact the segment's revenues and income from operations include revenue growth, customer growth, medical cost trend, the medical care ratio ("MCR") and the SG&A expense ratio. These key factors are discussed further below. See Note 2 to the Consolidated Financial Statements included in this Form 10-K for additional information on revenue and cost recognition policies for this segment.

- Revenue growth includes increases to premium rates in consideration of anticipated medical cost increases, customer growth driven by new clients and customers, and increased fee revenue from the expansion of products and services to existing clients and customers, including solutions provided by Evernorth Health Services.
- Higher medical costs (also referred to as higher medical cost trend) are impacted by utilization (the quantity of medical services consumed by our customers), unit costs (the cost per medical service) and mix of services.

- MCR represents medical costs as a percentage of premiums for our segment's insured businesses, and it is impacted by medical cost trend and premium rates. Affordability initiatives that serve to mitigate medical cost inflation also impact the MCR.
- The SG&A expense ratio represents the segment's selling, general and administrative expenses divided by adjusted revenues.

Results of Operations

Financial Summary

| (Dollars in millions) | For the Years Ended December 31, | | | Change | | Change | |
|--|----------------------------------|-----------|-----------|---------------|----------|---------------|-----------|
| | 2025 | 2024 | 2023 | 2025 vs. 2024 | | 2024 vs. 2023 | |
| Adjusted revenues ⁽¹⁾ | \$ 47,163 | \$ 52,914 | \$ 51,205 | \$ (5,751) | (11) % | \$ 1,709 | 3 % |
| Pre-tax adjusted income from operations ⁽¹⁾ | \$ 4,153 | \$ 4,229 | \$ 4,478 | \$ (76) | (2) % | \$ (249) | (6) % |
| Pre-tax margin ⁽¹⁾⁽²⁾ | 8.8 % | 8.0 % | 8.7 % | | 80 bps | | (70) bps |
| Medical care ratio | 84.4 % | 83.2 % | 81.3 % | | 120 bps | | 190 bps |
| SG&A expense ratio ⁽³⁾ | 20.2 % | 20.4 % | 21.6 % | | (20) bps | | (120) bps |

⁽¹⁾ See Note 23 to the Consolidated Financial Statements for reconciliation of adjusted revenues and pre-tax adjusted income from operations to Total revenues and Income before income taxes, respectively.

⁽²⁾ Pre-tax margin is calculated as pre-tax adjusted income from operations divided by adjusted revenues.

⁽³⁾ SG&A expense ratio is calculated as segment selling, general and administrative expenses divided by adjusted revenues. See Note 23 to the Consolidated Financial Statements for further details.

2025 versus 2024

Commentary regarding percentage changes (or bps) and dollar variances represents the driver's impact on the overall category.

Adjusted revenues decreased 11%, or \$5,751 million, primarily due to the impact of the HCSC transaction (-\$8,498 million), partially offset by higher premiums within employer insured (+\$1,276 million) and stop loss (+\$855 million), primarily reflecting premium rate increases.

Pre-tax adjusted income from operations decreased 2%, or \$76 million, primarily due to lower contributions from the Individual and Family Plans business.

The **medical care ratio** increased 120 bps, primarily due to higher medical costs, driven by the Individual and Family Plans business.

The **SG&A expense ratio** decreased 20 bps, primarily due to revenue growth outpacing volume-related expenses within the ongoing businesses (-70 bps), partially offset by higher technology spend (+30 bps) and the impact of the HCSC transaction (+20 bps).

Medical Customers

Medical customers include individuals who meet any of the following criteria: (i) are covered under a medical insurance policy, managed care arrangement or administrative services agreement issued by Cigna Healthcare; (ii) have access to the Cigna Healthcare provider network for covered services under their medical plan; or (iii) have medical claims that are administered by Cigna Healthcare.

Cigna Healthcare Medical Customers

| (In thousands) | As of December 31, | | | Change | | Change | |
|-------------------------------------|--------------------|---------------|---------------|----------------|---------------|---------------|--------------|
| | 2025 | 2024 | 2023 | 2025 vs. 2024 | | 2024 vs. 2023 | |
| U.S. Healthcare | 2,548 | 3,853 | 4,280 | (1,305) | (34) % | (427) | (10) % |
| International Health ⁽¹⁾ | 1,260 | 1,211 | 1,184 | 49 | 4 | 27 | 2 |
| Insured | 3,808 | 5,064 | 5,464 | (1,256) | (25) % | (400) | (7) % |
| U.S. Healthcare | 13,875 | 13,649 | 13,890 | 226 | 2 % | (241) | (2) % |
| International Health ⁽¹⁾ | 435 | 434 | 426 | 1 | — | 8 | 2 |
| Administrative services only | 14,310 | 14,083 | 14,316 | 227 | 2 % | (233) | (2) % |
| Total | 18,118 | 19,147 | 19,780 | (1,029) | (5) % | (633) | (3) % |

⁽¹⁾ International Health excludes medical customers served by less than 100%-owned subsidiaries, as well as certain customers served by our third-party administrator.

Total medical customers decreased 5%, primarily due to the HCSC transaction.

Unpaid Claims and Claim Expenses

| (In millions) | As of December 31, | | | Change | | Change | |
|----------------------------------|--------------------|----------|----------|---------------|--------|---------------|-------|
| | 2025 | 2024 | 2023 | 2025 vs. 2024 | | 2024 vs. 2023 | |
| Unpaid claims and claim expenses | \$ 4,241 | \$ 5,018 | \$ 5,092 | \$ (777) | (15) % | \$ (74) | (1) % |

Our unpaid claims and claim expenses liability decreased 15%, primarily due to the HCSC transaction.

Other Operations

Other Operations includes corporate-owned life insurance ("COLI"), the Company's run-off operations and other non-strategic businesses. As described in the introduction of Segment Reporting, performance of Other Operations is measured using adjusted revenues and pre-tax adjusted income from operations.

Results of Operations

Financial Summary

| (Dollars in millions) | For the Years Ended December 31, | | | Change | | Change | |
|--|----------------------------------|---------|--------|---------------|--------|---------------|-------|
| | 2025 | 2024 | 2023 | 2025 vs. 2024 | | 2024 vs. 2023 | |
| Adjusted revenues | \$ 674 | \$ 828 | \$ 596 | \$ (154) | (19) % | \$ 232 | 39 % |
| Pre-tax adjusted income (loss) from operations | \$ 89 | \$ (9) | \$ 96 | \$ 98 | N/M % | \$ (105) | N/M % |
| Pre-tax margin | 13.2 % | (1.1) % | 16.1 % | 1,430 bps | | (1,720) bps | |

2025 versus 2024

Adjusted revenues primarily reflect premiums and net investment income associated with COLI and our run-off operations, as well as revenues from other non-strategic businesses.

Pre-tax adjusted income (loss) from operations increased, primarily driven by the decision to discontinue certain small non-strategic businesses.

Corporate

Corporate reflects amounts not allocated to operating segments, including net interest expense (defined as interest on corporate financing less net investment income on investments not supporting segment and other operations), certain litigation matters, expense associated with our frozen pension plans, charitable contributions, operating severance, certain overhead and enterprise-wide project costs, and eliminations for products and services sold between segments.

Financial Summary

| (In millions) | For the Years Ended December 31, | | | Change | | Change | |
|---------------------------------------|----------------------------------|------------|------------|---------------|-------|---------------|-------|
| | 2025 | 2024 | 2023 | 2025 vs. 2024 | | 2024 vs. 2023 | |
| Pre-tax adjusted loss from operations | \$ (1,593) | \$ (1,688) | \$ (1,698) | \$ 95 | (6) % | \$ 10 | (1) % |

2025 versus 2024

Commentary regarding percentage changes (or bps) and dollar variances represents the driver's impact on the overall category.

Pre-tax adjusted loss from operations decreased, primarily due to lower interest expense (-3%) and lower operating costs (-2%).

LIQUIDITY AND CAPITAL RESOURCES

Liquidity

We maintain liquidity at two levels: the subsidiary level and the parent company level.

Subsidiary Level. Cash requirements at the subsidiary level generally consist of pharmacy, medical costs and other benefit payments; expense requirements, primarily for employee compensation and benefits, information technology, and facilities costs; income taxes; and debt service.

Our subsidiaries normally meet their liquidity requirements by maintaining appropriate levels of cash, cash equivalents and short-term investments; using cash flows from operating activities; matching durations of investments to estimated durations for the related insurance and contractholder liabilities; selling investments; and borrowing from affiliates, subject to applicable regulatory limits.

Parent Company Level. Cash requirements at the parent company level generally consist of debt service, payment of declared dividends to shareholders, lending to subsidiaries as needed and pension plan funding.

The parent company normally meets its liquidity requirements by maintaining appropriate levels of cash and various types of marketable investments, collecting dividends from its subsidiaries, using proceeds from issuing debt and common stock, and borrowing from its subsidiaries, subject to applicable regulatory limits.

Regulatory Restrictions. Dividends from our insurance, Health Maintenance Organization ("HMO") and certain foreign subsidiaries are subject to regulatory restrictions. See Note 20 to the Consolidated Financial Statements in this Form 10-K for additional information regarding these restrictions. Most of the Evernorth Health Services segment operations are not subject to regulatory restrictions regarding dividends and therefore provide significant financial flexibility to The Cigna Group.

Investment Portfolio. We support the liquidity needs of our businesses by managing the duration of invested assets to be consistent with the duration of liabilities. We manage the portfolio to both optimize returns in the current economic environment and meet our liquidity needs.

Cash flows for the years ended December 31 were as follows:

| <i>(In millions)</i> | For the Years Ended December 31, | | |
|----------------------|----------------------------------|------------|------------|
| | 2025 | 2024 | 2023 |
| Operating activities | \$ 9,601 | \$ 10,363 | \$ 11,813 |
| Investing activities | \$ (4,407) | \$ (2,102) | \$ (5,174) |
| Financing activities | \$ (6,421) | \$ (7,647) | \$ (4,294) |

The following discussion explains variances in the various categories of cash flows for the year ended December 31, 2025 compared with the same period in 2024.

Operating Activities. Cash flows from operating activities consist principally of cash receipts and disbursements for pharmacy revenues and costs, premiums and medical costs, fees, investment income, taxes, and other expenses.

Operating cash flows decreased for the year ended December 31, 2025, primarily due to the unfavorable net impact related to clients that onboarded in 2024, as well as timing of settlements related to the accounts receivable factoring facility. These decreases are partially offset by the favorable impact of accrued liabilities and higher insurance liabilities.

Investing Activities. The increase in cash used in investing activities reflects higher investment purchases, partially offset by the net proceeds from the HCSC transaction.

Financing Activities. The decrease in net cash used in financing activities in 2025 is primarily driven by lower share repurchases, partially offset by higher debt repayments.

Capital Resources

Our capital resources consist primarily of cash, cash equivalents and investments maintained at regulated subsidiaries required to underwrite insurance risks, cash flows from operating activities, our commercial paper program, revolving credit facility, and the issuance of long-term debt and equity securities. Our businesses generate significant cash flows from operations, some of which is subject to regulatory restrictions relative to the amount and timing of dividend payments to the parent company. Dividends received from U.S.-regulated subsidiaries were \$0.9 billion for the year ended December 31, 2025 and \$2.4 billion for the year ended December 31, 2024. Non-regulated subsidiaries also generate significant cash flows from operating activities, which are typically available immediately to the parent company for general corporate purposes.

We prioritize our use of capital resources to (i) invest in capital expenditures (primarily related to technology to support innovative solutions for our clients and customers), provide the capital necessary to maintain or improve the financial strength ratings of subsidiaries, and to repay debt and fund pension obligations if necessary; (ii) pay dividends to shareholders; (iii) consider acquisitions

and investments that are strategically and economically advantageous; and (iv) return capital to shareholders through share repurchases.

Funds Available

Commercial Paper Program. There was no commercial paper outstanding balance as of December 31, 2025.

Revolving Credit Agreement. Our revolving credit agreement provides us with the ability to borrow amounts for general corporate purposes, including for the purpose of providing liquidity support if necessary under our commercial paper program discussed above. In April 2025, the Company replaced its previous revolving credit agreements and entered into a \$6.5 billion, five-year revolving credit and letter of credit agreement that will mature in April 2030. See Note 7 to the Consolidated Financial Statements for further information on our credit agreement and commercial paper program.

As of December 31, 2025, we had \$6.5 billion of undrawn committed capacity under our revolving credit agreement (these amounts are available for general corporate purposes, including providing liquidity support for our commercial paper program), \$6.5 billion of remaining capacity under our commercial paper program, and \$7.9 billion in cash and short-term investments, approximately \$0.9 billion of which was held by the parent company or certain non-regulated subsidiaries.

Our debt-to-capitalization ratio (calculated as Short-term debt and Long-term debt ("Total debt") as a percentage of Total shareholders' equity and Total debt ("Total capitalization")) was 43.0% and 43.8% as of December 31, 2025 and 2024, respectively.

We actively monitor our debt obligations and engage in issuance and repayment activities as needed in accordance with our capital management strategy.

Debt Issuance and Term Loan. In September 2025, we issued \$4.5 billion of new senior notes. The proceeds from this debt issuance were used to repay the \$2.0 billion of loans outstanding under the Term Loan Facility, dated August 2025, the proceeds of which were used to partially fund an investment in Shields Health Solutions, a leading specialty pharmacy management company. We used the remainder for general corporate purposes, including investments and repayment of indebtedness. See Note 7 to the Consolidated Financial Statements for further information regarding our debt issuance and the Term Loan Facility.

Subsidiary Borrowings. In addition to the sources of liquidity discussed above, the parent company can borrow an additional \$1.2 billion from its subsidiaries without further approvals as of December 31, 2025.

Use of Capital Resources

Short-Term and Long-Term Debt. See Note 7 to the Consolidated Financial Statements for further information regarding changes to our short-term and long-term debt. The Company may, from time to time, repay or repurchase debt in advance of maturities when it deems appropriate.

Capital Expenditures. Capital expenditures for property, equipment and computer software were \$1.2 billion in the year ended December 31, 2025 compared with \$1.4 billion in the year ended December 31, 2024. We expect to deploy approximately \$1.3 billion in capital expenditures in 2026, which will be funded primarily from operating cash flows.

Dividends. The Company currently intends to pay regular quarterly dividends, with future declarations subject to approval by our Board of Directors and the Board's determination that the declaration of dividends remains in the best interests of The Cigna Group and its shareholders. See Note 8 to the Consolidated Financial Statements for further information regarding dividend payments and declarations.

Share Repurchases. The Company maintains a share repurchase program authorized by the Board of Directors, under which it may repurchase shares of its common stock from time to time. The timing and actual number of shares repurchased will depend on a variety of factors, including price, general business and market conditions, and alternate uses of capital. The share repurchase program may be effected through open market purchases in compliance with Rule 10b-18 under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), including through Rule 10b5-1 trading plans or privately negotiated transactions. The program may be suspended or discontinued at any time.

We repurchased 11.9 million shares for approximately \$3.6 billion during the year ended December 31, 2025, compared with 20.9 million shares for approximately \$7.0 billion during the year ended December 31, 2024.

Other Sources of Funds and Uses of Capital Resources

Divestiture. As discussed in the "Key Transactions and Business Developments" section above, the HCSC transaction was completed on March 19, 2025. We used the proceeds in alignment with our capital deployment priorities, with the majority allocated to share repurchases.

Risks to Liquidity and Capital Resources

Risks to our liquidity and capital resources outlook include cash projections that may not be realized, and the demand for funds could exceed available cash if our ongoing businesses experience unexpected shortfalls in earnings or we experience material adverse effects from one or more risks or uncertainties described more fully in the "Risk Factors" section in this Form 10-K.

Guarantees and Contractual Obligations

We are contingently liable for various contractual obligations and financial and other guarantees entered into in the ordinary course of business. See Note 22 to the Consolidated Financial Statements for discussion of various guarantees.

On Balance Sheet:

Long-Term Debt. Total scheduled payments on long-term debt are \$49.9 billion through January 2056 (of which \$2.0 billion relate to the fiscal year ending December 31, 2026), which include scheduled interest payments and maturities of long-term debt. See Note 7 to the Consolidated Financial Statements for information regarding principal maturities of long-term debt.

Other Non-Current Liabilities. These include other long-term liabilities reflected in our Consolidated Balance Sheets as of December 31, 2025, including obligations associated with other postretirement and postemployment benefit obligations, reinsurance liabilities, supplemental and deferred compensation plans, and derivative financial instruments.

Uncertain Tax Positions. In the event we are unable to sustain all of our \$1.5 billion of uncertain tax positions, it could result in future tax payments of approximately \$1.2 billion. We are adequately reserved for such positions. As a result, there is minimal direct risk to earnings should we fail to sustain our positions. We cannot reasonably estimate the timing of such future payments. See Note 21 to the Consolidated Financial Statements for additional information on uncertain tax positions.

Off-Balance Sheet:

Purchase Obligations. These include agreements to purchase goods or services that are enforceable and legally binding. Purchase obligations exclude contracts that are cancellable without penalty and those that do not contractually require minimum levels of goods or services to be purchased. As of December 31, 2025, purchase obligations consisted of a total of \$6.3 billion of estimated payments required under contractual arrangements (of which we expect \$2.1 billion of purchase obligations to be paid within the next 12 months beginning January 1, 2026). This includes the following:

- \$3.2 billion of investment commitments (of which we expect \$1.0 billion of the committed amounts to be disbursed in 2026). See Note 11 of the Consolidated Financial Statements for additional information on investment commitments.
- \$3.1 billion of future service commitments (of which we expect \$1.1 billion of the committed amounts to be disbursed in 2026), primarily comprised of contracts for information technology maintenance and support and certain outsourced business processes.

CRITICAL ACCOUNTING ESTIMATES

The preparation of Consolidated Financial Statements in accordance with GAAP requires management to make estimates and assumptions that affect reported amounts and related disclosures in the Consolidated Financial Statements. Management considers an accounting estimate to be critical if:

- it requires assumptions to be made that were uncertain at the time the estimate was made; and
- changes in the estimate or different estimates that could have been selected could have a material effect on our consolidated results of operations or financial condition.

Management has discussed how critical accounting estimates are developed and selected with the Audit Committee of our Board of Directors, and the Audit Committee has reviewed the disclosures presented in this Form 10-K. We regularly evaluate items that may impact critical accounting estimates.

In addition to the estimates described below, the Notes to the Consolidated Financial Statements describe other estimates that management has made in preparation of the financial statements. Management believes the current assumptions used to estimate amounts reflected in our Consolidated Financial Statements are appropriate. However, if actual experience significantly differs from the assumptions used in estimating amounts reflected in our Consolidated Financial Statements, the resulting changes could have a material adverse effect on our consolidated results of operations and, in certain situations, could have a material adverse effect on liquidity and our financial condition. The information below presents the adverse impacts of certain possible changes in assumptions. The effect of assumption changes in the opposite direction would be a positive impact to our consolidated results of operations, liquidity or financial condition, except for assessing impairment of goodwill.

Goodwill and Other Intangible Assets

Nature of Critical Accounting Estimate. Goodwill represents the excess of the cost of businesses acquired over the fair value of their net assets at the acquisition date. Intangible assets primarily reflect the value of customer relationships and other intangibles acquired in business combinations.

Fair values of reporting units are estimated based on discounted cash flow analysis and market approach models using assumptions that we believe a hypothetical market participant would use to determine a current transaction price. The significant assumptions and estimates used in determining fair value primarily include the discount rate and future cash flows. A discount rate is selected to correspond with each reporting unit's weighted average cost of capital, consistent with that used for investment decisions considering the specific and detailed operating plans and strategies within each reporting unit. Projections of future cash flows differ by reporting unit and are consistent with our ongoing strategic projections. Future cash flows for the Evernorth Health Services reporting units are primarily driven by the forecasted gross margins of the business, as well as operating expenses and long-term growth rates. Future cash flows for our other reporting units are primarily driven by forecasted revenues, benefit expenses, operating expenses and long-term growth rates.

The fair value of intangibles and the amortization method were determined using an income approach that relies on projected future cash flows, including key assumptions for customer attrition and discount rates. Management revises amortization periods if it believes there has been a change in the length of time that an intangible asset will continue to have value.

The Company conducts its quantitative evaluation for goodwill impairment at least annually during the third quarter at the reporting unit level and performs qualitative impairment assessments on a quarterly basis to determine if events or changes in circumstances indicate that it is more likely than not that the carrying value of a reporting unit exceeds its estimated fair value.

Goodwill and Other intangible assets as of December 31, 2025 were \$44,924 million and \$28,560 million, respectively, and as of December 31, 2024, were \$44,370 million and \$29,417 million, respectively, excluding amounts classified as held for sale. See Note 19 to the Consolidated Financial Statements for additional discussion of our goodwill and other intangibles.

Effect if Different Assumptions Used. We completed our normal annual evaluations for impairment of goodwill and intangible assets during the third quarter of 2025. The evaluations support that as of December 31, 2025, the fair value estimates of our reporting units exceed their carrying values by substantial margins. Changes in assumptions concerning future financial results or other underlying assumptions, including macroeconomic factors, government legislation, changes in the competitive landscape or other market conditions (including business models), could impact our ability to achieve profitability projections. If we consistently do not achieve our earnings and cash flow projections or our cost of capital rises significantly, the assumptions and estimates underlying the goodwill and intangible asset impairment evaluations could be adversely affected and result in future impairment charges that would negatively impact our operating results and financial position.

Income Taxes - Uncertain Tax Positions

Nature of Critical Accounting Estimate. We evaluate tax positions to determine whether the benefits are more likely than not to be sustained on audit based on their technical merits. The Company establishes a liability if the probability that the position will be sustained is 50% or less. For uncertain positions that management believes are more likely than not to be sustained, the Company recognizes a liability based upon management's estimate of the most likely settlement outcome with the taxing authority. These amounts primarily relate to federal and state uncertain positions of the value and timing of deductions and uncertain positions of attributing taxable income to states.

Balances that are included in the Consolidated Balance Sheets within Accrued expenses and other liabilities were \$1,538 million and \$1,477 million as of December 31, 2025 and 2024, respectively. See Note 21 to the Consolidated Financial Statements for additional discussion around uncertain tax positions and the Liquidity and Capital Resources section of this MD&A for a discussion of their potential impact on liquidity.

Effect if Different Assumptions Used. The factors that could impact our estimates of uncertain tax positions include the likelihood of

sustaining our tax position (and related assumed interest and penalties) under audit. If our positions are upheld upon audit, our net income would increase.

Income Taxes - Valuation Allowance

Nature of Critical Accounting Estimate. Deferred income taxes in the Consolidated Balance Sheets reflect differences between the financial and income tax reporting bases of the Company's underlying assets and liabilities, and are established based upon enacted tax rates and laws. Deferred income tax assets are recognized when available evidence indicates that realization is more likely than not and a valuation allowance is established to the extent this standard is not met. It is possible that the realization of deferred tax assets may be impacted by changes in forecasted future earnings in various foreign jurisdictions or the Company's ability to generate future capital gains.

Valuation allowances that are included in the Consolidated Balance Sheets within Deferred tax liabilities, net were \$2,374 million and \$2,332 million as of December 31, 2025 and 2024, respectively. See Note 21 to the Consolidated Financial Statements for additional discussion around valuation allowances.

Effect if Different Assumptions Used. The factors that could impact our estimates of valuation allowances include changes in forecasted future earnings in foreign jurisdictions, potential international tax reform, and the Company's future ability to generate capital gains. Decreases in our valuation allowance would increase net income, while increases in our valuation allowance would decrease net income.

Unpaid Claims and Claims Expenses - Cigna Healthcare

Nature of Critical Accounting Estimate. Unpaid claims and claim expenses reflect estimates of the ultimate cost of claims that have been incurred but not reported, expected development on reported claims, claims that have been reported but not yet paid (reported claims in process) and other medical care expenses and services payable that are primarily comprised of accruals for incentives and other amounts payable to health care professionals and facilities.

Unpaid claims and claim expenses in Cigna Healthcare are primarily impacted by assumptions related to completion factors and medical cost trend. Variation of actual results from either assumption could impact the unpaid claims balance as noted below. A large number of factors may cause the medical cost trend to vary from the Company's estimates, including changes in health management practices, changes in the level and mix of benefits offered and services utilized, and changes in medical practices. Completion factors may be affected if actual claims submission rates from providers differ from estimates (that can be influenced by a number of factors, including provider mix and electronic versus manual submissions), or if changes to the Company's internal claims processing patterns occur.

Unpaid claims and claim expenses for the Cigna Healthcare segment, both gross and net of reinsurance and other recoverables, as of December 31, 2025 were \$4,241 million gross and \$4,094 million net and as of December 31, 2024 were \$5,018 million gross and \$4,859 million net. See Note 9 to the Consolidated Financial Statements for additional information regarding assumptions and methods used to estimate this liability.

Effect if Different Assumptions Used. Based on studies of our claim experience, it is reasonably possible that a 100 basis point change in the medical cost trend and a 50 basis point change in completion factors could occur in the near term. A 100 basis point increase in the medical cost trend rate would increase this liability by approximately \$115 million, resulting in a decrease in net income of approximately \$90 million after-tax, and a 50 basis point decrease in completion factors would increase this liability by approximately \$180 million, resulting in a decrease in net income of approximately \$140 million after-tax.

Valuation of Debt Security Investments

Nature of Critical Accounting Estimate. Most debt securities are classified as available for sale and are carried at fair value with changes in fair value recorded in Accumulated other comprehensive loss within Shareholders' equity. Fair value is defined as the price at which an asset could be exchanged in an orderly transaction between market participants at the balance sheet date.

Determining fair value for a financial instrument requires management judgment. The degree of judgment involved generally correlates to the level of pricing readily observable in the markets. Financial instruments with quoted prices in active markets or with market-observable inputs to determine fair value, such as public securities, generally require less judgment. Conversely, private placements including more complex securities that are traded infrequently are typically measured using pricing models that require more judgment as to the inputs and assumptions used to estimate fair value. There may be a number of alternative inputs to select based on an understanding of the issuer, the structure of the security and overall market conditions. In addition, these factors are inherently variable in nature as they change frequently in response to market conditions. Approximately 60% of our debt securities are public securities and approximately 40% are private placement securities.

Typically, the most significant input in the measurement of fair value is the market interest rate used to discount the estimated future cash flows of the instrument. Such market rates are derived by calculating the appropriate spreads over comparable U.S. Treasury securities, based on the credit quality, industry and structure of the asset.

Balances that are included in the Consolidated Balance Sheets within Investments and Long-term investments were \$8,362 million and \$9,423 million as of December 31, 2025 and 2024, respectively (inclusive of amounts held for sale as of December 31, 2024). See Notes 11A and 12 to the Consolidated Financial Statements for a discussion of our fair value measurements, the procedures performed by management to determine that the amounts represent appropriate estimates and our accounting policy regarding unrealized appreciation on debt securities.

Effect if Different Assumptions Used. If the derived market rates used to calculate fair value increased by 100 basis points, the fair value of the total debt security portfolio of \$8.4 billion would decrease by approximately \$0.4 billion, resulting in an after-tax decrease to shareholders' equity of approximately \$0.3 billion as of December 31, 2025.

INVESTMENT ASSETS

Information regarding our investment assets is included in Notes 11, 12, 13 and 15 to the Consolidated Financial Statements.

Investment Outlook

Future realized and unrealized investment results will be driven largely by market conditions, and these future conditions are not reasonably predictable. We believe that the vast majority of our investments will continue to perform under their contractual terms. We manage the portfolio for long-term economics; therefore, we expect to hold a significant portion of these assets for the long term. Although future declines in investment fair values remain possible due to interest rate movements and credit deterioration due to both investment-specific uncertainties and global economic uncertainties as discussed below, we do not expect these losses to have a material unfavorable effect on our financial condition or liquidity. The below discussion addresses the strategies and risks associated with our various classes of investment assets. See Part I, Item 1A - "Risk Factors" of this Form 10-K for additional information regarding risks associated with our investment portfolio.

Debt Securities

The carrying value of our debt securities portfolio decreased from \$9.4 billion as of December 31, 2024 to \$8.4 billion as of December 31, 2025, primarily reflecting the HCSC transaction. See Note 5 to the Consolidated Financial Statements for further information. Our portfolio remains in a net unrealized depreciation position due to generally increasing interest rates over the past few years.

As of December 31, 2025, \$7.3 billion, or 87%, of the debt securities in our investment portfolio were investment grade (Baa and above, or equivalent) and the remaining \$1.1 billion were below investment grade. The majority of the bonds that are below investment grade were rated at the higher end of the non-investment-grade spectrum. These quality characteristics have not materially changed since the prior year and remain consistent with our investment strategy.

Investments in debt securities are diversified by issuer, geography and industry. On an aggregate basis, the debt securities portfolio continues to perform according to original expectations, which includes a long-term economic investment strategy. Primary risks facing many of the issuers in our portfolio include ongoing geopolitical events and economic conditions. To date, most issuers have been successful in managing these issues without a meaningful change in credit quality. We continue to monitor the economic environment and its effect on our portfolio; we also continue to consider the impact of various factors in determining the allowance for credit losses on debt securities, which is discussed in Note 11 to the Consolidated Financial Statements.

Commercial Mortgage Loans

As of December 31, 2025, our \$1.2 billion commercial mortgage loan portfolio consisted of approximately 40 fixed-rate loans, diversified by property type, location and borrower. These loans are carried in our Consolidated Balance Sheets at their unpaid principal balance, net of an allowance for expected credit losses. As a result of increasing market interest rates since the majority of these loans were made, the carrying value exceeds the market value of these loans as of December 31, 2025. Given the quality and diversity of the underlying real estate, positive debt service coverage, and significant borrower cash invested in the property generally ranging between 30% and 40%, we remain confident that the vast majority of borrowers will continue to perform as expected under their contract terms. For further discussion of the results and changes in key credit quality indicators, see Note 11 to the Consolidated Financial Statements.

Office sector fundamentals are weak but have begun to stabilize for higher-quality assets. Lower-quality assets will likely continue to experience value erosion due to weak tenant demand and low investor interest. Additionally, the current macroeconomic headwinds

are impacting capital markets and reducing investor appetite for capital-intensive assets (e.g., offices and regional shopping malls). Our commercial mortgage loan portfolio has no exposure to regional shopping malls and less than 25% exposure to office properties. Although future losses remain possible due to further credit deterioration, we do not expect these losses to have a material unfavorable effect on our results of operations, financial condition or liquidity.

Other Long-Term Investments

Other long-term investments of \$5.0 billion as of December 31, 2025 included investments in securities limited partnerships and real estate limited partnerships, direct investments in real estate joint ventures, and other deposit activity that is required to support various insurance and health services businesses. These limited partnership entities typically invest in mezzanine debt or equity of privately held companies and equity real estate. Given our subordinate position in the capital structure of these underlying entities, we assume a higher level of risk for higher expected returns. To mitigate risk, these investments are diversified by industry sector or property type and geographic region. No single partnership investment exceeded 3% of our securities and real estate limited partnership portfolio.

We expect continued volatility in private equity and real estate fund performance going forward as fair market valuations are adjusted to reflect market and portfolio transactions. Less than 4% of our other long-term investments are exposed to real estate in the office sector.

Unconsolidated Subsidiary Investments Portfolio

We participate in an insurance joint venture in China with a 50% ownership interest. We account for this joint venture under the equity method of accounting. Our 50% share of the investment portfolio supporting the joint venture's liabilities was approximately \$18.2 billion as of December 31, 2025. These investments were comprised of approximately 70% debt securities, including government and corporate debt diversified by issuer, industry and geography; 20% equities, including mutual funds, equity securities and private equity partnerships; and 10% long-term deposits and policy loans. We continuously review the joint venture's investment strategy and its execution. There were no investments with a material unrealized loss as of December 31, 2025. See Note 14 to the Consolidated Financial Statements in this Form 10-K for additional information regarding unconsolidated subsidiaries.

MARKET RISK

Our assets and liabilities include financial instruments subject to the risk of potential losses from adverse changes in market rates and prices. Our primary market risk exposure from financial instruments is our interest-rate risk exposure to fixed-rate, medium-term instruments. Changes in market interest rates affect the value of instruments that promise a fixed return.

Consistent with disclosure requirements, the following items have been excluded from this consideration of market risk for financial instruments: changes in the fair values of insurance-related assets and liabilities as disclosed in Note 9 to the Consolidated Financial Statements (because their primary risks are insurance rather than market risk); changes in the fair values of investments recorded using the equity method of accounting and liabilities for pension and other postretirement and postemployment benefit plans (and related assets); and changes in the fair values of other significant assets and liabilities, such as goodwill, taxes and various accrued liabilities (because they are not financial instruments, their primary risks are other than market risks).

Our Management of Market Risks

We predominantly rely on two techniques to manage our exposure to market risk:

- ***Investment/liability matching.*** We generally select investment assets with characteristics (such as duration, yield, currency and liquidity) that correspond to the underlying characteristics of our related insurance and contractholder liabilities so that we can match the investments to our obligations. Shorter-term investments generally support shorter-term life and health liabilities. Medium-term, fixed-rate investments support interest-sensitive and medium-term health liabilities. Longer-term investments generally support products with longer payout periods such as annuities.
- ***Use of derivatives.*** We use derivative financial instruments to reduce our primary market risks. See Note 11 to the Consolidated Financial Statements for additional information about derivative financial instruments.

Effect of Market Fluctuations

We determine the sensitivity of market risk for our fixed income financial instruments, including debt securities and commercial mortgage loans, by estimating the present value of future cash flows using duration modeling and applying a 100 basis point increase in interest rates. The effect of these hypothetical changes in market rates or prices on the fair value of certain noninsurance financial instruments would have been as follows:

Market scenario for certain noninsurance financial instruments

| <i>(in billions)</i> | Loss in Fair Value | |
|---|------------------------------|------------------------------|
| | December 31, 2025 | December 31, 2024 |
| 100 basis point increase in interest rates (excluding the Company's long-term debt) | \$ 0.5 | \$ 0.6 |

In the event of a hypothetical 100 basis point increase in interest rates, the fair value of the Company's long-term debt would decrease approximately \$2.1 billion at December 31, 2025 and \$1.8 billion at December 31, 2024. Changes in the fair value of our long-term debt do not impact our financial position or operating results since long-term debt is not required to be recorded at fair value. See Note 7 to the Consolidated Financial Statements for additional information about the Company's debt.

Item 7A. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

The information contained under the caption "Market Risk" in the MD&A section of this Form 10-K is incorporated by reference.

Item 8. FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA

Report of Independent Registered Public Accounting Firm

To the Board of Directors and Shareholders of The Cigna Group

Opinions on the Financial Statements and Internal Control over Financial Reporting

We have audited the accompanying consolidated balance sheets of The Cigna Group and its subsidiaries (the "Company") as of December 31, 2025 and 2024, and the related consolidated statements of income, comprehensive income, changes in total equity and cash flows for each of the three years in the period ended December 31, 2025, including the related notes and financial statement schedules listed in the index appearing on page FS-1 of this Form 10-K (collectively referred to as the "consolidated financial statements"). We also have audited the Company's internal control over financial reporting as of December 31, 2025, based on criteria established in *Internal Control - Integrated Framework* (2013) issued by the Committee of Sponsoring Organizations of the Treadway Commission (COSO).

In our opinion, the consolidated financial statements referred to above present fairly, in all material respects, the financial position of the Company as of December 31, 2025 and 2024, and the results of its operations and its cash flows for each of the three years in the period ended December 31, 2025 in conformity with accounting principles generally accepted in the United States of America. Also in our opinion, the Company maintained, in all material respects, effective internal control over financial reporting as of December 31, 2025, based on criteria established in *Internal Control - Integrated Framework* (2013) issued by the COSO.

Basis for Opinions

The Company's management is responsible for these consolidated financial statements, for maintaining effective internal control over financial reporting, and for its assessment of the effectiveness of internal control over financial reporting, included in Management's Annual Report on Internal Control over Financial Reporting appearing under Item 9A. Our responsibility is to express opinions on the Company's consolidated financial statements and on the Company's internal control over financial reporting based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (PCAOB) and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.

We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audits to obtain reasonable assurance about whether the consolidated financial statements are free of material misstatement, whether due to error or fraud, and whether effective internal control over financial reporting was maintained in all material respects.

Our audits of the consolidated financial statements included performing procedures to assess the risks of material misstatement of the consolidated financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the consolidated financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the consolidated financial statements. Our audit of internal control over financial reporting included obtaining an understanding of internal control over financial reporting, assessing the risk that a material weakness exists, and testing and evaluating the design and operating effectiveness of internal control based on the assessed risk. Our audits also included performing such other procedures as we considered necessary in the circumstances. We believe that our audits provide a reasonable basis for our opinions.

Definition and Limitations of Internal Control over Financial Reporting

A company's internal control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. A company's internal control over financial reporting includes those policies and procedures that (i) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the company; (ii) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the company are being made only in accordance with authorizations of management and directors of the company; and (iii) provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use, or disposition of the company's assets that could have a material effect on the financial statements.

Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.

Critical Audit Matters

The critical audit matter communicated below is a matter arising from the current period audit of the consolidated financial statements that was communicated or required to be communicated to the audit committee and that (i) relates to accounts or disclosures that are material to the consolidated financial statements and (ii) involved our especially challenging, subjective, or complex judgments. The communication of critical audit matters does not alter in any way our opinion on the consolidated financial statements, taken as a whole, and we are not, by communicating the critical audit matter below, providing a separate opinion on the critical audit matter or on the accounts or disclosures to which it relates.

Valuation of incurred but not reported (IBNR) liabilities plus expected development on reported claims and reported claims in process for the Cigna Healthcare segment

As described in Note 9 to the consolidated financial statements, the total of incurred but not reported (IBNR) liabilities plus expected development on reported claims and reported claims in process for the Cigna Healthcare segment as of December 31, 2025 was \$4.0 billion. Management estimates the liability for claims incurred in each month by applying the current estimates of completion factors to the current paid claims data. As disclosed by management, the unpaid claims liability is primarily impacted by assumptions related to completion factors and medical cost trend. Management develops completion factors by comparing the claim incurral date to the date claims were paid. Completion factors are impacted by several key items including changes in: 1) electronic (auto-adjudication) versus manual claim processing; 2) frequency and timeliness of provider claims submissions; 3) number of customers and 4) the mix of products. Management uses historical completion factors combined with an analysis of current trends and operational factors to develop current estimates of completion factors. Medical cost trend is primarily impacted by medical service utilization and unit costs.

The principal considerations for our determination that performing procedures relating to the valuation of IBNR liabilities plus expected development on reported claims and reported claims in process for the Cigna Healthcare segment is a critical audit matter are (i) the significant judgment by management when developing the estimate of IBNR liabilities plus expected development on reported claims and reported claims in process for the Cigna Healthcare segment; (ii) a high degree of auditor judgment, subjectivity and effort in performing procedures and evaluating management's significant assumptions related to completion factors and medical cost trend; and (iii) the audit effort involved the use of professionals with specialized skill and knowledge.

Addressing the matter involved performing procedures and evaluating audit evidence in connection with forming our overall opinion on the consolidated financial statements. These procedures included testing the effectiveness of controls relating to the valuation of IBNR liabilities plus expected development on reported claims and reported claims in process for the Cigna Healthcare segment, including controls over the development of significant assumptions related to completion factors and medical cost trend. These procedures also included, among others, (i) testing the completeness and accuracy of data provided by management and (ii) the involvement of professionals with specialized skill and knowledge to assist in evaluating the reasonableness of management's estimate by performing one or a combination of procedures, including (a) developing an independent estimate of IBNR liabilities plus expected development on reported claims and reported claims in process for the Cigna Healthcare segment, and comparing the independent range of outcomes to management's estimate; (b) evaluating the appropriateness of management's actuarial methodologies and the reasonableness of management's significant assumptions related to completion factors and medical cost trend by considering claims reporting and payment experience, historical trends, and other industry data; and (c) evaluating the consistency of management's actuarial methodologies period-over-period.

/s/ PricewaterhouseCoopers LLP
Hartford, Connecticut
February 26, 2026

We have served as the Company's auditor since 1983.

The Cigna Group
Consolidated Statements of Income

| | For the Years Ended December 31, | | |
|---|----------------------------------|-----------------|-----------------|
| | 2025 | 2024 | 2023 |
| <i>(In millions, except per share amounts)</i> | | | |
| Revenues | | | |
| Pharmacy revenues | \$ 216,672 | \$ 185,362 | \$ 137,243 |
| Premiums | 40,261 | 45,996 | 44,237 |
| Fees and other revenues | 16,921 | 14,790 | 12,619 |
| Net investment income | 1,046 | 973 | 1,166 |
| TOTAL REVENUES | 274,900 | 247,121 | 195,265 |
| Benefits and expenses | | | |
| Pharmacy and other service costs | 214,991 | 182,509 | 133,801 |
| Medical costs and other benefit expenses | 34,349 | 38,648 | 36,287 |
| Selling, general and administrative expenses | 14,617 | 14,844 | 14,822 |
| Amortization of acquired intangible assets | 1,743 | 1,703 | 1,819 |
| TOTAL BENEFITS AND EXPENSES | 265,700 | 237,704 | 186,729 |
| Income from operations | 9,200 | 9,417 | 8,536 |
| Interest expense and other | (1,408) | (1,435) | (1,446) |
| Net gain (loss) on sale of businesses | 13 | 24 | (1,499) |
| Net investment losses | (24) | (2,737) | (78) |
| Income before income taxes | 7,781 | 5,269 | 5,513 |
| TOTAL INCOME TAXES | 1,493 | 1,491 | 141 |
| Net income | 6,288 | 3,778 | 5,372 |
| Less: Net income attributable to noncontrolling interests | 331 | 344 | 208 |
| SHAREHOLDERS' NET INCOME | \$ 5,957 | \$ 3,434 | \$ 5,164 |
| Shareholders' net income per share | | | |
| Basic | \$ 22.33 | \$ 12.25 | \$ 17.57 |
| Diluted | \$ 22.18 | \$ 12.12 | \$ 17.39 |

The accompanying Notes to the Consolidated Financial Statements are an integral part of these statements.

The Cigna Group
Consolidated Statements of Comprehensive Income

| <i>(In millions)</i> | For the Years Ended December 31, | | |
|--|----------------------------------|----------|----------|
| | 2025 | 2024 | 2023 |
| Net income | \$ 6,288 | \$ 3,778 | \$ 5,372 |
| Other comprehensive income (loss), net of tax | | | |
| Net unrealized (depreciation) appreciation on securities and derivatives | (238) | 661 | 503 |
| Net long-duration insurance and contractholder liabilities measurement adjustments | (291) | (1,067) | (715) |
| Net translation gains (losses) on foreign currencies | 71 | (49) | 5 |
| Postretirement benefits liability adjustment | (7) | (22) | 1 |
| Other comprehensive loss, net of tax | (465) | (477) | (206) |
| Total comprehensive income | 5,823 | 3,301 | 5,166 |
| Comprehensive income attributable to noncontrolling interests | | | |
| Net income attributable to redeemable noncontrolling interests | — | — | 180 |
| Net income attributable to other noncontrolling interests | 331 | 344 | 28 |
| Total comprehensive income attributable to noncontrolling interests | 331 | 344 | 208 |
| SHAREHOLDERS' COMPREHENSIVE INCOME | \$ 5,492 | \$ 2,957 | \$ 4,958 |

The accompanying Notes to the Consolidated Financial Statements are an integral part of these statements.

The Cigna Group
Consolidated Balance Sheets

| <i>(In millions)</i> | As of December 31, | |
|--|--------------------|-------------------|
| | 2025 | 2024 |
| Assets | | |
| Cash and cash equivalents | \$ 7,676 | \$ 7,550 |
| Investments | 1,056 | 665 |
| Accounts receivable, net | 28,768 | 24,227 |
| Inventories | 7,338 | 6,692 |
| Other current assets | 2,976 | 2,732 |
| Assets of businesses held for sale | — | 7,004 |
| Total current assets | 47,814 | 48,870 |
| Long-term investments | 18,471 | 15,128 |
| Reinsurance recoverables | 4,103 | 4,378 |
| Property and equipment | 3,651 | 3,654 |
| Goodwill | 44,924 | 44,370 |
| Other intangible assets | 28,560 | 29,417 |
| Other assets | 2,885 | 2,786 |
| Separate account assets | 7,511 | 7,278 |
| TOTAL ASSETS | \$ 157,919 | \$ 155,881 |
| Liabilities | | |
| Current insurance and contractholder liabilities | \$ 5,710 | \$ 5,388 |
| Pharmacy and other service costs payable | 30,333 | 28,465 |
| Accounts payable | 10,659 | 9,294 |
| Accrued expenses and other liabilities | 9,048 | 9,387 |
| Short-term debt | 592 | 3,035 |
| Liabilities of businesses held for sale | — | 2,410 |
| Total current liabilities | 56,342 | 57,979 |
| Non-current insurance and contractholder liabilities | 9,938 | 10,254 |
| Deferred tax liabilities, net | 7,145 | 6,975 |
| Other non-current liabilities | 4,238 | 3,215 |
| Long-term debt | 30,871 | 28,937 |
| Separate account liabilities | 7,511 | 7,278 |
| TOTAL LIABILITIES | 116,045 | 114,638 |
| Contingencies — Note 22 | | |
| Shareholders' equity | | |
| Common stock ⁽¹⁾ | 4 | 4 |
| Additional paid-in capital | 31,790 | 31,288 |
| Accumulated other comprehensive loss | (2,806) | (2,341) |
| Retained earnings | 47,865 | 43,519 |
| Less: Treasury stock, at cost | (35,140) | (31,437) |
| TOTAL SHAREHOLDERS' EQUITY | 41,713 | 41,033 |
| Noncontrolling interests | 161 | 210 |
| Total equity | 41,874 | 41,243 |
| Total liabilities and equity | \$ 157,919 | \$ 155,881 |

⁽¹⁾ Par value per share, \$0.01; shares issued, 405 million as of December 31, 2025 and 403 million as of December 31, 2024; authorized shares, 600 million.

The accompanying Notes to the Consolidated Financial Statements are an integral part of these statements.

The Cigna Group

Consolidated Statements of Changes in Total Equity

| <i>(In millions)</i> | Common Stock | Additional Paid-in Capital | Accumulated Other Comprehensive (Loss) | Retained Earnings | Treasury Stock | Shareholders' Equity | Other Non- controlling Interests | Total Equity | Redeemable Noncontrolling Interests |
|---|-----------------|----------------------------------|---|----------------------|--------------------|-------------------------|---|------------------|---|
| Balance at December 31, 2022 | \$ 4 | \$ 30,233 | \$ (1,658) | \$ 37,940 | \$ (21,844) | \$ 44,675 | \$ 13 | \$ 44,688 | \$ 66 |
| Effect of issuing stock for employee benefit plans | | 477 | | | (112) | 365 | | 365 | |
| Other comprehensive loss | | | (206) | | | (206) | | (206) | — |
| Net income | | | | 5,164 | | 5,164 | 28 | 5,192 | 180 |
| Common dividends declared (per share: \$4.92) | | | | (1,452) | | (1,452) | | (1,452) | |
| Repurchase of common stock | | — | | | (2,282) | (2,282) | | (2,282) | |
| Other transactions impacting noncontrolling interests | | (41) | | | | (41) | (20) | (61) | (139) |
| Balance at December 31, 2023 | \$ 4 | \$ 30,669 | \$ (1,864) | \$ 41,652 | \$ (24,238) | \$ 46,223 | \$ 21 | \$ 46,244 | \$ 107 |
| Effect of issuing stock for employee benefit plans | | 619 | | | (120) | 499 | | 499 | |
| Other comprehensive loss | | | (477) | | | (477) | | (477) | — |
| Net income | | | | 3,434 | | 3,434 | 344 | 3,778 | — |
| Common dividends declared (per share: \$5.60) | | | | (1,567) | | (1,567) | | (1,567) | |
| Repurchase of common stock | | — | | | (7,079) | (7,079) | | (7,079) | |
| Other transactions impacting noncontrolling interests | | — | | | | — | (155) | (155) | (107) |
| Balance at December 31, 2024 | \$ 4 | \$ 31,288 | \$ (2,341) | \$ 43,519 | \$ (31,437) | \$ 41,033 | \$ 210 | \$ 41,243 | \$ — |
| Effect of issuing stock for employee benefit plans | | 502 | | | (114) | 388 | | 388 | |
| Other comprehensive loss | | | (465) | | | (465) | | (465) | — |
| Net income | | | | 5,957 | | 5,957 | 331 | 6,288 | — |
| Common dividends declared (per share: \$6.04) | | | | (1,611) | | (1,611) | | (1,611) | |
| Repurchase of common stock | | — | | | (3,589) | (3,589) | | (3,589) | |
| Other transactions impacting noncontrolling interests | | — | | | | — | (380) | (380) | — |
| Balance at December 31, 2025 | \$ 4 | \$ 31,790 | \$ (2,806) | \$ 47,865 | \$ (35,140) | \$ 41,713 | \$ 161 | \$ 41,874 | \$ — |

The accompanying Notes to the Consolidated Financial Statements are an integral part of these statements.

The Cigna Group
Consolidated Statements of Cash Flows

| <i>(In millions)</i> | For the Years Ended December 31, | | |
|--|---|----------------|----------------|
| | 2025 | 2024 | 2023 |
| Cash Flows from Operating Activities | | | |
| Net income | \$ 6,288 | \$ 3,778 | \$ 5,372 |
| Adjustments to reconcile net income to net cash provided by operating activities: | | | |
| Depreciation and amortization | 2,775 | 2,775 | 3,035 |
| Investment losses, net | 24 | 2,737 | 78 |
| Deferred income tax expense (benefit) | 326 | (95) | (1,659) |
| Net (gain) loss on sale of businesses | (13) | (24) | 1,499 |
| Net changes in assets and liabilities, net of non-operating effects: | | | |
| Accounts receivable, net | (4,630) | (7,369) | (1,663) |
| Inventories | (646) | (1,032) | (868) |
| Reinsurance recoverable and Other assets | (897) | (485) | (539) |
| Insurance liabilities | 1,247 | (591) | 584 |
| Pharmacy and other service costs payable | 1,868 | 8,757 | 2,030 |
| Accounts payable and Accrued expenses and other liabilities | 2,797 | 1,138 | 3,481 |
| Other, net | 462 | 774 | 463 |
| NET CASH PROVIDED BY OPERATING ACTIVITIES | 9,601 | 10,363 | 11,813 |
| Cash Flows from Investing Activities | | | |
| Proceeds from investments sold: | | | |
| Debt securities and equity securities | 782 | 856 | 1,078 |
| Investment maturities and repayments: | | | |
| Debt securities and equity securities | 986 | 839 | 972 |
| Commercial mortgage loans | 223 | 188 | 186 |
| Other sales, maturities and repayments (primarily short-term and other long-term investments) | 884 | 752 | 586 |
| Investments purchased or originated: | | | |
| Debt securities and equity securities | (5,788) | (1,386) | (4,334) |
| Commercial mortgage loans | (117) | (54) | (118) |
| Other (primarily short-term and other long-term investments) | (1,416) | (1,309) | (1,205) |
| Property and equipment purchases, net | (1,212) | (1,406) | (1,573) |
| Acquisitions, net of cash acquired | (597) | (131) | (447) |
| Divestitures, net of cash sold | 2,984 | 521 | 13 |
| Renewable energy tax credit equity investments | (1,102) | (1,030) | (313) |
| Other, net | (34) | 58 | (19) |
| NET CASH USED IN INVESTING ACTIVITIES | (4,407) | (2,102) | (5,174) |
| Cash Flows from Financing Activities | | | |
| Deposits and interest credited to contractholder deposit funds | 152 | 166 | 167 |
| Withdrawals and benefit payments from contractholder deposit funds | (253) | (228) | (223) |
| Net change in short-term debt, excluding term loan | (927) | (402) | 1,198 |
| Net proceeds on issuance of term loan | 1,999 | — | — |
| Repayment of term loan | (2,000) | — | — |
| Repayment of long-term debt | (4,197) | (3,000) | (2,967) |
| Net proceeds on issuance of long-term debt | 4,458 | 4,462 | 1,491 |
| Repurchase of common stock | (3,621) | (7,034) | (2,284) |
| Issuance of common stock | 203 | 305 | 187 |
| Common stock dividend paid | (1,611) | (1,567) | (1,450) |
| Other, net | (624) | (349) | (413) |
| NET CASH USED IN FINANCING ACTIVITIES | (6,421) | (7,647) | (4,294) |
| Effect of foreign currency rate changes on cash, cash equivalents and restricted cash | 32 | (20) | 16 |
| Net (decrease) increase in cash, cash equivalents and restricted cash | (1,195) | 594 | 2,361 |
| Cash, cash equivalents and restricted cash January 1, ⁽¹⁾ | 8,931 | 8,337 | 5,976 |
| Cash, cash equivalents and restricted cash December 31, ⁽¹⁾ | 7,736 | 8,931 | 8,337 |
| Cash and cash equivalents reclassified to assets of businesses held for sale | — | (1,339) | (467) |
| Cash, cash equivalents and restricted cash December 31, per Consolidated Balance Sheets ⁽¹⁾ | \$ 7,736 | \$ 7,592 | \$ 7,870 |
| Supplemental Disclosure of Cash Information: | | | |
| Interest paid | \$ 1,350 | \$ 1,342 | \$ 1,330 |

⁽¹⁾ Restricted cash and cash equivalents were reported in other long-term investments and Other assets.

The accompanying Notes to the Consolidated Financial Statements are an integral part of these statements.

THE CIGNA GROUP

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

TABLE OF CONTENTS

| <u>Note Number</u> | <u>Footnote</u> | <u>Page</u> |
|---|--|-------------|
| BUSINESS AND CAPITAL STRUCTURE | | |
| 1 | Description of Business | 61 |
| 2 | Summary of Significant Accounting Policies | 61 |
| 3 | Accounts Receivable, Net | 65 |
| 4 | Supplier Finance Program | 66 |
| 5 | Divestiture | 66 |
| 6 | Earnings Per Share | 67 |
| 7 | Debt | 68 |
| 8 | Common and Preferred Stock | 70 |
| INSURANCE INFORMATION | | |
| 9 | Insurance and Contractholder Liabilities | 71 |
| 10 | Reinsurance | 75 |
| INVESTMENTS | | |
| 11 | Investments | 77 |
| 12 | Fair Value Measurements | 82 |
| 13 | Variable Interest Entities | 86 |
| 14 | Collectively Significant Operating Unconsolidated Subsidiaries | 87 |
| 15 | Accumulated Other Comprehensive Income (Loss) | 89 |
| WORKFORCE MANAGEMENT AND COMPENSATION | | |
| 16 | Strategic Optimization Program | 90 |
| 17 | Pension | 90 |
| 18 | Employee Incentive Plans | 93 |
| PROPERTY AND OTHER ASSET BALANCES | | |
| 19 | Goodwill, Other Intangibles, and Property and Equipment | 96 |
| COMPLIANCE, REGULATION AND CONTINGENCIES | | |
| 20 | Shareholders' Equity and Dividend Restrictions | 98 |
| 21 | Income Taxes | 99 |
| 22 | Contingencies and Other Matters | 103 |
| RESULTS DETAILS | | |
| 23 | Segment Information | 104 |

Note 1 – Description of Business

The Cigna Group®, together with its subsidiaries (either individually or collectively referred to as the "Company," "we," "us" or "our"), is a global health company committed to creating a better future for every individual and every community. Powered by our dedicated people and valued brands, we advance our mission to improve the health and vitality of those we serve.

Our subsidiaries offer a differentiated set of pharmacy, medical, behavioral, dental, and related products and services. The majority of these products and services are offered through employers and other entities, such as governmental and nongovernmental organizations, unions and associations. Certain subsidiaries also offer health and dental insurance products to individuals in the United States and select international markets. In addition to these operations, The Cigna Group also has certain run-off operations.

A full description of our segments follows:

The **Evernorth Health Services**® reportable segment includes the Pharmacy Benefit Services and the Specialty and Care Services operating segments, which provide independent and coordinated health solutions and capabilities to enable the health care system to work better and help people live healthier lives.

Pharmacy Benefit Services drives high-quality, cost-effective pharmacy care through various services, such as drug claim adjudication, retail pharmacy network administration, benefit design consultation, drug utilization review, drug formulary management and access to our home delivery pharmacy. Specialty and Care Services provides specialty drugs for the treatment of complex and rare diseases, specialty distribution of pharmaceuticals and medical supplies, as well as clinical programs to help our clients drive better whole-person health outcomes through care services.

The **Cigna Healthcare**® reportable segment includes the U.S. Healthcare and International Health operating segments, which provide comprehensive medical and coordinated solutions to clients and customers. U.S. Healthcare provides medical plans and other benefits and solutions for insured and self-insured clients as well as for individual and family plan customers. International Health provides health care solutions in our international markets, as well as health solutions for globally mobile individuals and employees of multinational organizations. U.S. Healthcare also included the Medicare Advantage and related businesses until the divestiture of such businesses to Health Care Services Corporation ("HCSC") on March 19, 2025 (see Note 5 to the Consolidated Financial Statements for further information).

Other Operations comprises the remainder of our business operations, which includes certain continuing business (corporate-owned life insurance ("COLI")), as well as run-off and other non-strategic businesses. Our run-off businesses include the (i) variable annuity reinsurance business that was effectively exited through reinsurance with Berkshire Hathaway Life Insurance Company of Nebraska ("Berkshire") in 2013; (ii) settlement annuity business; and (iii) individual life insurance and annuity and retirement benefits businesses, which were sold through reinsurance agreements.

Corporate reflects amounts not allocated to operating segments, including net interest expense (defined as interest on corporate financing less net investment income on investments not supporting segment and other operations), certain litigation matters, expense associated with our frozen pension plans, charitable contributions, operating severance, certain overhead and enterprise-wide project costs, and eliminations for products and services sold between segments.

Note 2 – Summary of Significant Accounting Policies

Basis of Presentation

The Consolidated Financial Statements include the accounts of The Cigna Group and its consolidated subsidiaries. Intercompany transactions and accounts have been eliminated in consolidation. These Consolidated Financial Statements were prepared in conformity with accounting principles generally accepted in the United States of America ("GAAP").

Amounts recorded in the Consolidated Financial Statements necessarily reflect management's estimates and assumptions about medical costs, investment, tax and receivable valuations, interest rates, and other factors. Significant estimates are discussed throughout these Notes; however, actual results could differ from those estimates. The impact of a change in estimate is generally included in earnings in the period of adjustment.

Recent Accounting Pronouncements

There were no new accounting standards adopted during the year ended December 31, 2025 that had a material impact on our Consolidated Financial Statements.

Accounting Guidance Not Yet Adopted

Accounting Standards Update ("ASU") 2025-06, Targeted Improvements to the Accounting for Internal-Use Software (Subtopic 350-40). Required to be adopted January 1, 2028, with early adoption permitted and requires the following:

- Seeks to improve the operability of the recognition guidance considering different methods of software development, mainly more iterative methods, by:
 - Aligning internal-use software capitalization requirements to probable completion and required funding and authorization.
 - Clarifying certain criteria for probable completion, including that the significant performance requirements of the software be identified and no longer subject to substantial revision.
- Transition options include prospective from the date of adoption as well as retrospective and modified retrospective adoption.

The Company is currently evaluating the impact of this guidance on our results of operations and financial position, as well as potential impacts to information systems and controls.

ASU 2024-03, Disaggregation of Income Statement Expenses (Subtopic 220-40). Required to be adopted for the annual reporting period ending December 31, 2027 and for interim reporting periods beginning January 1, 2028 and requires:

- Additional expense detail in the footnotes disaggregating income statement captions including any of the following: inventory purchases; employee compensation; depreciation; and intangible asset amortization, as well as a qualitative description of remaining expenses to reconcile to the total expense within those income statement captions;
- Disclosure of the definition and total amount of selling expenses; and
- Transition options include prospective from the date of adoption as well as retrospective adoption.

The only financial statement impact resulting from adoption will be increased disclosure. The Company continues to evaluate the effects the adoption requirements on information systems and controls.

Significant Accounting Policies

The Company's accounting policies are described either in this Note or in the applicable Notes to the Consolidated Financial Statements as listed in the table of contents on page [60](#).

A. Cash and Cash Equivalents

Cash and cash equivalents are carried at cost that approximates fair value. Cash equivalents consist of short-term investments with maturities of three months or less from the time of purchase. The Company reclassifies cash overdraft positions to liabilities when the legal right of offset does not exist.

B. Inventories

Inventories consist of prescription drugs and medical supplies and are stated at the lower of first-in-first-out cost or net realizable value.

C. Translation of Foreign Currencies

The Company generally conducts its international business through foreign operating entities that maintain assets and liabilities in local currencies that are their functional currencies. The Company uses exchange rates as of the balance sheet date to translate assets and liabilities into U.S. dollars. Translation gains or losses on functional currencies, net of applicable taxes, are recorded in Accumulated other comprehensive loss. The Company uses average monthly exchange rates during the year to translate revenues and expenses into U.S. dollars.

D. Pharmacy Revenues and Costs

Pharmacy Revenues. Pharmacy revenues are primarily derived from providing pharmacy benefit management services to clients and customers. Pharmacy revenues are recognized when control of the promised goods or services is transferred to clients and customers in an amount that reflects the consideration the Company expects to receive for those goods or services.

The Company provides or makes available various services supporting benefit management and claims administration and is generally obligated to provide prescription drugs to clients' members using multiple distribution methods, including retail networks, home delivery and specialty pharmacies. These goods and services are integrated into a single performance obligation to process claims, dispense prescription drugs and provide other services over the contract period (generally three years). This performance obligation is satisfied as the business stands ready to fulfill its obligation.

Revenues for dispensing prescription drugs through retail pharmacies are reported gross and consist of the prescription price (ingredient cost and dispensing fee) contracted with clients, including the customer copayment, and any associated fees for services, because the Company acts as the principal in these arrangements. When a prescription is presented to a retail network pharmacy, the Company is solely responsible for customer eligibility, drug utilization review, drug-to-drug interaction review, any required clinical intervention, plan provision information, payment to the pharmacy and client billing. These revenues are recognized based on the full prescription price when the pharmacy claim is processed and approved for payment. The Company also provides benefit design and formulary consultation services to clients and negotiates separate contractual relationships with clients and network pharmacies. These factors indicate that the Company has control over these transactions until the prescription is processed. Revenues are billed, due and recognized at contract rates either on a periodic basis or as services are provided (such as based on volume of claims processed). This recognition pattern aligns with the benefits from services provided.

Home delivery and specialty pharmacy revenues are due and recognized as each prescription is shipped, net of reserves for discounts and contractual allowances estimated based on historical experience. Any differences between estimates and actual collections are reflected in Pharmacy revenues when payments are received. Historically, adjustments to original estimates and returns have not been material. The Company has elected the practical expedient to account for shipping and handling as a fulfillment activity.

We may also provide certain financial and performance guarantees, including a minimum level of discounts a client may receive, generic utilization rates and various service levels. Clients may be entitled to receive compensation if we fail to meet the guarantees. Actual performance is compared to the contractual guarantee for each measure throughout the period and the Company defers revenue for any estimated payouts within Accrued expenses and other liabilities (current). These estimates are adjusted and paid at the end of the annual guarantee period. Historically, adjustments to original estimates have not been material. The liability for these financial and performance guarantees was \$1.8 billion as of December 31, 2025 and \$1.9 billion as of December 31, 2024.

The Company administers programs through which we may receive rebates and other vendor consideration from pharmaceutical manufacturers. The amounts of such rebates or other vendor consideration shared with pharmacy benefit management services clients vary based on the contractual arrangement with the client and in some cases the type of consideration received from the pharmaceutical manufacturer. Rebates and other vendor consideration payable to pharmacy benefit management services clients are recorded as a reduction of Pharmacy revenues. Estimated amounts payable to clients are based on contractual sharing arrangements between the Company and the client and these amounts are adjusted when amounts are collected from pharmaceutical manufacturers in accordance with the contractual arrangement between the Company and the client. Historically, these adjustments have not been material.

Other pharmacy service revenues are earned by distributing specialty pharmaceuticals and medical supplies to providers, clinics and hospitals. These revenues are billed, due and recognized at contracted rates as prescriptions and supplies are shipped and services are provided.

Pharmacy Costs. Pharmacy costs include the cost of prescriptions sold, network pharmacy claim costs and copayments. Also included are direct costs of dispensing prescriptions including supplies, shipping and handling, and direct costs associated with clinical programs, such as drug utilization management and medication adherence counseling. Home delivery and specialty pharmacy costs are recognized when the drug is shipped, and retail network costs are recognized when the drug is processed and approved for payment. Rebates and other vendor consideration received when providing pharmacy benefit management services are recorded as a reduction of pharmacy costs. Rebates are recognized as prescriptions are shipped or processed and approved for payment. Historically, the effect of adjustments resulting from the reconciliation of rebates recognized to the amounts billed and collected, net of contractual allowances, has not been material. The Company maintains reimbursement guarantees with certain retail network pharmacies. For each such guarantee, the Company records a pharmacy and other service costs payable or prepaid asset for applicable retail network claims based on our actual performance throughout the period against the contractual reimbursement rate. The Company's contracts with certain retail pharmacies give the Company the right to adjust reimbursement rates during the annual guarantee period.

E. Premiums and Related Expenses

Premiums for short-duration group health, accident and life insurance and managed care coverages are recognized as revenue on a pro rata basis over the contract period. Benefits and expenses are recognized when incurred and, for our Cigna Healthcare business, are presented net of pharmaceutical manufacturer rebates. For experience-rated contracts, premium revenue includes an adjustment for

experience-rated refunds based on contract terms and calculated using the customer's experience (including estimates of incurred but not reported claims).

The Patient Protection and Affordable Care Act ("ACA") established a risk adjustment program that transfers funds among insurers based on the relative risk of their covered populations of individuals who purchased insurance on a public exchange. We recognize receivables or payables from the Centers for Medicare and Medicaid Services ("CMS") for the Company's Individual and Family Plans as adjustments to premium revenue when amounts are reasonably estimable and collection is reasonably assured, using year-to-date experience and industry data. Final settlements are determined by the United States Department of Health and Human Services ("HHS") in the subsequent year.

Premium revenue may also include an adjustment to reflect the estimated effect of rebates due to customers under medical loss ratio provisions of the ACA. These rebate liabilities are settled in the subsequent year.

Liabilities related to experience-rated refunds, risk adjustment programs and the minimum medical loss ratio are included in Accrued expenses and other liabilities (current).

Premiums for supplemental health, accident and individual life insurance and annuity long-duration products are recognized as revenue when due. Cigna Healthcare long-duration premium revenues are associated with contracts that provide coverage greater than one year or are guaranteed to be renewed at the option of the policyholder beyond one year. Benefits and expenses are matched with premiums.

Revenue for universal life products is recognized as follows:

- Investment income on assets supporting universal life products is recognized in Net investment income/losses as earned.
- Charges for mortality, administration and policy surrender are recognized in Premiums as earned. Administrative fees are considered earned when services are provided.

Benefits and expenses for universal life products consist of benefit claims in excess of policyholder account balances and income earned by policyholders. Expenses are recognized when claims are incurred and income is credited to policyholders in accordance with contract provisions.

The unrecognized portion of premiums received is recorded as unearned premiums included in Insurance and contractholder liabilities (current and non-current). See Note 9 to the Consolidated Financial Statements for further information.

F. Fees and Related Expenses

The majority of the Company's service fee revenues are derived from the following programs:

- Administrative Services Only ("ASO") arrangements allow plan sponsors to self-fund claims and assume the risk of medical or other benefit costs. In return for fees from these clients, the Company provides access to our participating provider networks and other services supporting benefit management.
- Fee-for-service clinical solutions offered to clients, such as drug utilization management and medication adherence counseling help clients to drive better health outcomes at a lower cost by identifying and addressing potentially unsafe or wasteful prescribing, dispensing and utilization of prescription drugs, and communicating with, or supporting communications with, physicians, pharmacies and patients.
- Wholesale Marketplace Drug Formulary Management services include either our drug formulary administrative service arrangements or our formulary processing arrangements. Drug formulary administrative services may include formulary consultation, administration of rebate contracts, rebate submission, collection from drug manufacturers and the distribution of rebates to clients. Services may also include facilitating audits of data submissions and reporting of rebates to clients.
- Health benefit management solutions are offered primarily to sponsors of health benefit plans to drive cost reductions and improve quality outcomes for clients as well as provide behavioral health services to third-party health plans, employers and administrators. In certain arrangements, the Company assumes the financial obligation for third-party provider costs for medical services provided to the health plan's customers.

Arrangements are generally short-term (one year or less) except for certain three-year health benefit management solutions contracts, and each consists of a single performance obligation. Performance obligations are satisfied as services are provided to clients, either on a stand-ready or utilization basis. Fees are billed, due and recognized at contracted rates on a periodic basis, generally monthly or agreed-upon arrangements terms. Fee revenues for services are generally recorded on a gross basis with the associated direct and indirect costs presented in Pharmacy and other service costs, or Selling, general and administrative expenses.

Retained rebates reported in Fees and other revenues in our formulary processing arrangements are either recognized gross as services are provided to clients, consistent with the related service fee, or net as rebates are processed. The latter applies in arrangements in which the Company is permitted to retain a portion of rebates collected in exchange for services, but the Company does not obtain control of the retained rebate until rebates are transferred to the client.

Fees for services may include variable consideration as a component of the transaction price, which is estimated at contract inception, recognized and adjusted through the contract period through Accrued expenses and other liabilities. Variable consideration includes certain health benefit management contracts requiring the Company to share the results of medical cost experience that differ from specified targets and ASO performance guarantees that compensate clients if certain service standards, clinical outcomes or financial metrics are not met.

Note 3 – Accounts Receivable, Net

Accounting Policy. We bill pharmaceutical manufacturers based on management's interpretation of contractual terms and estimate a contractual allowance based on the best information available at the time a claim is processed. Contractual allowances for certain rebates receivable from pharmaceutical manufacturers are determined by reviewing payment experience and specific known items that could be adjusted under contract terms. The Company's estimation process for contractual allowances for pharmaceutical manufacturer receivables generally results in an allowance for balances outstanding greater than 90 days.

Contractual allowances for certain receivables from third-party payors are based on their contractual terms and are estimated based on the Company's best information available at the time revenue is recognized.

The allowance for expected credit losses for current accounts receivable is based primarily on past collections experience relative to the length of time receivables are past due; however, when available evidence reasonably supports an assumption that counterparty credit risk over the expected payment period will differ from current and historical payment collections, a forecasting adjustment is reflected in the allowance for expected credit losses.

Discounts and claims adjustments issued to customers in the form of client credits and other non-credit adjustments are based on the current status of each customer's receivable balance, current economic and market conditions and a variety of other factors, including the length of time the receivables are past due, the financial health of customers and our past experience.

Receivables and any associated allowance are written off only when all collection attempts have failed and such amounts are determined unrecoverable. We regularly review the adequacy of these allowances based on a variety of factors, including age of the outstanding receivable and collection history. When circumstances related to specific collection patterns change, estimates of the recoverability of receivables are adjusted.

The Company's accounts receivable include amounts due from clients, third-party payors, customers and pharmaceutical manufacturers, and are presented net of allowances. These balances include the following:

- **Noninsurance customer receivables** - amounts due from customers for noninsurance services, primarily pharmacy benefit management and ASO contracts.
- **Pharmaceutical manufacturers receivables** - amounts due from pharmaceutical manufacturers.
- **Insurance customer receivables** - amounts due from customers under insurance and managed care contracts, primarily premiums receivable and amounts due from CMS.
- **Other receivables** - all other accounts receivable not included in the categories above.

The following amounts were included within Accounts receivable, net:

| <i>(In millions)</i> | December 31, 2025 | December 31, 2024 |
|---|----------------------|----------------------|
| Noninsurance customer receivables | \$ 14,707 | \$ 11,879 |
| Pharmaceutical manufacturers receivables | 12,437 | 10,914 |
| Insurance customer receivables | 1,385 | 3,199 |
| Other receivables | 239 | 162 |
| Total | | \$ 26,154 |
| Accounts receivable, net classified as assets of businesses held for sale | | (1,927) |
| Total | \$ 28,768 | \$ 24,227 |

These receivables are reported net of our allowances of \$6.8 billion and \$5.0 billion as of December 31, 2025 and 2024, respectively. As of December 31, 2025 and 2024, these allowances were primarily comprised of \$6.2 billion and \$4.3 billion, respectively,

associated with contractual allowances for certain pharmaceutical manufacturers rebate receivables; \$270 million and \$388 million, respectively, associated with contractual allowances for third-party payor noninsurance customer receivables; and \$199 million and \$84 million, respectively, associated with allowances for current expected credit losses. The remaining allowances include discounts and claims adjustments issued to customers in the form of client credits and other non-credit adjustments.

Accounts Receivable Factoring Facility

The Company maintains an uncommitted factoring facility (the "Facility") with a total capacity of \$1.5 billion under which certain accounts receivable may be sold on a non-recourse basis to a financial institution. The Facility automatically renewed in July 2025 and is subject to one-year renewal terms unless terminated by either party. The transactions under the Facility are accounted for as a sale and recorded as a reduction to accounts receivable in the Consolidated Balance Sheets because control of, and risk related to, the accounts receivable are transferred to the financial institution. Although the sale is made without recourse, we provide collection services related to the transferred assets. Amounts associated with this Facility are reflected within Net cash provided by operating activities in the Consolidated Statements of Cash Flows. Factoring fees paid under this Facility are reflected in Interest expense and other in the Consolidated Statements of Income.

We sold pharmaceutical manufacturers receivables under the Facility of \$4.4 billion and \$5.5 billion during the years ended December 31, 2025 and December 31, 2024, respectively. For the years ended December 31, 2025, 2024 and 2023, factoring fees paid were not material. As of December 31, 2025 and December 31, 2024, all sold accounts receivable had been collected from pharmaceutical manufacturers and had been removed from the Company's Consolidated Balance Sheets. As of December 31, 2025 and December 31, 2024, there were \$0.4 billion and \$1.0 billion, respectively, of collections from pharmaceutical manufacturers that had not been remitted to the financial institution. Such amounts are recorded within Accrued expenses and other liabilities in the Consolidated Balance Sheets.

Note 4 – Supplier Finance Program

The Company facilitates a voluntary supplier finance program (the "Program") that provides suppliers the opportunity to sell their accounts receivable due from us (i.e., our payment obligations to the suppliers) to a financial institution, on a non-recourse basis, in order to be paid earlier than our payment terms require. The Cigna Group is not a party to the Program and agrees to commercial terms with its suppliers independently of their participation in the Program. Amounts due to suppliers that participate in the Program are generally paid within one month following the invoice date. A supplier's participation in the Program has no impact on the Company's payment terms and the Company has no economic interest in a supplier's decision to participate in the Program. The suppliers, at their sole discretion, determine which invoices, if any, to sell to the financial institution. No guarantees or pledged assets are provided by the Company or any of our subsidiaries under the Program.

The obligations confirmed as valid within the Program by the financial institutions were as follows and are reflected in Accounts payable in the Consolidated Balance Sheets:

| <i>(in millions)</i> | For the Years Ended December 31, | |
|--|---|-------------|
| | 2025 | 2024 |
| Confirmed obligations outstanding at the beginning of the year | \$ 1,637 | \$ 1,536 |
| Invoices confirmed during the year | 39,108 | 39,091 |
| Less: confirmed invoices paid during the year | 39,143 | 38,990 |
| Confirmed obligations outstanding at the end of the year | \$ 1,602 | \$ 1,637 |

The amounts confirmed as valid for both periods are predominately associated with one supplier.

Note 5 – Divestiture

Accounting Policy. The Company classifies assets and liabilities as held for sale ("disposal group") when management commits to a plan to sell the disposal group, the sale is probable within one year and the disposal group is available for immediate sale in its present condition. The Company considers various factors, particularly whether actions required to complete the plan indicate it is unlikely that significant changes to the plan will be made or the plan will be withdrawn. Assets held for sale are measured at the lower of carrying value or fair value less costs to sell. Any loss resulting from the measurement is recognized in the period the held for sale criteria are met. Conversely, gains are not recognized until the date of the sale. When the disposal group is classified as held for sale, depreciation and amortization for most long-lived assets ceases, and the Company tests the assets for impairment. Deferred policy acquisition costs continue to be amortized.

The Company completed the sale of our Medicare Advantage, Medicare Individual Stand-Alone Prescription Drug Plans, Medicare and Other Supplemental Benefits, and CareAllies® businesses (the "Disposal Group") on March 19, 2025 (the "HCSC transaction"). The final purchase price and total cash proceeds collected in 2025 were \$4.9 billion, representing an increase from the initial \$3.3 billion purchase price, driven by higher statutory surplus for the legal entities when conveyed to HCSC and post-closing contractual adjustments.

The Company recognized within Net gain (loss) on sale of businesses in the Consolidated Statements of Income a gain of \$9 million pre-tax (\$401 million after-tax) for the year ended December 31, 2025, a loss of \$472 million (\$363 million after-tax) for the year ended December 31, 2024, and a loss of \$1.5 billion (\$1.4 billion after-tax) for the year ended December 31, 2023. See Note 21 to the Consolidated Financial Statements for discussion of tax matters for the year ended December 31, 2025 resulting in an after-tax gain on sale of businesses. The estimated loss on sale for both the years ended December 31, 2024 and December 31, 2023 primarily represented goodwill impairments of \$302 million pre-tax in 2024 and \$1.2 billion pre-tax in 2023.

The Company determined that the Disposal Group met the criteria to be classified as held for sale and aggregated and classified the assets and liabilities as held for sale in our Consolidated Balance Sheets as of December 31, 2024. The assets and liabilities held for sale as of December 31, 2024 were as follows:

| <i>(In millions)</i> | December 31, 2024 |
|--|------------------------------|
| Cash and cash equivalents | \$ 1,339 |
| Investments | 1,444 |
| Accounts receivable, net | 1,927 |
| Other assets, including Goodwill ⁽¹⁾ | 2,294 |
| Total assets of businesses held for sale | 7,004 |
| Insurance and contractholder liabilities | 1,579 |
| All other liabilities | 831 |
| Total liabilities of businesses held for sale | \$ 2,410 |

⁽¹⁾ Included Goodwill of \$94 million.

Integration and Transaction-Related Costs

In 2025, 2024 and 2023, the Company incurred transaction-related costs associated with the HCSC transaction. These costs incurred consisted primarily of certain projects to separate the Company's systems, products and services; fees for legal, advisory and other professional services; and certain employment-related costs. These costs were \$327 million pre-tax (\$247 million after-tax) for the year ended December 31, 2025, compared with \$275 million pre-tax (\$211 million after-tax) for the year ended December 31, 2024, and \$45 million pre-tax (\$35 million after-tax) for the year ended December 31, 2023.

Note 6 – Earnings Per Share

Accounting Policy. The Company computes basic earnings per share using the weighted-average number of unrestricted common and deferred shares outstanding. Diluted earnings per share also includes the dilutive effect of outstanding employee stock options and restricted stock using the treasury stock method and the effect of strategic performance shares.

Basic and diluted earnings per share were computed as follows:

| | For the Years Ended December 31, | | | | | | | | |
|---|---|---------------------------|----------------|--------------|---------------------------|----------------|--------------|---------------------------|----------------|
| | 2025 | | | 2024 | | | 2023 | | |
| <i>(Shares in thousands, dollars in millions, except per share amounts)</i> | Basic | Effect of Dilution | Diluted | Basic | Effect of Dilution | Diluted | Basic | Effect of Dilution | Diluted |
| Shareholders' net income | \$ 5,957 | | \$ 5,957 | \$ 3,434 | | \$ 3,434 | \$ 5,164 | | \$ 5,164 |
| Shares: | | | | | | | | | |
| Weighted average | 266,744 | | 266,744 | 280,294 | | 280,294 | 293,892 | | 293,892 |
| Common stock equivalents | | 1,819 | 1,819 | | 2,924 | 2,924 | | 2,990 | 2,990 |
| Total shares | 266,744 | 1,819 | 268,563 | 280,294 | 2,924 | 283,218 | 293,892 | 2,990 | 296,882 |
| Earnings per share | \$ 22.33 | \$ (0.15) | \$ 22.18 | \$ 12.25 | \$ (0.13) | \$ 12.12 | \$ 17.57 | \$ (0.18) | \$ 17.39 |

The following outstanding employee stock options were not included in the computation of diluted earnings per share because their effect was anti-dilutive:

| <i>(In millions)</i> | For the Years Ended December 31, | | |
|-----------------------|----------------------------------|------|------|
| | 2025 | 2024 | 2023 |
| Anti-dilutive options | 2.0 | 1.1 | 0.9 |

Note 7 – Debt

The outstanding amounts of debt (net of issuance costs, discounts or premiums) and finance leases were as follows:

| <i>(In millions)</i> | December 31, 2025 | December 31, 2024 |
|--|----------------------|----------------------|
| Short-term debt | | |
| Commercial paper | \$ — | \$ 880 |
| \$900 million, 3.250% Notes due April 2025 | — | 897 |
| \$1,216 million, 4.125% Notes due November 2025 | — | 1,215 |
| \$550 million, 1.250% Notes due March 2026 | 549 | — |
| Other, including finance leases | 43 | 43 |
| Total short-term debt | \$ 592 | \$ 3,035 |
| Long-term debt | | |
| \$1,284 million, 4.500% Notes due February 2026 | \$ — | \$ 1,285 |
| \$700 million, 5.685% Notes due March 2026 | — | 699 |
| \$550 million, 1.250% Notes due March 2026 | — | 549 |
| \$1,500 million, 3.400% Notes due March 2027 | 1,481 | 1,466 |
| \$259 million, 7.875% Debentures due May 2027 | 260 | 259 |
| \$600 million, 3.050% Notes due October 2027 | 599 | 598 |
| \$3,800 million, 4.375% Notes due October 2028 | 3,792 | 3,790 |
| \$1,000 million, 5.000% Notes due May 2029 | 996 | 995 |
| \$1,400 million, 2.400% Notes due March 2030 ⁽¹⁾ | 1,406 | 1,386 |
| \$1,000 million, 4.500% Notes due September 2030 | 993 | — |
| \$1,500 million, 2.375% Notes due March 2031 ⁽¹⁾ | 1,420 | 1,384 |
| \$750 million, 5.125% Notes due May 2031 ⁽¹⁾ | 750 | 745 |
| \$1,250 million, 4.875% Notes due September 2032 | 1,243 | — |
| \$45 million, 8.080% Step Down Notes due January 2033 | 45 | 45 |
| \$800 million, 5.400% Notes due March 2033 ⁽¹⁾ | 796 | 795 |
| \$1,250 million, 5.250% Notes due February 2034 ⁽¹⁾ | 1,250 | 1,226 |
| \$1,500 million, 5.250% Notes due January 2036 | 1,488 | — |
| \$190 million, 6.150% Notes due November 2036 | 190 | 190 |
| \$2,200 million, 4.800% Notes due August 2038 ⁽¹⁾ | 2,194 | 2,193 |
| \$750 million, 3.200% Notes due March 2040 | 748 | 744 |
| \$121 million, 5.875% Notes due March 2041 | 119 | 119 |
| \$448 million, 6.125% Notes due November 2041 | 484 | 485 |
| \$317 million, 5.375% Notes due February 2042 | 315 | 315 |
| \$1,500 million, 4.800% Notes due July 2046 | 1,469 | 1,469 |
| \$1,000 million, 3.875% Notes due October 2047 | 990 | 990 |
| \$3,000 million, 4.900% Notes due December 2048 | 2,972 | 2,971 |
| \$1,184 million, 3.400% Notes due March 2050 | 1,172 | 1,237 |
| \$1,429 million, 3.400% Notes due March 2051 | 1,410 | 1,479 |
| \$1,500 million, 5.600% Notes due February 2054 | 1,486 | 1,482 |
| \$750 million, 6.000% Notes due January 2056 | 735 | — |
| Other, including finance leases | 68 | 41 |
| Total long-term debt | \$ 30,871 | \$ 28,937 |

⁽¹⁾ The Company has entered into interest rate swap contracts hedging a portion of these fixed-rate debt instruments as of December 31, 2025. See Note 11 to the Consolidated Financial Statements for further information about the Company's interest rate risk management and these derivative instruments.

Debt Issuance. In September 2025, we issued \$4.5 billion of new senior notes, as detailed in the table below. The proceeds from this debt issuance were used to repay the \$2.0 billion of loans outstanding under the Term Loan Facility as described below. We used the remaining net proceeds for general corporate purposes, including investments and repayment of indebtedness. Interest on this debt is paid semiannually.

| Principal | Maturity Date | Interest Rate | Net Proceeds | Redeemable Date ⁽¹⁾ | "Make Whole" Premium ⁽²⁾ |
|-----------------|--------------------|---------------|-----------------|--------------------------------|-------------------------------------|
| \$1,000 million | September 15, 2030 | 4.500% | \$994 million | August 15, 2030 | 15 |
| \$1,250 million | September 15, 2032 | 4.875% | \$1,245 million | July 15, 2032 | 15 |
| \$1,500 million | January 15, 2036 | 5.250% | \$1,490 million | October 15, 2035 | 15 |
| \$750 million | January 15, 2056 | 6.000% | \$736 million | July 15, 2055 | 20 |

⁽¹⁾ Redeemable at any time prior to this date at a "make whole" premium, defined below. Redeemable at par on or after this date.

⁽²⁾ "Make whole" premium calculated using a comparable U.S. Treasury rate plus the amount of basis points set forth in this column.

Term Loan. In August 2025, the Company entered into a new 364-day term loan facility (the "Term Loan Facility") and borrowed \$2.0 billion to partially fund an investment in Shields Health Solutions ("Shields"), a leading specialty pharmacy management company. The full outstanding balance was repaid and the Term Loan Facility was terminated in September 2025, using proceeds from the debt issuance described above.

Revolving Credit Agreement. Our Credit Agreement (defined below) provides us with the ability to borrow amounts for general corporate purposes, including providing liquidity support if necessary under our commercial paper program discussed below. As of December 31, 2025, there was no outstanding balance under the Credit Agreement.

In April 2025, the Company replaced its previous revolving credit agreements and entered into a \$6.5 billion, five-year revolving credit and letter of credit agreement that will mature in April 2030, with an option to extend the maturity date for an additional one-year period, subject to consent of the banks (the "Credit Agreement"). The Company can borrow up to \$6.5 billion under the Credit Agreement for general corporate purposes, with up to \$500 million available for issuance of letters of credit.

The Credit Agreement includes an option to increase commitments up to \$1.5 billion for a maximum total commitment of \$8.0 billion. The Credit Agreement allows for borrowings at either a base rate, term Secured Overnight Financing Rate ("SOFR") or daily simple SOFR, plus, in each case, an applicable margin based on the Company's senior unsecured credit ratings.

The Credit Agreement also contains customary covenants and restrictions, including a financial covenant that the Company's leverage ratio, as defined in the Credit Agreement, may not exceed 60%, subject to certain exceptions upon the consummation of an acquisition.

Commercial Paper. Under our commercial paper program, we may issue short-term, unsecured commercial paper notes privately placed on a discounted basis through certain broker-dealers at any time not to exceed an aggregate amount of \$6.5 billion. Amounts available under the program may be borrowed, repaid and re-borrowed from time to time. The net proceeds of issuances have been and are expected to be used for general corporate purposes. There was no commercial paper balance as of December 31, 2025.

Debt Maturities. Maturities of outstanding long-term debt as of December 31, 2025 are as follows:

| (In millions) | Scheduled Maturities ⁽¹⁾ |
|-----------------------|-------------------------------------|
| 2026 | \$ 550 |
| 2027 | \$ 2,359 |
| 2028 | \$ 3,800 |
| 2029 | \$ 1,000 |
| 2030 | \$ 2,400 |
| Maturities after 2030 | \$ 21,485 |

⁽¹⁾ Long-term debt maturity amounts include current maturities of long-term debt. Finance leases are excluded from this table.

Interest Expense. Interest expense on long-term and short-term debt was \$1.4 billion in 2025, \$1.5 billion in 2024 and \$1.4 billion in 2023.

Debt Covenants. The Company was in compliance with its debt covenants as of December 31, 2025.

Note 8 – Common and Preferred Stock

The Cigna Group has a total of 25 million shares of \$1 par value preferred stock authorized for issuance. No shares of preferred stock were outstanding at December 31, 2025, 2024 or 2023.

The following table presents the share activity of The Cigna Group:

| <i>(Shares in thousands)</i> | For the Years Ended December 31, | | |
|---|---|-------------|-------------|
| | 2025 | 2024 | 2023 |
| Common: Par value \$0.01; 600,000 shares authorized | | | |
| Outstanding- January 1, | 273,789 | 292,504 | 298,676 |
| Net issued for stock option exercises and other benefit plans | 1,569 | 2,198 | 1,619 |
| Repurchased common stock | (11,894) | (20,913) | (7,791) |
| Outstanding- December 31, | 263,464 | 273,789 | 292,504 |
| Treasury stock | 141,136 | 128,723 | 107,390 |
| Issued- December 31, | 404,600 | 402,512 | 399,894 |

Dividends

The following table provides details of the Company's dividend payments:

| Record Date | Payment Date | Amount per Share | Total Amount Paid <i>(in millions)</i> |
|--------------------------|---------------------------|-------------------------|---|
| 2025 | | | |
| March 5, 2025 | March 20, 2025 | \$1.51 | \$412 |
| June 3, 2025 | June 18, 2025 | \$1.51 | \$401 |
| September 4, 2025 | September 18, 2025 | \$1.51 | \$402 |
| December 4, 2025 | December 18, 2025 | \$1.51 | \$396 |
| 2024 | | | |
| March 6, 2024 | March 21, 2024 | \$1.40 | \$401 |
| June 4, 2024 | June 20, 2024 | \$1.40 | \$392 |
| September 4, 2024 | September 19, 2024 | \$1.40 | \$390 |
| December 4, 2024 | December 19, 2024 | \$1.40 | \$384 |
| 2023 | | | |
| March 8, 2023 | March 23, 2023 | \$1.23 | \$368 |
| June 7, 2023 | June 22, 2023 | \$1.23 | \$362 |
| September 6, 2023 | September 21, 2023 | \$1.23 | \$362 |
| December 6, 2023 | December 21, 2023 | \$1.23 | \$358 |

On February 5, 2026, the Board of Directors of The Cigna Group (the "Board") declared the first quarter cash dividend of \$1.56 per share of The Cigna Group common stock to be paid on March 19, 2026 to shareholders of record on March 5, 2026. The Company currently intends to pay regular quarterly dividends, with future declarations subject to approval by the Board and the Board's determination that the declaration of dividends remains in the best interests of The Cigna Group and its shareholders. The decision of whether to pay future dividends and the amount of any such dividends will be based on the Company's financial position, results of operations, cash flows, capital requirements, the requirements of applicable law and any other factors the Board may deem relevant.

Note 9 – Insurance and Contractholder Liabilities

A. Account Balances – Insurance and Contractholder Liabilities

The Company's insurance and contractholder liabilities were comprised of the following:

| <i>(In millions)</i> | December 31, 2025 | | | December 31, 2024 | | |
|---|-------------------|-------------|-----------|-------------------|-------------|-----------|
| | Current | Non-current | Total | Current | Non-current | Total |
| Unpaid claims and claim expenses | | | | | | |
| Cigna Healthcare | \$ 4,180 | \$ 61 | \$ 4,241 | \$ 4,932 | \$ 86 | \$ 5,018 |
| Other | 167 | 176 | 343 | 147 | 144 | 291 |
| Future policy benefits | | | | | | |
| Cigna Healthcare | 38 | 153 | 191 | 91 | 507 | 598 |
| Other Operations | 142 | 3,081 | 3,223 | 157 | 3,140 | 3,297 |
| Contractholder deposit funds | | | | | | |
| Cigna Healthcare | — | — | — | 9 | 115 | 124 |
| Other Operations | 336 | 5,778 | 6,114 | 366 | 5,958 | 6,324 |
| Market risk benefits | 25 | 649 | 674 | 25 | 760 | 785 |
| Unearned premiums | 822 | 40 | 862 | 753 | 31 | 784 |
| Total | | | | 6,480 | 10,741 | 17,221 |
| Insurance and contractholder liabilities classified as liabilities of businesses held for sale ⁽¹⁾ | | | | (1,092) | (487) | (1,579) |
| Total insurance and contractholder liabilities | \$ 5,710 | \$ 9,938 | \$ 15,648 | \$ 5,388 | \$ 10,254 | \$ 15,642 |

⁽¹⁾ Amounts classified as liabilities of businesses held for sale include \$983 million of Unpaid claims, \$408 million of Future policy benefits, \$85 million of Unearned premiums and \$103 million of Contractholder deposit funds as of December 31, 2024.

Insurance and contractholder liabilities expected to be paid within one year are classified as current.

Accounting Policy - Unearned Premium. The unrecognized portion of premiums received is recorded as unearned premiums included in Insurance and contractholder liabilities (current and non-current).

The Company evaluates certain insurance contracts subject to premium deficiency testing and recognizes a premium deficiency loss and corresponding reserve when expected claims costs, claims adjustment expenses, maintenance costs, and unamortized acquisition costs exceed unearned premium. Anticipated investment income is considered in the calculation of premium deficiency.

B. Unpaid Claims and Claim Expenses – Cigna Healthcare

This liability reflects estimates of the ultimate cost of claims that have been incurred but not reported, expected development on reported claims, claims that have been reported but not yet paid (reported claims in process), and other medical care expenses and services payable that are primarily comprised of accruals for incentives and other amounts payable to health care professionals and facilities.

Accounting Policy. The Company uses actuarial principles and assumptions that are consistently applied each reporting period and recognizes the actuarial best estimate of the ultimate liability along with a margin for adverse deviation. This approach is consistent with actuarial standards of practice that the liabilities be adequate under moderately adverse conditions.

The Company compares key assumptions used to establish the medical costs payable to actual experience for each reporting period. The unpaid claims liability is adjusted through current period Shareholders' net income when actual experience differs from these assumptions. Additionally, the Company evaluates expected future developments and emerging trends that may impact key assumptions. The process used to determine this liability requires the Company to make critical accounting estimates that involve considerable judgment, reflecting the variability inherent in forecasting future claim payments. These estimates are highly sensitive to changes in the Company's key assumptions, specifically completion factors and medical cost trend.

The liability is primarily calculated using "completion factors" developed by comparing the claim incurrual date to the date claims were paid. Completion factors are impacted by several key items including changes in: (i) electronic (auto-adjudication) versus manual claim processing; (ii) frequency and timeliness of provider claims submissions; (iii) number of customers; and (iv) the mix of products. The Company uses historical completion factors combined with an analysis of current trends and operational factors to

develop current estimates of completion factors. The Company estimates the liability for claims incurred in each month by applying the current estimates of completion factors to the current paid claims data. This approach implicitly assumes that historical completion rates will be a useful indicator for the current period.

The Company relies more heavily on medical cost trend analysis that reflects expected claim payment patterns and other relevant operational considerations for more recent months. Medical cost trend is primarily impacted by medical service utilization and unit costs that are affected by changes in the level and mix of health benefits offered, including inpatient, outpatient and pharmacy; the impact of copays and deductibles; changes in provider practices; and changes in consumer demographics and consumption behavior.

The total of incurred but not reported liabilities plus expected development on reported claims and reported claims in process was \$4.0 billion as of December 31, 2025 and \$4.6 billion as of December 31, 2024. The decrease was driven by the HCSC transaction.

Activity, net of intercompany transactions, in the unpaid claims liability for the Cigna Healthcare segment was as follows:

| <i>(In millions)</i> | For the Years Ended December 31, | | |
|---|----------------------------------|---------------------|---------------------|
| | 2025 ⁽¹⁾ | 2024 ⁽¹⁾ | 2023 ⁽¹⁾ |
| Beginning balance | \$ 5,018 | \$ 5,092 | \$ 4,176 |
| Less: Reinsurance and other amounts recoverable | 159 | 236 | 221 |
| Beginning balance, net | 4,859 | 4,856 | 3,955 |
| Incurred costs related to: | | | |
| Current year | 33,816 | 38,347 | 35,953 |
| Prior years | (342) | (456) | (279) |
| Total incurred | 33,474 | 37,891 | 35,674 |
| Paid costs related to: | | | |
| Current year | 28,769 | 33,718 | 31,322 |
| Prior years | 4,147 | 4,170 | 3,451 |
| Total paid | 32,916 | 37,888 | 34,773 |
| Less: Divestiture and other | 1,323 | — | — |
| Ending balance, net | 4,094 | 4,859 | 4,856 |
| Add: Reinsurance and other amounts recoverable | 147 | 159 | 236 |
| Ending balance | \$ 4,241 | \$ 5,018 | \$ 5,092 |

⁽¹⁾ Includes unpaid claims amounts classified as liabilities of businesses held for sale prior to the completion of the HCSC transaction. As of December 31, 2024 and December 31, 2023, includes \$983 million and \$823 million, respectively, classified as liabilities of businesses held for sale.

Reinsurance and other amounts recoverable reflect amounts due from reinsurers and policyholders to cover incurred but not reported and pending claims of certain business for which the Company administers the plan benefits without any right of offset. See Note 10 to the Consolidated Financial Statements for additional information on reinsurance.

Variances in incurred costs related to prior years' unpaid claims and claim expenses that resulted from the differences between actual experience and the Company's key assumptions were as follows:

| <i>(Dollars in millions)</i> | For the Years Ended December 31, | | | |
|-------------------------------------|----------------------------------|------------------|--------|------------------|
| | 2025 | | 2024 | |
| | \$ | % ⁽¹⁾ | \$ | % ⁽²⁾ |
| Actual completion factors and other | \$ 200 | 0.5 % | \$ 223 | 0.6 % |
| Medical cost trend | 142 | 0.4 | 233 | 0.7 |
| Total favorable variance | \$ 342 | 0.9 % | \$ 456 | 1.3 % |

⁽¹⁾ Percentage of current year incurred costs as reported for the year ended December 31, 2024.

⁽²⁾ Percentage of current year incurred costs as reported for the year ended December 31, 2023.

Favorable prior year development in both years primarily reflects lower than expected utilization of medical services as compared to our assumptions.

The following table depicts the incurred and paid claims development and unpaid claims liability as of December 31, 2025 (net of reinsurance) reported in the Cigna Healthcare segment. The information about incurred and paid claims development for the year ended December 31, 2024 is presented as supplementary information and is unaudited.

| Incurral Year | Incurred Costs | | Unpaid Claims and Claim Expenses |
|---|-----------------------------|-------------|---|
| | 2024 (Unaudited) | 2025 | |
| <i>(In millions)</i> | | | |
| 2024 | \$ 37,179 | \$ 36,853 | 88 |
| 2025 | | 33,530 | 4,006 |
| Cumulative incurred costs for the periods presented | | \$ 70,383 | |

| Incurral Year | Cumulative Costs Paid | |
|---|------------------------------|-------------|
| | 2024 (Unaudited) | 2025 |
| <i>(In millions)</i> | | |
| 2024 | \$ 32,719 | \$ 36,544 |
| 2025 | | 28,635 |
| Cumulative paid costs for the periods presented | | \$ 65,179 |
| Outstanding liabilities for the periods presented, net of reinsurance | | \$ 5,204 |
| Divestiture and other | | (1,110) |
| Net unpaid claims and claims expenses - Cigna Healthcare | | 4,094 |
| Reinsurance and other amounts recoverable | | 147 |
| Unpaid claims and claim expenses - Cigna Healthcare | | \$ 4,241 |

Incurred claims do not typically remain outstanding for multiple years; more than 95% of health claims incurred in a year are paid by the end of the following year.

There is no single or common claim frequency metric used in the health care industry. The Company believes a relevant metric for its health insurance business is the number of customers for whom an insured medical claim was paid. Customers for whom no insured medical claim was paid are excluded from the calculation. Claims that did not result in a liability are not included in the frequency metric. The claim frequency for 2025 and 2024 was approximately 4.9 million and 5.3 million, respectively.

C. Future Policy Benefits

Accounting Policy. Future policy benefits represent the present value of estimated future obligations, estimated using actuarial methods, for long-duration insurance policies and annuity products currently in force, consisting primarily of reserves for annuity contracts, life insurance benefits and certain supplemental health products that are guaranteed renewable beyond one year.

Contracts are grouped at a level no higher than issue year, based on the original contract issue date, and at lower levels of disaggregation within each issue year for certain businesses to reflect factors including product type, plan type and currency. Management estimates these obligations based on assumptions for premiums, interest rates, mortality or morbidity, future claim adjudication expenses, and surrenders. Mortality, morbidity and surrender assumptions are based on the Company's own experience and published actuarial tables and are updated at least annually, to the extent changes in circumstances require. Interest rate assumptions are based on market-level yields for low credit risk fixed income instruments ("upper-medium grade fixed income instruments"). For interest accretion purposes, interest rates are fixed at the year of the cohort's inception; however, for purposes of liability measurement, they are updated to the current rate quarterly, with all changes in the interest rate from inception to current period reported through Accumulated other comprehensive loss. For contracts issued domestically, we use observable inputs from a published spot rate curve for terms up to 30 years and extrapolate for longer terms using a constant forward rate approach. For contracts issued by foreign operating entities with functional currencies other than the U.S. dollar, we use observable inputs to approximate a risk-free rate and add a credit spread adjustment to align with a low credit risk fixed income instrument. For terms beyond the last observable risk-free rates, which vary by international market, we extrapolate to the ultimate forward rate assuming a constant credit spread.

For the annuity business, the premium paying period is shorter than the benefit coverage period, and a deferred profit liability is reported in future policy benefits representing gross premium received in excess of net premiums. Deferred profit liability is amortized based on expected future benefit payments.

As of December 31, 2025, approximately 36% of the liability for future policy benefits was supported by assets in trust for the benefit of the ceding company under reinsurance agreements.

Cigna Healthcare

Future policy benefits for the Cigna Healthcare segment were primarily related to the businesses divested to HCSC on March 19, 2025. Excluding the divestiture, changes in the future policy benefits for the years ended December 31, 2025 and December 31, 2024 were not material.

Other Operations

The weighted average interest rates applied and duration for future policy benefits in Other Operations, consisting of annuity and life insurance products, were as follows:

| | As of | |
|---------------------------|----------------------|----------------------|
| | December 31, 2025 | December 31, 2024 |
| Interest accretion rate | 5.64 % | 5.64 % |
| Current discount rate | 5.18 % | 5.42 % |
| Weighted average duration | 10.6 years | 10.8 years |

Obligations for annuities represent discounted periodic benefits to be paid to an individual or groups of individuals over their remaining lives. Other Operations' traditional insurance contracts, which are in run-off, have no premium remaining to be collected; therefore, future policy benefit reserves represent the present value of expected future policy benefits, discounted using the current discount rate, and the remaining amortizable deferred profit liability.

Future policy benefits for Other Operations include deferred profit liability of \$347 million and \$366 million as of December 31, 2025 and December 31, 2024, respectively. As of December 31, 2025, December 31, 2024 and December 31, 2023, future policy benefits excluding deferred profit liability were \$2.9 billion, \$2.9 billion and \$3.2 billion, respectively. Undiscounted expected future policy benefits were \$4.2 billion and \$4.3 billion as of December 31, 2025 and December 31, 2024, respectively. As of December 31, 2025 and December 31, 2024, \$0.8 billion and \$0.9 billion, respectively, of the future policy benefit reserve was recoverable through treaties with external reinsurers.

D. Contractholder Deposit Funds

Accounting Policy. Liabilities for contractholder deposit funds primarily include deposits received from customers for investment-related and universal life products as well as investment earnings on their fund balances in Other Operations. These liabilities are adjusted to reflect administrative charges and, for universal life fund balances, mortality charges. Interest credited on these funds is accrued ratably over the contract period.

Contractholder deposit fund liabilities within Other Operations were \$6.1 billion, \$6.3 billion and \$6.5 billion as of December 31, 2025, December 31, 2024 and December 31, 2023, respectively. Approximately 37% and 38% of the balance is reinsured externally as of December 31, 2025 and December 31, 2024, respectively. Activity in these liabilities is presented net of reinsurance in the Consolidated Statements of Cash Flows. The net year-to-date decrease in contractholder deposit fund liabilities generally relates to withdrawals and benefit payments from contractholder deposit funds, partially offset by deposits and interest credited to contractholder deposit funds.

As of December 31, 2025, the weighted average crediting rate, net amount at risk and cash surrender value for contractholder deposit fund liabilities not effectively exited through reinsurance were 3.29%, \$2.5 billion and \$2.8 billion, respectively. The comparative amounts as of December 31, 2024 were 3.33%, \$2.8 billion and \$2.8 billion, respectively. More than 99% of the \$3.9 billion liability as of December 31, 2025 and the \$4.0 billion liability as of December 31, 2024 not reinsured externally is for contracts with guaranteed interest rates of 3% - 4%, and approximately \$1.2 billion represented contracts with policies at the guarantee for both period ends. At these same period ends, \$1.1 billion and \$1.2 billion was 50 - 150 basis points ("bps") above the guarantee, and the remaining \$1.6 billion as of both December 31, 2025 and December 31, 2024 represented contracts above the guarantee that pay the policyholder based on the greater of a guaranteed minimum cash value or the actual cash value. As of both December 31, 2025 and December 31, 2024, more than 90% of these contracts have actual cash values of at least 110% of the guaranteed cash value.

E. Market Risk Benefits

Liabilities for market risk benefits ("MRBs") consist of variable annuity reinsurance contracts in Other Operations. These liabilities arise under annuities and riders to annuities written by ceding companies that guarantee the benefit received at death and, for a subset of policies, also provide contractholders the option, within 30 days of a policy anniversary after the appropriate waiting period, to elect minimum income payments. The Company's capital market risk exposure on variable annuity reinsurance contracts arises when the reinsured guaranteed minimum benefit exceeds the contractholder's account value in the related underlying mutual funds at the time the insurance benefit is payable under the respective contract. The Company receives and pays premium periodically based on the terms of the reinsurance agreements.

Accounting Policy. Variable annuity reinsurance liabilities are measured as MRBs at fair value, net of nonperformance risk, with fluctuations in value gross of reinsurer nonperformance risk reported in benefit expenses, while fluctuations in the Company's own nonperformance risk (own credit risk) are reported in Accumulated other comprehensive loss. Nonperformance risk reflects risk that a party might default and therefore not fulfill its obligations (i.e., nonpayment risk). The nonperformance risk adjustment reflects a market participant's view of nonpayment risk by adding an additional spread to the discount rate in the calculation of both (a) the variable annuity reinsurance liabilities to be paid by the Company and (b) the variable annuity reinsurance assets to be paid by the reinsurers, after considering collateral. The Company classifies variable annuity assets and liabilities in Level 3 of the fair value hierarchy described in Note 12 to the Consolidated Financial Statements because assumptions related to future annuitant behavior are largely unobservable. As discussed further in Note 10 to the Consolidated Financial Statements, due to the reinsurance agreements covering these liabilities, the liabilities do not generally impact net income except for the change in nonperformance risk on the reinsurance recoverable, which is reported in benefit expenses and does not offset the nonperformance risk valuation on the liability. Variable annuity liabilities are established using capital market assumptions and assumptions related to future annuitant behavior (including mortality, lapse and annuity election rates).

Market risk benefits activity was as follows:

| <i>(In millions)</i> | For the Years Ended December 31, | |
|---|---|-------------|
| | 2025 | 2024 |
| Balance, beginning of year | \$ 785 | \$ 1,003 |
| Balance, beginning of year, before the effect of nonperformance risk (own credit risk) | 838 | 1,085 |
| Changes due to expected run-off | (20) | (12) |
| Changes due to capital markets versus expected | (63) | (233) |
| Changes due to policyholder behavior versus expected | (24) | (39) |
| Assumption changes | (17) | 37 |
| Balance, end of period, before the effect of changes in nonperformance risk (own credit risk) | 714 | 838 |
| Nonperformance risk (own credit risk), end of period | (40) | (53) |
| Balance, end of period | \$ 674 | \$ 785 |
| Reinsured market risk benefit, end of period | \$ 712 | \$ 836 |

The following table presents the account value, net amount at risk, average attained age of contractholders (weighted by exposure) and the number of contractholders for guarantees assumed by the Company. The net amount at risk is the amount that the Company would have to pay to contractholders if all deaths or annuitizations occurred as of the earliest possible date in accordance with the insurance contract. As of December 31, 2025, the account value and net amount at risk decreased, reflecting a reduction in contractholders and favorable equity market performance. The Company should be reimbursed in full for these payments unless the Berkshire reinsurance limit is exceeded.

| <i>(Dollars in millions, excludes impact of reinsurance ceded)</i> | December 31, 2025 | December 31, 2024 |
|--|------------------------------|------------------------------|
| Account value | \$ 7,281 | \$ 7,777 |
| Net amount at risk | \$ 1,115 | \$ 1,283 |
| Average attained age of contractholders (weighted by exposure) | 78.3 years | 77.7 years |
| Number of contractholders (estimated) | 110,000 | 130,000 |

Note 10 – Reinsurance

The Company's insurance subsidiaries enter into agreements with other insurance companies to limit losses from large exposures and to permit recovery of a portion of incurred losses. Reinsurance is ceded primarily in acquisition and disposition transactions when the underwriting company is not being acquired. Reinsurance does not relieve the originating insurer of liability. Therefore, reinsured

liabilities must continue to be reported along with the related reinsurance recoverables. The Company regularly evaluates the financial condition of its reinsurers and monitors concentrations of its credit risk.

Accounting Policy. Reinsurance recoverables represent amounts due from reinsurers for both paid and unpaid claims of the Company's insurance businesses. The Company bears the risk of loss if its reinsurers and retrocessionaires do not meet or are unable to meet their reinsurance obligations to the Company. Most reinsurance recoverables are classified as non-current assets. The current portion of reinsurance recoverables is reported in Other current assets and consists primarily of recoverables on paid claims expected to be settled within one year. Reinsurance recoverables are presented net of allowances, consisting primarily of an allowance for expected credit losses, which is recognized on reinsurance recoverable balances each period and adjusted through Medical costs and other benefit expenses. Estimates of the allowance for expected credit losses are based on internal and external data used to develop expected loss rates over the anticipated duration of the recoverable asset that vary by external credit rating and collateral level.

Collateral levels are defined internally based on the fair value of the collateral relative to the carrying amount of the reinsurance recoverable, the frequency at which collateral is required to be replenished and the potential for volatility in the collateral's fair value.

The Company's reinsurance recoverables as of December 31, 2025 are presented at amount due by range of external credit rating and collateral level in the following table, with reinsurance recoverables that are market risk benefits separately presented at fair value:

| <i>(In millions)</i> | Fair Value of Collateral Contractually Required to Meet or Exceed Carrying Value of Recoverable | Collateral Provisions Exist That May Mitigate Risk of Credit Loss ⁽¹⁾ | No Collateral | Total |
|---|--|---|---------------|----------|
| Ongoing operations | | | | |
| A- equivalent and higher current ratings ⁽²⁾ | \$ — | \$ 5 | \$ 211 | \$ 216 |
| BBB- to BBB+ equivalent current credit ratings ⁽²⁾ | — | — | 64 | 64 |
| Not rated | 85 | 1 | 4 | 90 |
| Acquisition, disposition or run-off activities | | | | |
| BBB+ equivalent and higher current ratings ⁽²⁾⁽³⁾ | 288 | 2,838 | 32 | 3,158 |
| Not rated | — | 5 | 1 | 6 |
| Total reinsurance recoverables before market risk benefits | \$ 373 | \$ 2,849 | \$ 312 | \$ 3,534 |
| Allowance for uncollectible reinsurance | | | | (23) |
| Market risk benefits | | | | 712 |
| Total reinsurance recoverables ⁽⁴⁾ | | | \$ | 4,223 |

⁽¹⁾ Includes collateral provisions requiring the reinsurer to fully collateralize its obligation if its external credit rating is downgraded to a specified level.

⁽²⁾ Certified by a nationally recognized statistical ratings organization ("NRSRO").

⁽³⁾ Comprised of six reinsurers, of which 76% is held by two reinsurers, Lincoln National Life Insurance Company and Lincoln Life and Annuity Company of New York.

⁽⁴⁾ Includes \$120 million of current reinsurance recoverables that are reported in Other current assets.

The Company entered into an agreement with Berkshire to effectively exit the variable annuity reinsurance business via a reinsurance transaction in 2013. Variable annuity contracts are accounted for as assumed and ceded reinsurance and categorized as market risk benefits as discussed in Note 9 to the Consolidated Financial Statements. Berkshire reinsured 100% of the Company's future cash flows in this business, net of other reinsurance arrangements existing at that time. The reinsurance agreement is subject to an overall limit, with approximately \$3.0 billion remaining as of December 31, 2025. As a result of the reinsurance transaction, amounts payable are offset by a corresponding reinsurance recoverable, provided the increased recoverable remains within the overall Berkshire limit. As of both December 31, 2025 and 2024, market risk benefits (shown in the table net of nonperformance risk as of December 31, 2025) were predominantly reinsured by Berkshire, which is rated AA+ by an NRSRO. As of December 31, 2025, approximately 100% of the Berkshire recoverable is secured by assets in a trust.

Effects of Reinsurance

Net short-duration contract premiums (direct, assumed and ceded) were \$39.3 billion, \$43.9 billion and \$42.3 billion for the years ended December 31, 2025, 2024 and 2023, respectively. Net long-duration contract premiums (direct, assumed and ceded) were \$1.0 billion, \$2.0 billion and \$1.9 billion for the years ended December 31, 2025, 2024 and 2023, respectively. Reinsurance recoveries of \$671 million, \$573 million and \$456 million as of December 31, 2025, 2024 and 2023, respectively, have been netted against Medical costs and other benefit expenses in the Company's Consolidated Statements of Income.

Both short- and long-duration premiums are primarily direct premiums; the amounts assumed and ceded were not material. Written premiums for short-duration contracts were not materially different from the recognized premium amounts.

Note 11 – Investments

The following table summarizes the Company's investments by category and current or long-term classification:

| (In millions) | December 31, 2025 | | | December 31, 2024 | | |
|---|-------------------|-----------|-----------|-------------------|-----------|-----------|
| | Current | Long-Term | Total | Current | Long-Term | Total |
| Debt securities | \$ 691 | \$ 7,671 | \$ 8,362 | \$ 463 | \$ 8,960 | \$ 9,423 |
| Equity securities | 22 | 3,534 | 3,556 | 7 | 554 | 561 |
| Commercial mortgage loans | 86 | 1,147 | 1,233 | 108 | 1,243 | 1,351 |
| Policy loans | — | 1,082 | 1,082 | — | 1,156 | 1,156 |
| Other long-term investments | — | 5,037 | 5,037 | — | 4,576 | 4,576 |
| Short-term investments | 257 | — | 257 | 170 | — | 170 |
| Total | | | | \$ 748 | \$ 16,489 | \$ 17,237 |
| Investments classified as assets of businesses held for sale ⁽¹⁾ | | | | (83) | (1,361) | (1,444) |
| Investments per Consolidated Balance Sheets | \$ 1,056 | \$ 18,471 | \$ 19,527 | \$ 665 | \$ 15,128 | \$ 15,793 |

⁽¹⁾ Investments related to the HCSC transaction that were held for sale as of December 31, 2024. These investments were primarily comprised of debt securities.

Accounting Policy. Debt securities, commercial mortgage loans, derivative financial instruments and short-term investments with contractual maturities during the next 12 months are classified on the balance sheet as current investments unless they are held as statutory deposits or restricted for other purposes, in which case they are classified as Long-term investments. All other investments are classified as Long-term investments, with the exception of equity security funds that are used in our cash management strategy and are classified as current investments. See Note 12 to the Consolidated Financial Statements for information about the valuation of the Company's investment portfolio.

A. Investment Portfolio

Debt Securities

Accounting Policy. Debt securities (including bonds, mortgage and other asset-backed securities, and preferred stocks redeemable by the investor) are classified as available for sale and are carried at fair value with changes in fair value recorded either in Accumulated other comprehensive loss within Shareholders' equity or in credit loss expense based on fluctuations in the allowance for credit losses, as further discussed below. When the Company intends to sell or determines that it is more likely than not to be required to sell an impaired debt security, the excess of amortized cost over fair value is directly written down with a charge to Net investment gains/losses. Certain asset-backed securities are considered variable interest entities. See Note 13 to the Consolidated Financial Statements for additional information.

The Company reviews declines in fair value from a debt security's amortized cost basis to determine whether a credit loss exists and, when appropriate, recognizes a credit loss allowance with a corresponding charge to credit loss expense, presented in Net investment gains/losses in the Company's Consolidated Statements of Income. The allowance for credit loss represents the excess of amortized cost over the greater of its fair value or the net present value of the debt security's projected future cash flows (based on qualitative and quantitative factors, including the probability of default and the estimated timing and amount of recovery). Each period, the allowance for credit loss is adjusted as needed through credit loss expense.

The Company does not measure an allowance for credit losses for accrued interest receivables. When interest payments are delinquent based on contractual terms or when certain terms (interest rate or maturity date) of the investment have been restructured, accrued interest, reported in Other current assets, is written off through a charge to Net investment income/losses and interest income is recognized on a cash basis.

The amortized cost and fair value by contractual maturity periods for debt securities were as follows as of December 31, 2025:

| (In millions) | Amortized Cost | Fair Value |
|--|----------------|------------|
| Due in one year or less | \$ 695 | \$ 598 |
| Due after one year through five years | 3,700 | 3,703 |
| Due after five years through ten years | 2,030 | 1,995 |
| Due after ten years | 1,968 | 1,822 |
| Mortgage and other asset-backed securities | 267 | 244 |
| Total | \$ 8,660 | \$ 8,362 |

Actual maturities of these securities could differ from their contractual maturities used in the table above because issuers may have the right to call or prepay obligations, with or without penalties.

Gross unrealized appreciation (depreciation) on debt securities by type of issuer is shown below:

| <i>(In millions)</i> | Amortized Cost | Allowance for Credit Loss | Unrealized Appreciation | Unrealized Depreciation | Fair Value |
|---------------------------------|-------------------|------------------------------|----------------------------|----------------------------|-----------------|
| December 31, 2025 | | | | | |
| Federal government and agency | \$ 215 | \$ — | \$ 15 | \$ (3) | \$ 227 |
| State and local government | 24 | — | 1 | — | 25 |
| Foreign government | 450 | — | 12 | (6) | 456 |
| Corporate | 7,704 | (137) | 175 | (332) | 7,410 |
| Mortgage and other asset-backed | 267 | — | 3 | (26) | 244 |
| Total | \$ 8,660 | \$ (137) | \$ 206 | \$ (367) | \$ 8,362 |
| December 31, 2024 | | | | | |
| Federal government and agency | \$ 276 | \$ — | \$ 14 | \$ (9) | \$ 281 |
| State and local government | 37 | — | 1 | (1) | 37 |
| Foreign government | 350 | — | 5 | (11) | 344 |
| Corporate | 9,091 | (111) | 102 | (659) | 8,423 |
| Mortgage and other asset-backed | 371 | — | 1 | (34) | 338 |
| Total | \$ 10,125 | \$ (111) | \$ 123 | \$ (714) | \$ 9,423 |

Review of Declines in Fair Value. Management reviews debt securities in an unrealized loss position to determine whether a credit loss allowance is needed based on criteria that include severity of decline; financial health and specific prospects of the issuer; and changes in the regulatory, economic or general market environment of the issuer's industry or geographic region.

The table below summarizes debt securities with a decline in fair value from amortized cost for which an allowance for credit losses has not been recorded (by investment grade and the length of time these securities have been in an unrealized loss position). Unrealized depreciation on these debt securities is primarily due to declines in fair value resulting from increasing interest rates since these securities were purchased.

| <i>(Dollars in millions)</i> | December 31, 2025 | | | | December 31, 2024 | | | |
|------------------------------|-------------------|-------------------|----------------------------|---------------------|-------------------|-------------------|----------------------------|---------------------|
| | Fair Value | Amortized Cost | Unrealized Depreciation | Number of Issues | Fair Value | Amortized Cost | Unrealized Depreciation | Number of Issues |
| One year or less | | | | | | | | |
| Investment grade | \$ 384 | \$ 386 | \$ (2) | 149 | \$ 1,203 | \$ 1,227 | \$ (24) | 545 |
| Below investment grade | 120 | 125 | (5) | 239 | 245 | 250 | (5) | 739 |
| More than one year | | | | | | | | |
| Investment grade | 3,044 | 3,382 | (338) | 799 | 4,687 | 5,319 | (632) | 1,297 |
| Below investment grade | 185 | 207 | (22) | 86 | 416 | 469 | (53) | 123 |
| Total | \$ 3,733 | \$ 4,100 | \$ (367) | 1,273 | \$ 6,551 | \$ 7,265 | \$ (714) | 2,704 |

Equity Securities

Accounting Policy. Equity securities with a readily determinable fair value consist primarily of public equity investments in the health care sector and mutual funds that invest in fixed income debt securities while those without a readily determinable fair value consist of private equity investments. Changes in the fair values of equity securities that have a readily determinable fair value are reported in Net investment gains/losses. Equity securities without a readily determinable fair value are carried at cost minus impairment plus or minus changes resulting from observable price changes.

The following table provides the values of the Company's equity security investments:

| <i>(In millions)</i> | December 31, 2025 | | December 31, 2024 | |
|---|-------------------|-------------------|-------------------|-------------------|
| | Cost | Carrying Value | Cost | Carrying Value |
| Equity securities with readily determinable fair values | \$ 78 | \$ 92 | \$ 635 | \$ 37 |
| Equity securities with no readily determinable fair value | 6,792 | 3,464 | 3,215 | 524 |
| Total | \$ 6,870 | \$ 3,556 | \$ 3,850 | \$ 561 |

In the third quarter of 2025, the Company invested \$3.5 billion in preferred stock of Shields, and a compounding dividend is recorded in Fees and other revenues within the Consolidated Statements of Income. The investment is included in equity securities with no readily determinable fair value in the table above.

Commercial Mortgage Loans

Accounting Policy. Commercial mortgage loans are carried at unpaid principal balances, net of an allowance for expected credit losses, and classified as either current or long-term investments based on their contractual maturities. Changes in the allowance for expected credit losses are recognized as credit loss expense and presented in Net investment gains/losses in the Company's Consolidated Statements of Income.

Each period, the Company establishes (or adjusts) its allowance for expected credit losses for commercial mortgage loans. The allowance for expected credit losses is based on a credit risk category that is assigned to each loan at origination using key credit quality indicators, including debt service coverage and loan-to-value ratios. Credit risk categories are updated as key credit quality indicators change. An expected loss rate, assigned based on the credit risk category, is applied to each loan's unpaid principal balance to develop the aggregate allowance for expected credit losses. Commercial mortgage loans are considered impaired and written off against the allowance when it is probable that the Company will not collect all amounts due per the terms of the promissory note. In situations involving foreclosure or the use of real estate operations to recover value, the allowance for credit losses is determined by the extent to which the mortgage loan's carrying value exceeds the fair value of its underlying collateral.

Mortgage loans held by the Company are made exclusively to commercial borrowers and are diversified by property type, location and borrower. Loans are generally issued at fixed rates of interest and are secured by high-quality, primarily completed and substantially leased operating properties.

Credit Quality. The Company regularly evaluates and monitors credit risk. Mortgage origination professionals employ an internal credit quality rating system designed to evaluate the relative risk of the transaction at origination that is then updated each year as part of the annual portfolio loan review. The Company evaluates and monitors credit quality on a consistent and ongoing basis. The annual portfolio review performed in the second quarter of 2025 confirmed ongoing strong overall credit quality in line with the previous year's results.

Quality ratings are based on our evaluation of a number of key inputs related to the loan. The two most significant contributors to the credit quality rating are the debt service coverage and loan-to-value ratios. The debt service coverage ratio measures the amount of property cash flow available to meet annual interest and principal payments on debt, with a ratio below 1.0 indicating that there is not enough cash flow to cover the required loan payments. The loan-to-value ratio, commonly expressed as a percentage, compares the amount of the loan to the fair value of the underlying property collateralizing the loan.

The following table summarizes the credit risk profile of the Company's commercial mortgage loan portfolio:

| <i>(Dollars in millions)</i> | December 31, 2025 | | | December 31, 2024 | | |
|------------------------------|-------------------|-------------------------------------|-----------------------------|-------------------|-------------------------------------|-----------------------------|
| | Carrying Value | Average Debt Service Coverage Ratio | Average Loan-to-Value Ratio | Carrying Value | Average Debt Service Coverage Ratio | Average Loan-to-Value Ratio |
| Loan-to-Value Ratio | | | | | | |
| Below 60% | \$ 355 | 2.13 | | \$ 547 | 2.07 | |
| 60% to 79% | 694 | 1.81 | | 595 | 1.83 | |
| 80% to 100% | 184 | 0.79 | | 209 | 0.51 | |
| Total | \$ 1,233 | 1.72 | 71 % | \$ 1,351 | 1.70 | 69 % |

Policy Loans

Accounting Policy. Policy loans, primarily associated with our corporate-owned life insurance business, are carried at unpaid principal balances plus accumulated interest, the total of which approximates fair value. These loans are collateralized by life insurance policy cash values and therefore have minimal exposure to credit loss. Interest rates are reset annually based on a rolling average of benchmark interest rates.

Other Long-Term Investments

Accounting Policy. Other long-term investments include investments in unconsolidated entities, including certain limited partnerships and limited liability companies holding real estate, securities or loans, and health care-related investments. These investments are carried at cost plus the Company's ownership percentage of reporting income or loss, based on the financial statements of the

underlying investments that are generally reported at fair value. Income or loss from these investments is reported on a one-quarter lag due to the timing of when financial information is received from the general partner or manager of the investments.

Other long-term investments also include investment real estate carried at depreciated cost less any impairment write-downs to fair value when cash flows indicate that the carrying value may not be recoverable. Depreciation is generally recorded using the straight-line method based on the estimated useful life of each asset. Investment real estate as of December 31, 2025 and 2024 is expected to be held longer than one year and may include real estate acquired through the foreclosure of commercial mortgage loans.

Additionally, foreign currency swaps carried at fair value and certain restricted deposits are reported in the table below as "Other." See discussion below for information on the Company's accounting policies for derivative financial instruments.

Other long-term investments and related commitments are diversified by issuer, property type and geographic region. These investments are primarily unconsolidated variable interest entities (see Note 13 to the Consolidated Financial Statements for additional information). The following table provides unfunded commitment and carrying value information for these investments. The Company expects to disburse approximately 30% of the committed amounts in 2026.

Our limited partnership investments are reduced as the Company receives cash distributions for returns on its investment that were previously recognized in Net investment income/losses. The amount of these cash distributions was \$314 million in 2025, \$344 million in 2024 and \$253 million in 2023.

| <i>(In millions)</i> | <u>Carrying Value as of December 31,</u> | | <u>Unfunded</u> |
|-------------------------|--|-------------|--|
| | <u>2025</u> | <u>2024</u> | <u>Commitments as of</u> <u>December 31, 2025</u> |
| Real estate investments | \$ 1,895 | \$ 1,763 | \$ 1,106 |
| Securities partnerships | 2,948 | 2,587 | 2,058 |
| Other | 194 | 226 | — |
| Total | \$ 5,037 | \$ 4,576 | \$ 3,164 |

Short-Term Investments

Accounting Policy. Security investments with maturities of greater than three months to one year from time of purchase are classified as short-term, available for sale and carried at fair value that approximates cost.

Concentration of Risk

The Company did not have a concentration of investments in a single issuer or borrower exceeding 10% of shareholders' equity as of December 31, 2025 or 2024.

B. Derivative Financial Instruments

The Company uses derivative financial instruments to manage the characteristics of investment assets (such as duration, yield, currency and liquidity) to meet the varying demands of the related insurance and contractholder liabilities. The Company also uses derivative financial instruments to hedge the risk of changes in the net assets of certain of its foreign subsidiaries due to changes in foreign currency exchange rates and to hedge the interest rate risk of certain long-term debt. The Company also has derivative instruments associated with certain equity securities; see Note 12 to the Consolidated Financial Statements for further discussion.

Accounting Policy. Derivatives are recorded in our Consolidated Balance Sheets at fair value and are classified as current or non-current according to their contractual maturities. Further information on our policies for determining fair value are discussed in Note 12. The Company applies hedge accounting when derivatives are designated, qualified and highly effective as hedges. Under hedge accounting, the changes in fair value of the derivative and the hedged risk are generally recognized together and offset each other when reported in Shareholders' net income. Various qualitative or quantitative methods appropriate for each hedge are used to formally assess and document hedge effectiveness at inception and each period throughout the life of a hedge.

Fair Value Hedges of the Foreign Exchange-Related Changes in Fair Values of Certain Foreign-Denominated Bonds:

This program hedges the foreign exchange-related changes in fair values of certain foreign-denominated bonds. The notional value of these derivatives matches the amortized cost of the hedged bonds. A majority of these instruments are denominated in Euros, with the remaining instruments denominated in British Pounds Sterling and Australian Dollars. Swap fair values are reported in Long-term investments or Other non-current liabilities. Offsetting changes in fair values attributable to the foreign exchange risk of the swap contracts and the hedged bonds are reported in Net investment gains/losses. The portion of the swap contracts' changes in fair value excluded from the assessment of hedge effectiveness is recorded in Other comprehensive loss and recognized in Net investment

income/losses as swap coupon payments are accrued, offsetting the foreign-denominated coupons received on the designated bonds. Net cash flows are reported in Operating activities, while exchanges of notional principal amounts are reported in Investing activities.

Fair Value Hedges of the Interest Rate Exposure on the Company's Long-Term Debt:

This program converts a portion of the interest rate exposure on the Company's long-term debt from fixed to variable rates. This more closely aligns the Company's interest expense with the interest income received on its cash equivalent and short-term investment balances. The variable rates are benchmarked to SOFR. Using fair value hedge accounting, the fair values of the swap contracts are reported in other assets or other liabilities. The critical terms of these swaps match those of the long-term debt being hedged. As a result, the carrying value of the hedged debt is adjusted to reflect changes in its fair value driven by SOFR. The effects of those adjustments on interest expense are offset by the effects of corresponding changes in the swaps' fair value. The net impact from the hedge reported in Interest expense and other reflects interest expense on the hedged debt at the variable interest rate. Cash flows relating to these contracts are reported in Operating activities.

Net Investment Hedges of Certain Foreign Subsidiaries Operating Principally in Currencies Other than the U.S. Dollar:

This program reduces the risk of changes in net assets due to changes in foreign currency spot exchange rates for certain foreign subsidiaries that conduct their business principally in currencies other than the U.S. Dollar. The notional value of hedging instruments matches the hedged amount of subsidiary net assets. Foreign currency swap contracts are denominated in Euros. The fair values of the foreign currency swap and forward contracts are reported in other assets or other liabilities. The changes in fair values of these instruments are reported in Other comprehensive loss, specifically in translation of foreign currencies. The portion of the change in fair values relating to foreign exchange spot rates will be recognized in earnings upon deconsolidation of the hedged foreign subsidiaries. Cash flows relating to these contracts are reported in Investing activities.

The effects of derivative financial instruments used in our individual hedging strategies were not material to the Consolidated Financial Statements as of December 31, 2025 and December 31, 2024. The gross fair values of our derivative financial instruments are presented in Note 12 to the Consolidated Financial Statements. The following table summarizes the types and notional quantity of derivative instruments held by the Company:

| <i>(In millions)</i> | Notional Value as of | |
|--|------------------------------|------------------------------|
| | December 31, 2025 | December 31, 2024 |
| Type of Instrument | | |
| Fair value hedge - Foreign currency swap contracts | \$ 908 | \$ 975 |
| Fair value hedge - Interest rate swap contracts | \$ 3,150 | \$ 2,700 |
| Net investment hedge - Foreign currency swap contracts | \$ 415 | \$ 415 |

C. Net Investment Income

Accounting Policy. When interest and principal payments on investments are current, the Company recognizes interest income when it is earned. The Company recognizes interest income on a cash basis when interest payments are delinquent based on contractual terms or when certain terms (interest rate or maturity date) of the investment have been restructured. For unconsolidated entities that are included in other long-term investments, investment income is generally recognized according to the Company's share of the reported income or loss on the underlying investments. Investment income attributed to the Company's separate accounts is excluded from our earnings because associated gains and losses generally accrue directly to separate account policyholders.

The components of Net investment income were as follows:

| <i>(In millions)</i> | For the Years Ended December 31, | | |
|----------------------------------|---|-------------|-------------|
| | 2025 | 2024 | 2023 |
| Debt securities | \$ 454 | \$ 492 | \$ 500 |
| Equity securities ⁽¹⁾ | 6 | (114) | 123 |
| Commercial mortgage loans | 52 | 61 | 65 |
| Policy loans | 51 | 56 | 60 |
| Other long-term investments | 232 | 75 | 123 |
| Short-term investments and cash | 294 | 447 | 339 |
| Total investment income | 1,089 | 1,017 | 1,210 |
| Less investment expenses | 43 | 44 | 44 |
| Net investment income | \$ 1,046 | \$ 973 | \$ 1,166 |

⁽¹⁾ Includes a \$182 million impairment of dividend receivable for the year ended December 31, 2024.

D. Investment Gains and Losses

Accounting Policy. Investment gains and losses are based on specifically identified assets and result from sales, investment asset write-downs, changes in the fair value of certain derivatives and equity securities and changes in allowances for credit losses on debt securities and commercial mortgage loan investments.

Net investment losses before income taxes were \$24 million, \$2,737 million and \$78 million for the years ended December 31, 2025, 2024 and 2023, respectively. Net investment losses in 2024 were primarily driven by the impairment of equity securities in 2024. These amounts exclude investment gains and losses attributed to the Company's separate accounts because those gains and losses generally accrue directly to separate account policyholders.

Note 12 – Fair Value Measurements

Accounting Policy. The Company carries certain financial instruments at fair value in the financial statements including debt securities, certain equity securities, short-term investments and derivatives. Other financial instruments are measured at fair value only under certain conditions, such as when impaired or when there are observable price changes for equity securities with no readily determinable fair value.

Fair value is defined as the price at which an asset could be exchanged in an orderly transaction between market participants at the balance sheet date. A liability's fair value is defined as the amount that would be paid to transfer the liability to a market participant, not the amount that would be paid to settle the liability with the creditor.

The Company's financial assets and liabilities carried at fair value have been classified based upon a hierarchy defined by GAAP. The hierarchy gives the highest ranking to fair values determined using unadjusted quoted prices in active markets for identical assets and liabilities (Level 1) and the lowest ranking to fair values determined using methodologies and models with unobservable inputs (Level 3). An asset's or a liability's classification is based on the lowest level of input that is significant to its measurement. For example, a financial asset or liability carried at fair value would be classified in Level 3 if unobservable inputs were significant to the instrument's fair value, even though the measurement may be derived using inputs that are both observable (Levels 1 and 2) and unobservable (Level 3).

The Company estimates fair values using prices from third parties or internal pricing methods. Fair value estimates received from third-party pricing services are based on reported trade activity and quoted market prices when available and other market information that a market participant would use to estimate fair value. The internal pricing methods are performed by the Company's investment professionals and generally involve using discounted cash flow analyses, incorporating current market inputs for similar financial instruments with comparable terms and credit quality as well as other qualitative factors. In instances where there is little or no market activity for the same or similar instruments, fair value is estimated using methods, models and assumptions that the Company believes a hypothetical market participant would use to determine a current transaction price. These valuation techniques involve some level of estimation and judgment that becomes significant with increasingly complex instruments or pricing models.

The Company is responsible for determining fair value and for assigning the appropriate level within the fair value hierarchy based on the significance of unobservable inputs. The Company reviews methodologies, processes and controls of third-party pricing services and compares prices on a test basis to those obtained from other external pricing sources or internal estimates. The Company performs ongoing analyses of both prices received from third-party pricing services and those developed internally to determine that they represent appropriate estimates of fair value. The controls executed by the Company include evaluating changes in prices and monitoring for potentially stale valuations. The Company also performs sample testing of sales values to confirm the accuracy of prior fair value estimates. The minimal exceptions identified during these processes indicate that adjustments to prices are infrequent and do not significantly impact valuations. An annual due diligence review of the most significant pricing service is conducted to review their processes, methodologies and controls. This review includes a walk-through of inputs for a sample of securities held across various asset types to validate the documented pricing process.

A. Financial Assets and Financial Liabilities Carried at Fair Value

The following table provides information about the Company's investment and derivative financial assets and liabilities carried at fair value on a recurring basis. Further information regarding insurance assets and liabilities carried at fair value is provided in Note 9E to the Consolidated Financial Statements. Separate account assets are also recorded at fair value on the Company's Consolidated Balance Sheets and are reported separately in the Separate Accounts section below as gains and losses related to these assets generally accrue directly to contractholders.

| <i>(In millions)</i> | Quoted Prices in Active Markets for Identical Assets (Level 1) | | Significant Other Observable Inputs (Level 2) | | Significant Unobservable Inputs (Level 3) | | Total | |
|--|--|-------------------|---|-------------------|---|-------------------|-------------------|-------------------|
| | December 31, 2025 | December 31, 2024 | December 31, 2025 | December 31, 2024 | December 31, 2025 | December 31, 2024 | December 31, 2025 | December 31, 2024 |
| Financial assets at fair value | | | | | | | | |
| Debt securities | | | | | | | | |
| Federal government and agency | \$ 105 | \$ 165 | \$ 122 | \$ 116 | \$ — | \$ — | \$ 227 | \$ 281 |
| State and local government | — | — | 25 | 37 | — | — | 25 | 37 |
| Foreign government | — | — | 446 | 344 | 10 | — | 456 | 344 |
| Corporate | — | — | 7,133 | 8,049 | 277 | 374 | 7,410 | 8,423 |
| Mortgage and other asset-backed | — | — | 206 | 295 | 38 | 43 | 244 | 338 |
| Total debt securities | 105 | 165 | 7,932 | 8,841 | 325 | 417 | 8,362 | 9,423 |
| Equity securities ⁽¹⁾ | 54 | 1 | 36 | 36 | 2 | — | 92 | 37 |
| Short-term investments | — | — | 257 | 170 | — | — | 257 | 170 |
| Derivative assets | — | — | 68 | 168 | 923 | — | 991 | 168 |
| Financial liabilities at fair value | | | | | | | | |
| Derivative liabilities | \$ — | \$ — | \$ 22 | \$ 1 | \$ 354 | \$ — | \$ 376 | \$ 1 |

⁽¹⁾ Excludes certain equity securities that have no readily determinable fair value.

Level 1 Financial Assets

Inputs for instruments classified in Level 1 include unadjusted quoted prices for identical assets in active markets accessible at the measurement date. Active markets provide pricing data for trades occurring at least weekly and include exchanges and dealer markets. Assets in Level 1 include actively traded U.S. government bonds and exchange-listed equity securities.

Level 2 Financial Assets and Financial Liabilities

Inputs for instruments classified in Level 2 include quoted prices for similar assets or liabilities in active markets, quoted prices from those willing to trade in markets that are not active, or other inputs that are market-observable or can be corroborated by market data for the term of the instrument. Such other inputs include market interest rates and volatilities, spreads, and yield curves. An instrument is classified in Level 2 if the Company determines that unobservable inputs are insignificant.

Debt and Equity Securities. Third-party pricing services and internal methods often use recent trades of securities with similar features and characteristics because many debt securities do not trade daily. Pricing models are used to determine these prices when recent trades are not available. These models calculate fair values by discounting future cash flows at estimated market interest rates. Such market rates are derived by calculating the appropriate spreads over comparable U.S. Treasury securities based on the credit quality, industry and structure of the asset. Typical inputs and assumptions to pricing models include, but are not limited to, a combination of benchmark yields, reported trades, issuer spreads, liquidity, benchmark securities, bids, offers, reference data, and industry and economic events. For mortgage-backed securities, inputs and assumptions may also include characteristics of the issuer, collateral attributes, prepayment speeds and credit rating. Nearly all of these instruments are valued using recent trades or pricing models.

Short-term Investments are carried at fair value that approximates cost. The Company compares market prices for these securities to recorded amounts on a regular basis to validate that current carrying amounts approximate exit prices. The short-term nature of the investments and corroboration of the reported amounts over the holding period support their classification in Level 2.

Derivative Assets and Liabilities classified in Level 2 represent over-the-counter instruments, such as foreign currency forward and swap contracts. Fair values for these instruments are determined using market-observable inputs, including forward currency and

interest rate curves and widely published market-observable indices. Credit risk related to the counterparty and the Company is considered when estimating the fair values of these derivatives. The nature and use of these derivative financial instruments are described in Note 11.

Level 3 Financial Assets and Financial Liabilities

Certain inputs for instruments classified in Level 3 are unobservable (supported by little or no market activity) and significant to their resulting fair value measurement. Unobservable inputs reflect the Company's best estimate of what hypothetical market participants would use to determine a transaction price for the asset or liability at the reporting date. Additionally, as discussed in Note 9E, the Company classifies variable annuity assets and liabilities in Level 3 of the fair value hierarchy.

The Company classifies certain newly issued, privately placed, complex or illiquid securities in Level 3. Approximately 4% of debt securities are priced using significant unobservable inputs and classified in this category.

Fair values of mortgage and other asset-backed securities, as well as corporate and government debt securities, are primarily determined using pricing models that incorporate the specific characteristics of each asset and related assumptions, including the investment type and structure, credit quality, industry and maturity date in comparison to current market indices, spreads, and liquidity of assets with similar characteristics. Inputs and assumptions for pricing may also include characteristics of the issuer, collateral attributes, and prepayment speeds for mortgage and other asset-backed securities. Recent trades in the subject security or similar securities are assessed when available, and the Company may also review published research in its evaluation, as well as the issuer's financial statements.

Information about Debt Securities. The significant unobservable input used to value our corporate and government debt securities, and mortgage and other asset-backed securities, is an adjustment for liquidity. This adjustment is needed to reflect current market conditions and issuer circumstances when there is limited trading activity for the security.

The following table summarizes the fair value and significant unobservable inputs that were developed directly by the Company and used in pricing these debt securities. The range and weighted average basis point amounts for liquidity reflect the Company's best estimates of the unobservable adjustments a market participant would make to calculate these fair values. An increase in liquidity spread adjustments would result in a lower fair value measurement, while a decrease would result in a higher fair value measurement.

| <i>(Fair value in millions)</i> | Fair Value as of | | Unobservable Input December 31, 2025 | Unobservable Adjustment Range (Weighted Average by Quantity) as of | |
|--|----------------------|----------------------|---|---|----------------------|
| | December 31, 2025 | December 31, 2024 | | December 31, 2025 | December 31, 2024 |
| Debt securities | | | | | |
| Corporate | \$ 286 | \$ 373 | Liquidity | 60 - 920 (175) bps | 60 - 1520 (370) bps |
| Mortgage and other asset-backed securities | 38 | 43 | Liquidity | 105 - 350 (160) bps | 100 - 550 (280) bps |
| Other debt securities | 1 | 1 | | | |
| Total Level 3 debt securities | \$ 325 | \$ 417 | | | |

Information about Derivative Instruments. Derivative instruments associated with certain equity securities are valued each reporting period using a Monte Carlo simulation of enterprise value and are recorded in Other assets and Other non-current liabilities in the Consolidated Balance Sheets. The estimation of enterprise value is derived from a discounted cash flow model utilizing management's forecasts and industry benchmarks. The significant unobservable Level 3 measurement inputs used as of December 31, 2025 are: volatility of adjusted earnings before interest, taxes, depreciation and amortization ("adjusted EBITDA") (55%), volatility of equity (85%), correlation (35%), purchaser credit spread (0.7%) and weighted average cost of capital (13.5%). Changes in these assumptions could increase or decrease the fair value measurements. See Note 11A to the Consolidated Financial Statements for further information.

Changes in Level 3 Financial Assets and Financial Liabilities Carried at Fair Value

The following table summarizes the changes in financial assets and financial liabilities classified in Level 3. Gains and losses reported in the table may include net changes in fair value that are attributable to both observable and unobservable inputs.

| <i>(In millions)</i> | Years Ended December 31, | |
|---|-----------------------------|---------|
| | 2025 | 2024 |
| Beginning balance | \$ 417 | \$ 447 |
| Losses included in Shareholders' net income | (90) | (69) |
| Gains (losses) included in Other comprehensive loss | 33 | (9) |
| Purchases, sales and settlements | | |
| Purchases | 655 | 17 |
| Sales | (8) | (2) |
| Settlements | (105) | (21) |
| Total purchases, sales and settlements | 542 | (6) |
| Transfers into / (out of) Level 3 | | |
| Transfers into Level 3 | 59 | 72 |
| Transfers out of Level 3 | (65) | (18) |
| Total transfers into / (out of) Level 3 | (6) | 54 |
| Ending balance | \$ 896 | \$ 417 |
| Total losses included in Shareholders' net income attributable to instruments held at the reporting date | \$ (94) | \$ (69) |
| Change in unrealized gain or (loss) included in Other comprehensive loss for assets held at the end of the reporting period | \$ 19 | \$ (9) |

Total gains and losses included in Shareholders' net income in the table above are reflected in the Consolidated Statements of Income as Net investment gains/losses and as Net investment income/losses. Gains and losses included in Other comprehensive loss, net of tax, in the table above are reflected in Net unrealized (depreciation) appreciation on securities and derivatives in the Consolidated Statements of Comprehensive Income.

Transfers into or out of the Level 3 category occur when unobservable inputs, such as the Company's best estimate of what a market participant would use to determine a current transaction price, become more or less significant to the fair value measurement. Market activity typically decreases during periods of economic uncertainty, and this decrease in activity reduces the availability of market observable data. As a result, the level of unobservable judgment that must be applied to the pricing of certain instruments increases and is typically observed through the widening of liquidity spreads. Transfers between Level 2 and Level 3 during 2025 and 2024 primarily reflected changes in liquidity estimates for certain private placement issuers across several sectors. See discussion under Level 3 Financial Assets and Financial Liabilities above for more information.

Separate Accounts

Accounting Policy. Separate account assets and liabilities are contractholder funds maintained in accounts with specific investment objectives. Our subsidiaries or external advisors manage invested assets of separate accounts on behalf of contractholders, including The Cigna Group Pension Plan, variable universal life products sold through our corporate-owned life insurance products and the run-off businesses. The assets of these accounts are legally segregated and are not subject to claims that arise out of any of the Company's other businesses. These separate account assets are carried at fair value with equal amounts recorded for related separate account liabilities. The investment income and fair value gains and losses of separate account assets generally accrue directly to the contractholders and, together with their deposits and withdrawals, are excluded from the Company's Consolidated Statements of Income and Cash Flows. Fees and charges earned for mortality risks, asset management or administrative services are reported in either Premiums or Fees and other revenues. Investments that are measured using the practical expedient of net asset value are excluded from the fair value hierarchy. The separate account activity for the years ended December 31, 2025 and 2024 was primarily driven by changes in the market values of the underlying separate account investments.

Fair values of Separate account assets were as follows:

| (In millions) | Quoted Prices in Active Markets for Identical Assets (Level 1) | | Significant Other Observable Inputs (Level 2) | | Significant Unobservable Inputs (Level 3) | | Total | |
|--|--|-------------------|---|-------------------|---|-------------------|-------------------|-------------------|
| | December 31, 2025 | December 31, 2024 | December 31, 2025 | December 31, 2024 | December 31, 2025 | December 31, 2024 | December 31, 2025 | December 31, 2024 |
| Guaranteed separate accounts (see Note 22) | \$ 247 | \$ 231 | \$ 330 | \$ 345 | \$ — | \$ — | \$ 577 | \$ 576 |
| Non-guaranteed separate accounts ⁽¹⁾ | 271 | 267 | 5,769 | 5,575 | 209 | 228 | 6,249 | 6,070 |
| Subtotal | \$ 518 | \$ 498 | \$ 6,099 | \$ 5,920 | \$ 209 | \$ 228 | \$ 6,826 | \$ 6,646 |
| Non-guaranteed separate accounts priced at net asset value as a practical expedient ⁽¹⁾ | | | | | | | 661 | 632 |
| Total | | | | | | | \$ 7,487 | \$ 7,278 |

⁽¹⁾ Non-guaranteed separate accounts include \$3.8 billion as of both December 31, 2025 and December 31, 2024 in assets supporting the Company's pension plans, including \$0.2 billion classified in Level 3 as of both December 31, 2025 and December 31, 2024. Non-guaranteed separate accounts are primarily comprised of securities partnerships, real estate and real estate funds.

Separate account assets classified in Level 1 primarily include exchange-listed equity securities. Level 2 assets primarily include corporate and structured bonds valued using recent trades of similar securities or pricing models that discount future cash flows at estimated market interest rates, as described above, and actively traded institutional and retail mutual fund investments.

Separate account assets classified in Level 3 primarily support the Company's pension plans and include certain newly issued, privately placed, complex or illiquid securities that are priced using methods discussed above, as well as commercial mortgage loans. Activity, including transfers into and out of Level 3, was not material for the years ended December 31, 2025 or 2024.

B. Assets and Liabilities Measured at Fair Value under Certain Conditions

Some financial assets and liabilities are not carried at fair value, such as commercial mortgage loans that are carried at unpaid principal, investment real estate that is carried at depreciated cost and equity securities with no readily determinable fair value when there are no observable market transactions. However, these financial assets and liabilities may be measured using fair value under certain conditions, such as when investments become impaired and are written down to their fair value, or when there are observable price changes from orderly market transactions of equity securities that otherwise had no readily determinable fair value.

For the year ended December 31, 2025, impairments recognized requiring the assets and liabilities described above to be measured at fair value were not material. For the year ended December 31, 2024, we determined our investment in VillageMD was fully impaired and recorded a \$2.7 billion loss in Net investment gains/losses in the Company's Consolidated Statements of Income. Observable price changes for equity securities with no readily determinable fair value were not material for the years ended December 31, 2025 or December 31, 2024.

C. Fair Value Disclosures for Financial Instruments Not Carried at Fair Value

The following table includes the Company's financial instruments not recorded at fair value but for which fair value disclosure is required. In addition to universal life products and finance leases, financial instruments that are carried in the Company's Consolidated Balance Sheets at amounts that approximate fair value are excluded from the following table.

| (In millions) | Classification in Fair Value Hierarchy | December 31, 2025 | | December 31, 2024 | |
|--|--|-------------------|----------------|-------------------|----------------|
| | | Fair Value | Carrying Value | Fair Value | Carrying Value |
| Commercial mortgage loans | Level 3 | \$ 1,195 | \$ 1,233 | \$ 1,256 | \$ 1,351 |
| Long-term debt, including current maturities, excluding finance leases | Level 2 | \$ 29,907 | \$ 31,352 | \$ 28,392 | \$ 31,008 |

Note 13 – Variable Interest Entities

When the Company becomes involved with a variable interest entity and when there is a change in the Company's involvement with an entity, the Company must determine if it is the primary beneficiary and must consolidate the entity. The Company is considered the primary beneficiary if it has the power to direct the entity's most significant economic activities and has the right to receive benefits or obligation to absorb losses that could be significant to the entity.

The Company evaluates the following criteria: the structure and purpose of the entity; the risks and rewards created by and shared through the entity; and the Company's ability to direct its activities, receive its benefits and absorb its losses relative to the other parties involved with the entity, including its sponsors, equity holders, guarantors, creditors and servicers.

The Company determined it was not a primary beneficiary in any material variable interest entity as of December 31, 2025 or 2024. The Company's involvement in variable interest entities for which it is not the primary beneficiary is described below.

Securities Limited Partnerships and Real Estate Limited Partnerships. The Company owns interests in securities limited partnerships and real estate limited partnerships that are defined as unconsolidated variable interest entities. These partnerships invest in the equity or mezzanine debt of privately held companies and real estate properties. General partners unaffiliated with the Company control decisions that most significantly impact the partnership's operations, and the limited partners do not have substantive kick-out or participating rights. The Company has invested in approximately 215 limited partnerships that have a carrying value of \$3.7 billion as of December 31, 2025 reported in other long-term investments. As of December 31, 2025, we have commitments to contribute an additional \$2.8 billion to these entities, and the Company's maximum exposure to loss from these investments is \$6.5 billion, calculated as the sum of our carrying value and the additional funding commitments. Our noncontrolling interest in each of these limited partnerships is generally less than 9% of the partnership ownership interests. See Note 11 to the Consolidated Financial Statements for further information on the Company's accounting policy for other long-term investments.

The Company has guaranteed debt payments to mortgage lenders for certain real estate limited partnerships should potential environmental obligations arise. No liability has been incurred related to these guarantees, and the Company's maximum exposure to these guarantees was approximately \$380 million as of December 31, 2025.

Other Variable Interest Entities. The Company is involved in other types of variable interest entities, including certain asset-backed and corporate securities, real estate joint ventures that develop properties for residential and commercial use, and international health care joint ventures. As of December 31, 2025, the Company's maximum exposure to loss is \$0.4 billion from certain asset-backed and corporate securities and \$1.0 billion from real estate joint ventures, which represents the sum of our carrying value and the additional funding commitments for these entities. The carrying values and maximum exposures for the remaining unconsolidated variable interest entities were not material as of December 31, 2025.

The Company has not provided, and does not intend to provide, financial support to any of the variable interest entities in excess of its maximum exposure. We perform ongoing qualitative analyses of our involvement with these variable interest entities to determine if consolidation is required.

Note 14 – Collectively Significant Operating Unconsolidated Subsidiaries

In addition to equity method investments in certain limited partnerships and limited liability companies holding real estate, securities or loans (as disclosed in Note 11), we maintain a portfolio of operating joint ventures accounted for as equity method investments. Operating joint ventures had a carrying value of \$(211) million as of December 31, 2025 and \$656 million as of December 31, 2024, of which \$(296) million as of December 31, 2025 and \$43 million as of December 31, 2024 related to our joint venture in China. The carrying value of our joint venture in China includes the Company's share of Accumulated Other Comprehensive Income (Loss) ("AOCI") losses of \$1,672 million as of December 31, 2025 and \$979 million as of December 31, 2024, primarily related to the requirement to update discount rate assumptions for certain long-duration liabilities as well as the impact of unrealized investment gains and losses.

For the years ended December 31, 2025, 2024 and 2023, none of our equity method investments were individually significant.

In the fourth quarter of 2024, we sold a portion of an operating joint venture, reducing our ownership. As a result, we recognized \$496 million within Net gain (loss) on sale of businesses in our Consolidated Statements of Income.

Accounting Policy. We record in our Consolidated Statements of Income our proportionate share of net income or loss generated by operating joint ventures within Fees and other revenues. In certain instances, income or loss is reported on a one-month lag due to the timing of when financial information is received.

The below summarized results of operations and financial position of the operating joint ventures reflects the latest available financial information and does not represent the Company's proportionate share of the assets, liabilities or earnings of such entities.

| <i>(In millions)</i> | For the Years Ended December 31, | | |
|----------------------|---|-------------|-------------|
| | 2025 | 2024 | 2023 |
| Revenues | \$ 7,747 | \$ 7,309 | \$ 5,962 |
| Net income | \$ 755 | \$ 607 | \$ 98 |

| <i>(In millions)</i> | December 31, | December 31, |
|----------------------|---------------------|---------------------|
| | 2025 | 2024 |
| Total assets | \$ 39,547 | \$ 34,395 |
| Total liabilities | \$ 40,009 | \$ 33,892 |

Note 15 – Accumulated Other Comprehensive Income (Loss)

AOCI includes net unrealized (depreciation) appreciation on securities and derivatives, change in discount rate and instrument-specific credit risk for certain long-duration insurance contractholder liabilities (see Note 9 to the Consolidated Financial Statements), foreign currency translation, and the net postretirement benefits liability adjustment. AOCI includes the Company's share from unconsolidated entities reported on the equity method. Generally, tax effects in AOCI are established at the currently enacted tax rate and reclassified to Shareholders' net income in the same period that the related pre-tax AOCI reclassifications are recognized.

Shareholders' other comprehensive loss, net of tax, for the years ended December 31, 2025, 2024 and 2023 is primarily attributable to the change in discount rates for certain long-duration liabilities and unrealized changes in the market values of securities and derivatives, including the impacts from unconsolidated entities reported on the equity method.

Changes in the components of AOCI were as follows:

| <i>(In millions)</i> | For The Years Ended December 31, | | |
|---|---|-------------|-------------|
| | 2025 | 2024 | 2023 |
| Securities and derivatives | | | |
| Beginning balance | \$ 832 | \$ 171 | \$ (332) |
| Unrealized (depreciation) appreciation on securities and derivatives, before reclassification, net of tax benefit (expense) of \$118, \$(207) and \$(146), respectively | (309) | 601 | 474 |
| Amounts reclassified to Shareholders' net income, net of tax (benefit) of \$(20), \$(16) and \$(8), respectively | 71 | 60 | 29 |
| Shareholders' other comprehensive (loss) income, net of tax | (238) | 661 | 503 |
| Ending balance | \$ 594 | \$ 832 | \$ 171 |
| Net long-duration insurance and contractholder liabilities measurement adjustments | | | |
| Beginning balance | \$ (2,038) | \$ (971) | \$ (256) |
| Net current period change in discount rate for certain long-duration liabilities, before reclassification, net of tax benefit of \$71, \$357 and \$222, respectively | (225) | (1,044) | (691) |
| Amounts reclassified to Shareholders' net income, net of tax expense of \$16, \$— and \$— respectively | (56) | — | — |
| Net current period change in discount rate for certain long-duration liabilities, net of tax benefit of \$87, \$357 and \$222, respectively | (281) | (1,044) | (691) |
| Net current period change in instrument-specific credit risk for market risk benefits, net of tax benefit of \$3, \$6 and \$5, respectively | (10) | (23) | (24) |
| Shareholders' other comprehensive (loss), net of tax | (291) | (1,067) | (715) |
| Ending balance | \$ (2,329) | \$ (2,038) | \$ (971) |
| Translation of foreign currencies | | | |
| Beginning balance | \$ (198) | \$ (149) | \$ (154) |
| Net translation of foreign currencies, before reclassification, net of tax (expense) benefit of \$(9), \$2 and \$5, respectively | 71 | (60) | 5 |
| Amounts reclassified to Shareholders' net income, net of tax expense of \$—, \$— and \$—, respectively | — | 11 | — |
| Shareholders' other comprehensive income (loss), net of tax | 71 | (49) | 5 |
| Ending balance | \$ (127) | \$ (198) | \$ (149) |
| Postretirement benefits liability | | | |
| Beginning balance | \$ (937) | \$ (915) | \$ (916) |
| Amounts reclassified to Shareholders' net income, net of tax (benefit) of \$(8), \$(7) and \$(11), respectively | 25 | 22 | 35 |
| Net change due to valuation update, before reclassification, net of tax benefit of \$9, \$14 and \$12, respectively | (32) | (44) | (34) |
| Shareholders' other comprehensive (loss) income, net of tax | (7) | (22) | 1 |
| Ending balance | \$ (944) | \$ (937) | \$ (915) |
| Total Accumulated other comprehensive loss | | | |
| Beginning balance | \$ (2,341) | \$ (1,864) | \$ (1,658) |
| Shareholders' other comprehensive (loss), net of tax benefit of \$180, \$149 and \$79, respectively | (465) | (477) | (206) |
| Ending balance | \$ (2,806) | \$ (2,341) | \$ (1,864) |

Note 16 – Strategic Optimization Program

In the first quarter of 2025, the Company commenced an enterprise-wide initiative to evolve our business and deliver a more efficient and improved experience for our patients, providers and customers. At commencement, this program was expected to continue through December 2026; however, the Company is continuing to evaluate additional opportunities and expects that the program will continue through 2028. The program includes severance and other employee costs, asset impairments and accelerated asset amortization, and the operating results of certain small non-strategic businesses that we plan to discontinue. As we continue to evaluate additional opportunities to improve the overall efficiency and effectiveness of our operations, we anticipate future charges.

During the year ended December 31, 2025, we reported total costs of \$749 million pre-tax (\$565 million after-tax) associated with this initiative. The total costs included \$616 million, pre-tax in Selling, general and administrative expenses which were primarily associated with severance (\$378 million) and asset impairments (\$101 million). The remainder reflects the operating results of certain non-strategic businesses. We expect substantially all of the accrued liability to be paid by the end of 2026. See Note 23 to the Consolidated Financial Statements for further details of the strategic optimization program by segment.

The following table presents a roll forward of the accrued liability recorded in Accrued expenses and other liabilities during the year ended December 31, 2025:

| <i>(In millions)</i> | |
|----------------------------|--------|
| Balance, December 31, 2024 | \$ — |
| 2025 charges | 378 |
| 2025 payments | (238) |
| Balance, December 31, 2025 | \$ 140 |

Note 17 – Pension

A. About Our Plans

The Company sponsors U.S. and non-U.S. defined benefit pension plans; future benefit accruals for the domestic plans are frozen.

Accounting Policy. The Company measures the assets and liabilities of its domestic pension plans as of December 31. Benefit obligations are measured at the present value of estimated future payments based on actuarial assumptions. The Company uses the corridor method to account for changes in the benefit obligation when actual results differ from those assumed or when assumptions change. These changes are called net unrecognized actuarial gains (losses). Under the corridor method, net unrecognized actuarial gains (losses) are initially recorded in Accumulated other comprehensive loss. When the unrecognized gain (loss) exceeds 10% of the benefit obligation, that excess is amortized to expense over the expected remaining lives of plan participants. The net plan expense is reported in Interest expense and other in the Consolidated Statements of Income.

We measure plan assets at fair value for balance sheet purposes and to measure pension benefit costs. When the actual return differs from the expected return, those differences are reflected in the net unrealized actuarial gain (loss) discussed above.

B. Funded Status and Amounts Included in Accumulated Other Comprehensive Loss

The following table summarizes the projected benefit obligations and assets related to our U.S. and non-U.S. pension plans:

| <i>(In millions)</i> | For the Years Ended December 31, | |
|---|-------------------------------------|----------|
| | 2025 | 2024 |
| Change in benefit obligation | | |
| Benefit obligation, January 1 | \$ 3,643 | \$ 3,934 |
| Service cost | — | 1 |
| Interest cost | 196 | 194 |
| Actuarial losses (gains), net ⁽¹⁾ | 109 | (146) |
| Benefits paid from plan assets | (309) | (328) |
| Other | (9) | (12) |
| Benefit obligation, December 31 | 3,630 | 3,643 |
| Change in plan assets | | |
| Fair value of plan assets, January 1 | 3,854 | 4,138 |
| Actual return on plan assets | 302 | 40 |
| Benefits paid | (309) | (328) |
| Contributions | 1 | 4 |
| Fair value of plan assets, December 31 | 3,848 | 3,854 |
| Funded status | \$ 218 | \$ 211 |
| Amounts presented in Consolidated Balance Sheets | | |
| Other assets | \$ 218 | \$ 211 |

⁽¹⁾ 2025 losses reflect a decrease in the discount rate, while 2024 gains reflect an increase in the discount rate.

We fund our qualified pension plans at least at the minimum amount required by the Employee Retirement Income Security Act of 1974 and the Pension Protection Act of 2006. Contributions made by the Company to the qualified pension plan in 2025 and anticipated contributions for 2026 are immaterial. Future years' contributions will ultimately be based on a wide range of factors, including but not limited to asset returns, discount rates and funding targets. Nonqualified pension plans are generally funded on a pay-as-you-go basis as there are no plan assets for these plans.

Benefit Payments. The following benefit payments are expected to be paid in:

| <i>(In millions)</i> | |
|----------------------|----------|
| 2026 | \$ 316 |
| 2027 | \$ 312 |
| 2028 | \$ 310 |
| 2029 | \$ 307 |
| 2030 | \$ 304 |
| 2031 - 2035 | \$ 1,409 |

Amounts reflected in the pension assets (liabilities) shown above that have not yet been reported in Net income and, therefore, have been included in Accumulated other comprehensive loss consisted of the following:

| <i>(In millions)</i> | December 31, 2025 | December 31, 2024 |
|--|----------------------|----------------------|
| Unrecognized net losses | \$ (1,230) | \$ (1,228) |
| Unrecognized prior service cost | (4) | (4) |
| Postretirement benefits liability adjustment | \$ (1,234) | \$ (1,232) |

C. Cost of Our Plans

Net pension cost (benefit) was as follows:

| <i>(In millions)</i> | For the Years Ended December 31, | | |
|--|----------------------------------|---------|-------|
| | 2025 | 2024 | 2023 |
| Service cost | \$ — | \$ 1 | \$ 1 |
| Interest cost | 196 | 194 | 204 |
| Expected long-term return on plan assets | (232) | (247) | (204) |
| Amortization of: | | | |
| Prior actuarial losses, net | 38 | 39 | 52 |
| Curtailment loss | — | 1 | — |
| Net cost (benefit) | \$ 2 | \$ (12) | \$ 53 |

D. Assumptions Used for Pension

| | For the Years Ended December 31, | |
|--|--|--|
| | 2025 | 2024 |
| Discount rate: | | |
| Pension benefit obligation | 5.27% | 5.57% |
| Pension benefit cost | 5.57% | 5.10% |
| Expected long-term return on plan assets: | | |
| Pension benefit cost | 6.50% | 6.50% |
| Mortality table for pension obligations | White Collar mortality table with MP 2021 projection scale | White Collar mortality table with MP 2021 projection scale |

The Company develops discount rates by applying actual annualized yields for high-quality bonds by duration to the expected pension plan liability cash flows. The bond yields represent a diverse mix of actively traded, high-quality fixed-income securities that have an above-average return at each duration, as management believes this approach is representative of the yield achieved through plan asset investment strategy. The expected long-term return on plan assets was developed considering historical long-term actual returns, expected long-term market conditions, plan asset mix and management's plan asset investment strategy.

E. Pension Plan Assets

As of December 31, 2025, pension assets included \$3.8 billion invested in the separate accounts of Connecticut General Life Insurance Company, a subsidiary of the Company, and an additional \$0.1 billion invested in funds of unaffiliated investment managers.

The fair values of pension assets by category are as follows:

| <i>(In millions)</i> | December 31, 2025 | December 31, 2024 |
|--|-------------------|-------------------|
| Debt securities: | | |
| Federal government and agency | \$ 100 | \$ 99 |
| Corporate | 2,674 | 2,673 |
| Asset-backed | 138 | 138 |
| Fund investments | 66 | 76 |
| Total debt securities | 2,978 | 2,986 |
| Equity securities: | | |
| Domestic | 23 | 21 |
| International, including funds and pooled separate accounts ⁽¹⁾ | — | 6 |
| Total equity securities | 23 | 27 |
| Securities partnerships, including pooled separate accounts ⁽¹⁾ | 447 | 402 |
| Real estate and real estate funds, including pooled separate accounts ⁽¹⁾ | 212 | 228 |
| Commercial mortgage loans | 21 | 27 |
| Guaranteed deposit account contract | 48 | 47 |
| Cash equivalents and other current assets, net | 119 | 137 |
| Total pension assets at fair value | \$ 3,848 | \$ 3,854 |

⁽¹⁾ A pooled separate account has several participating benefit plans and each owns a share of the total pool of investments.

The Company's current target investment allocation percentages are 90% fixed income and 10% in other investments, including private equity (securities partnerships), public equity securities, and real estate, and are developed by management as guidelines, although the fair values of each asset category are expected to vary as a result of changes in market conditions. The Company will evaluate further allocation changes to equity securities, other investments and fixed-income securities as funding levels change.

See Note 12 to the Consolidated Financial Statements for further details regarding how fair value is determined, including the level within the fair value hierarchy and the procedures we use to validate fair value measurements. The Company classifies substantially all debt securities in Level 2 for pension plan assets. These assets are valued using recent trades of similar securities or are fund investments priced using their daily net asset value that is the exit price. All domestic equity securities and international equity funds within pension assets are classified in Level 3.

Securities partnerships, real estate and hedge funds are valued using net asset value as a practical expedient and are excluded from the fair value hierarchy. See Note 12 to the Consolidated Financial Statements for additional disclosures related to these assets invested in the separate accounts of the Company's subsidiary. Certain securities as described in Note 12 to the Consolidated Financial Statements, as well as commercial mortgage loans and guaranteed deposit account contracts, are classified in Level 3 because unobservable inputs used in their valuation are significant.

F. 401(k) Plan

The Company sponsors a 401(k) plan. All employees are immediately eligible for the plan at hire. The Company matches a portion of employees' contributions to the plan and may increase its matching contributions if the Company's annual performance meets certain targets. Plan participants may invest in various funds that invest in the Company's common stock, several diversified stock funds, a bond fund or stable value funds. The Company common stock fund under the plan constitutes an "employee stock ownership plan" as defined in the Internal Revenue Code. Dividends from the Company common stock fund are reinvested in a participant's stock fund account unless the participant elects to receive the dividends in cash. The Company's annual expense for the plan was \$280 million, \$301 million and \$296 million for the years ended December 31, 2025, 2024 and 2023, respectively.

Note 18 – Employee Incentive Plans

A. About Our Plans

The People Resources Committee (the "Committee") of the Board of Directors awards stock options, restricted stock grants, restricted stock units, deferred stock and strategic performance shares to certain employees. The Company issues original issue shares for these awards.

The Company records compensation expense for stock and option awards over their vesting periods primarily based on the estimated fair value at the grant date. Fair value is determined differently for each type of award as discussed below.

Shares of common stock available for award were as follows:

| <i>(In millions)</i> | December 31, 2025 | December 31, 2024 | December 31, 2023 |
|-----------------------------------|------------------------------|------------------------------|------------------------------|
| Common shares available for award | 10.4 | 12.4 | 14.4 |

B. Stock Options

Accounting Policy. The Company awards options to purchase The Cigna Group common stock at the market price of the stock on the grant date. Options vest over periods ranging from one year to three years and expire no later than 10 years from grant date. Fair value is estimated using the Black-Scholes option pricing model by applying the assumptions presented below. That fair value is reduced by options expected to be forfeited during the vesting period. The Company estimates forfeitures at the grant date based on our experience and adjusts the expense to reflect actual forfeitures over the vesting period. The fair value of options, net of forfeitures, is recognized in Selling, general and administrative expenses on a straight-line basis over the vesting period.

Black-Scholes option pricing model assumptions and the resulting fair value of options are presented in the following table:

| | 2025 | 2024 | 2023 |
|--|-----------|-----------|-----------|
| Dividend yield | 2.04 % | 1.74 % | 1.58 % |
| Expected volatility | 31.0 % | 30.0 % | 30.0 % |
| Risk-free interest rate | 4.4 % | 4.0 % | 3.6 % |
| Expected option life | 4.9 years | 4.8 years | 4.7 years |
| Weighted average fair value of options | \$ 86.13 | \$ 92.36 | \$ 79.66 |

The dividend yield reflects expected future dividends. The Company intends to continue to pay dividends for the foreseeable future. The expected volatility reflects the past daily stock price volatility of The Cigna Group stock. The Company does not consider volatility implied in the market prices of traded options to be a good indicator of future volatility because remaining traded options will expire within one year. The risk-free interest rate is derived using the four-year U.S. Treasury bond yield rate as of the award date for the primary annual grant. Expected option life reflects the Company's historical experience.

The following table shows the status of, and changes in, common stock options:

| | For the Years Ended December 31, | | | | | |
|---------------------------------|----------------------------------|---------------------------------|---------|---------------------------------|---------|---------------------------------|
| | 2025 | | 2024 | | 2023 | |
| | Options | Weighted Average Exercise Price | Options | Weighted Average Exercise Price | Options | Weighted Average Exercise Price |
| <i>(Options in thousands)</i> | | | | | | |
| Outstanding - January 1 | 5,655 | \$ 226.38 | 6,696 | \$ 202.02 | 6,992 | \$ 186.54 |
| Granted | 857 | \$ 305.86 | 781 | \$ 336.48 | 915 | \$ 294.37 |
| Exercised | (1,088) | \$ 192.40 | (1,727) | \$ 178.82 | (1,080) | \$ 174.66 |
| Expired or canceled | (222) | \$ 314.78 | (95) | \$ 278.78 | (131) | \$ 246.95 |
| Outstanding - December 31 | 5,202 | \$ 242.81 | 5,655 | \$ 226.38 | 6,696 | \$ 202.02 |
| Options exercisable at year-end | 3,806 | \$ 216.90 | 3,941 | \$ 196.01 | 4,616 | \$ 179.28 |

Compensation expense of \$62 million related to unvested stock options as of December 31, 2025 will be recognized over the next two years (weighted average period).

The table below summarizes information for stock options exercised:

| | For the Years Ended December 31, | | |
|--------------------------------------|----------------------------------|--------|--------|
| | 2025 | 2024 | 2023 |
| <i>(In millions)</i> | | | |
| Intrinsic value of options exercised | \$ 128 | \$ 275 | \$ 126 |
| Cash received for options exercised | \$ 203 | \$ 305 | \$ 187 |
| Tax benefit from options exercised | \$ 16 | \$ 34 | \$ 17 |

The following table summarizes information for outstanding common stock options:

| | December 31, 2025 | |
|---|---------------------|---------------------|
| | Options Outstanding | Options Exercisable |
| Number (in thousands) | 5,202 | 3,806 |
| Total intrinsic value (in millions) | \$ 246 | \$ 246 |
| Weighted average exercise price | \$ 242.81 | \$ 216.90 |
| Weighted average remaining contractual life | 5.7 years | 4.6 years |

C. Restricted Stock

The Company awards restricted stock (grants and units) to the Company's employees that vest over periods ranging from one year to three years. Recipients of restricted stock awards accumulate dividends during the vesting period but generally forfeit their awards and accumulated dividends if their employment terminates before the vesting date.

Accounting Policy. Fair value of restricted stock awards is equal to the market price of The Cigna Group common stock on the date of grant. This fair value is reduced by awards that are expected to be forfeited. At the grant date, the Company estimates forfeitures based on experience and adjusts the expense to reflect actual forfeitures over the vesting period. This fair value, net of forfeitures, is recognized in Selling, general and administrative expenses over the vesting period on a straight-line basis.

The following table shows the status of, and changes in, restricted stock awards:

| <i>(Awards in thousands)</i> | For the Years Ended December 31, | | | | | |
|------------------------------|----------------------------------|---|--------------|---|--------------|---|
| | 2025 | | 2024 | | 2023 | |
| | Grants/Units | Weighted Average Fair Value at Award Date | Grants/Units | Weighted Average Fair Value at Award Date | Grants/Units | Weighted Average Fair Value at Award Date |
| Outstanding - January 1 | 1,250 | \$ 302.42 | 1,404 | \$ 257.38 | 1,535 | \$ 219.25 |
| Awarded | 701 | \$ 305.67 | 624 | \$ 319.39 | 700 | \$ 294.60 |
| Vested | (664) | \$ 284.20 | (713) | \$ 245.35 | (759) | \$ 214.70 |
| Forfeited | (149) | \$ 316.12 | (65) | \$ 283.62 | (72) | \$ 256.24 |
| Outstanding - December 31 | 1,138 | \$ 313.25 | 1,250 | \$ 302.42 | 1,404 | \$ 257.38 |

The fair value of vested restricted stock at the vesting date was as follows:

| <i>(In millions)</i> | For the Years Ended December 31, | | |
|---------------------------------------|----------------------------------|--------|--------|
| | 2025 | 2024 | 2023 |
| Fair value of vested restricted stock | \$ 203 | \$ 238 | \$ 220 |

Approximately 8,400 employees held 1.1 million restricted stock awards at the end of 2025 with \$187 million of related compensation expense to be recognized over the next two years (weighted average period).

D. Strategic Performance Shares ("SPSs")

The Company awards SPSs to executives and certain other key employees generally with a performance period of three years. Half of these shares are subject to a market condition (total shareholder return relative to industry peer companies), and half are subject to a performance condition (cumulative adjusted net income). These targets are set by the Committee at the beginning of the performance period. Holders of these awards receive shares of The Cigna Group common stock at the end of the performance period ranging anywhere from 0% to 200% of the original awards.

Accounting Policy. Compensation expense for SPSs is recorded over the performance period. Fair value is determined at the grant date for "market condition" SPSs using a Monte Carlo simulation model and not subsequently adjusted regardless of the final outcome. Expense is initially accrued for "performance condition" SPSs based on the most likely outcome but evaluated for adjustment each period for updates in the expected outcome. Expense is adjusted to the actual outcome (number of shares awarded multiplied by the share price at the grant date) at the end of the performance period.

The following table shows the status of, and changes in, SPSs:

| <i>(Awards in thousands)</i> | For the Years Ended December 31, | | | | | |
|------------------------------|----------------------------------|---|--------|---|--------|---|
| | 2025 | | 2024 | | 2023 | |
| | Shares | Weighted Average Fair Value at Award Date | Shares | Weighted Average Fair Value at Award Date | Shares | Weighted Average Fair Value at Award Date |
| Outstanding - January 1 | 601 | \$ 282.83 | 686 | \$ 243.90 | 780 | \$ 212.68 |
| Awarded | 217 | \$ 305.28 | 195 | \$ 336.81 | 219 | \$ 293.85 |
| Vested | (233) | \$ 231.75 | (242) | \$ 214.93 | (250) | \$ 191.78 |
| Forfeited | (80) | \$ 317.01 | (38) | \$ 289.35 | (63) | \$ 237.50 |
| Outstanding - December 31 | 505 | \$ 310.78 | 601 | \$ 282.83 | 686 | \$ 243.90 |

The weighted average fair value per share of SPSs for expense purposes, including the Monte Carlo factor, at the award date for the years ended December 31, 2025, 2024 and 2023 was \$323.60, \$377.23 and \$329.11, respectively.

The fair value of vested SPSs at the vesting date was as follows:

| <i>(Shares in thousands; \$ in millions)</i> | For the Years Ended December 31, | | | | | |
|---|----------------------------------|------------|--------|------------|--------|------------|
| | 2025 | | 2024 | | 2023 | |
| | Shares | Fair Value | Shares | Fair Value | Shares | Fair Value |
| Shares of The Cigna Group common stock distributed upon SPS vesting | 301 | \$ 92 | 257 | \$ 86 | 257 | \$ 76 |

Approximately 600 employees held 505,000 SPSs at the end of 2025, and \$43 million of related compensation expense is expected to be recognized over the next two years. The amount of expense for "performance condition" SPSs will vary based on actual performance in 2026 and 2027.

E. Compensation Cost and Tax Effects of Share-Based Compensation

The Company records tax benefits in Shareholders' net income during the vesting period based on the amount of expense being recognized. The difference between tax benefits based on the expense and the actual tax benefit realized are also recorded in income tax expense when stock options are exercised, or when restricted stock and SPSs vest.

| <i>(In millions)</i> | For the Years Ended December 31, | | |
|---|----------------------------------|--------|--------|
| | 2025 | 2024 | 2023 |
| Total compensation cost for shared-based awards | \$ 291 | \$ 308 | \$ 286 |
| Tax benefits recognized | \$ 69 | \$ 94 | \$ 92 |

Note 19 – Goodwill, Other Intangibles, and Property and Equipment

A. Goodwill

Accounting Policy. Goodwill represents the excess of the cost of businesses acquired over the fair value of their net assets. The resulting goodwill is assigned to those reporting units expected to realize cash flows from the acquisition, based on those reporting units' relative fair values. The Company's reporting units are aligned with its operating segments as described in Note 1.

The Company conducts its annual quantitative evaluation for goodwill impairment during the third quarter at the reporting unit level and writes it down through Shareholders' net income if impaired. On a quarterly basis, the Company performs a qualitative impairment assessment to determine if events or changes in circumstances indicate that it is more likely than not that the carrying value of a reporting unit exceeds its estimated fair value. The fair value of a reporting unit is generally estimated based on discounted cash flow analysis and market approach models using assumptions that the Company believes a hypothetical market participant would use to determine a current transaction price. Following a change in reporting units or held for sale determination, goodwill is allocated using relative fair value. The significant assumptions and estimates used in determining fair value primarily include the discount rate and future cash flows. A discount rate is selected to correspond with each reporting unit's weighted average cost of capital, consistent with that used for investment decisions considering the specific and detailed operating plans and strategies within each reporting unit. Projections of future cash flows differ by reporting unit and are consistent with our ongoing strategic projections. Future cash flows for Evernorth Health Services reporting units are primarily driven by the forecasted gross margins of the business, as well as operating expenses and long-term growth rates. Future cash flows for our other reporting units are primarily driven by forecasted revenues, benefit expenses, operating expenses and long-term growth rates.

Goodwill Activity. Goodwill activity was as follows:

| <i>(In millions)</i> | Evernorth Health Services | Cigna Healthcare | Total |
|--|------------------------------|---------------------|-----------|
| Balance at January 1, 2024 | \$ 35,130 | \$ 9,129 | \$ 44,259 |
| Goodwill acquired | 114 | — | 114 |
| Impact of foreign currency translation and other adjustments | 190 | (193) | (3) |
| Goodwill at December 31, 2024 | 35,434 | 8,936 | 44,370 |
| Goodwill acquired | 548 | — | 548 |
| Impact of foreign currency translation and other adjustments | — | 6 | 6 |
| Goodwill at December 31, 2025 | \$ 35,982 | \$ 8,942 | \$ 44,924 |

B. Other Intangible Assets

Accounting Policy. The Company's Other intangible assets primarily include purchased customer and producer relationships, trademarks, and provider networks. The fair value of purchased customer relationships and the amortization method were determined as of the dates of purchase using an income approach that relies on projected future net cash flows, including key assumptions for customer attrition and discount rates. The Company's definite-lived intangible assets are amortized on an accelerated or straight-line basis, reflecting their pattern of economic benefits, over periods from 1 year to 30 years. Management revises amortization periods if it believes there has been a change in the length of time that an intangible asset will continue to have value. Costs incurred to renew or extend the terms of these intangible assets are generally expensed as incurred.

The Company's amortized intangible assets are tested for impairment whenever events or changes in circumstances indicate that the carrying amount may not be recoverable. If the total of the expected future undiscounted cash flows generated by the underlying asset group is less than the carrying amount of the asset group, the Company recognizes an impairment charge equal to the difference between the carrying value of the asset group and its estimated fair value. The Company's indefinite-lived intangible assets are reviewed for impairment at least annually by comparing their fair value with their carrying value. If the carrying value exceeds fair value, that excess is recognized as an impairment loss.

Components of Other Assets, Including Other Intangibles. Other intangible assets were comprised of the following:

| <i>(In millions)</i> | Cost | Accumulated Amortization | Net Carrying Value |
|---|------------------|-----------------------------|-----------------------|
| December 31, 2025 | | | |
| Customer relationships | \$ 30,624 | \$ 10,655 | \$ 19,969 |
| Trade name - Express Scripts | 8,400 | | 8,400 |
| Other | 346 | 155 | 191 |
| Total | 39,370 | 10,810 | 28,560 |
| December 31, 2024 | | | |
| Customer relationships | \$ 29,971 | \$ 9,119 | \$ 20,852 |
| Trade name - Express Scripts | 8,400 | | 8,400 |
| Other | 316 | 131 | 185 |
| Other intangible assets ⁽¹⁾ | 38,687 | 9,250 | 29,437 |
| Value of business acquired ("VOBA") (reported in Other assets) ⁽²⁾ | 211 | 142 | 69 |
| Total | \$ 38,898 | \$ 9,392 | \$ 29,506 |

⁽¹⁾ Includes \$20 million of Other intangible assets classified as assets of businesses held for sale as of December 31, 2024.

⁽²⁾ Includes \$69 million of VOBA classified as assets of businesses held for sale as of December 31, 2024.

The Company has indefinite-lived intangible assets totaling \$8.4 billion as of December 31, 2025 and \$8.5 billion as of December 31, 2024, largely consisting of the Express Scripts trade name.

C. Property and Equipment

Accounting Policy. Property and equipment is carried at cost less accumulated depreciation. Cost includes interest, real estate taxes and other costs incurred during construction when applicable. Internal-use software that is acquired, developed or modified solely to meet the Company's internal needs, with no plan to market externally, is also included in this category. Costs directly related to acquiring, developing or modifying internal-use software are capitalized.

The Company calculates depreciation and amortization principally using the straight-line method generally based on the estimated useful life of each asset as follows: buildings and improvements, 10 to 40 years; purchased and internally developed software, 3 to 5 years; and furniture and equipment (including computer equipment), 3 to 10 years. Improvements to leased facilities are depreciated over the lesser of the remaining lease term or the estimated life of the improvement. The Company considers events and circumstances that would indicate the carrying value of property, equipment or capitalized software might not be recoverable. An impairment charge is recorded if the Company determines the carrying value of any of these assets is not recoverable. The Company also reviews and shortens the estimated useful lives of these assets, if necessary.

Components of Property and Equipment. Property and equipment were comprised of the following:

| <i>(In millions)</i> | Cost | Accumulated Amortization | Net Carrying Value |
|---|-----------|-----------------------------|-----------------------|
| December 31, 2025 | | | |
| Internal-use software | \$ 11,678 | \$ 8,904 | \$ 2,774 |
| Other property and equipment | 2,075 | 1,198 | 877 |
| Total property and equipment | 13,753 | 10,102 | 3,651 |
| December 31, 2024 | | | |
| Internal-use software | \$ 11,295 | \$ 8,167 | \$ 3,128 |
| Other property and equipment | 2,115 | 1,287 | 828 |
| Total property and equipment ⁽¹⁾ | 13,410 | 9,454 | 3,956 |

⁽¹⁾ Includes \$302 million of Property and equipment net carrying value classified as assets of businesses held for sale as of December 31, 2024.

Components of Depreciation and Amortization. Depreciation and amortization expense was comprised of the following:

| <i>(In millions)</i> | For the Years Ended December 31, | | |
|---|----------------------------------|----------|----------|
| | 2025 | 2024 | 2023 |
| Internal-use software | \$ 987 | \$ 1,021 | \$ 1,216 |
| Other property and equipment | 239 | 248 | 260 |
| Value of business acquired (reported in Other assets) | — | — | 7 |
| Other intangibles | 1,549 | 1,506 | 1,552 |
| Total depreciation and amortization | \$ 2,775 | \$ 2,775 | \$ 3,035 |

The Company estimates annual pre-tax amortization for intangible assets, including internal-use software, over the next five calendar years to be as follows:

| <i>(In millions)</i> | Pre-tax Amortization |
|----------------------|-------------------------|
| 2026 | \$ 2,360 |
| 2027 | \$ 2,237 |
| 2028 | \$ 2,062 |
| 2029 | \$ 1,821 |
| 2030 | \$ 1,592 |

Note 20 – Shareholders' Equity and Dividend Restrictions

State insurance departments and foreign jurisdictions that regulate certain of the Company's subsidiaries prescribe accounting practices (differing in some respects from GAAP) to determine statutory net income and surplus. The Company's life, accident, and health insurance and Health Maintenance Organization ("HMO") subsidiaries are regulated by such statutory requirements. The statutory net income of the Company's life, accident, and health insurance and HMO subsidiaries for the years ended, and their statutory surplus as of, December 31 were as follows:

| <i>(In billions)</i> | 2025 | 2024 | 2023 |
|----------------------|---------|---------|---------|
| Net income | \$ 3.7 | \$ 3.9 | \$ 5.3 |
| Surplus | \$ 13.0 | \$ 16.0 | \$ 14.9 |

The Company's HMO and life, accident and health insurance subsidiaries are also subject to minimum statutory surplus requirements and may be required to maintain investments on deposit with state departments of insurance or other regulatory bodies. Additionally, these subsidiaries may be subject to regulatory restrictions on the amount of annual dividends or other distributions (such as loans or cash advances) that insurance companies may extend to their parent companies without prior approval. These amounts, including restricted GAAP net assets of the Company's subsidiaries, were as follows:

| <i>(In billions)</i> | December 31, 2025 |
|--|------------------------------|
| Minimum statutory surplus required by regulators ⁽¹⁾ | \$ 4.5 |
| Investments on deposit with regulatory bodies | \$ 0.3 |
| Maximum dividend distributions permitted in 2026 without regulatory approval | \$ 2.0 |
| Maximum loans to the parent company permitted without regulatory approval | \$ 1.2 |
| Restricted GAAP net assets of subsidiaries of The Cigna Group | \$ 11.3 |

⁽¹⁾ Excludes amounts associated with foreign operated equity method joint ventures.

Permitted practices used by the Company's insurance subsidiaries in 2025 that differed from prescribed regulatory accounting had an immaterial impact on statutory surplus.

Undistributed earnings for equity method investments are \$1.6 billion as of December 31, 2025.

Note 21 – Income Taxes

Accounting Policy. Deferred income taxes are reflected in the Consolidated Balance Sheets for differences between the financial and income tax reporting bases of the Company's underlying assets and liabilities and are established based upon enacted tax rates and laws. Deferred income tax assets are recognized when available evidence indicates that realization is more likely than not, and a valuation allowance is established to the extent this standard is not met. The deferred income tax provision generally represents the net change in deferred income tax assets and liabilities during the reporting period excluding adjustments to Accumulated other comprehensive income (loss) or amounts recorded in connection with a business combination. The current income tax provision generally represents estimated amounts due on income tax returns for the year reported to various jurisdictions plus the effect of any uncertain tax positions. The Company uses the deferral method of accounting on investments that generate tax credits. Under this method, the investment tax credits are recognized as a reduction to the related asset, which are generally reported in Other assets in the Consolidated Balance Sheets. The Company recognizes a liability for uncertain tax positions if management believes the probability that the positions will be sustained is 50% or less. For uncertain positions that management believes are more likely than not to be sustained, the Company recognizes a liability based upon management's estimate of the most likely settlement outcome with the taxing authority. The liabilities for uncertain tax positions are classified as current when the position is expected to be settled within 12 months or the statute of limitation expires within 12 months.

Income taxes attributable to the Company's foreign operations are provided using the foreign jurisdictions' applicable tax rate.

The Company prospectively adopted ASU 2023-09, *Improvements to Income Tax Disclosures*. As a result, disclosures for 2025 reflect the requirements of ASU 2023-09, including the reconciliation of the statutory federal income tax rate and disaggregated tax payment information. Prior years (2024 and 2023) are presented under the previous disclosure requirements.

A. Income Tax Expense

The components of income taxes were as follows:

| <i>(In millions)</i> | For the Years Ended December 31, | | |
|--------------------------------------|----------------------------------|----------|----------|
| | 2025 | 2024 | 2023 |
| Current taxes | | | |
| U.S. income taxes | \$ 807 | \$ 1,167 | \$ 1,459 |
| Foreign income taxes | 191 | 248 | 161 |
| State income taxes | 169 | 171 | 180 |
| Total current taxes | 1,167 | 1,586 | 1,800 |
| Deferred taxes (tax benefits) | | | |
| U.S. income tax benefits | (69) | (142) | (533) |
| Foreign income taxes (tax benefits) | 447 | 64 | (1,046) |
| State income tax benefits | (52) | (17) | (80) |
| Total deferred taxes (tax benefits) | 326 | (95) | (1,659) |
| Total income taxes | \$ 1,493 | \$ 1,491 | \$ 141 |

Total income taxes were different from the amount computed using the statutory federal income tax rate in 2025 for the following reasons:

| <i>(in millions)</i> | For the Year Ended December 31, | |
|--|---------------------------------|--------|
| | 2025 | |
| | \$ | % |
| Tax expense at statutory rate | \$ 1,634 | 21.0 % |
| State income tax effect, net of federal income tax effect ⁽¹⁾ | 93 | 1.2 |
| Nontaxable or nondeductible items | 13 | 0.2 |
| Effects of cross-border tax laws: | | |
| Global intangible low-taxed income ("GILTI") | 127 | 1.6 |
| Other cross-border tax laws | 11 | 0.1 |
| Tax credits | (83) | (1.1) |
| Change in valuation allowance | (74) | (1.0) |
| Change in unrecognized tax benefits | 37 | 0.5 |
| Other | | |
| Impact of sale of business | (173) | (2.2) |
| Tax equity investments | (102) | (1.3) |
| Other reconciling items | 3 | 0.2 |
| Foreign tax effects: | | |
| Switzerland | | |
| Effect of rates different than U.S. statutory | (360) | (4.6) |
| Cantonal income taxes | 206 | 2.6 |
| Change in valuation allowance | 384 | 4.9 |
| Other countries | (223) | (2.9) |
| Total income taxes | \$ 1,493 | 19.2 % |

⁽¹⁾ The jurisdictions that make up the majority (greater than 50 percent) of the state and local tax impact are Florida and California.

Total income taxes were different from the amount computed using the statutory federal income tax rate in 2024 and 2023 for the following reasons:

| <i>(In millions)</i> | For the Years Ended December 31, | | | |
|---|---|---------------|---------------|--------------|
| | 2024 | | 2023 | |
| | \$ | % | \$ | % |
| Tax expense at statutory rate | \$ 1,107 | 21.0 % | \$ 1,158 | 21.0 % |
| Change in valuation allowance | 767 | 14.6 | 1,290 | 23.4 |
| State income tax effect, net of federal income tax effect | 62 | 1.2 | (39) | (0.7) |
| Investment tax credits | (111) | (2.1) | (48) | (0.8) |
| Impact of businesses held for sale | (129) | (2.4) | (213) | (3.9) |
| Effect of foreign earnings | (252) | (4.9) | (173) | (3.1) |
| Other foreign tax attributes | — | — | (153) | (2.8) |
| Swiss tax attributes | — | — | (1,674) | (30.4) |
| Other | 47 | 0.9 | (7) | (0.1) |
| Total income taxes | \$ 1,491 | 28.3 % | \$ 141 | 2.6 % |

Tax Equity Investments. Company investments in renewable energy projects provided \$968 million, \$1,057 million and \$453 million of investment tax credits for the years ended December 31, 2025, 2024 and 2023, respectively. The Company accounted for the tax credits using the deferral method and accordingly reduced the associated carrying value of the related assets by these amounts.

Pre-tax Income Disaggregation. Consolidated pre-tax income from the Company's foreign operations was approximately 53% of the Company's pre-tax income in 2025, 62% in 2024 and 48% in 2023. The change relative to 2024 is primarily attributable to lower 2024 domestic earnings driven by the impairment of equity securities in 2024 (see Note 11 to the Consolidated Financial Statements).

B. Deferred Income Taxes

Deferred income tax assets and liabilities were as follows:

| <i>(In millions)</i> | December 31, 2025 | December 31, 2024 |
|---|------------------------------|------------------------------|
| Deferred tax assets | | |
| Foreign tax attributes | \$ 1,615 | \$ 1,752 |
| Deferred loss - sale of business | — | 773 |
| Investments | 587 | 561 |
| Other insurance and contractholder liabilities | 241 | 300 |
| Loss carryforwards | 492 | 270 |
| Other accrued liabilities | 321 | 207 |
| Employee and retiree benefit plans | 190 | 177 |
| Unrealized depreciation on investments and foreign currency translation | 10 | 93 |
| Policy acquisition expenses | 53 | — |
| Other | 339 | 256 |
| Deferred tax assets before valuation allowance | 3,848 | 4,389 |
| Valuation allowance for deferred tax assets | (2,374) | (2,332) |
| Deferred tax assets, net of valuation allowance | 1,474 | 2,057 |
| Deferred tax liabilities | | |
| Acquisition-related basis differences | 7,558 | 7,822 |
| Depreciation and amortization | 602 | 243 |
| Policy acquisition expenses | — | 74 |
| Total deferred tax liabilities | 8,160 | 8,139 |
| Net deferred income tax liabilities ⁽¹⁾ | \$ (6,686) | \$ (6,082) |

⁽¹⁾ *Deferred tax liabilities, net in the Consolidated Balance Sheets excludes \$459 million and \$954 million reported in Other assets as of December 31, 2025 and December 31, 2024, respectively, and \$61 million reported in liabilities of businesses held for sale as of December 31, 2024.*

Management believes that it is more likely than not that future results will be sufficient to realize the Company's gross deferred tax assets ("DTAs") that remain after valuation allowance. Valuation allowances have been established against certain federal, state and foreign tax attributes. There are multiple expiration dates associated with these tax attributes.

Foreign Jurisdiction Tax Attributes. As of December 31, 2025 and 2024, the Company had DTAs of approximately \$1.6 billion and \$1.8 billion, respectively, and had a related \$1.2 billion and \$0.8 billion valuation allowance, respectively, against these deferred tax assets based on projections of future earnings and requirements to utilize the assets within certain time periods. In 2025, the Company recorded an increase to the valuation allowance as a result of management's reassessment of the composition of future foreign and domestic earnings. It is possible that the Company may revalue these net deferred tax assets in future periods due to modifications in certain assumptions, such as forecasted future earnings.

Capital DTAs: Impairments, Unrealized Investment Losses and Sale of Medicare Advantage and Related Businesses. As of December 31, 2025 and 2024, the Company had approximately \$819 million and \$880 million, respectively, in DTAs associated with the impairment of equity securities and other unrealized investment losses (see Note 11 to the Consolidated Financial Statements), as well as \$237 million and \$773 million, respectively, of DTAs in connection with the HCSC transaction, reflecting total capital DTAs of approximately \$1,056 million and \$1,653 million, respectively. A valuation allowance of \$1,025 million and \$1,351 million, respectively, has been established against these DTAs as of December 31, 2025 and 2024 due to the uncertainty relative to the recovery of the deferred tax benefits as the Company does not anticipate having sufficient sources of capital income to support these capital losses. We have determined that a valuation allowance against the remaining capital DTAs is not currently required based on the Company's loss carryback capacity and ability and intent to hold certain investment securities until recovery. We continue to monitor and evaluate the need for any additional valuation allowance.

During 2025, the reallocation of the HCSC transaction purchase price by legal entity resulted in an equal write-off of the DTAs and valuation allowance associated with the tax-deductible capital loss on the sale, resulting in zero net impact to the Company's total tax provision. Additionally, a reallocation of available sources of capital income generated a substantial portion of the after-tax gain on sale presented in Note 5 to the Consolidated Financial Statements. There was no material change to the realizability assessment of the Company's consolidated DTAs and no material net impact to the Company's consolidated tax expense as a result of this reallocation.

C. Uncertain Tax Positions

Reconciliations of unrecognized tax benefits were as follows:

| <i>(In millions)</i> | For the Years Ended December 31, | | |
|---|---|-------------|-------------|
| | 2025 | 2024 | 2023 |
| Balance at January 1, | \$ 1,477 | \$ 1,399 | \$ 1,343 |
| Decrease due to prior year positions | (50) | (7) | (26) |
| Increase due to current year positions | 187 | 165 | 107 |
| Reduction related to settlements with taxing authorities | (62) | (22) | (13) |
| Reduction related to lapse of applicable statute of limitations | (14) | (58) | (12) |
| Balance at December 31, | \$ 1,538 | \$ 1,477 | \$ 1,399 |

Substantially all unrecognized tax benefits would increase Shareholders' net income if recognized.

The Company classifies net interest expense on uncertain tax positions as a component of income tax expense and in Other non-current liabilities in the Consolidated Balance Sheets. In addition to the amounts in the table above, the liability for net interest expense on uncertain tax positions was approximately \$223 million, \$228 million and \$220 million as of December 31, 2025, 2024 and 2023, respectively.

D. Other Tax Matters

The statutes of limitations for the Company's consolidated federal income tax returns through 2016 have closed. The statute of limitations for the Company's 2020 and 2021 tax returns have also closed. However, The Cigna Group filed amended returns for both the 2015 and 2016 tax years, which are under review by the Internal Revenue Service ("IRS"). Additionally, the IRS is examining the Company's returns for 2017, 2018, 2019, 2022 and 2023. The IRS has examined Express Scripts' tax returns for 2010 through 2017, for which there remain significant disputed matters. In addition, the Company has pending refund claims for various years. The Company has established adequate reserves for these matters.

The Company conducts business in a number of state and foreign jurisdictions and may be engaged in multiple audit proceedings at any given time. Generally, no further state or foreign audit activity is expected for tax years prior to 2013 for Express Scripts entities and 2014 for all other entities of The Cigna Group.

Pillar Two. The Organization for Economic Co-operation and Development ("OECD") Pillar Two Framework defines a minimum effective tax rate of 15%. The Company is within the scope of the OECD Pillar Two model rules, which did not have a significant impact on our 2025 results. We will continue to monitor the potential impact on future periods but do not currently expect Pillar Two to significantly impact future periods.

E. Income Taxes Paid

For the year ended December 31, 2025, the Company made tax payments, net of refunds, in the amount of \$399 million to the following jurisdictions: U.S. federal refund (\$4 million), U.S. state payment (\$140 million), and foreign payments (\$263 million), primarily Switzerland. The Company's federal tax payments reflect the benefit of \$968 million of renewable energy tax credits, which have been applied against the Company's federal tax liability under existing tax rules.

For the years ended December 31, 2024 and 2023, the company made tax payments, net of refunds in the amount of \$898 million and \$1,471 million, respectively. For the years ended December 31, 2024 and 2023, the Company's federal tax payments reflect the benefit of \$1,057 million and \$453 million, respectively, of renewable energy tax credits, which were applied against the Company's federal tax liability under existing tax rules.

Note 22 – Contingencies and Other Matters

The Company, through its subsidiaries, is contingently liable for various guarantees provided in the ordinary course of business.

A. Financial Guarantees: Retiree and Life Insurance Benefits

The Company guarantees that separate account assets will be sufficient to pay certain life insurance or retiree benefits. For the majority of these benefits, the sponsoring employers are primarily responsible for ensuring that assets are sufficient to pay these benefits and are required to maintain assets that exceed a certain percentage of benefit obligations. If employers fail to do so, the Company or an affiliate of the buyer of the retirement benefits business has the right to redirect the management of the related assets to provide for benefit payments. As of December 31, 2025, employers maintained assets that generally exceeded the benefit obligations under these arrangements of approximately \$400 million. An additional liability is established if management believes that the Company will be required to make payments under the guarantees; there were no additional liabilities required for these guarantees, net of reinsurance, as of December 31, 2025. Separate account assets supporting these guarantees are classified in Levels 1 and 2 of the GAAP fair value hierarchy.

The Company does not expect that these financial guarantees will have a material effect on the Company's consolidated results of operations, liquidity or financial condition.

B. Certain Other Guarantees

The Company had indemnification obligations as of December 31, 2025 in connection with acquisition and disposition transactions. These indemnification obligations are triggered by the breach of representations or covenants provided by the Company, such as representations for the presentation of financial statements, filing of tax returns, compliance with laws or regulations, or identification of outstanding litigation. These obligations are typically subject to various time limitations, defined by the contract or by operation of law, such as statutes of limitation. In some cases, the maximum potential amount due is subject to contractual limitations based on a stated dollar amount or a percentage of the transaction purchase price, while in other cases limitations are not specified or applicable. The Company does not believe that it is possible to determine the maximum potential amount due under these obligations because not all amounts due under these indemnification obligations are subject to limitation. There were no recorded liabilities for these indemnification obligations as of December 31, 2025.

C. Guaranty Fund Assessments

The Company operates in a regulatory environment that may require its participation in assessments under state insurance guaranty association laws. The Company's exposure to assessments for certain obligations of insolvent insurance companies to policyholders and claimants is based on its share of business written in the relevant jurisdictions. There were no material charges or credits resulting from existing or new guaranty fund assessments for the year ended December 31, 2025.

D. Legal and Regulatory Matters

The Company is routinely involved in numerous claims, lawsuits, regulatory inquiries and audits, government investigations, including under the federal False Claims Act and state false claims acts initiated by a government investigating body or by a *qui tam* relator's filing of a complaint under court seal, and other legal matters arising, for the most part, in the ordinary course of managing a global health company. Additionally, the Company has received and is cooperating with subpoenas or similar processes from various governmental agencies requesting information, all arising in the normal course of its business. Disputed tax matters arising from audits by the IRS or other state and foreign jurisdictions, including those resulting in litigation, are accounted for under GAAP guidance for uncertain tax positions, as described in Note 21.

Accounting Policy. The Company accrues for legal and regulatory matters when a loss contingency is both probable and estimable. The estimated loss is generally recorded in Selling, general and administrative expenses and represents the Company's best estimate of the loss contingency. If the loss estimate is a range, the Company accrues the minimum amount in the range if no amount is better than any other estimated amount in the range. Legal costs to defend the Company's litigation and arbitration matters are expensed as incurred in cases that the Company cannot reasonably estimate the ultimate cost to defend. If the Company can reasonably estimate the cost to defend, a liability for these costs is accrued when the claim is reported.

Note 23 – Segment Information

See Note 1 to the Consolidated Financial Statements for a description of our segments. A description of our basis for reporting segment operating results is outlined below. Intersegment revenues primarily reflect pharmacy and care services transactions between the Evernorth Health Services and Cigna Healthcare segments. The Chairman and Chief Executive Officer is the chief operating decision maker ("CODM") responsible for making decisions about resources to be allocated to each segment and assessing its performance.

The Company uses "pre-tax adjusted income (loss) from operations" and "adjusted revenues" as its principal financial measures of segment operating performance because management, including the CODM, believes these metrics reflect the underlying results of business operations and facilitate analysis of trends in underlying revenue, expenses and profitability to enable resource allocation decisions. We define pre-tax adjusted income (loss) from operations as income (loss) before income taxes excluding pre-tax income (loss) attributable to noncontrolling interests, net investment gains/losses, amortization of acquired intangible assets and special items. The Cigna Group's share of certain investment results of its joint ventures reported in the Cigna Healthcare segment using the equity method of accounting are also excluded. Special items are matters that management, including the CODM, believes are not representative of the underlying results of operations due to their nature or size. Adjusted income (loss) from operations is measured on an after-tax basis for consolidated results and on a pre-tax basis for segment results.

The Company defines adjusted revenues as total revenues excluding the following adjustments: special items and The Cigna Group's share of certain investment results of its joint ventures reported in the Cigna Healthcare segment using the equity method of accounting. Special items are matters that management, including the CODM, believes are not representative of the underlying results of operations due to their nature or size. We exclude these items from this measure because management, including the CODM, believes they are not indicative of past or future underlying performance of the business.

The Company does not report total assets by segment because this is not a metric used by the CODM to allocate resources or evaluate segment performance.

The following table presents the special items charges (benefits) recorded by the Company, as well as the respective financial statement line items impacted:

| <i>(In millions)</i> | For the Years Ended December 31, | | | | | |
|---|----------------------------------|---------------|---------------|---------------|-----------------|---------------|
| | 2025 | | 2024 | | 2023 | |
| | Pre-tax | After-tax | Pre-tax | After-tax | Pre-tax | After-tax |
| Strategic optimization program (primarily Selling, general and administrative expenses) | \$ 749 | \$ 565 | \$ — | \$ — | \$ — | \$ — |
| Deferred tax expenses (benefits), net (Income taxes, less amount attributable to noncontrolling interests) | — | 427 | — | 84 | — | (1,071) |
| Integration and transaction-related costs (Selling, general and administrative expenses) | 327 | 247 | 275 | 211 | 45 | 35 |
| (Benefits) charges associated with litigation matters (Selling, general and administrative expenses) | (17) | (13) | — | — | 201 | 171 |
| Net (gain) loss on sale of businesses | (13) | (404) | (24) | (2) | 1,499 | 1,429 |
| Impairment of dividend receivable (Net investment income) | — | — | 182 | 138 | — | — |
| Charge for organizational efficiency plan (Selling, general and administrative expenses) | — | — | — | — | 252 | 193 |
| Total impact from special items | \$ 1,046 | \$ 822 | \$ 433 | \$ 431 | \$ 1,997 | \$ 757 |

Summarized segment financial information was as follows:

| <i>(In millions)</i> | Evernorth Health Services | Cigna Healthcare | Other Operations | Corporate and Eliminations | Total |
|--|---------------------------------|---------------------|---------------------|----------------------------------|-----------------|
| 2025 | | | | | |
| Revenues from external customers | \$ 232,098 | \$ 41,426 | \$ 325 | \$ 5 | \$ 273,854 |
| Intersegment revenues | 2,713 | 5,405 | 51 | (8,169) | |
| Net investment income | 142 | 581 | 298 | 25 | 1,046 |
| Total revenues | 234,953 | 47,412 | 674 | (8,139) | 274,900 |
| Net investment results from certain equity method investments | — | (249) | — | — | (249) |
| Adjusted revenues | \$ 234,953 | \$ 47,163 | \$ 674 | \$ (8,139) | \$ 274,651 |
| Pharmacy and other service costs | 223,086 | — | | | |
| Medical costs | — | 33,474 | | | |
| Selling, general and administrative expenses | 4,170 | 9,545 | | | |
| Other segment items ⁽¹⁾ | | | | | |
| Interest (expense) and other | (1) | 9 | | | |
| Less: Income attributable to noncontrolling interests | 475 | — | | | |
| Pre-tax adjusted income (loss) from operations | 7,221 | 4,153 | 89 | (1,593) | 9,870 |
| Income (loss) before income taxes | \$ 5,826 | \$ 4,344 | \$ (46) | \$ (2,343) | \$ 7,781 |
| Pre-tax adjustments to reconcile to adjusted income from operations | | | | | |
| (Income) attributable to noncontrolling interests | (475) | — | — | — | (475) |
| Net investment (gains) losses ⁽²⁾ | (20) | (210) | 2 | 3 | (225) |
| Amortization of acquired intangible assets | 1,720 | 23 | — | — | 1,743 |
| Special items | | | | | |
| Strategic optimization program | 174 | 22 | 133 | 420 | 749 |
| Integration and transaction-related costs | — | — | — | 327 | 327 |
| Net (gain) on sale of businesses | (4) | (9) | — | — | (13) |
| (Benefits) associated with litigation matters | — | (17) | — | — | (17) |
| Pre-tax adjusted income (loss) from operations | \$ 7,221 | \$ 4,153 | \$ 89 | \$ (1,593) | \$ 9,870 |
| Other segment information | | | | | |
| Depreciation and amortization | \$ 2,400 | \$ 339 | \$ 16 | \$ 20 | \$ 2,775 |

⁽¹⁾ Other segment items represent the difference between segment adjusted revenues less significant segment expenses and pre-tax adjusted income (loss) from operations, and they do not represent significant segment items relative to the CODM's review and oversight.

⁽²⁾ Includes Net investment gains/losses as presented in our Consolidated Statements of Income, as well as the Company's share of certain investment results of its joint ventures reported in the Cigna Healthcare segment using the equity method of accounting, which are presented within Fees and other revenues in our Consolidated Statements of Income.

| <i>(In millions)</i> | Evernorth Health Services | Cigna Healthcare | Other Operations | Corporate and Eliminations | Total |
|--|---------------------------------|---------------------|---------------------|----------------------------------|-----------------|
| 2024 | | | | | |
| Revenues from external customers | \$ 198,177 | \$ 47,528 | \$ 440 | \$ 3 | \$ 246,148 |
| Intersegment revenues | 3,775 | 4,972 | 79 | (8,826) | |
| Net investment income | 21 | 618 | 309 | 25 | 973 |
| Total revenues | 201,973 | 53,118 | 828 | (8,798) | 247,121 |
| Net investment results from certain equity method investments | — | (204) | — | — | (204) |
| Special item related to impairment of dividend receivable | 182 | — | — | — | 182 |
| Adjusted revenues | \$ 202,155 | \$ 52,914 | \$ 828 | \$ (8,798) | \$ 247,099 |
| Pharmacy and other service costs | 190,968 | — | | | |
| Medical costs | — | 37,887 | | | |
| Selling, general and administrative expenses | 3,779 | 10,805 | | | |
| Other segment items ⁽¹⁾ | | | | | |
| Interest (expense) and other | (2) | 7 | | | |
| Less: Income attributable to noncontrolling interests | 405 | — | | | |
| Pre-tax adjusted income (loss) from operations | 7,001 | 4,229 | (9) | (1,688) | 9,533 |
| Income (loss) before income taxes | \$ 3,929 | \$ 3,315 | \$ (12) | \$ (1,963) | \$ 5,269 |
| Pre-tax adjustments to reconcile to adjusted income from operations | | | | | |
| (Income) attributable to noncontrolling interests | (405) | — | — | — | (405) |
| Net investment losses ⁽²⁾ | 2,129 | 401 | 3 | — | 2,533 |
| Amortization of acquired intangible assets | 1,662 | 41 | — | — | 1,703 |
| Special items | | | | | |
| Integration and transaction-related costs | — | — | — | 275 | 275 |
| Impairment of dividend receivable | 182 | — | — | — | 182 |
| Net (gain) loss on sale of businesses | (496) | 472 | — | — | (24) |
| Pre-tax adjusted income (loss) from operations | \$ 7,001 | \$ 4,229 | \$ (9) | \$ (1,688) | \$ 9,533 |
| Other segment information | | | | | |
| Depreciation and amortization | \$ 2,319 | \$ 417 | \$ 9 | \$ 30 | \$ 2,775 |

⁽¹⁾ Other segment items represent the difference between segment adjusted revenues less significant segment expenses and pre-tax adjusted income (loss) from operations, and they do not represent significant segment items relative to the CODM's review and oversight.

⁽²⁾ Includes Net investment gains/losses as presented in our Consolidated Statements of Income, as well as the Company's share of certain investment results of its joint ventures reported in the Cigna Healthcare segment using the equity method of accounting, which are presented within Fees and other revenues in our Consolidated Statements of Income.

| <i>(In millions)</i> | Evernorth Health Services | Cigna Healthcare | Other Operations | Corporate and Eliminations | Total |
|--|--|-----------------------------|-----------------------------|---|-----------------|
| 2023 | | | | | |
| Revenues from external customers | \$ 147,588 | \$ 46,219 | \$ 291 | \$ 1 | \$ 194,099 |
| Intersegment revenues | 5,670 | 4,332 | — | (10,002) | |
| Net investment income | 241 | 597 | 305 | 23 | 1,166 |
| Total revenues | 153,499 | 51,148 | 596 | (9,978) | 195,265 |
| Net investment results from certain equity method investments | — | 57 | — | — | 57 |
| Adjusted revenues | \$ 153,499 | \$ 51,205 | \$ 596 | \$ (9,978) | \$ 195,322 |
| Pharmacy and other service costs | 143,571 | — | | | |
| Medical costs | — | 35,678 | | | |
| Selling, general and administrative expenses | 3,340 | 11,055 | | | |
| Other segment items ⁽¹⁾ | | | | | |
| Interest (expense) and other | (2) | 8 | | | |
| Less income attributable to noncontrolling interests | 144 | 2 | | | |
| Pre-tax adjusted income (loss) from operations | 6,442 | 4,478 | 96 | (1,698) | 9,318 |
| Income (loss) before income taxes | \$ 4,768 | \$ 2,664 | \$ 76 | \$ (1,995) | \$ 5,513 |
| Pre-tax adjustments to reconcile to adjusted income from operations | | | | | |
| (Income) attributable to noncontrolling interests | (144) | (2) | — | — | (146) |
| Net investment losses ⁽²⁾ | — | 133 | 2 | — | 135 |
| Amortization of acquired intangible assets | 1,774 | 45 | — | — | 1,819 |
| Special items | | | | | |
| Net loss on sale of businesses | — | 1,481 | 18 | — | 1,499 |
| Charge for organizational efficiency plan | — | — | — | 252 | 252 |
| Charges associated with litigation matters | 44 | 157 | — | — | 201 |
| Integration and transaction-related costs | — | — | — | 45 | 45 |
| Pre-tax adjusted income (loss) from operations | \$ 6,442 | \$ 4,478 | \$ 96 | \$ (1,698) | \$ 9,318 |
| Other segment information | | | | | |
| Depreciation and amortization | \$ 2,438 | \$ 569 | \$ 3 | \$ 25 | \$ 3,035 |

⁽¹⁾ Other segment items represent the difference between segment adjusted revenues less significant segment expenses and pre-tax adjusted income (loss) from operations, and they do not represent significant segment items relative to the CODM's review and oversight.

⁽²⁾ Includes Net investment gains/losses as presented in our Consolidated Statements of Income, as well as the Company's share of certain investment results of its joint ventures reported in the Cigna Healthcare segment using the equity method of accounting, which are presented within Fees and other revenues in our Consolidated Statements of Income.

Revenue from external customers includes Pharmacy revenues, Premiums and Fees and other revenues. The following table presents these revenues by product, premium and service type:

| <i>(In millions)</i> | For the Years Ended December 31, | | |
|---|---|-------------|-------------|
| | 2025 | 2024 | 2023 |
| Products (Pharmacy revenues) (ASC 606) | | | |
| Network revenues | \$ 125,573 | \$ 105,340 | \$ 67,514 |
| Home delivery and specialty revenues | 80,492 | 72,476 | 65,732 |
| Other revenues | 13,329 | 11,545 | 9,047 |
| Total Evernorth Health Services | 219,394 | 189,361 | 142,293 |
| Other Operations | 54 | 60 | — |
| Corporate and eliminations | (2,776) | (4,059) | (5,050) |
| Total Pharmacy revenues | 216,672 | 185,362 | 137,243 |
| Insurance premiums (ASC 944) | | | |
| Cigna Healthcare | | | |
| U.S. Healthcare | | | |
| Employer insured | 18,852 | 17,576 | 16,490 |
| Medicare Advantage | 2,363 | 8,679 | 8,771 |
| Stop loss | 7,599 | 6,744 | 6,143 |
| Individual and Family Plans | 3,371 | 3,951 | 5,088 |
| Other | 3,366 | 4,938 | 4,095 |
| U.S. Healthcare | 35,551 | 41,888 | 40,587 |
| International Health | 4,126 | 3,624 | 3,295 |
| Total Cigna Healthcare | 39,677 | 45,512 | 43,882 |
| Other Operations | 288 | 380 | 281 |
| Corporate and eliminations | 296 | 104 | 74 |
| Total Premiums | 40,261 | 45,996 | 44,237 |
| Services (Fees) (ASC 606) and Other revenues⁽¹⁾ | | | |
| Evernorth Health Services | 15,417 | 12,591 | 10,965 |
| Cigna Healthcare | 7,154 | 6,988 | 6,669 |
| Other Operations | 34 | 79 | 10 |
| Corporate and eliminations | (5,684) | (4,868) | (5,025) |
| Total Fees and other revenues ⁽¹⁾ | 16,921 | 14,790 | 12,619 |
| Total revenues from external customers | \$ 273,854 | \$ 246,148 | \$ 194,099 |

⁽¹⁾ Other revenues for the years ended December 31, 2025, 2024 and 2023 were \$696 million, \$584 million and \$210 million, respectively.

Major Customers. Revenues from a single pharmacy benefit client were approximately 19% and 16% of total revenues from external customers for the years ended December 31, 2025 and 2024, respectively. These amounts were reported in the Evernorth Health Services segment.

Additionally, revenues from U.S. Federal Government agencies, under a number of contracts, were 11% and 15% of total revenues from external customers for the years ended December 31, 2024 and 2023, respectively. These amounts were reported in the Evernorth Health Services and Cigna Healthcare segments. For the year ended December 31, 2025, revenues from U.S. Federal Government agencies were less than 10%.

U.S. and Foreign Revenues. Revenues from U.S. external customers as a percentage of total revenues from external customers were 98% for the years ended December 31, 2025, 2024 and 2023.

Item 9. CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND FINANCIAL DISCLOSURE

None.

Item 9A. CONTROLS AND PROCEDURES

A. Disclosure Controls and Procedures

Based on an evaluation of the effectiveness of The Cigna Group's disclosure controls and procedures conducted under the supervision and with the participation of The Cigna Group's management (including The Cigna Group's Chief Executive Officer and Chief Financial Officer), The Cigna Group's Chief Executive Officer and Chief Financial Officer concluded that, as of the end of the period covered by this report, The Cigna Group's disclosure controls and procedures are effective to ensure that information required to be disclosed by The Cigna Group in the reports that it files or submits under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the Securities and Exchange Commission's rules and forms and is accumulated and communicated to The Cigna Group's management (including The Cigna Group's Chief Executive Officer and Chief Financial Officer) as appropriate to allow timely decisions regarding required disclosure.

B. Internal Control Over Financial Reporting

Management's Annual Report on Internal Control over Financial Reporting

Management of The Cigna Group is responsible for establishing and maintaining adequate internal control over financial reporting. The Company's internal controls were designed to provide reasonable assurance that the Company's consolidated published financial statements for external purposes were prepared in accordance with accounting principles generally accepted in the United States. The Company's internal control over financial reporting includes those policies and procedures that:

- (i) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the Company;
- (ii) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with accounting principles generally accepted in the United States and that receipts and expenditures of the Company are being made only in accordance with authorization of management and directors of the Company; and
- (iii) provide reasonable assurance regarding prevention or timely detection of unauthorized acquisitions, use or disposition of the Company's assets that could have a material effect on the financial statements.

Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements.

Management assessed the effectiveness of the Company's internal control over financial reporting as of December 31, 2025. In making this assessment, management used the criteria set forth by the Committee of Sponsoring Organizations of the Treadway Commission ("COSO") in *Internal Control-Integrated Framework (2013)*. Based on management's assessment and the criteria set forth by COSO, it was determined that the Company's internal control over financial reporting is effective as of December 31, 2025.

The Company's independent registered public accounting firm, PricewaterhouseCoopers LLP, has audited the effectiveness of and has issued an attestation report on the Company's internal control over financial reporting, as stated in their report located in Item 8 of this Form 10-K.

Change in Internal Control over Financial Reporting

There have been no changes in our internal control over financial reporting during the quarter ended December 31, 2025 that have materially affected, or are reasonably likely to materially affect, The Cigna Group's internal control over financial reporting.

Item 9B. OTHER INFORMATION

Rule 10b5-1 Plan Elections

During the three months ended December 31, 2025, the following 10b5-1 director and officer trading plan arrangement changes occurred:

1. On November 5, 2025, David Cordani, Chairman and Chief Executive Officer of The Cigna Group, terminated a 10b5-1 plan that was adopted on May 6, 2025. Mr. Cordani's plan provided for (i) the sale of shares of The Cigna Group common stock issuable upon vesting of a performance award (the actual number of shares depends on actual performance achieved and may range from 0% to 200% of the 32,586 shares subject to the award at the target level of performance) and (ii) the combined exercise of 212,543 vested stock options and sale of up to 50% of the after-tax shares of The Cigna Group common stock acquired from the option exercise, in each case through May 5, 2026.

This trading plan was terminated during an open insider trading window.

2. On May 5, 2025, Jamie Kates, Senior Vice President and Tax and Global Chief Accounting Officer, adopted a 10b5-1 plan. Ms. Kates' plan provides for (i) the sale of up to 170 shares of The Cigna Group common stock, (ii) the sale of shares of The Cigna Group common stock issuable upon vesting of a performance award (the actual number of shares depends on actual performance achieved and may range from 0% to 200% of the 281 shares subject to the award at the target level of performance), and (iii) the exercise of vested stock options and the associated sale of up to 2,014 shares of The Cigna Group common stock, in each case through May 5, 2026. No transactions have occurred pursuant to Ms. Kates' plan to date.

This trading plan was entered into during an open insider trading window and is intended to satisfy the affirmative defense of Rule 10b5-1(c) under the Securities Exchange Act of 1934 and the Company's policies regarding insider transactions.

Item 9C. DISCLOSURE REGARDING FOREIGN JURISDICTIONS THAT PREVENT INSPECTIONS

Not applicable.

PART III

Item 10. DIRECTORS, EXECUTIVE OFFICERS AND CORPORATE GOVERNANCE

A. Directors of the Registrant

The information under the captions "Corporate Governance Matters – Board of Directors' Nominees" and "Corporate Governance Matters – Committees of the Board" (as it relates to the Audit Committee disclosure) in the definitive proxy statement of The Cigna Group related to the 2026 Annual Meeting of Shareholders ("the 2026 Proxy Statement") is incorporated herein by reference.

B. Executive Officers of the Registrant

See Part I, "Information about our Executive Officers" in this Form 10-K.

C. Code of Ethics and Other Corporate Governance Disclosures

The information under the caption "Corporate Governance Matters – Codes of Ethics" in the 2026 Proxy Statement is incorporated herein by reference. We intend to promptly disclose on our website, in accordance with applicable rules, any required disclosure of changes to or waivers, if any, of our Code of Ethics or our Director Code of Business Conduct and Ethics.

D. Delinquent Section 16(a) Reports

The information under the caption "Ownership of The Cigna Group Common Stock – Delinquent Section 16(a) Reports," if included in the 2026 Proxy Statement, is incorporated herein by reference.

E. Insider Trading Arrangements and Policies

The information under the caption "Compensation Matters – Insider Trading Arrangements and Policies" in the 2026 Proxy Statement is incorporated herein by reference.

Item 11. EXECUTIVE COMPENSATION

The information under the captions "Corporate Governance Matters – Non-Employee Director Compensation," "Corporate Governance Matters – Corporate Governance Policies and Practices – Certain Transactions," "Compensation Matters – Compensation Discussion and Analysis," "Compensation Matters – Report of the People Resources Committee" and "Compensation Matters – Executive Compensation Tables" in the 2026 Proxy Statement is incorporated herein by reference.

Item 12. SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND RELATED STOCKHOLDER MATTERS

The following table presents information regarding The Cigna Group equity compensation plans as of December 31, 2025:

| Plan Category | (a) ⁽¹⁾ | (b) ⁽²⁾ | (c) ⁽³⁾ |
|--|---|---|---|
| | Number of securities to be issued upon exercise of outstanding options, warrants and rights | Weighted-average exercise price of outstanding options, warrants and rights | Number of securities remaining available for future issuance under equity compensation plans (excluding securities reflected in column (a)) |
| Equity compensation plans approved by security holders | 6,301,429 | \$ 242.81 | 10,418,601 |
| Equity compensation plans not approved by security holders | — | — | — |
| Total | 6,301,429 | \$ 242.81 | 10,418,601 |

⁽¹⁾ Includes, in addition to outstanding stock options:

(i) 55,653 restricted stock units, 35,920 deferred shares and 1,007,528 strategic performance shares that are reported at the maximum 200% payout rate granted under the Cigna Long-Term Incentive Plan and the Cigna Corporation Director Equity Plan; and

(ii) 144,269 shares of common stock underlying stock option awards granted under the Express Scripts Holding Company 2016 Long-Term Incentive Plan, 85,180 shares of common stock underlying stock option awards granted under the Express Scripts, Inc. 2011 Long-Term Incentive Plan and 46,534 shares of common stock underlying stock option awards granted under the Medco Health Solutions, Inc. 2002 Stock Incentive Plan that were all approved by the applicable company's shareholders before acquisition of Express Scripts by The Cigna Group in December 2018.

⁽²⁾ The weighted-average exercise price is based only on outstanding stock options. The outstanding stock options assumed due to the acquisition of Express Scripts by The Cigna Group, in aggregate, have a weighted-average exercise price of \$146.39. Excluding the assumed options from this acquisition results in a weighted-average exercise price of \$248.21.

⁽³⁾ Represents 10,418,601 shares of common stock available as of the close of business December 31, 2025 for future issuance under the Cigna Long-Term Incentive Plan. No further grants may be made and no shares remain available for future issuance under any plan other than the Cigna Long-Term Incentive Plan.

The information under the captions "Ownership of The Cigna Group Common Stock – Stock Held by Directors, Nominees, and Executive Officers" and "Ownership of The Cigna Group Common Stock – Stock Held by Certain Beneficial Owners" in the 2026 Proxy Statement is incorporated herein by reference.

Item 13. CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS, AND DIRECTOR INDEPENDENCE

The information under the captions "Corporate Governance Matters – Corporate Governance Policies and Practices – Director Independence" and "Corporate Governance Matters – Corporate Governance Policies and Practices – Certain Transactions" in the 2026 Proxy Statement is incorporated herein by reference.

Item 14. PRINCIPAL ACCOUNTANT FEES AND SERVICES

The information under the captions "Audit Matters – Ratification of Appointment of Independent Registered Public Accounting Firm (Proposal 3) – Policy for the Pre-Approval of Audit and Permissible Non-Audit Services" and "Audit Matters – Ratification of Appointment of Independent Registered Public Accounting Firm (Proposal 3) – Fees to Independent Registered Public Accounting Firm" in the 2026 Proxy Statement is incorporated herein by reference.

PART IV

Item 15. *EXHIBITS AND FINANCIAL STATEMENT SCHEDULES*

- (a) (1) The following Financial Statements can be found under Part II, Item 8 of this Form 10-K:

Report of Independent Registered Public Accounting Firm. (Public Company Accounting Oversight Board ID: 238)

Consolidated Statements of Income for the years ended December 31, 2025, 2024 and 2023.

Consolidated Statements of Comprehensive Income for the years ended December 31, 2025, 2024 and 2023.

Consolidated Balance Sheets as of December 31, 2025 and 2024.

Consolidated Statements of Changes in Total Equity for the years ended December 31, 2025, 2024 and 2023.

Consolidated Statements of Cash Flows for the years ended December 31, 2025, 2024 and 2023.

Notes to the Consolidated Financial Statements.

- (2) The financial statement schedules listed in the Index to Financial Statement Schedules on page FS-1, which list is incorporated herein.

(3) Set forth in this Item 15 is a list of exhibits filed or incorporated by reference as part of this Annual Report on Form 10-K.

- (b) The exhibits listed in the accompanying "Index to Exhibits" in this Item 15 are filed or incorporated by reference as part of this Annual Report on Form 10-K.
- (c) The financial statement schedules listed in the Index to Financial Statement Schedules on page FS-1 are filed as part of this Annual Report on Form 10-K.

INDEX TO EXHIBITS

| Number | Description | Method of Filing |
|---------------|---|---|
| 3.1 | Restated Certificate of Incorporation of the registrant effective as of April 26, 2023 | Filed by the registrant as Exhibit 3.1 to the Quarterly Report on Form 10-Q for the period ended March 31, 2023 and incorporated herein by reference. |
| 3.2 | Amended and Restated By-Laws of the registrant as last amended February 13, 2023 | Filed by the registrant as Exhibit 3.3 to the Current Report on Form 8-K on February 13, 2023 and incorporated herein by reference. |
| 4.1(a) | Indenture, dated as of September 17, 2018, between Cigna Corporation (formerly Halfmoon Parent, Inc.) and U.S. Bank National Association, as trustee | Filed by CHC as Exhibit 4.1 to the Current Report on Form 8-K on September 21, 2018 and incorporated herein by reference. |
| 4.1(b) | Supplemental Indenture, dated as of September 17, 2018, between Cigna Corporation (formerly Halfmoon Parent, Inc.) and U.S. Bank National Association, as trustee | Filed by CHC as Exhibit 4.2 to the Current Report on Form 8-K on September 21, 2018 and incorporated herein by reference. |
| 4.1(c) | Second Supplemental Indenture, dated as of December 20, 2018, by and among Express Scripts Holding Company, Cigna Holding Company and U.S. Bank National Association, as trustee | Filed by the registrant as Exhibit 4.7 to the Current Report on Form 8-K on December 20, 2018 and incorporated herein by reference. |
| 4.1(d) | Third Supplemental Indenture, dated as of October 11, 2019, by and among Cigna Corporation, as the Issuer, Cigna Holding Company and Express Scripts Holding Company, each as guarantors, and U.S. Bank, National Association, as trustee | Filed by the registrant as Exhibit 4.1 to the Current Report on Form 8-K on October 11, 2019 and incorporated herein by reference. |
| 4.1(e) | Fourth Supplemental Indenture, dated as of March 16, 2020, between Cigna Corporation and U.S. Bank, National Association, as trustee | Filed by the registrant as Exhibit 4.1 to the Current Report on Form 8-K on March 16, 2020 and incorporated herein by reference. |
| 4.1(f) | Fifth Supplemental Indenture, dated as of March 3, 2021, between Cigna Corporation and U.S. Bank National Association, as trustee | Filed by the registrant as Exhibit 4.1 to the Current Report on Form 8-K on March 3, 2021 and incorporated herein by reference. |
| 4.1 (g) | Sixth Supplemental Indenture, dated as of March 7, 2023, between Cigna Corporation and U.S. Bank National Association, as trustee | Filed by the registrant as Exhibit 4.1 to the Current Report on Form 8-K on March 7, 2023 and incorporated herein by reference. |
| 4.1 (h) | Seventh Supplemental Indenture, dated as of February 13, 2024, between Cigna Corporation and U.S. Bank National Association, as trustee | Filed by the registrant as Exhibit 4.1 to the Current Report on Form 8-K on February 13, 2024 and incorporated herein by reference. |
| 4.1 (i) | Eighth Supplemental Indenture, dated as of September 4, 2025, between The Cigna Group and U.S. Bank Trust Company, National Association, as trustee | Filed by the registrant as Exhibit 4.1 to the Current Report on Form 8-K on September 4, 2025 and incorporated herein by reference. |
| 4.2(a) | Senior Indenture dated as of August 16, 2006 between Cigna Holding Company (formerly Cigna Corporation) and U.S. Bank National Association | Filed by CHC as Exhibit 4.1(a) to the Annual Report on Form 10-K for the year ended December 31, 2012 and incorporated herein by reference. |
| 4.2(b) | Supplemental Indenture No. 1 dated as of November 10, 2006 between Cigna Holding Company and U.S. Bank National Association | Filed by CHC as Exhibit 4.1(b) to the Annual Report on Form 10-K for the year ended December 31, 2012 and incorporated herein by reference. |
| 4.2(c) | Supplemental Indenture No. 8 dated as of November 10, 2011 between Cigna Holding Company and U.S. Bank National Association | Filed by CHC as Exhibit 4.1 to the Current Report on Form 8-K on November 14, 2011 and incorporated herein by reference. |
| 4.2(d) | Supplemental Indenture No. 9 dated as of March 20, 2015, between Cigna Holding Company and U.S. Bank National Association, as trustee | Filed by CHC as Exhibit 4.1 to the Current Report on Form 8-K on March 26, 2015 and incorporated herein by reference. |
| 4.2(e) | Supplemental Indenture No. 10 dated as of September 14, 2017 between Cigna Holding Company and U.S. Bank National Association, as trustee | Filed by CHC as Exhibit 4.1 to the Current Report on Form 8-K filed September 14, 2017 and incorporated herein by reference. |
| 4.2(f) | Supplemental Indenture No. 11 dated as of December 20, 2018, by and among Cigna Corporation, Cigna Holding Company and U.S. Bank National Association, as trustee | Filed by the registrant as Exhibit 4.1 to the Current Report on Form 8-K on December 20, 2018 and incorporated herein by reference. |
| 4.2(g) | Supplemental Indenture No. 12, dated as of October 11, 2019, among Cigna Holding Company, as Issuer, Cigna Corporation, as parent guarantor, and U.S. Bank National Association, as trustee | Filed by the registrant as Exhibit 4.3 to the Current Report on Form 8-K on October 11, 2019 and incorporated herein by reference. |

| | | |
|--------|--|---|
| 4.3(a) | Indenture dated as of January 1, 1994 between Cigna Holding Company (formerly Cigna Corporation) and Marine Midland Bank | Filed by CHC as Exhibit 4.2 to the Annual Report on Form 10-K for the year ended December 31, 2009 and incorporated herein by reference. |
| 4.3(b) | Supplemental Indenture No. 1 dated as of December 20, 2018, by and among Cigna Corporation (formerly Halfmoon Parent, Inc.), Cigna Holding Company and HSBC Bank USA, National Association (as successor to Marine Midland Bank, N.A.), as trustee | Filed by the registrant as Exhibit 4.2 to the Current Report on Form 8-K on December 20, 2018 and incorporated herein by reference. |
| 4.3(c) | Supplemental Indenture No. 2, dated as of October 11, 2019, among Cigna Holding Company, as Issuer, Cigna Corporation, as parent guarantor, and HSBC Bank USA, National Association, as trustee | Filed by the registrant as Exhibit 4.4 to the Current Report on Form 8-K on October 11, 2019 and incorporated herein by reference. |
| 4.4 | Indenture dated as of June 30, 1988 between Cigna Holding Company (formerly Cigna Corporation) and Bankers Trust Company | Filed by CHC as Exhibit 4.3 to the Annual Report on Form 10-K for the year ended December 31, 2009 and incorporated herein by reference. |
| 4.5(a) | Indenture, dated as of November 21, 2011, among Express Scripts, Inc., Express Scripts Holding Company (formerly Aristotle Holding, Inc.), the other subsidiaries of Express Scripts Holding Company party thereto and Wells Fargo Bank, National Association, as trustee | Filed by Express Scripts, Inc. ("ESI") as Exhibit 4.1 to the Current Report on Form 8-K filed November 25, 2011 and incorporated herein by reference. |
| 4.5(b) | Fourth Supplemental Indenture, dated as of November 21, 2011, among Express Scripts, Inc., Express Scripts Holding Company, the other subsidiaries of Express Scripts Holding Company party thereto and Wells Fargo Bank, National Association, as trustee | Filed by ESI as Exhibit 4.5 to the Current Report on Form 8-K on November 25, 2011 and incorporated herein by reference. |
| 4.5(c) | Eighth Supplemental Indenture, dated as of April 2, 2012, among Express Scripts, Inc., Express Scripts Holding Company, Medco Health Solutions, Inc., the other subsidiaries of Express Scripts Holding Company party thereto and Wells Fargo Bank, National Association, as trustee | Filed by Express Scripts Holding Company ("ESRX") as Exhibit 4.1 to the Current Report on Form 8-K on April 6, 2012 and incorporated herein by reference. |
| 4.5(d) | Seventeenth Supplemental Indenture, dated as of February 25, 2016, among Express Scripts Holding Company, the Subsidiary Guarantors party thereto and Wells Fargo Bank, National Association, as trustee | Filed by ESRX as Exhibit 4.2 to the Current Report on Form 8-K on February 25, 2016 and incorporated herein by reference. |
| 4.5(e) | Nineteenth Supplemental Indenture, dated as of July 5, 2016, among Express Scripts Holding Company, the Subsidiary Guarantors party thereto and Wells Fargo Bank, National Association, as trustee | Filed by ESRX as Exhibit 4.2 to the Current Report on Form 8-K on July 5, 2016 and incorporated herein by reference. |
| 4.5(f) | Twentieth Supplemental Indenture, dated as of July 5, 2016, among Express Scripts Holding Company, the Subsidiary Guarantors party thereto and Wells Fargo Bank, National Association, as trustee | Filed by ESRX as Exhibit 4.3 to the Current Report on Form 8-K on July 5, 2016 and incorporated herein by reference. |
| 4.5(g) | Twenty-Fifth Supplemental Indenture dated as of December 20, 2018, by and among Cigna Corporation, Express Scripts Holding Company and Wells Fargo Bank, National Association, as trustee | Filed by the registrant as Exhibit 4.4 to the Current Report on Form 8-K on December 20, 2018 and incorporated herein by reference. |
| 4.5(h) | Twenty-Sixth Supplemental Indenture, dated as of October 11, 2019, among Express Scripts Holding Company, as Issuer, Cigna Corporation, as parent guarantor, and Wells Fargo Bank, National Association, as trustee | Filed by the registrant as Exhibit 4.5 to the Current Report on Form 8-K on October 11, 2019 and incorporated herein by reference. |
| 4.6 | Description of Securities | Filed by the registrant as Exhibit 4.7 to the Annual Report on Form 10-K for the year ended December 31, 2023 and incorporated herein by reference. |

Exhibits 10.1 through 10.22 are identified as compensatory plans, management contracts or arrangements pursuant to Item 15 of Form 10-K.

| | | |
|---------|--|---|
| 10.1(a) | Cigna Long-Term Incentive Plan, amended and restated effective April 28, 2021 (the "Cigna LTIP") | Filed by the registrant as Exhibit 10.1 to the Current Report on Form 8-K on May 3, 2021 and incorporated herein by reference. |
| 10.1(b) | Amendment No.1 to the Cigna LTIP effective December 1, 2022 | Filed by the registrant as Exhibit 10.1(b) to the Annual Report on Form 10-K for the year ended December 31, 2022 and incorporated herein by reference. |

| | | |
|---------|--|--|
| 10.1(c) | Form of Cigna LTIP: Nonqualified Stock Option Grant Agreement | Filed by CHC as Exhibit 10.3 to Form 10-Q for the period ended March 31, 2017 and incorporated herein by reference. |
| 10.1(d) | Form of Cigna LTIP: Nonqualified Stock Option Grant Agreement | Filed by CHC as Exhibit 10.5 to Quarterly Report on Form 10-Q for the period ended March 31, 2018 and incorporated herein by reference. |
| 10.1(e) | Form of Cigna LTIP: Nonqualified Stock Option Grant Agreement | Filed by the registrant as Exhibit 10.2 to Quarterly Report on Form 10-Q for the period ended March 31, 2019 and incorporated herein by reference. |
| 10.1(f) | Form of Cigna LTIP: Nonqualified Stock Option Grant Agreement | Filed by the registrant as Exhibit 10.2 to Quarterly Report on Form 10-Q for the period ended March 31, 2020 and incorporated herein by reference. |
| 10.1(g) | Form of Cigna LTIP: Strategic Performance Share Grant Agreement | Filed by the registrant as Exhibit 10.1 to Quarterly Report on Form 10-Q for the period ended March 31, 2021 and incorporated herein by reference. |
| 10.1(h) | Form of Cigna LTIP: Nonqualified Stock Option Grant Agreement | Filed by the registrant as Exhibit 10.2 to Quarterly Report on Form 10-Q for the period ended March 31, 2021 and incorporated herein by reference. |
| 10.1(i) | Form of Cigna LTIP: Restricted Stock Grant Agreement | Filed by the registrant as Exhibit 10.3 to Quarterly Report on Form 10-Q for the period ended March 31, 2021 and incorporated herein by reference. |
| 10.1(j) | Form of Cigna LTIP: Restricted Stock Unit Grant Agreement | Filed by the registrant as Exhibit 10.4 to Quarterly Report on Form 10-Q for the period ended March 31, 2021 and incorporated herein by reference. |
| 10.1(k) | Form of Cigna LTIP: Covenant Agreement | Filed by the registrant as Exhibit 10.5 to Quarterly Report on Form 10-Q for the period ended March 31, 2020 and incorporated herein by reference. |
| 10.2(a) | Express Scripts Holding Company 2016 Long-Term Incentive Plan (the "ESRX LTIP") | Filed by ESRX as Appendix A to ESRX's Definitive Proxy Statement on Schedule 14A for its 2016 Annual Meeting of Stockholders, filed March 21, 2016 and incorporated herein by reference. |
| 10.2(b) | Form of Stock Option Grant Notice for Non-Employee Directors used with respect to grants of stock options by Express Scripts Holding Company to non-employee directors under the ESRX LTIP | Filed by ESRX as Exhibit 10.4 to the Current Report on Form 8-K on May 4, 2016 and incorporated herein by reference. |
| 10.2(c) | Form of Stock Option Grant Notice used with respect to grants of stock options by Express Scripts Holding Company under the ESRX LTIP | Filed by ESRX as Exhibit 10.7 to Current Report on Form 8-K on May 4, 2016 and incorporated herein by reference. |
| 10.3(a) | Express Scripts, Inc. 2011 Long-Term Incentive Plan (as amended and restated effective April 2, 2012) (the "ESI LTIP") | Filed by the registrant as Exhibit 4.10 to the Registration Statement on Form S-8 (No. 333-228930) on December 20, 2018 and incorporated herein by reference. |
| 10.3(b) | Form of Stock Option Grant Notice for Non-Employee Directors used with respect to grants of stock options by Express Scripts Holding Company under the ESI LTIP | Filed by ESRX as Exhibit 10.6 to Quarterly Report on Form 10-Q for the quarter ended June 30, 2012 and incorporated herein by reference. |
| 10.3(c) | Form of Stock Option Grant Notice used with respect to grants of stock options by Express Scripts Holding Company under the ESI LTIP | Filed by ESRX as Exhibit 10.1 to the Quarterly Report on Form 10-Q for the quarter ended March 31, 2013 and incorporated herein by reference. |
| 10.4 | Medco Health Solutions, Inc. 2002 Stock Incentive Plan (as amended and restated effective April 2, 2012) | Filed by the registrant as Exhibit 4.11 to the Registration Statement on Form S-8 (No. 333-228930) on December 20, 2018 and incorporated herein by reference. |
| 10.5 | Deferred Compensation Plan for Directors of Cigna Corporation, as amended and restated January 1, 1997 | Filed by CHC as Exhibit 10.1 to the Annual Report on Form 10-K for the year ended December 31, 2011 and incorporated herein by reference. |
| 10.6 | Cigna Deferred Compensation Plan, as amended and restated October 24, 2001 | Filed by CHC as Exhibit 10.14 to the Annual Report on Form 10-K for the year ended December 31, 2011 and incorporated herein by reference. |

| | | |
|----------|--|---|
| 10.7 | Cigna Deferred Compensation Plan of 2005 effective as of January 1, 2005 | Filed by the registrant as Exhibit 4.6 to the Registration Statement on Form S-8 (No. 333-228930) on December 20, 2018 and incorporated herein by reference. |
| 10.8 | Express Scripts, Inc. Amended and Restated Executive Deferred Compensation Plan (effective December 31, 2004 and grandfathered for the purposes of Section 409A of the Code) | Filed by ESI as Exhibit No. 10.1 to the Current Report on Form 8-K on May 25, 2007 and incorporated herein by reference. |
| 10.9(a) | Express Scripts, Inc. Executive Deferred Compensation Plan of 2005 (as amended and restated effective December 20, 2018) | Filed by the registrant as Exhibit 4.13 to the Registration Statement on Form S-8 (No. 333-228930) on December 20, 2018 and incorporated herein by reference. |
| 10.9(b) | Amendment No. 1 to the Express Scripts, Inc. Executive Deferred Compensation Plan of 2005 | Filed by the registrant as Exhibit 10.12(b) to the Annual Report on Form 10-K for the year ended December 31, 2019 and incorporated herein by reference. |
| 10.9(c) | Amendment No. 2 to the Express Scripts, Inc. Executive Deferred Compensation Plan of 2005 | Filed by the registrant as Exhibit 10.3 to Quarterly Report on Form 10-Q for the period ended June 30, 2021 and incorporated herein by reference. |
| 10.10(a) | Cigna Supplemental Pension Plan as amended and restated effective August 1, 1998 | Filed by CHC as Exhibit 10.15(a) to the Annual Report on Form 10-K for the year ended December 31, 2009 and incorporated herein by reference. |
| 10.10(b) | Amendment No. 1 dated December 21, 1999 to the Cigna Supplemental Pension Plan, amended and restated effective as of September 1, 1999 | Filed by CHC as Exhibit 10.15(b) to the Annual Report on Form 10-K for the year ended December 31, 2009 and incorporated herein by reference. |
| 10.10(c) | Amendment No. 2 dated December 6, 2000 to the Cigna Supplemental Pension Plan | Filed by CHC as Exhibit 10.16(c) to the Annual Report on Form 10-K for the year ended December 31, 2011 and incorporated herein by reference. |
| 10.11(a) | Cigna Supplemental Pension Plan of 2005 effective as of January 1, 2005 | Filed by CHC as Exhibit 10.15 to the Annual Report on Form 10-K for the year ended December 31, 2007 and incorporated herein by reference. |
| 10.11(b) | Amendment No. 1 to the Cigna Supplemental Pension Plan of 2005 | Filed by CHC as Exhibit 10.1 to the Quarterly Report on Form 10-Q for the period ended June 30, 2009 and incorporated herein by reference. |
| 10.12(a) | The Cigna Group Supplemental 401(k) Plan effective January 1, 2010 | Filed by the registrant as Exhibit 4.7 to the Registration Statement on Form S-8 (No. 333-228930) on December 20, 2018 and incorporated herein by reference. |
| 10.12(b) | Amendment No. 1 to The Cigna Group Supplemental 401(k) Plan | Filed by the registrant as Exhibit 10.15(b) to the Annual Report on Form 10-K for the year ended December 31, 2019 and incorporated herein by reference. |
| 10.12(c) | Amendment No. 2 to The Cigna Group Supplemental 401(k) Plan | Filed by the registrant as Exhibit 10.15(c) to the Annual Report on Form 10-K for the year ended December 31, 2019 and incorporated herein by reference. |
| 10.12(d) | Amendment No. 3 to The Cigna Group Supplemental 401(k) Plan | Filed by the registrant as Exhibit 10.15(d) to the Annual Report on Form 10-K for the year ended December 31, 2019 and incorporated herein by reference. |
| 10.13 | Cigna Corporation Non-Employee Director Compensation Program amended and restated effective February 26, 2014 | Filed by CHC as Exhibit 10.1 to the Quarterly Report on Form 10-Q for the period ended March 31, 2014 and incorporated herein by reference. |
| 10.14(a) | Cigna Corporation Non-Employee Director Compensation Program, amended and restated effective January 1, 2022 | Filed by the registrant as Exhibit 10.17(a) to the Annual Report on Form 10-K for the year ended December 31, 2021 and incorporated herein by reference. |

| | | |
|----------|--|--|
| 10.14(b) | Cigna Corporation Non-Employee Director Compensation Program, amended and restated effective April 1, 2022 | Filed by the registrant as Exhibit 10.17(b) to the Annual Report on Form 10-K for the year ended December 31, 2021 and incorporated herein by reference. |
| 10.14(c) | The Cigna Group Non-Employee Director Compensation Program, amended and restated effective July 24, 2024 | Filed by the registrant as Exhibit 10.14(c) to the Annual Report on Form 10-K for the year ended December 31, 2024 and incorporated herein by reference. |
| 10.15 | Cigna Corporation Director Equity Plan, as amended December 4, 2020 | Filed by the registrant as Exhibit 10.18 to the Annual Report on Form 10-K for the year ended December 31, 2020 and incorporated herein by reference. |
| 10.16 | Deferred Compensation Plan of 2005 for Directors of Cigna Corporation, Amended and Restated effective April 28, 2010 | Filed by the registrant as Exhibit 4.8 to the Registration Statement on Form S-8 (No. 333-228930) on December 20, 2018 and incorporated herein by reference. |
| 10.17 | Form of Indemnification Agreement with Express Scripts Holding Company's executive officers and former members of the Express Scripts Holding Company's board of directors | Filed by ESRX as Exhibit 10.1 to the Current Report on Form 8-K on March 5, 2014 and incorporated herein by reference. |
| 10.18 | Cigna Executive Severance Benefits Plan as amended and restated effective December 21, 2020 | Filed by the registrant as Exhibit 10.1 to the Current Report on Form 8-K on October 30, 2020 and incorporated herein by reference. |
| 10.19 | Description of Cigna Corporation Financial Services Program | Filed by CHC as Exhibit 10.18 to the Annual Report on Form 10-K for the year ended December 31, 2009 and incorporated herein by reference. |
| 10.20 | Offer Letter for Nicole S. Jones dated September 14, 2023 | Filed by the registrant as Exhibit 10.2 to the Quarterly Report on Form 10-Q for the period ended September 30, 2023 and incorporated herein by reference. |
| 10.21 | Offer letter for Brian Evanko dated January 16, 2024 | Filed by the registrant as Exhibit 10.26 to the Annual Report on Form 10-K for the year ended December 31, 2023 and incorporated herein by reference. |
| 10.22 | Agreement and Release between The Cigna Group and Eric Palmer dated April 15, 2025 | Filed by the registrant as Exhibit 10.1 to the Quarterly Report on Form 10-Q for the period ended June 30, 2025 and incorporated herein by reference. |
| 10.23 | Master Transaction Agreement, dated February 4, 2013 among Connecticut General Life Insurance Company, Berkshire Hathaway Life Insurance Company of Nebraska and, solely for purposes of Sections 3.10, 6.1, 6.3, 6.4, 6.6, 6.9 and Articles II, V, VII and VIII, thereof, National Indemnity Company (including the Forms of Retrocession Agreement, the Collateral Trust Agreement, the Security and Control Agreement, the Surety Policy and the ALC Model Purchase Option Agreement as exhibits) | Filed by CHC as Exhibit 10.29 to the Annual Report on Form 10-K for the year ended December 31, 2012 and incorporated herein by reference. |
| 10.24 | Revolving Credit and Letter of Credit Agreement, dated as of April 24, 2025, with the banks named therein, JPMorgan Chase Bank, N.A., as administrative agent, and BofA Securities, Inc., Citibank, N.A., Morgan Stanley Senior Funding, Inc. and Wells Fargo Securities, LLC, as joint lead arrangers and joint bookrunners | Filed by the registrant as Exhibit 10.2 to the Quarterly Report on Form 10-Q for the period ended June 30, 2025 and incorporated herein by reference. |
| 19.1 | Securities Transactions and Insider Trading Policy | Filed by the registrant as Exhibit 19.1 to the Annual Report on Form 10-K for the year ended December 31, 2024 and incorporated by reference. |
| 21 | Subsidiaries of the Registrant | Filed herewith. |
| 23 | Consent of Independent Registered Public Accounting Firm | Filed herewith. |
| 31.1 | Certification of Chief Executive Officer of The Cigna Group pursuant to Rule 13a-14(a) or Rule 15d-14(a) of the Securities Exchange Act of 1934 | Filed herewith. |

| | | |
|------|---|--|
| 31.2 | Certification of Chief Financial Officer of The Cigna Group pursuant to Rule 13a-14(a) or Rule 15d-14(a) of the Securities Exchange Act of 1934 | Filed herewith. |
| 32.1 | Certification of Chief Executive Officer of The Cigna Group pursuant to Rule 13a-14(b) or Rule 15d-14(b) and 18 U.S.C. Section 1350 | Furnished herewith. |
| 32.2 | Certification of Chief Financial Officer of The Cigna Group pursuant to Rule 13a-14(b) or Rule 15d-14(b) and 18 U.S.C. Section 1350 | Furnished herewith. |
| 97.1 | Incentive Compensation Clawback Policy | Filed by the registrant as Exhibit 97.1 to the Annual Report on Form 10-K for the period ended December 31, 2023 and incorporated herein by reference. |
| 101 | The following materials from The Cigna Group's Annual Report on Form 10-K for the year ended December 31, 2025, formatted in inline XBRL (Extensible Business Reporting Language): (i) the Consolidated Balance Sheets; (ii) the Consolidated Statements of Income; (iii) the Consolidated Statements of Comprehensive Income; (iv) the Consolidated Statements of Cash Flows; (v) the Consolidated Statements of Changes in Total Equity; (vi) the Notes to Consolidated Financial Statements; and (vii) Financial Statement Schedules I and II. | Filed herewith. |
| 104 | Cover Page Interactive Data File (formatted as inline XBRL and contained in Exhibit 101) | Filed herewith. |

The agreements and other documents filed as exhibits to this report are not intended to provide factual information or other disclosure other than the terms of the agreements or other documents themselves and you should not rely on them for that purpose. In particular, any representations and warranties made by the Company in these agreements or other documents were made solely within the specific context of the relevant agreement or document and may not describe the actual state of affairs at the date they were made or at any other time.

Item 16. FORM 10-K SUMMARY

None.

| | |
|---|---------------------------|
| <u>/s/ Kathleen M. Mazzarella</u> Kathleen M. Mazzarella | Director |
| <u>/s/ Mark B. McClellan, M.D., Ph.D.</u> Mark B. McClellan, M.D., Ph.D. | Director |
| <u>/s/ Philip O. Ozuah, M.D., Ph.D.</u> Philip O. Ozuah, M.D., Ph.D. | Director |
| <u>/s/ Kimberly A. Ross</u> Kimberly A. Ross | Director |
| <u>/s/ Eric C. Wiseman</u> Eric C. Wiseman | Lead Independent Director |
| <u>/s/ Donna F. Zarcone</u> Donna F. Zarcone | Director |

THE CIGNA GROUP AND SUBSIDIARIES
INDEX TO FINANCIAL STATEMENT SCHEDULES

| | <u>PAGE</u> |
|---|-------------|
| Schedules | |
| I Condensed Financial Information of The Cigna Group (Registrant) | FS-2 |
| Statements of Income for the Years Ended December 31, 2025, 2024 and 2023 | FS-2 |
| Balance Sheets as of December 31, 2025 and 2024 | FS-3 |
| Statements of Cash Flows for the Years Ended December 31, 2025, 2024 and 2023 | FS-4 |
| Notes to Condensed Financial Statements | FS-5 |
| II Valuation and Qualifying Accounts and Reserves for the Years Ended December 31, 2025, 2024 and 2023 | FS-7 |

Schedules other than those listed above are omitted because they are not required or are not applicable, or the required information is shown in the financial statements or notes thereto.

THE CIGNA GROUP AND SUBSIDIARIES

**SCHEDULE I
CONDENSED FINANCIAL INFORMATION OF THE CIGNA GROUP
(REGISTRANT)
STATEMENTS OF INCOME**

| <i>(In millions)</i> | For the Years Ended December 31, | | |
|--|----------------------------------|-----------------|-----------------|
| | 2025 | 2024 | 2023 |
| Revenues | | | |
| Net investment income and other revenue | \$ 21 | \$ 26 | \$ 22 |
| Intercompany interest income | 469 | 469 | 516 |
| Total revenues | 490 | 495 | 538 |
| Operating expenses | | | |
| Selling, general and administrative expenses | 5 | 14 | 2 |
| Total operating expenses | 5 | 14 | 2 |
| Income from operations | 485 | 481 | 536 |
| Interest expense and other | (1,365) | (1,388) | (1,332) |
| Gain on sale of businesses | 4,890 | — | — |
| Intercompany interest expense | — | (2) | (118) |
| Income (loss) before income taxes | 4,010 | (909) | (914) |
| Income tax benefits | (201) | (189) | (192) |
| Income (loss) of parent company | 4,211 | (720) | (722) |
| Equity in income of subsidiaries | 1,746 | 4,154 | 5,886 |
| Shareholders' net income | 5,957 | 3,434 | 5,164 |
| Shareholders' other comprehensive (loss) income, net of tax | | | |
| Net unrealized (depreciation) appreciation on securities and derivatives | (238) | 661 | 503 |
| Net long-duration insurance and contractholder liabilities measurement adjustments | (291) | (1,067) | (715) |
| Net translation gains (losses) of foreign currencies | 71 | (49) | 5 |
| Postretirement benefits liability adjustment | (7) | (22) | 1 |
| Shareholders' other comprehensive loss, net of tax | (465) | (477) | (206) |
| Shareholders' comprehensive income | \$ 5,492 | \$ 2,957 | \$ 4,958 |

See Notes to Financial Statements on the following pages.

THE CIGNA GROUP AND SUBSIDIARIES

**SCHEDULE I
CONDENSED FINANCIAL INFORMATION OF THE CIGNA GROUP
(REGISTRANT)
BALANCE SHEETS**

| <i>(In millions)</i> | As of December 31, | |
|--|--------------------|------------------|
| | 2025 | 2024 |
| Assets | | |
| Cash and cash equivalents | \$ 118 | \$ 164 |
| Other current assets | 29 | 103 |
| Total current assets | 147 | 267 |
| Investments in subsidiaries | 61,382 | 62,887 |
| Intercompany receivable | 14,146 | 10,546 |
| Other non-current assets | 48 | 71 |
| TOTAL ASSETS | \$ 75,723 | \$ 73,771 |
| Liabilities | | |
| Short-term debt | \$ 550 | \$ 2,848 |
| Other current liabilities | 1,983 | 1,528 |
| Total current liabilities | 2,533 | 4,376 |
| Long-term debt | 30,268 | 28,134 |
| Intercompany payable | 1,134 | 195 |
| Other non-current liabilities | 75 | 33 |
| TOTAL LIABILITIES | 34,010 | 32,738 |
| Shareholders' equity | | |
| Common stock (shares issued, 405 and 403; authorized, 600) | 4 | 4 |
| Additional paid-in capital | 31,790 | 31,288 |
| Accumulated other comprehensive loss | (2,806) | (2,341) |
| Retained earnings | 47,865 | 43,519 |
| Less treasury stock, at cost | (35,140) | (31,437) |
| TOTAL SHAREHOLDERS' EQUITY | 41,713 | 41,033 |
| TOTAL LIABILITIES AND SHAREHOLDERS' EQUITY | \$ 75,723 | \$ 73,771 |

See Notes to Financial Statements on the following pages.

THE CIGNA GROUP AND SUBSIDIARIES

**SCHEDULE I
CONDENSED FINANCIAL INFORMATION OF THE CIGNA GROUP
(REGISTRANT)
STATEMENTS OF CASH FLOWS**

| <i>(In millions)</i> | For the Years Ended December 31, | | |
|---|----------------------------------|----------------|----------------|
| | 2025 | 2024 | 2023 |
| Cash Flows from Operating Activities | | | |
| Shareholders' net income | \$ 5,957 | \$ 3,434 | \$ 5,164 |
| Adjustments to reconcile Shareholders' net income to net cash provided by operating activities | | | |
| Equity in income from subsidiaries | (1,746) | (4,154) | (5,886) |
| Dividends received from subsidiaries | 1,171 | 2,916 | 1,381 |
| Gain on sale of businesses | (4,890) | — | — |
| Other liabilities | 496 | (306) | 540 |
| Other, net | 592 | 243 | 640 |
| NET CASH PROVIDED BY OPERATING ACTIVITIES | 1,580 | 2,133 | 1,839 |
| Cash Flows from Investing Activities | | | |
| Net change in amounts due from affiliates | — | — | 622 |
| Proceeds from divestiture of businesses | 4,891 | — | — |
| NET CASH PROVIDED BY INVESTING ACTIVITIES | 4,891 | — | 622 |
| Cash Flows from Financing Activities | | | |
| Net change in amounts due to/from affiliates | (1,101) | 4,761 | 1,473 |
| Net change in commercial paper | (880) | (357) | 1,237 |
| Repayment of term loan | (2,000) | — | — |
| Net proceeds on issuance of term loan | 1,999 | — | — |
| Repayment of long-term debt | (3,861) | (2,731) | (2,822) |
| Net proceeds on issuance of long-term debt | 4,458 | 4,462 | 1,491 |
| Issuance of common stock | 203 | 305 | 187 |
| Common stock dividend paid | (1,611) | (1,567) | (1,450) |
| Repurchase of common stock | (3,621) | (7,034) | (2,284) |
| Other, net | (108) | (117) | (110) |
| NET CASH USED IN FINANCING ACTIVITIES | (6,522) | (2,278) | (2,278) |
| Net (decrease) increase in cash, cash equivalents and restricted cash | (51) | (145) | 183 |
| Cash, cash equivalents and restricted cash, beginning of year | 190 | 335 | 152 |
| Cash, cash equivalents and restricted cash, end of year ⁽¹⁾ | \$ 139 | \$ 190 | \$ 335 |
| Noncash Investing and Financing Activities: | | | |
| Net amounts due from affiliates settled through capital transactions | \$ (1,617) | \$ (7,565) | \$ (5,221) |

⁽¹⁾ Includes restricted cash reported in Other non-current assets.

See Notes to Financial Statements on the following pages.

THE CIGNA GROUP AND SUBSIDIARIES

SCHEDULE I CONDENSED FINANCIAL INFORMATION OF THE CIGNA GROUP (REGISTRANT) NOTES TO CONDENSED FINANCIAL STATEMENTS

The accompanying condensed financial statements should be read in conjunction with the Consolidated Financial Statements and the accompanying notes thereto contained in this Annual Report on Form 10-K ("Form 10-K").

Note 1 - For purposes of these condensed financial statements, The Cigna Group (the "Company") accounts for investments in wholly owned and majority-owned subsidiaries using the equity method of accounting. The Cigna Group, through its predecessor companies, was incorporated in Delaware in 1981. Cigna Corporation was renamed The Cigna Group in February 2023.

Note 2 - See Note 7 – Debt included in Part II, Item 8 of this Form 10-K for a description of the short-term and long-term debt obligations of The Cigna Group and its subsidiaries.

Short-term and Credit Facilities Debt

Term Loan. In August 2025, the Company entered into a new 364-day term loan facility (the "Term Loan Facility") and borrowed \$2.0 billion to partially fund an investment in Shields Health Solutions ("Shields"), a leading specialty pharmacy management company. The full outstanding balance was repaid and the Term Loan Facility was terminated in September 2025, using proceeds from the debt issuance described below.

Revolving Credit Agreement. Our Credit Agreement (defined below) provides us with the ability to borrow amounts for general corporate purposes, including providing liquidity support if necessary under our commercial paper program discussed below. As of December 31, 2025, there were no outstanding balances under the Credit Agreement.

In April 2025, The Cigna Group replaced its previous revolving credit agreements and entered into a \$6.5 billion, five-year revolving credit and letter of credit agreement that will mature in April 2030, with an option to extend the maturity date for an additional one-year period, subject to consent of the banks (the "Credit Agreement"). The Company can borrow up to \$6.5 billion under the Credit Agreement for general corporate purposes, with up to \$500 million available for issuance of letters of credit.

The Credit Agreement includes an option to increase commitments up to \$1.5 billion for a maximum total commitment of \$8.0 billion. The Credit Agreement allows for borrowings at either a base rate, term Secured Overnight Financing Rate ("SOFR") or daily simple SOFR, plus, in each case, an applicable margin based on the Company's senior unsecured credit ratings.

The Credit Agreement also contains customary covenants and restrictions, including a financial covenant that the Company's leverage ratio, as defined in the Credit Agreement, may not exceed 60%, subject to certain exceptions upon the consummation of an acquisition.

Commercial Paper. Under our commercial paper program, we may issue short-term, unsecured commercial paper notes privately placed on a discounted basis through certain broker-dealers at any time not to exceed an aggregate amount of \$6.5 billion. Amounts available under the program may be borrowed, repaid and re-borrowed from time to time. The net proceeds of issuances have been and are expected to be used for general corporate purposes. There was no commercial paper balance as of December 31, 2025.

Long-Term Debt

Debt Issuance. In September 2025, we issued \$4.5 billion of new senior notes, as detailed in the table below. The proceeds from this debt issuance were used to repay the \$2.0 billion of loans outstanding under the Term Loan Facility as described above. We used the remaining net proceeds for general corporate purposes, including investments and repayment of indebtedness. Interest on this debt is paid semiannually.

| Principal | Maturity Date | Interest Rate | Net Proceeds | Redeemable Date ⁽¹⁾ | "Make Whole" Premium ⁽²⁾ |
|-----------------|--------------------|---------------|-----------------|--------------------------------|-------------------------------------|
| \$1,000 million | September 15, 2030 | 4.500% | \$994 million | August 15, 2030 | 15 |
| \$1,250 million | September 15, 2032 | 4.875% | \$1,245 million | July 15, 2032 | 15 |
| \$1,500 million | January 15, 2036 | 5.250% | \$1,490 million | October 15, 2035 | 15 |
| \$750 million | January 15, 2056 | 6.000% | \$736 million | July 15, 2055 | 20 |

⁽¹⁾ Redeemable at any time prior to this date at a "make whole" premium, defined below. Redeemable at par on or after this date.

⁽²⁾ "Make whole" premium calculated using the most directly comparable U.S. Treasury rate plus the amount of basis points set forth in this column.

Debt Maturities. Maturities of the Company's long-term debt as of December 31, 2025 are as follows:

(In millions)

| | |
|-----------------------|-----------|
| 2026 | \$ 550 |
| 2027 | \$ 2,055 |
| 2028 | \$ 3,800 |
| 2029 | \$ 1,000 |
| 2030 | \$ 2,400 |
| Maturities after 2030 | \$ 21,255 |

Debt Covenants. The Company was in compliance with its debt covenants as of December 31, 2025.

Note 3 - The Company's intercompany receivables consist primarily of net intercompany loan amounts due from Evernorth Health, Inc. of \$8.5 billion as of both December 31, 2025 and December 31, 2024. Interest income on the loan receivable was accrued at an average rate of 5.50% in 2025.

The Company's intercompany payables primarily reflect intercompany balances due to affiliates as of December 31, 2025. During the year ended December 31, 2025, the Company settled a portion of the outstanding intercompany payables via non-cash capital transactions.

Note 4 - The Company guaranteed approximately \$8.5 billion primarily related to intercompany indebtedness and financial obligations of certain direct and indirect wholly-owned subsidiaries. There were immaterial liabilities required for these guarantees as of December 31, 2025.

Note 5 - The Company completed the sale of our Medicare Advantage, Medicare Individual Stand-Alone Prescription Drug Plans, Medicare and Other Supplemental Benefits, and CareAllies® businesses on March 19, 2025. The Company received cash proceeds of \$4.9 billion and recorded the related gain on sale of businesses.

THE CIGNA GROUP AND SUBSIDIARIES

SCHEDULE II
VALUATION AND QUALIFYING ACCOUNTS AND RESERVES

(In millions)

| Description | Balance at Beginning of Year | Charged (Credited) to Costs and Expenses | Charged (Credited) to Other Accounts | Other Deductions | Balance at End of Year |
|--|---------------------------------|---|---|---------------------|---------------------------|
| 2025 | | | | | |
| Investment asset valuation reserves | | | | | |
| Available-for-sale debt securities | \$ 111 | \$ 58 | \$ — | \$ (32) | \$ 137 |
| Commercial mortgage loans | \$ 30 | \$ 6 | \$ — | \$ — | \$ 36 |
| Accounts receivable, net | \$ 186 | \$ 245 | \$ 2 | \$ (175) | \$ 258 |
| Deferred tax asset valuation allowance | \$ 2,332 | \$ 317 | \$ (275) | \$ — | \$ 2,374 |
| Reinsurance recoverables | \$ 30 | \$ (7) | \$ — | \$ — | \$ 23 |
| 2024 | | | | | |
| Investment asset valuation reserves | | | | | |
| Available-for-sale debt securities | \$ 33 | \$ 87 | \$ — | \$ (9) | \$ 111 |
| Commercial mortgage loans | \$ 31 | \$ (1) | \$ — | \$ — | \$ 30 |
| Accounts receivable, net | \$ 163 | \$ 176 | \$ (1) | \$ (152) | \$ 186 |
| Deferred tax asset valuation allowance | \$ 1,498 | \$ 866 | \$ (32) | \$ — | \$ 2,332 |
| Reinsurance recoverables | \$ 35 | \$ (5) | \$ — | \$ — | \$ 30 |
| 2023 | | | | | |
| Investment asset valuation reserves | | | | | |
| Available-for-sale debt securities | \$ 44 | \$ 11 | \$ — | \$ (22) | \$ 33 |
| Commercial mortgage loans | \$ 21 | \$ 10 | \$ — | \$ — | \$ 31 |
| Accounts receivable, net | \$ 160 | \$ 90 | \$ 1 | \$ (88) | \$ 163 |
| Deferred tax asset valuation allowance | \$ 208 | \$ 1,286 | \$ 4 | \$ — | \$ 1,498 |
| Reinsurance recoverables | \$ 35 | \$ — | \$ — | \$ — | \$ 35 |

Exhibit 21 – Subsidiaries of the Registrant

Listed below are subsidiaries of The Cigna Group as of December 31, 2025 with their jurisdictions of organization. Those subsidiaries not listed would not, in the aggregate, constitute a “significant subsidiary” of The Cigna Group, as that term is defined in Rule 1-02(w) of Regulation S-X.

| 2025 Subsidiaries Or Affiliates | Jurisdiction |
|---|---------------------|
| Accredo Health, Incorporated | Delaware |
| Allegiance Life & Health Insurance Company | Montana |
| Care Alliance of Florida, LLC | Florida |
| Care Continuum, Inc. | Kentucky |
| CareCore NJ, LLC | New Jersey |
| Chiro Alliance Corporation | Florida |
| Cigna & CMB Life Insurance Company Limited | China |
| Cigna Arbor Life Insurance Company | Connecticut |
| Cigna Dental Health Of California, Inc. | California |
| Cigna Dental Health Of Colorado, Inc. | Colorado |
| Cigna Dental Health Of Delaware, Inc. | Delaware |
| Cigna Dental Health Of Florida, Inc. | Florida |
| Cigna Dental Health Of Kansas, Inc. | Kansas |
| Cigna Dental Health Of Kentucky, Inc. | Kentucky |
| Cigna Dental Health Of Maryland, Inc. | Maryland |
| Cigna Dental Health Of Missouri, Inc. | Missouri |
| Cigna Dental Health Of New Jersey, Inc. | New Jersey |
| Cigna Dental Health Of North Carolina, Inc. | North Carolina |
| Cigna Dental Health Of Ohio, Inc. | Ohio |
| Cigna Dental Health Of Pennsylvania, Inc. | Pennsylvania |
| Cigna Dental Health Of Texas, Inc. | Texas |
| Cigna Dental Health Of Virginia, Inc. | Virginia |
| Cigna Dental Health Plan Of Arizona, Inc. | Arizona |
| Cigna Europe Insurance Company S.A.-N.V. | Belgium |
| Cigna Global Insurance Company Limited | Guernsey |
| Cigna Global Reinsurance Company, Ltd. | Bermuda |
| Cigna Health and Life Insurance Company | Connecticut |
| Cigna HealthCare of Arizona, Inc. | Arizona |
| Cigna HealthCare of California, Inc. | California |
| Cigna HealthCare of Connecticut, Inc. | Connecticut |
| Cigna HealthCare of Florida, Inc. | Florida |
| Cigna HealthCare of Georgia, Inc. | Georgia |
| Cigna HealthCare of Illinois, Inc. | Illinois |
| Cigna HealthCare of Indiana, Inc. | Indiana |
| Cigna HealthCare of New Hampshire, Inc. | New Hampshire |
| Cigna HealthCare of New Jersey, Inc. | New Jersey |
| Cigna HealthCare of North Carolina, Inc. | North Carolina |

| | |
|--|----------------|
| Cigna HealthCare of South Carolina, Inc. | South Carolina |
| Cigna HealthCare of St. Louis, Inc. | Missouri |
| Cigna HealthCare of Tennessee, Inc. | Tennessee |
| Cigna HealthCare of Texas, Inc. | Texas |
| Cigna Holding Company | Delaware |
| Cigna Holdings, Inc. | Delaware |
| Cigna Insurance Middle East S.A.L. | Lebanon |
| Cigna Life Insurance Company of Canada | Canada |
| Cigna Life Insurance Company of Europe S.A.-N.V. | Belgium |
| Cigna Services Middle East FZE | Dubai |
| Cigna Worldwide General Insurance Company Limited | Hong Kong |
| Cigna Worldwide Insurance Company | Delaware |
| Cigna-Evernorth Enterprise Services, Inc. | Delaware |
| Connecticut General Corporation | Connecticut |
| Connecticut General Life Insurance Company | Connecticut |
| CPRx MSO, LLC | Delaware |
| Evernorth Accountable Care, LLC | Delaware |
| Evernorth Health, Inc. | Delaware |
| Evernorth Wholesale Distribution, Inc. | Delaware |
| Evernorth-VillageMD Care Alliance of NJ, LLC (F/K/A "ENAC of NJ, LLC") | New Jersey |
| eviCore Healthcare MSI, LLC | Tennessee |
| Express Scripts Administrators LLC | Delaware |
| Express Scripts Utilization Management Company | Delaware |
| Express Scripts, Inc. | Delaware |
| Inside RX, LLC | Delaware |
| ManipalCigna Health Insurance Company Limited | India |
| Matrix Healthcare Services, Inc. | Florida |
| Medco Health Solutions, Inc. | Delaware |
| MSI Health Organization of Texas, Inc. | Texas |
| Pipeline Health Holdings LLC | Delaware |
| Prohealth Pharmacy Solutions, LLC | Florida |
| Temple Insurance Company Limited | Bermuda |

CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

We hereby consent to the incorporation by reference in the Registration Statements on Form S-3 (No. 333-289983) and S-8 (Nos. 333-228930, 333-228931 and 333-258507) of The Cigna Group of our report dated February 26, 2026 relating to the financial statements, financial statement schedules, and the effectiveness of internal control over financial reporting, which appears in this Form 10-K.

/s/ PricewaterhouseCoopers LLP
Hartford, Connecticut
February 26, 2026

CERTIFICATION

I, DAVID M. CORDANI, certify that:

1. I have reviewed this Annual Report on Form 10-K of The Cigna Group;
2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4. The registrant's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
 - a) designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
 - b) designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
 - c) evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
 - d) disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and
5. The registrant's other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):
 - a) all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and
 - b) any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

Date: February 26, 2026

/s/ David M. Cordani

Chairman and Chief Executive Officer of The Cigna Group

CERTIFICATION

I, ANN M. DENNISON, certify that:

1. I have reviewed this Annual Report on Form 10-K of The Cigna Group;
2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4. The registrant's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
 - a) designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
 - b) designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
 - c) evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
 - d) disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and
5. The registrant's other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):
 - a) all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and
 - b) any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

Date: February 26, 2026

/s/ Ann M. Dennison

Executive Vice President and Chief Financial Officer

Certification of Chief Executive Officer of
The Cigna Group pursuant to 18 U.S.C. Section 1350

I certify that, to the best of my knowledge and belief, the Annual Report on Form 10-K of The Cigna Group for the fiscal period ending December 31, 2025 (the “Report”):

- (1) complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
- (2) the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of The Cigna Group.

/s/ David M. Cordani

David M. Cordani

Chairman and Chief Executive Officer of The Cigna Group

February 26, 2026

Certification of Chief Financial Officer of
The Cigna Group pursuant to 18 U.S.C. Section 1350

I certify that, to the best of my knowledge and belief, the Annual Report on Form 10-K of The Cigna Group for the fiscal period ending December 31, 2025 (the “Report”):

- (1) complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
- (2) the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of The Cigna Group.

/s/ Ann M. Dennison

Ann M. Dennison

Executive Vice President and Chief Financial Officer

February 26, 2026